<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>regeneron_10q.htm
<DESCRIPTION>QUARTERLY REPORT
<TEXT>
<HTML>
<HEAD>
<TITLE></TITLE>
</HEAD>
<BODY>

<BR>
<P align=center><FONT face="Times New Roman" size=2>UNITED STATES<BR></FONT><FONT face="Times New Roman" size=2>SECURITIES AND EXCHANGE COMMISSION<BR>Washington, DC 20549 </FONT></P>
<P align=center><B><FONT face="Times New Roman" size=2>Form 10-Q </FONT></B></P>
<TABLE style="LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="10%"><FONT face="Times New Roman" size=2>(Mark One)</FONT></TD>
    <TD noWrap align=left width="15%"></TD>
    <TD noWrap align=left width="73%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="1%"><FONT face="Times New Roman" size=2>(X)</FONT></TD>
    <TD noWrap align=left width="1%"><FONT size=2 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD noWrap align=left width="98%" colSpan=3><FONT face="Times New Roman" size=2>QUARTERLY REPORT PURSUANT
      TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%">&nbsp;</TD>
    <TD noWrap align=left width="10%">&nbsp;</TD>
    <TD noWrap align=left width="15%"></TD>
    <TD noWrap align=left width="73%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="10%"><FONT face="Times New Roman" size=2>For the quarterly period
      ended&nbsp;&nbsp;</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid; text-align: center" noWrap width="15%"><FONT size=2 face="Times New Roman">June 30, 2012</FONT></TD>
    <TD noWrap align=left width="73%">&nbsp;</TD></TR>
  <TR>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="10%">&nbsp;</TD>
    <TD noWrap align=left width="15%"></TD>
    <TD noWrap align=left width="73%">&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap style="text-align: center" width="100%" colSpan=5><FONT face="Times New Roman" size=2>OR</FONT></TD></TR>
  <TR>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="10%">&nbsp;</TD>
    <TD noWrap align=left width="15%"></TD>
    <TD noWrap align=left width="73%">&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="1%"><FONT face="Times New Roman" size=2>( )</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="98%" colSpan=3><FONT face="Times New Roman" size=2>TRANSITION REPORT PURSUANT
      TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF
1934</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="1%">&nbsp;</TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="10%"></TD>
    <TD noWrap align=left width="15%"></TD>
    <TD noWrap align=left width="73%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="98%" colSpan=3><FONT face="Times New Roman" size=2>For the transition period
      from __________ </FONT><FONT face="Times New Roman" size=2>to __________</FONT></TD></TR></TABLE><BR>
<DIV align=center>
<TABLE style="LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="20%" border=0>

  <TR vAlign=bottom>
    <TD noWrap align=left width="50%"><FONT face="Times New Roman" size=2>Commission File Number&nbsp;&nbsp;</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="50%"><FONT size=2 face="Times New Roman">0-19034</FONT></TD></TR></TABLE></DIV><BR>
<P align=center><U><FONT face="Times New Roman" size=2>REGENERON PHARMACEUTICALS,
INC.<BR></FONT></U><FONT face="Times New Roman" size=2>(Exact name of registrant as
specified in its charter) </FONT></P>
<TABLE style="LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD noWrap style="text-align: center" width="33%"><U><FONT face="Times New Roman" size=2>New
    York</FONT></U></TD>
    <TD noWrap style="text-align: center" width="34%"></TD>
    <TD noWrap style="text-align: center" width="33%"><U><FONT face="Times New Roman" size=2>13-3444607</FONT></U></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap style="text-align: center" width="33%"><FONT face="Times New Roman" size=2>(State or other jurisdiction
    of</FONT></TD>
    <TD noWrap style="text-align: center" width="34%"></TD>
    <TD noWrap style="text-align: center" width="33%"><FONT face="Times New Roman" size=2>(I.R.S. Employer Identification
      No.)</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap style="text-align: center" width="33%"><FONT face="Times New Roman" size=2>incorporation or
    organization)</FONT></TD>
    <TD noWrap style="text-align: center" width="34%"></TD>
    <TD noWrap style="text-align: center" width="33%"></TD></TR>
  <TR>
    <TD style="text-align: center" width="100%" colSpan=3>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap style="text-align: center" width="33%"><FONT face="Times New Roman" size=2>777 Old Saw Mill River Road</FONT></TD>
    <TD noWrap style="text-align: center" width="34%"></TD>
    <TD noWrap style="text-align: center" width="33%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap style="text-align: center" width="33%"><U><FONT face="Times New Roman" size=2>Tarrytown, New
      York</FONT></U></TD>
    <TD noWrap style="text-align: center" width="34%"></TD>
    <TD noWrap style="text-align: center" width="33%"><U><FONT face="Times New Roman" size=2>10591-6707</FONT></U></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap style="text-align: center" width="33%"><FONT face="Times New Roman" size=2>(Address of principal executive
      offices)</FONT></TD>
    <TD noWrap style="text-align: center" width="34%"></TD>
    <TD noWrap style="text-align: center" width="33%"><FONT face="Times New Roman" size=2>(Zip
Code)</FONT></TD></TR></TABLE><BR>
<P align=center><U><FONT face="Times New Roman" size=2>(914) 847-7000</FONT></U><FONT face="Times New Roman" size=2> <BR></FONT><FONT face="Times New Roman" size=2>(Registrant&#146;s telephone
number, including area code) </FONT></P>
<DIV align=justify><FONT face="Times New Roman" size=2>Indicate by check mark whether the
registrant: (1) has filed all reports required to be filed by Section 13 or
15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or
for such shorter period that the registrant was required to file such reports),
and (2) has been subject to such filing requirements for the past 90 days.
</FONT></DIV>
<DIV align=center>
<TABLE style="LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="30%" border=0>

  <TR vAlign=bottom>
    <TD noWrap align=left width="1%"><FONT face="Times New Roman" size=2>Yes&nbsp;</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid; TEXT-ALIGN: center" noWrap width="30%"><FONT face="Times New Roman" size=2>X</FONT></TD>
    <TD noWrap align=left width="37%">&nbsp;</TD>
    <TD noWrap align=left width="1%"><FONT face="Times New Roman" size=2>No&nbsp;</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="30%">&nbsp;</TD></TR></TABLE></DIV><BR>
<DIV align=justify><FONT face="Times New Roman" size=2>Indicate by check mark whether the
registrant has submitted electronically and posted on its corporate Web site, if
any, every Interactive Data File required to be submitted and posted pursuant to
Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12
months (or for such shorter period that the registrant was required to submit
and post such files).</FONT></DIV>
<DIV align=center>
<TABLE style="LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="30%" border=0>

  <TR vAlign=bottom>
    <TD noWrap align=left width="1%"><FONT face="Times New Roman" size=2>Yes&nbsp;</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid; TEXT-ALIGN: center" noWrap width="30%"><FONT face="Times New Roman" size=2>X</FONT></TD>
    <TD noWrap align=left width="37%">&nbsp;</TD>
    <TD noWrap align=left width="1%"><FONT face="Times New Roman" size=2>No&nbsp;</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="30%">&nbsp;</TD></TR></TABLE><BR>
</DIV>
<DIV align=justify><FONT face="Times New Roman" size=2>Indicate by check mark whether the
registrant is a large accelerated filer, an accelerated filer, a non-accelerated
filer, or a smaller reporting company. See the definitions of &#147;large accelerated
filer&#148;, &#147;accelerated filer&#148; and &#147;smaller reporting company&#148; in Rule 12b-2 of the
Exchange Act.</FONT></DIV>
<TABLE style="LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD noWrap align=left width="10%"><FONT face="Times New Roman" size=2>Large accelerated filer</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"><FONT face="Times New Roman" size=2>&nbsp; X&nbsp;
    &nbsp;</FONT></TD>
    <TD noWrap align=left width="58%"></TD>
    <TD noWrap align=left width="30%"><FONT face="Times New Roman" size=2>Accelerated filer ____</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="11%" colSpan=2><FONT face="Times New Roman" size=2>Non-accelerated filer ____</FONT></TD>
    <TD noWrap align=left width="58%"><FONT face="Times New Roman" size=2>(Do
      not check if a smaller reporting company)</FONT></TD>
    <TD noWrap align=left width="30%"><FONT face="Times New Roman" size=2>Smaller reporting company ____</FONT></TD></TR></TABLE><BR>
<DIV align=justify><FONT face="Times New Roman" size=2>Indicate by check mark whether the
registrant is a shell company (as defined in Rule 12b-2 of the Exchange
Act).</FONT></DIV>
<DIV align=center>
<TABLE style="LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="30%" border=0>

  <TR vAlign=bottom>
    <TD noWrap align=left width="1%"><FONT face="Times New Roman" size=2>Yes&nbsp;</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid; TEXT-ALIGN: center" noWrap width="30%"></TD>
    <TD noWrap align=left width="37%">&nbsp;</TD>
    <TD noWrap align=left width="1%"><FONT face="Times New Roman" size=2>No&nbsp;</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid; text-align: center" noWrap width="30%"><FONT size=2 face="Times New Roman">X</FONT></TD></TR></TABLE>&nbsp;</DIV>
<DIV align=justify><FONT face="Times New Roman" size=2>Number of shares outstanding of each
of the registrant&#146;s classes of common stock as of July 13, 2012: </FONT></DIV>
<DIV align=center>
<TABLE style="LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="80%" border=0>

  <TR vAlign=bottom>
    <TD style="BORDER-BOTTOM: #000000 1pt solid; text-align: center" noWrap width="10%"><FONT face="Times New Roman" size=2>Class of Common Stock</FONT></TD>
    <TD noWrap style="text-align: center" width="80%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid; text-align: center" noWrap width="10%"><FONT face="Times New Roman" size=2>Number of Shares</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="10%" bgColor=#cceeff><FONT face="Times New Roman" size=2>Class A Stock, $0.001 par
      value</FONT></TD>
    <TD noWrap align=right width="80%" bgColor=#cceeff>&nbsp;</TD>
    <TD noWrap style="text-align: center" width="10%" bgColor=#cceeff><FONT face="Times New Roman" size=2>2,089,512</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="10%"><FONT face="Times New Roman" size=2>Common Stock, $0.001 par value</FONT></TD>
    <TD noWrap align=right width="80%"></TD>
    <TD noWrap style="text-align: center" width="10%"><FONT face="Times New Roman" size=2>93,955,110</FONT></TD></TR></TABLE></DIV><BR>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<P align=center><B><FONT face="Times New Roman" size=2>REGENERON PHARMACEUTICALS, INC.<BR>
Table of Contents<BR>June 30, 2012 </FONT></B></P>
<TABLE style="LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD style="TEXT-ALIGN: center" noWrap width="4%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%">&nbsp;</TD>
    <TD style="TEXT-ALIGN: center" noWrap width="90%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid; TEXT-ALIGN: center" noWrap width="4%" colSpan=3><B><FONT face="Times New Roman" size=2>Page
      Numbers</FONT></B></TD></TR>
  <TR>
    <TD style="TEXT-ALIGN: center" width="95%" colSpan=3></TD>
    <TD style="TEXT-ALIGN: center" width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD style="TEXT-ALIGN: center" width="2%">&nbsp;</TD>
    <TD style="TEXT-ALIGN: center" width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="4%" bgColor=#cceeff><B><FONT face="Times New Roman" size=2><A href="#PartI">PART I</A></FONT></B></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="90%" bgColor=#cceeff><B><FONT face="Times New Roman" size=2><A href="#PartI">FINANCIAL
      INFORMATION</A></FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="2%" bgColor=#cceeff></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%" bgColor=#cceeff></TD></TR>
  <TR>
    <TD noWrap align=left width="4%">&nbsp;</TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="90%">&nbsp;</TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD noWrap align=left width="2%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="4%" bgColor=#cceeff><FONT face="Times New Roman" size=2><A href="#item1">Item 1</A></FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD align=left width="90%" bgColor=#cceeff><FONT face="Times New Roman" size=2><A href="#item1">Financial Statements (unaudited)</A></FONT></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="2%" bgColor=#cceeff></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%" bgColor=#cceeff></TD></TR>
  <TR>
    <TD noWrap align=left width="4%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD align=left width="90%">&nbsp;</TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD noWrap align=left width="2%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="4%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD align=left width="90%" bgColor=#cceeff><A href="#BalanceSheet"><FONT face="Times New Roman" size=2>Condensed Balance Sheets at June 30, 2012
      and December 31, 2011</FONT></A></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=2><A href="#BalanceSheet">3</A></FONT></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%" bgColor=#cceeff></TD></TR>
  <TR>
    <TD noWrap align=left width="4%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD align=left width="90%">&nbsp;</TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD noWrap align=left width="2%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="4%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD align=left width="90%" bgColor=#cceeff><A href="#Operations"><FONT face="Times New Roman" size=2>Condensed Statements of Operations and
      Comprehensive Income (Loss) </FONT><FONT face="Times New Roman" size=2>for
      the Three and Six Months Ended June 30, 2012 and 2011</FONT></A></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=2><A href="#Operations">4</A></FONT></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%" bgColor=#cceeff></TD></TR>
  <TR>
    <TD noWrap align=left width="4%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD align=left width="90%">&nbsp;</TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD noWrap align=left width="2%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="4%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD align=left width="90%" bgColor=#cceeff><A href="#PrincipalStockholders"><FONT face="Times New Roman" size=2>Condensed Statements of Stockholders&#146; Equity for the Six
      Months</FONT> <FONT face="Times New Roman" size=2>Ended June 30, 2012 and
      2011</FONT></A></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=2><A href="#PrincipalStockholders">5</A></FONT></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%" bgColor=#cceeff></TD></TR>
  <TR>
    <TD noWrap align=left width="4%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD align=left width="90%">&nbsp;</TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD noWrap align=left width="2%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="4%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD align=left width="90%" bgColor=#cceeff><FONT face="Times New Roman" size=2><A href="#CashFlow">Condensed Statements of Cash Flows for the Six
      Months Ended&nbsp;June 30, 2012 and 2011</A></FONT></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=2><A href="#CashFlow">6</A></FONT></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%" bgColor=#cceeff></TD></TR>
  <TR>
    <TD noWrap align=left width="4%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD align=left width="90%" bgColor=#ffffff>&nbsp;</TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="2%" bgColor=#ffffff></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%" bgColor=#ffffff></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="4%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD align=left width="90%" bgColor=#cceeff><FONT face="Times New Roman" size=2><A href="#FinancialStatements">Notes to Condensed Financial
      Statements</A></FONT></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=2><A href="#FinancialStatements">7-16</A></FONT></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%" bgColor=#cceeff></TD></TR>
  <TR>
    <TD noWrap align=left width="4%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD align=left width="90%">&nbsp;</TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD noWrap align=left width="2%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="4%" bgColor=#cceeff><A href="#item2"><FONT face="Times New Roman" size=2>Item 2</FONT></A></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD align=left width="90%" bgColor=#cceeff><A href="#item2"><FONT face="Times New Roman" size=2>Management's Discussion and Analysis of
      Financial Condition and Results of Operations</FONT></A></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="2%" bgColor=#cceeff><A href="#item2"><FONT face="Times New Roman" size=2>17-43</FONT></A></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%" bgColor=#cceeff></TD></TR>
  <TR>
    <TD noWrap align=left width="4%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD align=left width="90%" bgColor=#ffffff>&nbsp;</TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="2%" bgColor=#ffffff></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%" bgColor=#ffffff></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="4%" bgColor=#cceeff><A href="#item3"><FONT face="Times New Roman" size=2>Item 3</FONT></A></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD align=left width="90%" bgColor=#cceeff><A href="#item3"><FONT face="Times New Roman" size=2>Quantitative and Qualitative Disclosures
      About Market Risk</FONT></A></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=2><A href="#item3">43-44</A></FONT></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%" bgColor=#cceeff></TD></TR>
  <TR>
    <TD noWrap align=left width="4%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD align=left width="90%" bgColor=#ffffff>&nbsp;</TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="2%" bgColor=#ffffff></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%" bgColor=#ffffff></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="4%" bgColor=#cceeff><A href="#item4"><FONT face="Times New Roman" size=2>Item 4</FONT></A></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD align=left width="90%" bgColor=#cceeff><A href="#item4"><FONT face="Times New Roman" size=2>Controls and Procedures</FONT></A></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="2%" bgColor=#cceeff><A href="#item4"><FONT face="Times New Roman" size=2>44</FONT></A></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%" bgColor=#cceeff></TD></TR>
  <TR>
    <TD align=left width="98%" colSpan=5>&nbsp;</TD>
    <TD style="TEXT-ALIGN: center" width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="4%" bgColor=#cceeff><A href="#PartII"><B><FONT face="Times New Roman" size=2>PART
      II</FONT></B></A></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD align=left width="90%" bgColor=#cceeff><A href="#PartII"><B><FONT face="Times New Roman" size=2>OTHER INFORMATION</FONT></B></A></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="2%" bgColor=#cceeff></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%" bgColor=#cceeff></TD></TR>
  <TR>
    <TD noWrap align=left width="4%"></TD>
    <TD noWrap align=left width="1%">&nbsp;</TD>
    <TD align=left width="90%">&nbsp;</TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD noWrap align=left width="2%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="4%" bgColor=#cceeff><A href="#LegalProceedings"><FONT face="Times New Roman" size=2>Item
      1</FONT></A></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD align=left width="90%" bgColor=#cceeff><A href="#LegalProceedings"><FONT face="Times New Roman" size=2>Legal
      Proceedings</FONT></A></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="2%" bgColor=#cceeff><A href="#LegalProceedings"><FONT face="Times New Roman" size=2>44-45</FONT></A></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%" bgColor=#cceeff></TD></TR>
  <TR>
    <TD noWrap align=left width="4%"></TD>
    <TD noWrap align=left width="1%">&nbsp;</TD>
    <TD align=left width="90%">&nbsp;</TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD noWrap align=left width="2%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="4%" bgColor=#cceeff><A href="#RiskFactors"><FONT face="Times New Roman" size=2>Item
    1A</FONT></A></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD align=left width="90%" bgColor=#cceeff><A href="#RiskFactors"><FONT face="Times New Roman" size=2>Risk Factors</FONT></A></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="2%" bgColor=#cceeff><A href="#RiskFactors"><FONT face="Times New Roman" size=2>45-72</FONT></A></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%" bgColor=#cceeff></TD></TR>
  <TR>
    <TD noWrap align=left width="4%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD align=left width="90%">&nbsp;</TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD noWrap align=left width="2%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="4%" bgColor=#cceeff><A href="#item6"><FONT face="Times New Roman" size=2>Item 6</FONT></A></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD align=left width="90%" bgColor=#cceeff><A href="#item6"><FONT face="Times New Roman" size=2>Exhibits</FONT></A></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="2%" bgColor=#cceeff><A href="#item6"><FONT face="Times New Roman" size=2>72</FONT></A></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%" bgColor=#cceeff></TD></TR>
  <TR>
    <TD style="TEXT-ALIGN: center" width="98%" colSpan=5>&nbsp;</TD>
    <TD style="TEXT-ALIGN: center" width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="95%" bgColor=#cceeff colSpan=3><A href="#Signatures"><B><FONT face="Times New Roman" size=2>SIGNATURE
      PAGE</FONT></B></A></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="2%" bgColor=#cceeff><A href="#Signatures"><FONT face="Times New Roman" size=2>73</FONT></A></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%" bgColor=#cceeff></TD></TR></TABLE>

<BR>
<P align=justify><FONT face="Times New Roman" size=2>"ARCALYST<SUP>&#174;</SUP>", "EYLEA<SUP>&#174;</SUP>", "ZALTRAP<SUP>&#174;&#148;</SUP>,
<I><FONT STYLE="background-color: TRANSPARENT">&#147;VelocImmune<SUP>&#174;</SUP>&#148;</FONT></I>, <I><FONT STYLE="background-color: TRANSPARENT">&#147;VelociGene<SUP>&#174;</SUP>&#148;</FONT></I>,
<I><FONT STYLE="background-color: TRANSPARENT">&#148;VelociMouse<SUP>&#174;</SUP>&#148;</FONT></I>, <I><FONT STYLE="background-color: TRANSPARENT">&#147;VelociMab<SUP>&#174;</SUP>&#148;</FONT></I>,
and <I><FONT STYLE="background-color: TRANSPARENT">&#147;VelociSuite<FONT face="Times New Roman" size=1><SUP>TM</SUP></FONT>&#148;</FONT></I> are trademarks of Regeneron Pharmaceuticals, Inc. All other trademarks
in this Form 10-Q are the property of their respective owners. </FONT></P>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<P align=justify><B><FONT face="Times New Roman" size=2><A NAME="PartI"></A>PART I. FINANCIAL
INFORMATION<BR><A NAME="item1"></A>ITEM 1. FINANCIAL STATEMENTS</FONT></B></P>
<P align=justify><FONT STYLE="background-color: TRANSPARENT"><B><FONT face="Times New Roman" size=2>REGENERON PHARMACEUTICALS,
INC.<BR><A NAME="BalanceSheet"></A>CONDENSED BALANCE SHEETS (Unaudited)<BR></FONT></B><B><I><FONT face="Times New Roman" size=2><FONT STYLE="BACKGROUND-COLOR: TRANSPARENT">(In thousands, except share data)</FONT></FONT></I></B></FONT></P>
<TABLE style="LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD noWrap align=left width="87%"></TD>
    <TD noWrap style="text-align: center" width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD noWrap style="text-align: center" width="5%" colSpan=3><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2><B>June
    30,</B></FONT></TD>
    <TD noWrap style="text-align: center" width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD noWrap style="text-align: center" width="5%" colSpan=3><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2><B>December
    31,</B></FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap style="text-align: center" width="87%"><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2><B>ASSETS</B></FONT></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid; text-align: center" noWrap width="5%" colSpan=3><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2><B>2012</B></FONT></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid; text-align: center" noWrap width="5%" colSpan=3><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2><B>2011</B></FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="87%" bgColor=#cceeff><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>Current
    assets:</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="3%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="3%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="87%"><FONT STYLE="font: x-small Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="background-color: TRANSPARENT">Cash
    and cash equivalents</FONT></FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="3%"><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>171,943</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="3%"><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>483,610</FONT></TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="87%" bgColor=#cceeff><FONT STYLE="font: x-small Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="background-color: TRANSPARENT">Marketable
    securities</FONT></FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="3%" bgColor=#cceeff><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>129,079</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="3%" bgColor=#cceeff><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>43,332</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="87%"><FONT STYLE="font: x-small Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="background-color: TRANSPARENT">Accounts
    receivable - trade, net</FONT></FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>349,645</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>28,254</FONT></TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="87%" bgColor=#cceeff><FONT STYLE="font: x-small Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="background-color: TRANSPARENT">Accounts
    receivable from Sanofi</FONT></FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="3%" bgColor=#cceeff><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>85,735</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="3%" bgColor=#cceeff><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>74,781</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="87%"><FONT STYLE="font: x-small Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="background-color: TRANSPARENT">Prepaid
    expenses and other current assets</FONT></FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%"><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>32,791</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%"><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>22,898</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="87%" bgColor=#cceeff><FONT STYLE="font: x-small Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="background-color: TRANSPARENT">Total
    current assets</FONT></FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="3%" bgColor=#cceeff><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>769,193</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="3%" bgColor=#cceeff><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>652,875</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD></TR>
  <TR>
    <TD width="99%" colSpan=9>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="87%" bgColor=#cceeff><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>Restricted
    cash and marketable securities</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="3%" bgColor=#cceeff><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>8,141</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="3%" bgColor=#cceeff><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>7,721</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="87%"><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>Marketable securities</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>288,321</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>275,887</FONT></TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="87%" bgColor=#cceeff><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>Property,
    plant, and equipment, at cost, net of accumulated</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="3%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="3%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="87%" bgColor=#cceeff><FONT STYLE="font: x-small Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="background-color: TRANSPARENT">depreciation
    and amortization</FONT></FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="3%" bgColor=#cceeff><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>372,278</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="3%" bgColor=#cceeff><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>367,955</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="87%"><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>Other assets</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%"><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>19,567</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%"><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>19,145</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="87%" bgColor=#cceeff><FONT STYLE="font: x-small Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="background-color: TRANSPARENT">Total
    assets</FONT></FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%" bgColor=#cceeff><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="3%" bgColor=#cceeff><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>1,457,500</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%" bgColor=#cceeff><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>$</FONT>&nbsp;&nbsp;&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="3%" bgColor=#cceeff><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>1,323,583</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%" bgColor=#cceeff></TD></TR>
  <TR vAlign=bottom>
    <TD style="text-align: center" width="99%" colSpan=9>&nbsp;&nbsp;</TD></TR>
  <TR>
    <TD noWrap style="text-align: center" width="87%" bgColor=#cceeff><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2><B>LIABILITIES
    and STOCKHOLDERS' EQUITY</B></FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="3%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="3%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="87%"><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>Current liabilities:</FONT></TD>
    <TD noWrap align=left width="1%">&nbsp;</TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="3%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="3%"></TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="87%" bgColor=#cceeff><FONT STYLE="font: x-small Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="background-color: TRANSPARENT">Accounts
    payable and accrued expenses</FONT></FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="3%" bgColor=#cceeff><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>126,768</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="3%" bgColor=#cceeff><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>95,625</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="87%"><FONT STYLE="font: x-small Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="background-color: TRANSPARENT">Deferred
    revenue from Sanofi, current portion</FONT></FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>21,790</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>20,011</FONT></TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="87%" bgColor=#cceeff><FONT STYLE="font: x-small Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="background-color: TRANSPARENT">Deferred
    revenue - other, current portion</FONT></FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD noWrap align=right width="3%" bgColor=#cceeff><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>33,479</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="3%" bgColor=#cceeff><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>31,629</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="87%"><FONT STYLE="font: x-small Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="background-color: TRANSPARENT">Facility
    lease obligations, current portion</FONT></FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%"><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>1,183</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%"><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>1,006</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="87%" bgColor=#cceeff><FONT STYLE="font: x-small Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="background-color: TRANSPARENT">Total
    current liabilities</FONT></FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="3%" bgColor=#cceeff><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>183,220</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="3%" bgColor=#cceeff><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>148,271</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD></TR>
  <TR>
    <TD width="99%" colSpan=9>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="87%" bgColor=#cceeff><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>Deferred
    revenue from Sanofi</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="3%" bgColor=#cceeff><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>78,281</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="3%" bgColor=#cceeff><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>86,017</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="87%"><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>Deferred revenue -
    other</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>149,031</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>162,593</FONT></TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="87%" bgColor=#cceeff><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>Facility
    lease obligations</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="3%" bgColor=#cceeff><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>159,558</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="3%" bgColor=#cceeff><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>159,508</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="87%"><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>Convertible senior
    notes</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>285,491</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>275,019</FONT></TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="87%" bgColor=#cceeff><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>Other
    long term liabilities</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%" bgColor=#cceeff><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>7,262</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%" bgColor=#cceeff><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>6,443</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="87%"><FONT STYLE="font: x-small Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="background-color: TRANSPARENT">Total
    liabilities</FONT></FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%"><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>862,843</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%"><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>837,851</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD></TR>
  <TR>
    <TD width="99%" colSpan=9>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="87%" bgColor=#cceeff><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>Commitments
    and contingencies</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="3%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="3%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD></TR>
  <TR>
    <TD width="99%" colSpan=9>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="87%" bgColor=#cceeff><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>Stockholders'
    equity:</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="3%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="3%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="87%"><FONT STYLE="font: x-small Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="background-color: TRANSPARENT">Preferred
    stock, $.01 par value; 30,000,000 shares authorized; issued and outstanding - none</FONT></FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="3%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="3%"></TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="87%" bgColor=#cceeff><FONT STYLE="font: x-small Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="background-color: TRANSPARENT">Class
    A Stock, convertible, $.001 par value; 40,000,000 shares authorized;</FONT></FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="3%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="3%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="87%" bgColor=#cceeff><FONT STYLE="font: x-small Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="background-color: TRANSPARENT">shares
    issued and outstanding - 2,089,512 at June 30, 2012 and 2,109,512 at</FONT> <BR>
    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="background-color: TRANSPARENT">December
    31, 2011</FONT></FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="3%" bgColor=#cceeff><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>2</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="3%" bgColor=#cceeff><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>2</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="87%"><FONT STYLE="font: x-small Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="background-color: TRANSPARENT">Common
    Stock, $.001 par value; 160,000,000 shares authorized;</FONT></FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="3%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="3%"></TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="87%"><FONT STYLE="font: x-small Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="background-color: TRANSPARENT">shares
    issued and outstanding - 93,941,788 at June 30, 2012 and 90,692,071 at</FONT> <BR>
    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="background-color: TRANSPARENT">December
    31, 2011</FONT></FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>94</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>91</FONT></TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="87%" bgColor=#cceeff><FONT STYLE="font: x-small Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="background-color: TRANSPARENT">Additional
    paid-in capital</FONT></FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="3%" bgColor=#cceeff><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>1,775,861</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="3%" bgColor=#cceeff><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>1,754,824</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="87%"><FONT STYLE="font: x-small Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="background-color: TRANSPARENT">Accumulated
    deficit</FONT></FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>(1,178,929</FONT></TD>
    <TD noWrap align=left width="1%"><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>)</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>(1,267,323</FONT></TD>
    <TD noWrap align=left width="1%"><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>)</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="87%" bgColor=#cceeff><FONT STYLE="font: x-small Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="background-color: TRANSPARENT">Accumulated
    other comprehensive loss</FONT></FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%" bgColor=#cceeff><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>(2,371</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>)</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%" bgColor=#cceeff><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>(1,862</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>)</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="87%"><FONT STYLE="font: x-small Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="background-color: TRANSPARENT">Total
    stockholders' equity</FONT></FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%"><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>594,657</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%"><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>485,732</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="87%" bgColor=#cceeff><FONT STYLE="font: x-small Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="background-color: TRANSPARENT">Total
    liabilities and stockholders' equity</FONT></FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%" bgColor=#cceeff><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="3%" bgColor=#cceeff><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>1,457,500</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%" bgColor=#cceeff><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="3%" bgColor=#cceeff><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>1,323,583</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%" bgColor=#cceeff></TD></TR>
  <TR>
    <TD noWrap align=left width="99%" colSpan=9>&nbsp;</TD></TR>
  <TR>
    <TD noWrap style="text-align: center" width="99%" colSpan=9>
      <P align=center><B><FONT face="Times New Roman" size=2><FONT face="Times New Roman" size=2>The
      accompanying notes are an integral part of the financial
      statements.</FONT></FONT></B></P></TD></TR>
  <TR>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="99%" colSpan=9>&nbsp;</TD></TR></TABLE><BR>
<P align=center><FONT face="Times New Roman" size=1><FONT face="Times New Roman" size=2>3</FONT></FONT></P>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<P align=justify><B><FONT face="Times New Roman" size=2>REGENERON PHARMACEUTICALS,
INC.<BR></FONT></B><B><FONT face="Times New Roman" size=2><A NAME="Operations"></A>CONDENSED STATEMENTS OF OPERATIONS
AND COMPREHENSIVE INCOME (LOSS) (Unaudited)<BR></FONT></B><B><I><FONT face="Times New Roman" size=2>(In thousands, except per share data) </FONT></I></B></P>
<TABLE style="LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD noWrap align=left width="76%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="11%" colSpan=7><B><FONT face="Times New Roman" size=2>Three months ended June 30,</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="11%" colSpan=7><B><FONT face="Times New Roman" size=2>Six months ended June 30,</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="76%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid; TEXT-ALIGN: center" noWrap width="5%" colSpan=3><B><FONT face="Times New Roman" size=2>2012</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid; TEXT-ALIGN: center" noWrap width="5%" colSpan=3><B><FONT face="Times New Roman" size=2>2011</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid; TEXT-ALIGN: center" noWrap width="5%" colSpan=3><B><FONT face="Times New Roman" size=2>2012</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid; TEXT-ALIGN: center" noWrap width="5%" colSpan=3><B><FONT face="Times New Roman" size=2>2011</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="76%" bgColor=#cceeff><B><FONT face="Times New Roman" size=2>Condensed Statements of
    Operations</FONT></B></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="3%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="3%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="3%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="3%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="76%"><FONT face="Times New Roman" size=2>Revenues:</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="3%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="3%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="3%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="3%"></TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="76%" bgColor=#cceeff><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net product
    sales</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD noWrap align=right width="3%" bgColor=#cceeff><FONT face="Times New Roman" size=2>199,519</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD noWrap align=right width="3%" bgColor=#cceeff><FONT face="Times New Roman" size=2>5,039</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD noWrap align=right width="3%" bgColor=#cceeff><FONT face="Times New Roman" size=2>327,450</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD noWrap align=right width="3%" bgColor=#cceeff><FONT face="Times New Roman" size=2>9,466</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="76%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Sanofi collaboration
      revenue</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=2>88,988</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=2>84,446</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=2>173,993</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=2>169,775</FONT></TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="76%" bgColor=#cceeff><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Bayer HealthCare
      collaboration revenue</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="3%" bgColor=#cceeff><FONT face="Times New Roman" size=2>9,124</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="3%" bgColor=#cceeff><FONT face="Times New Roman" size=2>11,123</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="3%" bgColor=#cceeff><FONT face="Times New Roman" size=2>21,607</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="3%" bgColor=#cceeff><FONT face="Times New Roman" size=2>23,604</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="76%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Technology
      licensing</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=2>5,893</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=2>5,228</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=2>11,786</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=2>13,073</FONT></TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="76%" bgColor=#cceeff><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Contract research and
      other</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%" bgColor=#cceeff><FONT face="Times New Roman" size=2>875</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%" bgColor=#cceeff><FONT face="Times New Roman" size=2>1,974</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%" bgColor=#cceeff><FONT face="Times New Roman" size=2>1,352</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%" bgColor=#cceeff><FONT face="Times New Roman" size=2>4,096</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="76%">&nbsp;</TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%"><FONT face="Times New Roman" size=2>304,399</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%"><FONT face="Times New Roman" size=2>107,810</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%"><FONT face="Times New Roman" size=2>536,188</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%"><FONT face="Times New Roman" size=2>220,014</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD></TR>
  <TR>
    <TD width="100%" colSpan=17>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="76%" bgColor=#cceeff><FONT face="Times New Roman" size=2>Expenses:</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="3%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="3%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="3%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="3%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="76%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Research and
      development</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=2>147,373</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=2>143,149</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=2>286,235</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=2>272,541</FONT></TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="76%" bgColor=#cceeff><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Selling, general, and
      administrative</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="3%" bgColor=#cceeff><FONT face="Times New Roman" size=2>47,705</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="3%" bgColor=#cceeff><FONT face="Times New Roman" size=2>24,585</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="3%" bgColor=#cceeff><FONT face="Times New Roman" size=2>106,133</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="3%" bgColor=#cceeff><FONT face="Times New Roman" size=2>47,996</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="76%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cost of goods
    sold</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%"><FONT face="Times New Roman" size=2>21,843</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%"><FONT face="Times New Roman" size=2>395</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%"><FONT face="Times New Roman" size=2>34,141</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%"><FONT face="Times New Roman" size=2>777</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="76%" bgColor=#cceeff>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%" bgColor=#cceeff><FONT face="Times New Roman" size=2>216,921</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%" bgColor=#cceeff><FONT face="Times New Roman" size=2>168,129</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%" bgColor=#cceeff><FONT face="Times New Roman" size=2>426,509</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%" bgColor=#cceeff><FONT face="Times New Roman" size=2>321,314</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff></TD></TR>
  <TR>
    <TD noWrap align=left width="76%">&nbsp;</TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"></TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="76%" bgColor=#cceeff><FONT face="Times New Roman" size=2>Income (loss) from operations</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%" bgColor=#cceeff><FONT face="Times New Roman" size=2>87,478</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%" bgColor=#cceeff><FONT face="Times New Roman" size=2>(60,319</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>)</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%" bgColor=#cceeff><FONT face="Times New Roman" size=2>109,679</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%" bgColor=#cceeff><FONT face="Times New Roman" size=2>(101,300</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>)</FONT></TD></TR>
  <TR>
    <TD width="100%" colSpan=17>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="76%" bgColor=#cceeff><FONT face="Times New Roman" size=2>Other income (expense):</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="3%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="3%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="3%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="3%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="76%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Investment
    income</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=2>501</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=2>998</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=2>1,111</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=2>2,035</FONT></TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="76%" bgColor=#cceeff><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Interest
expense</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%" bgColor=#cceeff><FONT face="Times New Roman" size=2>(11,236</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>)</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%" bgColor=#cceeff><FONT face="Times New Roman" size=2>(4,047</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>)</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%" bgColor=#cceeff><FONT face="Times New Roman" size=2>(22,396</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>)</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%" bgColor=#cceeff><FONT face="Times New Roman" size=2>(7,766</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>)</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="76%">&nbsp;</TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%"><FONT face="Times New Roman" size=2>(10,735</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"><FONT face="Times New Roman" size=2>)</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%"><FONT face="Times New Roman" size=2>(3,049</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"><FONT face="Times New Roman" size=2>)</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%"><FONT face="Times New Roman" size=2>(21,285</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"><FONT face="Times New Roman" size=2>)</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%"><FONT face="Times New Roman" size=2>(5,731</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"><FONT face="Times New Roman" size=2>)</FONT></TD></TR>
  <TR style="VERTICAL-ALIGN: bottom">
    <TD style="TEXT-ALIGN: left" noWrap width="76%">&nbsp;</TD>
    <TD style="TEXT-ALIGN: left" noWrap width="1%">&nbsp;</TD>
    <TD style="TEXT-ALIGN: left" noWrap width="1%">&nbsp;</TD>
    <TD style="TEXT-ALIGN: right" noWrap width="3%">&nbsp;</TD>
    <TD style="TEXT-ALIGN: left" noWrap width="1%">&nbsp;</TD>
    <TD style="TEXT-ALIGN: left" noWrap width="1%">&nbsp;</TD>
    <TD style="TEXT-ALIGN: left" noWrap width="1%">&nbsp;</TD>
    <TD style="TEXT-ALIGN: right" noWrap width="3%">&nbsp;</TD>
    <TD style="TEXT-ALIGN: left" noWrap width="1%">&nbsp;</TD>
    <TD style="TEXT-ALIGN: left" noWrap width="1%">&nbsp;</TD>
    <TD style="TEXT-ALIGN: left" noWrap width="1%">&nbsp;</TD>
    <TD style="TEXT-ALIGN: right" noWrap width="3%">&nbsp;</TD>
    <TD style="TEXT-ALIGN: left" noWrap width="1%">&nbsp;</TD>
    <TD style="TEXT-ALIGN: left" noWrap width="1%">&nbsp;</TD>
    <TD style="TEXT-ALIGN: left" noWrap width="1%">&nbsp;</TD>
    <TD style="TEXT-ALIGN: right" noWrap width="3%">&nbsp;</TD>
    <TD style="TEXT-ALIGN: left" noWrap width="1%">&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="76%" bgColor=#cceeff><FONT face="Times New Roman" size=2>Net income (loss) before income tax
      benefit</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD NOWRAP STYLE="text-align: left; width: 1%; background-color: #cceeff"></TD>
    <TD NOWRAP STYLE="text-align: right; width: 3%; background-color: #cceeff"><FONT face="Times New Roman" size=2>76,743</FONT></TD>
    <TD NOWRAP STYLE="text-align: left; width: 1%; background-color: #cceeff"></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD NOWRAP STYLE="text-align: left; width: 1%; background-color: #cceeff"></TD>
    <TD NOWRAP STYLE="text-align: right; width: 3%; background-color: #cceeff"><FONT face="Times New Roman" size=2>(63,368</FONT></TD>
    <TD NOWRAP STYLE="text-align: left; width: 1%; background-color: #cceeff"><FONT face="Times New Roman" size=2>)</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD NOWRAP STYLE="text-align: left; width: 1%; background-color: #cceeff"></TD>
    <TD NOWRAP STYLE="text-align: right; width: 3%; background-color: #cceeff"><FONT face="Times New Roman" size=2>88,394</FONT></TD>
    <TD NOWRAP STYLE="text-align: left; width: 1%; background-color: #cceeff"></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD NOWRAP STYLE="text-align: left; width: 1%; background-color: #cceeff"></TD>
    <TD NOWRAP STYLE="text-align: right; width: 3%; background-color: #cceeff"><FONT face="Times New Roman" size=2>(107,031</FONT></TD>
    <TD NOWRAP STYLE="text-align: left; width: 1%; background-color: #cceeff"><FONT face="Times New Roman" size=2>)</FONT></TD></TR>
  <TR>
    <TD width="100%" colSpan=17>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="76%" bgColor=#cceeff><FONT face="Times New Roman" size=2>Income tax benefit</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="3%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%" bgColor=#cceeff><FONT face="Times New Roman" size=2>863</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="3%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%" bgColor=#cceeff><FONT face="Times New Roman" size=2>1,079</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff></TD></TR>
  <TR>
    <TD width="100%" colSpan=17>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="76%" bgColor=#cceeff><FONT face="Times New Roman" size=2>Net income (loss)</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="3%" bgColor=#cceeff><FONT face="Times New Roman" size=2>76,743</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="3%" bgColor=#cceeff><FONT face="Times New Roman" size=2>(62,505</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>)</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="3%" bgColor=#cceeff><FONT face="Times New Roman" size=2>88,394</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="3%" bgColor=#cceeff><FONT face="Times New Roman" size=2>(105,952</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>)</FONT></TD></TR>
  <TR>
    <TD width="100%" colSpan=17>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="76%" bgColor=#cceeff><FONT face="Times New Roman" size=2>Net income (loss) per share -
basic</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="3%" bgColor=#cceeff><FONT face="Times New Roman" size=2>0.81</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="3%" bgColor=#cceeff><FONT face="Times New Roman" size=2>(0.69</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>)</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="3%" bgColor=#cceeff><FONT face="Times New Roman" size=2>0.94</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="3%" bgColor=#cceeff><FONT face="Times New Roman" size=2>(1.18</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>)</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="76%"><FONT face="Times New Roman" size=2>Net
      income (loss) per share - diluted</FONT></TD>
    <TD noWrap align=left width="1%">&nbsp;</TD>
    <TD noWrap align=left width="1%"><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=2>0.70</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=2>(0.69</FONT></TD>
    <TD noWrap align=left width="1%"><FONT face="Times New Roman" size=2>)</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=2>0.81</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%">&nbsp;</TD>
    <TD noWrap align=left width="1%"><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=2>(1.18</FONT></TD>
    <TD noWrap align=left width="1%"><FONT face="Times New Roman" size=2>)</FONT></TD></TR>
  <TR>
    <TD width="100%" colSpan=17>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="76%" bgColor=#cceeff><FONT face="Times New Roman" size=2>Weighted average shares outstanding -
      basic</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="3%" bgColor=#cceeff><FONT face="Times New Roman" size=2>94,589</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="3%" bgColor=#cceeff><FONT face="Times New Roman" size=2>90,436</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="3%" bgColor=#cceeff><FONT face="Times New Roman" size=2>94,017</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="3%" bgColor=#cceeff><FONT face="Times New Roman" size=2>89,799</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="76%"><FONT face="Times New Roman" size=2>Weighted average shares outstanding - diluted</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=2>110,167</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=2>90,436</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=2>108,998</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=2>89,799</FONT></TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR>
    <TD width="100%" colSpan=17>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="76%" bgColor=#cceeff><B><FONT face="Times New Roman" size=2>Condensed Statements of Comprehensive Income
      (Loss)</FONT></B></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="3%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="3%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="3%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="3%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="76%"><FONT face="Times New Roman" size=2>Net
      income (loss)</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=2>76,743</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=2>(62,505</FONT></TD>
    <TD noWrap align=left width="1%"><FONT face="Times New Roman" size=2>)</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=2>88,394</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=2>(105,952</FONT></TD>
    <TD noWrap align=left width="1%"><FONT face="Times New Roman" size=2>)</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="76%" bgColor=#cceeff><FONT face="Times New Roman" size=2>Other comprehensive income (loss):</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="3%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="3%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="3%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="3%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="76%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Unrealized (loss) gain on
      marketable securities, net of tax</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%"><FONT face="Times New Roman" size=2>(1,034</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"><FONT face="Times New Roman" size=2>)</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%"><FONT face="Times New Roman" size=2>1,271</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%"><FONT face="Times New Roman" size=2>(509</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"><FONT face="Times New Roman" size=2>)</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%"><FONT face="Times New Roman" size=2>1,587</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="76%" bgColor=#cceeff><FONT face="Times New Roman" size=2>Comprehensive income (loss)</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="3%" bgColor=#cceeff><FONT face="Times New Roman" size=2>75,709</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="3%" bgColor=#cceeff><FONT face="Times New Roman" size=2>(61,234</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>)</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="3%" bgColor=#cceeff><FONT face="Times New Roman" size=2>87,885</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="3%" bgColor=#cceeff><FONT face="Times New Roman" size=2>(104,365</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>)</FONT></TD></TR>
  <TR>
    <TD noWrap align=left width="76%">&nbsp;</TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"></TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="100%" colSpan=17>
      <P align=center><B><FONT face="Times New Roman" size=2>The accompanying
      notes are an integral part of the financial
      statements.<BR>&nbsp;</FONT></B></P></TD></TR></TABLE>
<BR>
<P align=center><FONT face="Times New Roman" size=2>4</FONT></P>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<P align=justify><B><FONT face="Times New Roman" size=2>REGENERON
PHARMACEUTICALS, INC.<BR><A NAME="PrincipalStockholders"></A>CONDENSED STATEMENTS OF STOCKHOLDERS' EQUITY
(Unaudited)<BR>For the six months ended June 30, 2012 and 2011<BR><EM>(In
thousands)</EM></FONT></B></P>
	<TABLE style="LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD noWrap align=left width="59%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="3%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="3%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="3%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="3%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="4%" colSpan=3><B><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>Accumulated</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="3%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="59%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="3%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="3%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="5%" colSpan=3><B><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>Additional</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="3%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="4%" colSpan=3><B><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>Other</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="5%" colSpan=3><B><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>Total</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="59%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid; TEXT-ALIGN: center" noWrap width="7%" colSpan=5><B><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>Class A
      Stock</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid; TEXT-ALIGN: center" noWrap width="8%" colSpan=5><B><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>Common
      Stock</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="5%" colSpan=3><B><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>Paid-in</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="5%" colSpan=3><B><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>Accumulated</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="4%" colSpan=3><B><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>Comprehensive</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="5%" colSpan=3><B><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>Stockholders'</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="59%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%">&nbsp;&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid; TEXT-ALIGN: center" noWrap width="4%" colSpan=2><B><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>Shares</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%">&nbsp;&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid; TEXT-ALIGN: center" noWrap width="2%" colSpan=2><B><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>Amount</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%">&nbsp;&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid; TEXT-ALIGN: center" noWrap width="4%" colSpan=2><B><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>Shares</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%">&nbsp;&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid; TEXT-ALIGN: center" noWrap width="3%" colSpan=2><B><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>Amount</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%">&nbsp;&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid; TEXT-ALIGN: center" noWrap width="5%" colSpan=3><B><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>Capital</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%">&nbsp;&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid; TEXT-ALIGN: center" noWrap width="5%" colSpan=3><B><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>Deficit</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%">&nbsp;&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid; TEXT-ALIGN: center" noWrap width="4%" colSpan=3><B><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>Income
      (Loss)</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%">&nbsp;&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid; TEXT-ALIGN: center" noWrap width="5%" colSpan=3><B><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>Equity</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="59%" bgColor=#cceeff><B><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>Balance, December 31, 2011</FONT></B></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="3%" bgColor=#cceeff>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>2,109</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>$</FONT></TD>
    <TD align=right width="1%" bgColor=#cceeff><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>2</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="3%" bgColor=#cceeff><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>90,692</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>$</FONT></TD>
    <TD align=right width="2%" bgColor=#cceeff><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>91</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>$</FONT></TD>
    <TD align=right width="3%" bgColor=#cceeff><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>1,754,824</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="3%" bgColor=#cceeff>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>(1,267,323</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>)</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>$</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD noWrap align=right width="2%" bgColor=#cceeff><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>(1,862</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>)</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>$</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD align=right width="3%" bgColor=#cceeff><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>485,732</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="59%"><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>Issuance of Common Stock in connection with exercise</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="3%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="3%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="2%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="3%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="3%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="2%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="3%"></TD>
    <TD noWrap align=left width="1%">&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="59%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="background-color: TRANSPARENT">of stock
options</font></FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="3%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>3,234</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="2%"><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>3</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>39,631</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="3%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="2%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>39,634</FONT></TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="59%" bgColor=#cceeff><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>Common Stock tendered upon exercise of stock
      options</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="3%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="3%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="2%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="3%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="3%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="2%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="3%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="59%" bgColor=#cceeff><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="background-color: TRANSPARENT">in
      connection with employee tax obligations</font></FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="3%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="3%" bgColor=#cceeff><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>(568</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>)</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="2%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="3%" bgColor=#cceeff><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>(61,444</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>)</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="3%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="2%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="3%" bgColor=#cceeff><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>(61,444</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>)</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="59%"><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>Issuance of Common Stock in connection with Company</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="3%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="3%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="2%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="3%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="3%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="2%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="3%"></TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="59%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="background-color: TRANSPARENT">401(k) Savings Plan
      contribution</font></FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="3%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>64</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="2%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="3%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="3%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="2%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="3%"></TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="59%" bgColor=#cceeff><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>Issuance of restricted Common Stock under
      Long-Term</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="3%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="3%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="2%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="3%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="3%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="2%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="3%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="59%" bgColor=#cceeff><FONT  face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="background-color: TRANSPARENT">Incentive Plan</font></FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="3%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="3%" bgColor=#cceeff><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>500</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="2%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="3%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="3%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="2%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="3%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="59%"><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>Conversion of Class A Stock to Common Stock</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>(20</FONT></TD>
    <TD noWrap align=left width="1%"><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>)</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>20</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="2%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="3%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="3%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="2%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="3%"></TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="59%" bgColor=#cceeff><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>Stock-based compensation charges</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="3%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="3%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="2%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="3%" bgColor=#cceeff><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>42,850</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="3%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="2%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD noWrap align=right width="3%" bgColor=#cceeff><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>42,850</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="59%"><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>Net
      income</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="3%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="3%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="2%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="3%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>88,394</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="2%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>88,394</FONT></TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="59%" bgColor=#cceeff><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>Other comprehensive loss</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="3%" bgColor=#cceeff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="3%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="2%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="3%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="3%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="2%" bgColor=#cceeff><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>(509</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>)</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%" bgColor=#cceeff><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>(509</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>)</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="59%"><B><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>Balance, June 30, 2012</FONT></B></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="3%"><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>2,089</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%"><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" align=right width="1%"><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>2</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="3%"><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;93,942</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%"><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" align=right width="2%"><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>94</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%"><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" align=right width="3%"><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>1,775,861</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%"><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="3%"><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>(1,178,929</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%"><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>)</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%"><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="2%"><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>(2,371</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%"><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>)</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%"><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" align=right width="3%"><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>594,657</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%"></TD></TR>
  <TR>
    <TD width="99%" colSpan=29>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="59%" bgColor=#cceeff><B><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>Balance, December 31, 2010</FONT></B></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="3%" bgColor=#cceeff><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>2,182</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>$</FONT></TD>
    <TD align=right width="1%" bgColor=#cceeff><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>2</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="3%" bgColor=#cceeff><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>87,238</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>$</FONT></TD>
    <TD align=right width="2%" bgColor=#cceeff><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>87</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>$</FONT></TD>
    <TD align=right width="3%" bgColor=#cceeff><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>1,575,780</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="3%" bgColor=#cceeff><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>(1,045,563</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>)</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="2%" bgColor=#cceeff><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>(2,491</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>)</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>$</FONT></TD>
    <TD align=right width="3%" bgColor=#cceeff><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>527,815</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="59%"><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>Issuance of Common Stock in connection with exercise</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="3%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="3%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%">&nbsp;</TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="2%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="3%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="3%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="2%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="3%"></TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="59%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="background-color: TRANSPARENT">of stock
options</font></FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="3%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%">&nbsp;</TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>2,127</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="2%"><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>2</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>28,501</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="3%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="2%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>28,503</FONT></TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="59%" bgColor=#cceeff><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>Common Stock tendered upon exercise of stock
      options</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="3%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="3%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="2%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="3%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="3%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="2%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="3%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="59%" bgColor=#cceeff><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="background-color: TRANSPARENT">in
      connection with employee tax obligations</font></FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="3%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="3%" bgColor=#cceeff><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>(101</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>)</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="2%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="3%" bgColor=#cceeff><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>(4,709</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>)</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="3%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="2%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="3%" bgColor=#cceeff><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>(4,709</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>)</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="59%"><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>Issuance of Common Stock in connection with Company</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="3%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="3%">&nbsp;</TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%">&nbsp;</TD>
    <TD noWrap align=left width="2%"></TD>
    <TD noWrap align=left width="1%">&nbsp;</TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="3%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="3%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="2%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="3%"></TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="59%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="background-color: TRANSPARENT">401(k) Savings Plan
      contribution</font></FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="3%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>92</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="2%">&nbsp;</TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>3,405</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="3%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="2%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>3,405</FONT></TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="59%" bgColor=#cceeff><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>Issuance of restricted Common Stock under
      Long-Term</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="3%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="3%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="2%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="3%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="3%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="2%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="3%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="59%" bgColor=#cceeff><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="background-color: TRANSPARENT">Incentive Plan</font></FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="3%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="3%" bgColor=#cceeff><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>5</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="2%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="3%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="3%" bgColor=#cceeff>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="2%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="3%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="59%"><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>Conversion of Class A to Common Stock</FONT></TD>
    <TD align=right width="1%"></TD>
    <TD align=right width="3%"><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>(55</FONT></TD>
    <TD noWrap align=left width="1%"><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>)</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>55</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="2%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="3%"></TD>
    <TD noWrap align=left width="1%">&nbsp;</TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="3%"></TD>
    <TD noWrap align=left width="1%">&nbsp;</TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="2%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="3%"></TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="59%" bgColor=#cceeff><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>Stock-based compensation charges</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD noWrap align=left width="3%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="3%" bgColor=#cceeff>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="2%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD noWrap align=right width="3%" bgColor=#cceeff><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>27,385</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD noWrap align=left width="3%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="2%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="3%" bgColor=#cceeff><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>27,385</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="59%"><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>Net
      loss</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="3%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%">&nbsp;</TD>
    <TD noWrap align=left width="3%"></TD>
    <TD noWrap align=left width="1%">&nbsp;</TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="2%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="3%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>(105,952</FONT></TD>
    <TD noWrap align=left width="1%"><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>)</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%">&nbsp;</TD>
    <TD noWrap align=left width="2%">&nbsp;</TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>(105,952</FONT></TD>
    <TD noWrap align=left width="1%"><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>)</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="59%" bgColor=#cceeff><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>Other comprehensive income, net of
    tax</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="3%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="3%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="2%" bgColor=#cceeff>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="3%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="3%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="2%" bgColor=#cceeff><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>1,587</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%" bgColor=#cceeff><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>1,587</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="59%"><B><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>Balance, June 30, 2011</FONT></B></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="3%"><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>2,127</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%"><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="1%"><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>2</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="3%"><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>89,416</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%"><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="2%"><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>89</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%"><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" align=right width="3%"><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>1,630,362</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%"><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="3%"><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>(1,151,515</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%"><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>)</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%"><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="2%"><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>(904</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%"><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>)</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%"><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" align=right width="3%"><FONT STYLE="background-color: TRANSPARENT" face="Times New Roman" size=2>478,034</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%"></TD></TR>
  <TR>
    <TD noWrap align=left width="59%">&nbsp;</TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="3%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="3%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="2%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD align=right width="3%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="2%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD align=right width="3%"></TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR>
    <TD style="TEXT-ALIGN: center" width="99%" colSpan=29>
      <P align=center><B><FONT face="Times New Roman" size=2>The accompanying&nbsp;notes are an integral
      part of the financial
      statements.</FONT></B></P></TD></TR>
  <TR>
    <TD style="BORDER-BOTTOM: #000000 2pt double; TEXT-ALIGN: center" width="99%" colSpan=29>&nbsp;</TD></TR></TABLE>
<BR>
<P align=center><FONT size=2 face="Times New Roman">5</FONT></P>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<P align=justify><B><FONT face="Times New Roman" size=2>REGENERON PHARMACEUTICALS,
INC.<BR></FONT></B><B><FONT face="Times New Roman" size=2><A NAME="CashFlow"></A>CONDENSED STATEMENTS OF CASH FLOWS
(Unaudited)<BR></FONT></B><B><I><FONT face="Times New Roman" size=2>(In
thousands)</FONT></I></B></P>
<TABLE style="LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD noWrap align=left width="88%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="11%" colSpan=7><B><FONT face="Times New Roman" size=2>Six months ended June 30,</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="88%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid; TEXT-ALIGN: center" noWrap width="5%" colSpan=3><B><FONT face="Times New Roman" size=2>2012</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid; TEXT-ALIGN: center" noWrap width="5%" colSpan=3><B><FONT face="Times New Roman" size=2>2011</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="88%" bgColor=#cceeff><FONT face="Times New Roman" size=2>Cash flows from operating
    activities:</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="3%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="3%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="88%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net income
    (loss)</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"><FONT face="Times New Roman" size=2>$&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%"><FONT face="Times New Roman" size=2>88,394</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"><FONT face="Times New Roman" size=2>$&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%"><FONT face="Times New Roman" size=2>(105,952</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"><FONT face="Times New Roman" size=2>)</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="88%" bgColor=#cceeff><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Adjustments to reconcile
      net income (loss) to net cash</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="3%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="3%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="88%" bgColor=#cceeff><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;used
      in operating activities:</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="3%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="3%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="88%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Depreciation
      and amortization</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=2>17,833</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=2>14,880</FONT></TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="88%" bgColor=#cceeff><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Non-cash
      compensation expense</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="3%" bgColor=#cceeff><FONT face="Times New Roman" size=2>42,850</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="3%" bgColor=#cceeff><FONT face="Times New Roman" size=2>27,197</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="88%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other
      non-cash charges and expenses, net</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=2>13,373</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=2>832</FONT></TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="88%" bgColor=#cceeff><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Changes
      in assets and liabilities:</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="3%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="3%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="88%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Increase
      in Sanofi and trade accounts receivable</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=2>(332,345</FONT></TD>
    <TD noWrap align=left width="1%"><FONT face="Times New Roman" size=2>)</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=2>(1,138</FONT></TD>
    <TD noWrap align=left width="1%"><FONT face="Times New Roman" size=2>)</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="88%" bgColor=#cceeff><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(Increase)
      decrease in prepaid expenses and other assets</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="3%" bgColor=#cceeff><FONT face="Times New Roman" size=2>(10,643</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>)</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="3%" bgColor=#cceeff><FONT face="Times New Roman" size=2>1,528</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="88%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Decrease
      in deferred revenue</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=2>(17,669</FONT></TD>
    <TD noWrap align=left width="1%"><FONT face="Times New Roman" size=2>)</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=2>(20,554</FONT></TD>
    <TD noWrap align=left width="1%"><FONT face="Times New Roman" size=2>)</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="88%" bgColor=#cceeff><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Increase
      in accounts payable, accrued expenses, and other liabilities</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%" bgColor=#cceeff><FONT face="Times New Roman" size=2>32,789</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%" bgColor=#cceeff><FONT face="Times New Roman" size=2>38,577</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="88%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total
      adjustments</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%"><FONT face="Times New Roman" size=2>(253,812</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"><FONT face="Times New Roman" size=2>)</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%"><FONT face="Times New Roman" size=2>61,322</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="88%" bgColor=#cceeff><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net
      cash used in operating activities</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%" bgColor=#cceeff><FONT face="Times New Roman" size=2>(165,418</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>)</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%" bgColor=#cceeff><FONT face="Times New Roman" size=2>(44,630</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>)</FONT></TD></TR>
  <TR>
    <TD width="100%" colSpan=9>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="88%" bgColor=#cceeff><FONT face="Times New Roman" size=2>Cash flows from investing
    activities:</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="3%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="3%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="88%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Purchases of marketable
      securities</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=2>(270,907</FONT></TD>
    <TD noWrap align=left width="1%"><FONT face="Times New Roman" size=2>)</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=2>(15,638</FONT></TD>
    <TD noWrap align=left width="1%"><FONT face="Times New Roman" size=2>)</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="88%" bgColor=#cceeff><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Sales or maturities of
      marketable securities</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="3%" bgColor=#cceeff><FONT face="Times New Roman" size=2>171,881</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="3%" bgColor=#cceeff><FONT face="Times New Roman" size=2>216,631</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="88%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Increase in restricted
      cash and marketable securities</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=2>(469</FONT></TD>
    <TD noWrap align=left width="1%"><FONT face="Times New Roman" size=2>)</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=2>(681</FONT></TD>
    <TD noWrap align=left width="1%"><FONT face="Times New Roman" size=2>)</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="88%" bgColor=#cceeff><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Capital
      expenditures</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%" bgColor=#cceeff><FONT face="Times New Roman" size=2>(23,927</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>)</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%" bgColor=#cceeff><FONT face="Times New Roman" size=2>(37,030</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>)</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="88%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net
      cash (used in) provided by investing activities</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%"><FONT face="Times New Roman" size=2>(123,422</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"><FONT face="Times New Roman" size=2>)</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%"><FONT face="Times New Roman" size=2>163,282</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD></TR>
  <TR>
    <TD width="100%" colSpan=9>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="88%" bgColor=#cceeff><FONT face="Times New Roman" size=2>Cash flows from financing
    activities:</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="3%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="3%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="88%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Payments in connection
      with facility and capital lease obligations</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%">&nbsp;</TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=2>(1,014</FONT></TD>
    <TD noWrap align=left width="1%"><FONT face="Times New Roman" size=2>)</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=2>(704</FONT></TD>
    <TD noWrap align=left width="1%"><FONT face="Times New Roman" size=2>)</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="88%" bgColor=#cceeff><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net proceeds from
      issuances of Common Stock</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="3%" bgColor=#cceeff><FONT face="Times New Roman" size=2>39,631</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="3%" bgColor=#cceeff><FONT face="Times New Roman" size=2>28,501</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="88%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Payments in connection
      with Common Stock tendered for employee tax obligations</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%"><FONT face="Times New Roman" size=2>(61,444</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"><FONT face="Times New Roman" size=2>)</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%"><FONT face="Times New Roman" size=2>(4,709</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"><FONT face="Times New Roman" size=2>)</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="88%" bgColor=#cceeff><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net
      cash (used in) provided by financing activities</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%" bgColor=#cceeff><FONT face="Times New Roman" size=2>(22,827</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>)</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%" bgColor=#cceeff><FONT face="Times New Roman" size=2>23,088</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff></TD></TR>
  <TR>
    <TD width="100%" colSpan=9>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="88%" bgColor=#cceeff><FONT face="Times New Roman" size=2>Net (decrease) increase in cash and cash
      equivalents</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="3%" bgColor=#cceeff><FONT face="Times New Roman" size=2>(311,667</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>)</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="3%" bgColor=#cceeff><FONT face="Times New Roman" size=2>141,740</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD></TR>
  <TR>
    <TD width="100%" colSpan=9>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="88%" bgColor=#cceeff><FONT face="Times New Roman" size=2>Cash and cash equivalents at beginning of
      period</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%" bgColor=#cceeff><FONT face="Times New Roman" size=2>483,610</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%" bgColor=#cceeff><FONT face="Times New Roman" size=2>112,572</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff></TD></TR>
  <TR>
    <TD width="100%" colSpan=9>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="88%" bgColor=#cceeff><FONT face="Times New Roman" size=2>Cash and cash equivalents at end of
      period</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="3%" bgColor=#cceeff><FONT face="Times New Roman" size=2>171,943</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="3%" bgColor=#cceeff><FONT face="Times New Roman" size=2>254,312</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%" bgColor=#cceeff></TD></TR>
  <TR>
    <TD noWrap align=left width="88%">&nbsp;</TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"></TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR>
    <TD style="BORDER-BOTTOM: #000000 2pt double; TEXT-ALIGN: center" noWrap width="100%" colSpan=9>
      <P align=center><B><FONT face="Times New Roman" size=2>The accompanying
      notes are an integral part of the financial
      statements.<BR>&nbsp;</FONT></B></P></TD></TR></TABLE>
<BR>
<P align=center><FONT face="Times New Roman" size=2>6</FONT></P>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<P align=justify><B><FONT face="Times New Roman" size=2>REGENERON PHARMACEUTICALS,
INC.<BR><A NAME="FinancialStatements"></A>Notes to Condensed Financial Statements
(Unaudited)<BR></FONT></B><B><I><FONT face="Times New Roman" size=2>(Unless otherwise noted,
dollars in thousands, except per share data) </FONT></I></B></P>
<P align=justify><B><FONT face="Times New Roman" size=2>1.</FONT></B><B><FONT face="Times New Roman" size=2> </FONT></B><B><FONT face="Times New Roman" size=2>Interim Financial Statements
</FONT></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face="Times New Roman" size=2>The
interim Condensed Financial Statements of Regeneron Pharmaceuticals, Inc.
(&#147;Regeneron&#148; or the &#147;Company&#148;) have been prepared in accordance with the
instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do
not include all information and disclosures necessary for a presentation of the
Company&#146;s financial position, results of operations, and cash flows in
conformity with accounting principles generally accepted in the United States of
America. In the opinion of management, these financial statements reflect all
normal recurring adjustments and accruals necessary for a fair statement of the
Company&#146;s financial position, results of operations, and cash flows for such
periods. The results of operations for any interim periods are not necessarily
indicative of the results for the full year. The December 31, 2011 Condensed
Balance Sheet data were derived from audited financial statements, but do not
include all disclosures required by accounting principles generally accepted in
the United States of America. These financial statements should be read in
conjunction with the financial statements and notes thereto contained in the
Company&#146;s Annual Report on Form 10-K for the year ended December 31,
2011.</FONT></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Certain reclassifications have been
made to prior period amounts to conform with the current period&#146;s presentation.
</FONT></P>
<P align=justify><B><FONT face="Times New Roman" size=2>2.</FONT></B><B><FONT face="Times New Roman" size=2> </FONT></B><B><FONT face="Times New Roman" size=2>Product Revenue</FONT></B></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>In November 2011, the Company
received marketing approval from the U.S. Food and Drug Administration (&#147;FDA&#148;)
for EYLEA<SUP>&#174;</SUP> (aflibercept) Injection for the treatment of neovascular
wet age-related macular degeneration (&#147;wet AMD&#148;). EYLEA net product sales
totaled $194.0 million and $317.5 million for the three and six months ended
June 30, 2012, respectively. </FONT></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>In February 2008, the Company
received marketing approval from the FDA for ARCALYST<SUP>&#174;</SUP> Injection for
Subcutaneous Use for the treatment of Cryopyrin-Associated Periodic Syndromes
(&#147;CAPS&#148;). ARCALYST net product sales totaled $5.5 million and $5.0 million for
the three months ended June 30, 2012 and 2011, respectively, and $9.9 million
and $9.5 million for the six months ended June 30, 2012 and 2011,
respectively.</FONT></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>The Company sells EYLEA in the
United States to three distributors and several specialty pharmacies. The
Company sells ARCALYST in the United States to two specialty pharmacies. Under
these distribution models, the distributors and specialty pharmacies
(collectively, the Company&#146;s &#147;customers&#148;) generally take physical delivery of
product. For EYLEA, the distributors and specialty pharmacies generally sell the
product directly to healthcare providers; whereas for ARCALYST, the specialty
pharmacies sell the product directly to patients. The Company records revenue
from product sales upon delivery to its customers. For both the three and six
months ended June 30, 2012, the Company recorded 79% of its gross product
revenue from sales to Besse Medical, a subsidiary of AmerisourceBergen
Corporation.</FONT></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Revenue from product sales are
recorded net of applicable provisions for prompt pay discounts, rebates and
chargebacks under governmental programs (including Medicaid), product returns,
distribution-related fees, and other sales-related deductions. The following
table summarizes the provisions, and credits/payments, for government rebates
and chargebacks, distribution-related fees, and other sales-related deductions;
such amounts were not material as of and for the six months ended June 30,
2011.</FONT></P>
<TABLE style="LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD noWrap align=left width="76%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="5%" colSpan=3></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="5%" colSpan=3><B><FONT face="Times New Roman" size=2>Distribution-</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="5%" colSpan=3><B><FONT face="Times New Roman" size=2>Other Sales-</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="3%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="76%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="5%" colSpan=3><B><FONT face="Times New Roman" size=2>Rebates &amp;</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="5%" colSpan=3><B><FONT face="Times New Roman" size=2>Related</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="5%" colSpan=3><B><FONT face="Times New Roman" size=2>Related</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="3%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="76%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid; TEXT-ALIGN: center" noWrap width="5%" colSpan=3><B><FONT face="Times New Roman" size=2>Chargebacks</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid; TEXT-ALIGN: center" noWrap width="5%" colSpan=3><B><FONT face="Times New Roman" size=2>Fees</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid; TEXT-ALIGN: center" noWrap width="5%" colSpan=3><B><FONT face="Times New Roman" size=2>Deductions</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid; TEXT-ALIGN: center" noWrap width="5%" colSpan=3><B><FONT face="Times New Roman" size=2>Total</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="76%" bgColor=#cceeff><FONT face="Times New Roman" size=2>Balance as of December 31, 2011</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="3%" bgColor=#cceeff><FONT face="Times New Roman" size=2>585</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="3%" bgColor=#cceeff><FONT face="Times New Roman" size=2>1,451</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="3%" bgColor=#cceeff><FONT face="Times New Roman" size=2>182</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="3%" bgColor=#cceeff><FONT face="Times New Roman" size=2>2,218</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="76%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Provision related to
      current period sales</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=2>6,152</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=2>17,917</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%">&nbsp;</TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=2>2,407</FONT></TD>
    <TD noWrap align=left width="1%">&nbsp;</TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%">&nbsp;</TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=2>26,476</FONT></TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="76%" bgColor=#cceeff><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Credits/payments</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%" bgColor=#cceeff><FONT face="Times New Roman" size=2>(1,957</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>)</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%" bgColor=#cceeff><FONT face="Times New Roman" size=2>(8,314</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>)</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%" bgColor=#cceeff><FONT face="Times New Roman" size=2>(1,093</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>)</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%" bgColor=#cceeff><FONT face="Times New Roman" size=2>(11,364</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>)</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="76%"><FONT face="Times New Roman" size=2>Balance as of June 30, 2012</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%"><FONT face="Times New Roman" size=2>$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="3%"><FONT face="Times New Roman" size=2>4,780</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%"><FONT face="Times New Roman" size=2>$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="3%"><FONT face="Times New Roman" size=2>11,054</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%"><FONT face="Times New Roman" size=2>$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="3%"><FONT face="Times New Roman" size=2>1,496</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%"><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="3%"><FONT face="Times New Roman" size=2>17,330</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%"></TD></TR></TABLE>
<BR>
<P align=center><FONT face="Times New Roman" size=2>7</FONT></P>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<P align=justify><B><FONT face="Times New Roman" size=2>REGENERON PHARMACEUTICALS,
INC.<BR>Notes to Condensed Financial Statements
(Unaudited)<BR></FONT></B><B><I><FONT face="Times New Roman" size=2>(Unless otherwise noted,
dollars in thousands, except per share data) </FONT></I></B></P>
<P align=justify><B><FONT face="Times New Roman" size=2>3.</FONT></B><B><FONT face="Times New Roman" size=2> </FONT></B><B><FONT face="Times New Roman" size=2>Per Share Data </FONT></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face="Times New Roman" size=2>The
Company&#146;s basic net income (loss) per share amounts have been computed by
dividing net income (loss) by the weighted average number of shares of Common
Stock and Class A Stock outstanding. Net income (loss) per share is presented on
a combined basis, inclusive of Common Stock and Class A Stock outstanding, as
each class of stock has equivalent economic rights. Diluted net income per share
is based on the weighted average number of shares of Common Stock and Class A
Stock outstanding plus additional weighted average common stock equivalent
shares outstanding during the period when the effect is dilutive. For the three
and six months ended June 30, 2011, the Company reported a net loss; therefore,
no common stock equivalents were included in the computation of diluted net loss
per share for this period, since such inclusion would have been antidilutive.
The calculations of basic and diluted net income (loss) per share are as
follows: </FONT></P>
<DIV align=center>
<TABLE style="LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="80%" border=0>

  <TR vAlign=bottom>
    <TD noWrap align=left width="88%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid; text-align: center" noWrap width="10%" colSpan=6><B><FONT face="Times New Roman" size=2>Three Months Ended June
      30,</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="88%"></TD>
    <TD noWrap style="text-align: center" width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid; text-align: center" noWrap width="4%" colSpan=2><B><FONT face="Times New Roman" size=2>2012</FONT></B></TD>
    <TD noWrap style="text-align: center" width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid; text-align: center" noWrap width="5%" colSpan=3><B><FONT face="Times New Roman" size=2>2011</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="88%" bgColor=#cceeff><I><FONT face="Times New Roman" size=2>Numerator</FONT></I></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="3%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="3%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="88%"><FONT face="Times New Roman" size=2>Net income (loss) - basic and
    diluted</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"><FONT face="Times New Roman" size=2>$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=2>76,743</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"><FONT face="Times New Roman" size=2>$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=2>(62,505</FONT></TD>
    <TD noWrap align=left width="1%"><FONT face="Times New Roman" size=2>)</FONT></TD></TR>
  <TR>
    <TD width="99%" colSpan=8>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="88%" bgColor=#cceeff><I><FONT face="Times New Roman" size=2>Denominator (in thousands)</FONT></I></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="3%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="3%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="88%"><FONT face="Times New Roman" size=2>Weighted average shares - basic</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=2>94,589</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=2>90,436</FONT></TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="88%" bgColor=#cceeff><FONT face="Times New Roman" size=2>Effect of dilutive
      securities:</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="3%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="3%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="88%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Stock
      options</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=2>14,055</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="3%"></TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="88%" bgColor=#cceeff><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Restricted
      stock</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="3%" bgColor=#cceeff><FONT face="Times New Roman" size=2>692</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="3%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="88%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Warrants</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%"><FONT face="Times New Roman" size=2>831</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="3%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="88%" bgColor=#cceeff><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Dilutive
      potential shares</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%" bgColor=#cceeff><FONT face="Times New Roman" size=2>15,578</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="3%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="88%"><FONT face="Times New Roman" size=2>Weighted average shares - diluted</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="3%"><FONT face="Times New Roman" size=2>110,167</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="3%"><FONT face="Times New Roman" size=2>90,436</FONT></TD>
    <TD NOWRAP STYLE="text-align: left; width: 1%; border-bottom: Black 2pt double"></TD></TR>
  <TR>
    <TD width="99%" colSpan=8>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="88%" bgColor=#cceeff><FONT face="Times New Roman" size=2>Net income (loss) per
      share - basic</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="3%" bgColor=#cceeff><FONT face="Times New Roman" size=2>0.81</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="3%" bgColor=#cceeff><FONT face="Times New Roman" size=2>(0.69</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>)</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="88%"><FONT face="Times New Roman" size=2>Net income (loss) per share -
    diluted</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=2>0.70</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=2>(0.69</FONT></TD>
    <TD noWrap align=left width="1%"><FONT face="Times New Roman" size=2>)</FONT></TD></TR>
  <TR>
    <TD width="99%" colSpan=8>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="88%">&nbsp;</TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid; text-align: center" noWrap width="10%" colSpan=6><B><FONT face="Times New Roman" size=2>Six Months Ended June
      30,</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="88%">&nbsp;</TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid; text-align: center" noWrap width="4%" colSpan=2><B><FONT face="Times New Roman" size=2>2012</FONT></B></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid; text-align: center" noWrap width="5%" colSpan=3><B><FONT face="Times New Roman" size=2>2011</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="88%" bgColor=#cceeff><I><FONT face="Times New Roman" size=2>Numerator</FONT></I></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="3%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="3%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="88%"><FONT face="Times New Roman" size=2>Net income (loss) - basic and
    diluted</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=2>88,394</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=2>(105,952</FONT></TD>
    <TD noWrap align=left width="1%"><FONT face="Times New Roman" size=2>)</FONT></TD></TR>
  <TR>
    <TD width="99%" colSpan=8>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="88%" bgColor=#cceeff><I><FONT face="Times New Roman" size=2>Denominator (in thousands)</FONT></I></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="3%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="3%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="88%"><FONT face="Times New Roman" size=2>Weighted average shares - basic</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=2>94,017</FONT></TD>
    <TD noWrap align=left width="1%">&nbsp;</TD>
    <TD noWrap align=left width="1%">&nbsp;</TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=2>89,799</FONT></TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="88%" bgColor=#cceeff><FONT face="Times New Roman" size=2>Effect of dilutive
      securities:</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD noWrap align=left width="3%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="3%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="88%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Stock
      options</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=2>13,964</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="3%"></TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="88%" bgColor=#cceeff><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Restricted
      stock</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="3%" bgColor=#cceeff><FONT face="Times New Roman" size=2>676</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="3%" bgColor=#cceeff>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="88%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Warrants</FONT></TD>
    <TD noWrap align=left width="1%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%"><FONT face="Times New Roman" size=2>341</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="3%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="88%" bgColor=#cceeff><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Dilutive
      potential shares</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%" bgColor=#cceeff><FONT face="Times New Roman" size=2>14,981</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="3%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="88%"><FONT face="Times New Roman" size=2>Weighted average shares - diluted</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="3%"><FONT face="Times New Roman" size=2>108,998</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="3%"><FONT face="Times New Roman" size=2>89,799</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%">&nbsp;</TD></TR>
  <TR>
    <TD width="99%" colSpan=8>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="88%" bgColor=#cceeff><FONT face="Times New Roman" size=2>Net income (loss) per
      share - basic</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="3%" bgColor=#cceeff><FONT face="Times New Roman" size=2>0.94</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="3%" bgColor=#cceeff><FONT face="Times New Roman" size=2>(1.18</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>)</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="88%"><FONT face="Times New Roman" size=2>Net income (loss) per share -
    diluted</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=2>0.81</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=2>(1.18</FONT></TD>
    <TD noWrap align=left width="1%"><FONT face="Times New Roman" size=2>)</FONT></TD></TR></TABLE></DIV><BR>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Shares issuable upon the exercise of
stock options and warrants, vesting of restricted stock awards, and conversion
of convertible senior notes, which have been excluded from the June 30, 2012 and
2011 diluted per share amounts because their effect would have been
antidilutive, include the following: </FONT></P>
<P align=center><FONT face="Times New Roman" size=2></FONT><FONT face="Times New Roman" size=2>8</FONT></P>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<P align=justify><B><FONT face="Times New Roman" size=2>REGENERON PHARMACEUTICALS, INC.<BR>
Notes to Condensed Financial Statements (Unaudited)<BR>
<I>(Unless otherwise noted, dollars
in thousands, except per share data)</I></FONT></B></P>
<DIV align=center>
<TABLE style="LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="80%" border=0>

  <TR vAlign=bottom>
    <TD noWrap align=left width="90%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid; text-align: center" noWrap width="9%" colSpan=5><B><FONT face="Times New Roman" size=2>Three Months Ended June
      30,</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="90%"></TD>
    <TD noWrap style="text-align: center" width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid; text-align: center" noWrap width="4%" colSpan=2><B><FONT face="Times New Roman" size=2>2012</FONT></B></TD>
    <TD noWrap style="text-align: center" width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid; text-align: center" noWrap width="4%" colSpan=2><B><FONT face="Times New Roman" size=2>2011</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="90%" bgColor=#cceeff><FONT face="Times New Roman" size=2>Stock options:</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="3%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="3%" bgColor=#cceeff></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="90%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Weighted
      average number, in thousands</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=2>89</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=2>20,967</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="90%" bgColor=#cceeff><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Weighted
      average exercise price</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="3%" bgColor=#cceeff><FONT face="Times New Roman" size=2>124.64</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="3%" bgColor=#cceeff><FONT face="Times New Roman" size=2>20.71</FONT></TD></TR>
  <TR>
    <TD width="100%" colSpan=7>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="90%" bgColor=#cceeff><FONT face="Times New Roman" size=2>Restricted
stock:</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="3%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="3%" bgColor=#cceeff></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="90%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Weighted
      average number, in thousands</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="3%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=2>846</FONT></TD></TR>
  <TR>
    <TD width="100%" colSpan=7>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="90%" bgColor=#cceeff><FONT face="Times New Roman" size=2>Convertible senior
      notes:</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="3%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="3%" bgColor=#cceeff></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="90%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Weighted
      average number, in thousands</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=2>4,761</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="3%"></TD></TR>
  <TR>
    <TD width="100%" colSpan=7>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="90%" bgColor=#cceeff><FONT face="Times New Roman" size=2>Warrants:</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="3%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="3%" bgColor=#cceeff></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="90%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Weighted
      average number, in thousands</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=2>3,930</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="3%"></TD></TR>
  <TR>
    <TD width="100%" colSpan=7>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="90%">&nbsp;</TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid; text-align: center" noWrap width="9%" colSpan=5><B><FONT face="Times New Roman" size=2>Six Months Ended June
      30,</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="90%">&nbsp;</TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid; text-align: center" noWrap width="4%" colSpan=2><B><FONT face="Times New Roman" size=2>2012</FONT></B></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid; text-align: center" noWrap width="4%" colSpan=2><B><FONT face="Times New Roman" size=2>2011</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="90%" bgColor=#cceeff><FONT face="Times New Roman" size=2>Stock options:</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="3%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="3%" bgColor=#cceeff></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="90%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Weighted
      average number, in thousands</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=2>47</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=2>21,668</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="90%" bgColor=#cceeff><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Weighted
      average exercise price</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="3%" bgColor=#cceeff><FONT face="Times New Roman" size=2>123.29</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="3%" bgColor=#cceeff><FONT face="Times New Roman" size=2>20.48</FONT></TD></TR>
  <TR>
    <TD width="100%" colSpan=7>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="90%" bgColor=#cceeff><FONT face="Times New Roman" size=2>Restricted
stock:</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="3%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD noWrap align=left width="3%" bgColor=#cceeff></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="90%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Weighted
      average number, in thousands</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=2>11</FONT></TD>
    <TD noWrap align=left width="1%">&nbsp;</TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=2>846</FONT></TD></TR>
  <TR>
    <TD width="100%" colSpan=7>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="90%" bgColor=#cceeff><FONT face="Times New Roman" size=2>Convertible senior
      notes:</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="3%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="3%" bgColor=#cceeff></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="90%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Weighted
      average number, in thousands</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=2>4,761</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="3%"></TD></TR>
  <TR>
    <TD width="100%" colSpan=7>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="90%" bgColor=#cceeff><FONT face="Times New Roman" size=2>Warrants:</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="3%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="3%" bgColor=#cceeff></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="90%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Weighted
      average number, in thousands</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=2>4,420</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="3%"></TD></TR></TABLE></DIV><BR>
<P align=justify><B><FONT face="Times New Roman" size=2>4.</FONT></B><B><FONT face="Times New Roman" size=2> </FONT></B><B><FONT face="Times New Roman" size=2>Statement of Cash Flows
</FONT></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face="Times New Roman" size=2>Supplemental disclosure of noncash investing and financing activities:
</FONT></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Included in accounts payable and
accrued expenses at June 30, 2012 and December 31, 2011 were $5.9 million and
$6.2 million, respectively, of accrued capital expenditures. Included in
accounts payable and accrued expenses at June 30, 2011 and December 31, 2010
were $3.4 million and $10.7 million, respectively, of accrued capital
expenditures. In addition, during the six months ended June 30, 2012, the
Company incurred non-cash charges of $1.5 million in connection with disposals
and retirements of fixed assets.</FONT></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Included in marketable securities at
June 30, 2012 and December 31, 2011 were $0.9 million and $0.7 million,
respectively, of accrued interest income. Included in marketable securities at
June 30, 2011 and December 31, 2010 were $0.8 million and $1.4 million,
respectively, of accrued interest income.</FONT></P>
<P align=justify><B><FONT face="Times New Roman" size=2>5.</FONT></B><B><FONT face="Times New Roman" size=2> </FONT></B><B><FONT face="Times New Roman" size=2>Marketable Securities
</FONT></B></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Marketable securities at June 30,
2012 and December 31, 2011 consisted of debt securities, as detailed below, and
equity securities. The aggregate fair value of the equity securities was $2.4
million and $3.0 million at June 30, 2012 and December 31, 2011, respectively,
and the aggregate cost basis was $4.0 million at both June 30, 2012 and December
31, 2011. The Company also held restricted marketable securities at both June
30, 2012 and December 31, 2011, which consisted of debt securities, as detailed
below, that collateralize letters of credit and lease obligations.</FONT></P>
<P align=center><FONT face="Times New Roman" size=2></FONT><FONT face="Times New Roman" size=2>9</FONT></P>
<HR align=center width="100%" noShade SIZE=2>


<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>

<P align=justify><B><FONT face="Times New Roman" size=2>REGENERON PHARMACEUTICALS,
INC.<BR>Notes to Condensed Financial Statements
(Unaudited)<BR></FONT></B><B><I><FONT face="Times New Roman" size=2>(Unless otherwise noted,
dollars in thousands, except per share data)</FONT></I></B></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>The following tables summarize the
amortized cost basis of debt securities included in marketable securities, the
aggregate fair value of those securities, and gross unrealized gains and losses
on those securities at June 30, 2012 and December 31, 2011. The Company
classifies its debt securities, other than mortgage-backed securities, based on
their contractual maturity dates. Maturities of mortgage-backed securities have
been estimated based primarily on repayment characteristics and experience of
the senior tranches that the Company holds. The debt securities listed at June
30, 2012, excluding mortgage-backed securities, mature at various dates through
June 2015. The mortgage-backed securities listed at June 30, 2012 mature at
various dates through December 2019. </FONT></P>
<DIV align=center>
<TABLE style="LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD noWrap align=left width="73%" colSpan=2></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="4%" colSpan=2><STRONG><FONT size=2 face="Times New Roman">Amortized</FONT></STRONG></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="4%" colSpan=2><B><FONT face="Times New Roman" size=2>Fair</FONT></B></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid; text-align: center" noWrap width="16%" colSpan=10><B><FONT face="Times New Roman" size=2>Unrealized</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="4%"><B><FONT face="Times New Roman" size=2>At June 30, 2012</FONT></B></TD>
    <TD noWrap align=left width="69%">&nbsp;</TD>
    <TD noWrap style="text-align: center" width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid; text-align: center" noWrap width="4%" colSpan=2><B><FONT face="Times New Roman" size=2>Cost Basis</FONT></B></TD>
    <TD noWrap style="text-align: center" width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid; text-align: center" noWrap width="4%" colSpan=2><B><FONT face="Times New Roman" size=2>Value</FONT></B></TD>
    <TD noWrap style="text-align: center" width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid; text-align: center" noWrap width="3%" colSpan=2><B><FONT face="Times New Roman" size=2>Gains</FONT></B></TD>
    <TD noWrap style="text-align: center" width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid; text-align: center" noWrap width="7%" colSpan=3><B><FONT face="Times New Roman" size=2>(Losses)</FONT></B></TD>
    <TD noWrap style="text-align: center" width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid; text-align: center" noWrap width="4%" colSpan=3><B><FONT face="Times New Roman" size=2>Net</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="73%" bgColor=#cceeff colSpan=2><I><FONT face="Times New Roman" size=2>Unrestricted</FONT></I></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD noWrap align=left width="3%" bgColor=#cceeff>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD noWrap align=left width="3%" bgColor=#cceeff>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD noWrap align=left width="2%" bgColor=#cceeff>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD noWrap align=left width="5%" bgColor=#cceeff>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD noWrap align=left width="2%" bgColor=#cceeff>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="73%" colSpan=2><FONT face="Times New Roman" size=2>Maturities within one
      year:</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="3%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="3%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="2%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="5%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="2%"></TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="73%" bgColor=#cceeff colSpan=2><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;U.S. government obligations</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="3%" bgColor=#cceeff><FONT face="Times New Roman" size=2>65,959</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="3%" bgColor=#cceeff><FONT face="Times New Roman" size=2>66,025</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=2>78</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="5%" bgColor=#cceeff><FONT face="Times New Roman" size=2>(12</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>)</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=2>66</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="73%" colSpan=2><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;U.S. government
      guaranteed
      corporate<BR>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;bonds</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=2>50,635</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=2>50,654</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="2%"><FONT face="Times New Roman" size=2>23</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="5%"><FONT face="Times New Roman" size=2>(4</FONT></TD>
    <TD noWrap align=left width="1%"><FONT face="Times New Roman" size=2>)</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="2%"><FONT face="Times New Roman" size=2>19</FONT></TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="73%" bgColor=#cceeff colSpan=2><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Municipal bonds</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%" bgColor=#cceeff><FONT face="Times New Roman" size=2>12,385</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%" bgColor=#cceeff><FONT face="Times New Roman" size=2>12,386</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=2>1</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="5%" bgColor=#cceeff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=2>1</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="73%" colSpan=2></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%"><FONT face="Times New Roman" size=2>128,979</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%"><FONT face="Times New Roman" size=2>129,065</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="2%"><FONT face="Times New Roman" size=2>102</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="5%"><FONT face="Times New Roman" size=2>(16</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"><FONT face="Times New Roman" size=2>)</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="2%"><FONT face="Times New Roman" size=2>86</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD></TR>
  <TR>
    <TD align=left width="100%" colSpan=19>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="73%" bgColor=#cceeff colSpan=2><FONT face="Times New Roman" size=2>Maturities after one year through five years:</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD noWrap align=left width="3%" bgColor=#cceeff>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD noWrap align=left width="3%" bgColor=#cceeff>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD noWrap align=left width="2%" bgColor=#cceeff>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD noWrap align=left width="5%" bgColor=#cceeff>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD noWrap align=left width="2%" bgColor=#cceeff>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="73%" colSpan=2><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;U.S. government
      obligations</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=2>285,363</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=2>285,763</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="2%"><FONT face="Times New Roman" size=2>437</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="5%"><FONT face="Times New Roman" size=2>(37</FONT></TD>
    <TD noWrap align=left width="1%"><FONT face="Times New Roman" size=2>)</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="2%"><FONT face="Times New Roman" size=2>400</FONT></TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="73%" bgColor=#cceeff colSpan=2><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Mortgage-backed securities</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%" bgColor=#cceeff><FONT face="Times New Roman" size=2>102</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%" bgColor=#cceeff><FONT face="Times New Roman" size=2>29</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="2%" bgColor=#cceeff>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="5%" bgColor=#cceeff><FONT face="Times New Roman" size=2>(73</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>)</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=2>(73</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>)</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="73%" colSpan=2></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%"><FONT face="Times New Roman" size=2>285,465</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%"><FONT face="Times New Roman" size=2>285,792</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="2%"><FONT face="Times New Roman" size=2>437</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="5%"><FONT face="Times New Roman" size=2>(110</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"><FONT face="Times New Roman" size=2>)</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="2%"><FONT face="Times New Roman" size=2>327</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD></TR>
  <TR>
    <TD align=left width="100%" colSpan=19>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="73%" bgColor=#cceeff colSpan=2><FONT face="Times New Roman" size=2>Maturities after five years through ten years:</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD noWrap align=left width="3%" bgColor=#cceeff>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD noWrap align=left width="3%" bgColor=#cceeff>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD noWrap align=left width="2%" bgColor=#cceeff>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD noWrap align=left width="5%" bgColor=#cceeff>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD noWrap align=left width="2%" bgColor=#cceeff>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="73%" colSpan=2><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Mortgage-backed
      securities</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%"><FONT face="Times New Roman" size=2>161</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%"><FONT face="Times New Roman" size=2>88</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="2%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="5%"><FONT face="Times New Roman" size=2>(73</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"><FONT face="Times New Roman" size=2>)</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="2%"><FONT face="Times New Roman" size=2>(73</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"><FONT face="Times New Roman" size=2>)</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="73%" bgColor=#cceeff colSpan=2>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%" bgColor=#cceeff><FONT face="Times New Roman" size=2>414,605</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%" bgColor=#cceeff><FONT face="Times New Roman" size=2>414,945</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=2>539</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="5%" bgColor=#cceeff><FONT face="Times New Roman" size=2>(199</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>)</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=2>340</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff>&nbsp;</TD></TR>
  <TR>
    <TD align=left width="100%" colSpan=19>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="73%" bgColor=#cceeff colSpan=2><I><FONT face="Times New Roman" size=2>Restricted</FONT></I></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD noWrap align=left width="3%" bgColor=#cceeff>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD noWrap align=left width="3%" bgColor=#cceeff>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD noWrap align=left width="2%" bgColor=#cceeff>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD noWrap align=left width="5%" bgColor=#cceeff>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD noWrap align=left width="2%" bgColor=#cceeff>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="73%" colSpan=2><FONT face="Times New Roman" size=2>Maturities within one
      year:</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="3%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="3%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="2%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="5%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="2%"></TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="73%" bgColor=#cceeff colSpan=2><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;U.S. government obligations</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD noWrap align=right width="3%" bgColor=#cceeff><FONT face="Times New Roman" size=2>3,847</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD noWrap align=right width="3%" bgColor=#cceeff><FONT face="Times New Roman" size=2>3,853</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=2>6</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD noWrap align=left width="5%" bgColor=#cceeff>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=2>6</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff>&nbsp;</TD></TR>
  <TR>
    <TD align=left width="102%" colSpan=19>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="75%" bgColor=#cceeff colSpan=2><FONT face="Times New Roman" size=2>Maturities after one year through five years:</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD noWrap align=left width="3%" bgColor=#cceeff>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD noWrap align=left width="3%" bgColor=#cceeff>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD noWrap align=left width="2%" bgColor=#cceeff>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD noWrap align=left width="5%" bgColor=#cceeff>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD noWrap align=left width="2%" bgColor=#cceeff>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="75%" colSpan=2><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;U.S. government
      obligations</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%"><FONT face="Times New Roman" size=2>4,187</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%"><FONT face="Times New Roman" size=2>4,191</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="2%"><FONT face="Times New Roman" size=2>7</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="5%"><FONT face="Times New Roman" size=2>(3</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"><FONT face="Times New Roman" size=2>)</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="2%"><FONT face="Times New Roman" size=2>4</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="75%" bgColor=#cceeff colSpan=2>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%" bgColor=#cceeff><FONT face="Times New Roman" size=2>8,034</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%" bgColor=#cceeff><FONT face="Times New Roman" size=2>8,044</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=2>13</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="5%" bgColor=#cceeff><FONT face="Times New Roman" size=2>(3</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>)</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=2>10</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff>&nbsp;</TD></TR>
  <TR>
    <TD align=left width="102%" colSpan=19>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="75%" bgColor=#cceeff colSpan=2>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="3%" bgColor=#cceeff><FONT face="Times New Roman" size=2>422,639</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="3%" bgColor=#cceeff><FONT face="Times New Roman" size=2>422,989</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=2>552</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="5%" bgColor=#cceeff><FONT face="Times New Roman" size=2>(202</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>)</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=2>350</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%" bgColor=#cceeff>&nbsp;</TD></TR></TABLE></DIV><BR>
<P align=center><FONT face="Times New Roman" size=2>10</FONT></P>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<P align=justify><B><FONT face="Times New Roman" size=2>REGENERON PHARMACEUTICALS,
INC.<BR>Notes to Condensed Financial Statements
(Unaudited)</FONT></B><BR><B><I><FONT face="Times New Roman" size=2>(Unless otherwise noted,
dollars in thousands, except per share data) </FONT></I></B></P>
<TABLE style="LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD noWrap align=left width="73%" colSpan=2></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="4%" colSpan=2><B><FONT face="Times New Roman" size=2>Amortized</FONT></B></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="4%" colSpan=2><B><FONT face="Times New Roman" size=2>Fair</FONT></B></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid; text-align: center" noWrap width="16%" colSpan=10><B><FONT face="Times New Roman" size=2>Unrealized</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="10%"><B><FONT face="Times New Roman" size=2>At December 31, 2011</FONT></B></TD>
    <TD noWrap align=left width="63%"></TD>
    <TD noWrap style="text-align: center" width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid; text-align: center" noWrap width="4%" colSpan=2><B><FONT face="Times New Roman" size=2>Cost Basis</FONT></B></TD>
    <TD noWrap style="text-align: center" width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid; text-align: center" noWrap width="4%" colSpan=2><B><FONT face="Times New Roman" size=2>Value</FONT></B></TD>
    <TD noWrap style="text-align: center" width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid; text-align: center" noWrap width="3%" colSpan=2><B><FONT face="Times New Roman" size=2>Gains</FONT></B></TD>
    <TD noWrap style="text-align: center" width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid; text-align: center" noWrap width="7%" colSpan=3><B><FONT face="Times New Roman" size=2>(Losses)</FONT></B></TD>
    <TD noWrap style="text-align: center" width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid; text-align: center" noWrap width="4%" colSpan=3><B><FONT face="Times New Roman" size=2>Net</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="73%" bgColor=#cceeff colSpan=2><I><FONT face="Times New Roman" size=2>Unrestricted</FONT></I></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="3%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="3%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="2%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="5%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="2%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="73%" colSpan=2><FONT face="Times New Roman" size=2>Maturities within one
      year:</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="3%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="3%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="2%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="5%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="2%"></TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="73%" bgColor=#cceeff colSpan=2><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;U.S. government
      obligations</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="3%" bgColor=#cceeff><FONT face="Times New Roman" size=2>12,025</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="3%" bgColor=#cceeff><FONT face="Times New Roman" size=2>12,067</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=2>42</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="5%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=2>42</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="73%" colSpan=2><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;U.S. government
      guaranteed
      corporate<BR>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;bonds</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=2>15,263</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=2>15,316</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="2%"><FONT face="Times New Roman" size=2>53</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="5%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="2%"><FONT face="Times New Roman" size=2>53</FONT></TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="73%" bgColor=#cceeff colSpan=2><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;U.S. government
      guaranteed
      collateralized<BR>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;mortgage
      obligations</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="3%" bgColor=#cceeff><FONT face="Times New Roman" size=2>623</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="3%" bgColor=#cceeff><FONT face="Times New Roman" size=2>622</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="2%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="5%" bgColor=#cceeff><FONT face="Times New Roman" size=2>(1</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>)</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=2>(1</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>)</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="73%" colSpan=2><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Municipal
      bonds</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%"><FONT face="Times New Roman" size=2>15,314</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%"><FONT face="Times New Roman" size=2>15,326</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="2%"><FONT face="Times New Roman" size=2>13</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="5%"><FONT face="Times New Roman" size=2>(1</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"><FONT face="Times New Roman" size=2>)</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="2%"><FONT face="Times New Roman" size=2>12</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="73%" bgColor=#cceeff colSpan=2></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%" bgColor=#cceeff><FONT face="Times New Roman" size=2>43,225</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%" bgColor=#cceeff><FONT face="Times New Roman" size=2>43,331</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=2>108</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="5%" bgColor=#cceeff><FONT face="Times New Roman" size=2>(2</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>)</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=2>106</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff></TD></TR>
  <TR>
    <TD align=left width="100%" colSpan=19>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="73%" bgColor=#cceeff colSpan=2><FONT face="Times New Roman" size=2>Maturities after one year through five years:</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="3%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="3%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="2%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="5%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="2%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="73%" colSpan=2><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;U.S. government
      obligations</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=2>272,433</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=2>272,752</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="2%"><FONT face="Times New Roman" size=2>400</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="5%"><FONT face="Times New Roman" size=2>(81</FONT></TD>
    <TD noWrap align=left width="1%"><FONT face="Times New Roman" size=2>)</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="2%"><FONT face="Times New Roman" size=2>319</FONT></TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="73%" bgColor=#cceeff colSpan=2><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Mortgage-backed
      securities</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%" bgColor=#cceeff><FONT face="Times New Roman" size=2>104</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%" bgColor=#cceeff><FONT face="Times New Roman" size=2>28</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="2%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="5%" bgColor=#cceeff><FONT face="Times New Roman" size=2>(76</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>)</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=2>(76</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>)</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="73%" colSpan=2></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%"><FONT face="Times New Roman" size=2>272,537</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%"><FONT face="Times New Roman" size=2>272,780</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="2%"><FONT face="Times New Roman" size=2>400</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="5%"><FONT face="Times New Roman" size=2>(157</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"><FONT face="Times New Roman" size=2>)</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="2%"><FONT face="Times New Roman" size=2>243</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD></TR>
  <TR>
    <TD align=left width="100%" colSpan=19>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="73%" bgColor=#cceeff colSpan=2><FONT face="Times New Roman" size=2>Maturities after five years through ten years:</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="3%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="3%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="2%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="5%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="2%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="73%" colSpan=2><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Mortgage-backed
      securities</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%"><FONT face="Times New Roman" size=2>164</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%"><FONT face="Times New Roman" size=2>87</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="2%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="5%"><FONT face="Times New Roman" size=2>(77</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"><FONT face="Times New Roman" size=2>)</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="2%"><FONT face="Times New Roman" size=2>(77</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"><FONT face="Times New Roman" size=2>)</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="73%" bgColor=#cceeff colSpan=2></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%" bgColor=#cceeff><FONT face="Times New Roman" size=2>315,926</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%" bgColor=#cceeff><FONT face="Times New Roman" size=2>316,198</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=2>508</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="5%" bgColor=#cceeff><FONT face="Times New Roman" size=2>(236</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>)</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=2>272</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff></TD></TR>
  <TR>
    <TD align=left width="100%" colSpan=19>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="73%" bgColor=#cceeff colSpan=2><I><FONT face="Times New Roman" size=2>Restricted</FONT></I></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="3%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="3%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="2%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="5%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="2%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="73%" colSpan=2><FONT face="Times New Roman" size=2>Maturities within one
      year:</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="3%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="3%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="2%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="5%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="2%"></TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="73%" bgColor=#cceeff colSpan=2><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;U.S. government
      obligations</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="3%" bgColor=#cceeff><FONT face="Times New Roman" size=2>3,347</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="3%" bgColor=#cceeff><FONT face="Times New Roman" size=2>3,357</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=2>10</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="5%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=2>10</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD></TR>
  <TR>
    <TD align=left width="100%" colSpan=19>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="73%" bgColor=#cceeff colSpan=2><FONT face="Times New Roman" size=2>Maturities after one year through five years:</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="3%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="3%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="2%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="5%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="2%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="73%" colSpan=2><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;U.S. government
      obligations</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%"><FONT face="Times New Roman" size=2>2,572</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%"><FONT face="Times New Roman" size=2>2,583</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="2%"><FONT face="Times New Roman" size=2>11</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="5%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="2%"><FONT face="Times New Roman" size=2>11</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="73%" bgColor=#cceeff colSpan=2></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%" bgColor=#cceeff><FONT face="Times New Roman" size=2>5,919</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%" bgColor=#cceeff><FONT face="Times New Roman" size=2>5,940</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=2>21</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="5%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=2>21</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff></TD></TR>
  <TR>
    <TD align=left width="100%" colSpan=19>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="73%" bgColor=#cceeff colSpan=2></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="3%" bgColor=#cceeff><FONT face="Times New Roman" size=2>321,845</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="3%" bgColor=#cceeff><FONT face="Times New Roman" size=2>322,138</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=2>529</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="5%" bgColor=#cceeff><FONT face="Times New Roman" size=2>(236</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>)</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=2>293</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%" bgColor=#cceeff></TD></TR></TABLE><BR>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>At June 30, 2012 and December 31,
2011, marketable securities included an additional unrealized loss of $1.6
million and $1.0 million, respectively, related to one equity security in the
Company&#146;s marketable securities portfolio.</FONT></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>The following table shows the fair
value of the Company&#146;s marketable securities that have unrealized losses and
that are deemed to be only temporarily impaired, aggregated by investment
category and length of time that the individual securities have been in a
continuous unrealized loss position, at June 30, 2012 and December 31,
2011.</FONT></P>
<P align=center><FONT face="Times New Roman" size=2>11</FONT></P>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<P align=justify><B><FONT face="Times New Roman" size=2>REGENERON PHARMACEUTICALS,
INC.<BR>Notes to Condensed Financial Statements
(Unaudited)</FONT></B><BR><B><I><FONT face="Times New Roman" size=2>(Unless otherwise noted,
dollars in thousands, except per share data)</FONT></I></B></P>
<TABLE style="MARGIN-LEFT: 0pt; LINE-HEIGHT: 14pt; MARGIN-RIGHT: 0pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD noWrap align=left width="72%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid; text-align: center" noWrap width="8%" colSpan=6><B><FONT face="Times New Roman" size=2>Less than 12
      Months</FONT></B></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid; text-align: center" noWrap width="8%" colSpan=7><B><FONT face="Times New Roman" size=2>12 Months or Greater</FONT></B></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid; text-align: center" noWrap width="8%" colSpan=6><B><FONT face="Times New Roman" size=2>Total</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="72%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="2%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="4%" colSpan=3><B><FONT face="Times New Roman" size=2>Unrealized</FONT></B></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="3%" colSpan=2></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="4%" colSpan=4><B><FONT face="Times New Roman" size=2>Unrealized</FONT></B></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="2%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="4%" colSpan=3><B><FONT face="Times New Roman" size=2>Unrealized</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="72%"><DIV style="WIDTH: 3%; BORDER-BOTTOM: #000000 1pt solid"><B><FONT face="Times New Roman" size=2>At June 30,
      2012</FONT></B></DIV></TD>
    <TD noWrap style="text-align: center" width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid; text-align: center" noWrap width="3%" colSpan=2><B><FONT face="Times New Roman" size=2>Fair Value</FONT></B></TD>
    <TD noWrap style="text-align: center" width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid; text-align: center" noWrap width="4%" colSpan=3><B><FONT face="Times New Roman" size=2>Loss</FONT></B></TD>
    <TD noWrap style="text-align: center" width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid; text-align: center" noWrap width="3%" colSpan=2><B><FONT face="Times New Roman" size=2>Fair Value</FONT></B></TD>
    <TD noWrap style="text-align: center" width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid; text-align: center" noWrap width="4%" colSpan=4><B><FONT face="Times New Roman" size=2>Loss</FONT></B></TD>
    <TD noWrap style="text-align: center" width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid; text-align: center" noWrap width="3%" colSpan=2><B><FONT face="Times New Roman" size=2>Fair Value</FONT></B></TD>
    <TD noWrap style="text-align: center" width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid; text-align: center" noWrap width="4%" colSpan=3><B><FONT face="Times New Roman" size=2>Loss</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="72%" bgColor=#cceeff><I><FONT face="Times New Roman" size=2>Unrestricted</FONT></I></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="2%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="2%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="2%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="2%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="2%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="72%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;U.S. government obligations</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="2%"><FONT face="Times New Roman" size=2>89,055</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"><FONT face="Times New Roman" size=2>$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD noWrap align=right width="2%"><FONT face="Times New Roman" size=2><FONT STYLE="background-color: TRANSPARENT">(49</FONT></FONT></TD>
    <TD noWrap align=left width="1%"><FONT face="Times New Roman" size=2><FONT STYLE="background-color: TRANSPARENT">)</FONT></FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="2%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="2%"><FONT face="Times New Roman" size=2>89,055</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"><FONT face="Times New Roman" size=2>$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD noWrap align=right width="2%"><FONT STYLE="background-color: TRANSPARENT"><FONT face="Times New Roman" size=2>(49</FONT></FONT></TD>
    <TD noWrap align=left width="1%"><FONT STYLE="background-color: TRANSPARENT"><FONT face="Times New Roman" size=2>)</FONT></FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="72%" bgColor=#cceeff><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;U.S. government
      guaranteed<BR>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;corporate
      bonds</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=2>24,969</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="2%" bgColor=#cceeff><FONT STYLE="background-color: TRANSPARENT"><FONT face="Times New Roman" size=2>(4</FONT></FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff><FONT STYLE="background-color: TRANSPARENT"><FONT face="Times New Roman" size=2>)</FONT></FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="2%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=2>24,969</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="2%" bgColor=#cceeff><FONT STYLE="background-color: TRANSPARENT"><FONT face="Times New Roman" size=2>(4</FONT></FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff><FONT STYLE="background-color: TRANSPARENT"><FONT face="Times New Roman" size=2>)</FONT></FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="72%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Equity
      security</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="2%"><FONT face="Times New Roman" size=2>2,455</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="2%"><FONT face="Times New Roman" size=2>(1,589</FONT></TD>
    <TD noWrap align=left width="1%"><FONT face="Times New Roman" size=2>)</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="2%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="2%"><FONT face="Times New Roman" size=2>2,455</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="2%"><FONT face="Times New Roman" size=2>(1,589</FONT></TD>
    <TD noWrap align=left width="1%"><FONT face="Times New Roman" size=2>)</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="72%" bgColor=#cceeff><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Mortgage-backed
      securities</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="2%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="2%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=2>117</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>(146</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>)</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=2>117</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=2>(146</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>)</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="72%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="2%"><FONT face="Times New Roman" size=2>116,479</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="2%"><FONT face="Times New Roman" size=2>(1,642</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"><FONT face="Times New Roman" size=2>)</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="2%"><FONT face="Times New Roman" size=2>117</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="1%"><FONT face="Times New Roman" size=2>(146</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"><FONT face="Times New Roman" size=2>)</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="2%"><FONT face="Times New Roman" size=2>116,596</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="2%"><FONT face="Times New Roman" size=2>(1,788</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"><FONT face="Times New Roman" size=2>)</FONT></TD></TR>
  <TR>
    <TD align=left width="99%" colSpan=23>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="72%" bgColor=#cceeff><I><FONT face="Times New Roman" size=2>Restricted</FONT></I></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="2%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="2%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="2%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="2%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="2%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="72%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;U.S. government
      obligations</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="2%"><FONT face="Times New Roman" size=2>2,413</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="2%"><FONT face="Times New Roman" size=2>(3</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"><FONT face="Times New Roman" size=2>)</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="2%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="2%"><FONT face="Times New Roman" size=2>2,413</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="2%"><FONT face="Times New Roman" size=2>(3</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"><FONT face="Times New Roman" size=2>)</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="72%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=2>2,413</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=2>(3</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>)</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="2%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=2>2,413</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=2>(3</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>)</FONT></TD></TR>
  <TR>
    <TD align=left width="99%" colSpan=23>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="72%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=2>118,892</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=2>(1,645</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>)</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=2>117</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>(146</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>)</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=2>119,009</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=2>(1,791</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>)</FONT></TD></TR>
  <TR>
    <TD align=left width="99%" colSpan=23>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="72%" bgColor=#cceeff><DIV style="WIDTH: 3%; BORDER-BOTTOM: #000000 1pt solid"><B><FONT face="Times New Roman" size=2>At December 31, 2011</FONT></B></div></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="2%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="2%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="2%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="2%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="2%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="72%"><I><FONT face="Times New Roman" size=2>Unrestricted</FONT></I></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="2%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="2%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="2%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="2%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="2%"></TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="72%" bgColor=#cceeff><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;U.S. government
      obligations</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=2>103,529</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=2>(81</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>)</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="2%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=2>103,529</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=2>(81</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>)</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="72%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;U.S. government
      guaranteed<BR>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;collateralized
      mortgage<BR>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;obligations</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="2%"><FONT face="Times New Roman" size=2>623</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="2%"><FONT face="Times New Roman" size=2>(1</FONT></TD>
    <TD noWrap align=left width="1%"><FONT face="Times New Roman" size=2>)</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="2%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="2%"><FONT face="Times New Roman" size=2>623</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="2%"><FONT face="Times New Roman" size=2>(1</FONT></TD>
    <TD noWrap align=left width="1%"><FONT face="Times New Roman" size=2>)</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="72%" bgColor=#cceeff><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Municipal
      bonds</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=2>4,603</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=2>(1</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>)</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="2%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=2>4,603</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=2>(1</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>)</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="72%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Equity
      security</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="2%"><FONT face="Times New Roman" size=2>3,019</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="2%"><FONT face="Times New Roman" size=2>(1,025</FONT></TD>
    <TD noWrap align=left width="1%"><FONT face="Times New Roman" size=2>)</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="2%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="2%"><FONT face="Times New Roman" size=2>3,019</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="2%"><FONT face="Times New Roman" size=2>(1,025</FONT></TD>
    <TD noWrap align=left width="1%"><FONT face="Times New Roman" size=2>)</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="72%" bgColor=#cceeff><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Mortgage-backed
      securities</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="2%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="2%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=2>116</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>(152</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>)</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=2>116</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=2>(152</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>)</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="72%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%"><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="2%"><FONT face="Times New Roman" size=2>111,774</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%"><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="2%"><FONT face="Times New Roman" size=2>(1,108</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%"><FONT face="Times New Roman" size=2>)</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%"><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="2%"><FONT face="Times New Roman" size=2>116</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%"><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="1%"><FONT face="Times New Roman" size=2>(152</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%"><FONT face="Times New Roman" size=2>)</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%"><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="2%"><FONT face="Times New Roman" size=2>111,890</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%"><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="2%"><FONT face="Times New Roman" size=2>(1,260</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%"><FONT face="Times New Roman" size=2>)</FONT></TD></TR></TABLE><BR>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Realized gains and losses are
included as a component of investment income. For the three and six months ended
June 30, 2012 and 2011, total realized gains and losses on sales of marketable
securities were not material.</FONT></P>
<P align=center><FONT face="Times New Roman" size=2>12</FONT></P>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<P align=justify><B><FONT face="Times New Roman" size=2>REGENERON PHARMACEUTICALS,
INC.<BR>Notes to Condensed Financial Statements
(Unaudited)</FONT></B><BR><B><I><FONT face="Times New Roman" size=2>(Unless otherwise noted,
dollars in thousands, except per share data) </FONT></I></B></P>
<P align=justify><B><FONT face="Times New Roman" size=2>6.</FONT></B><B><FONT face="Times New Roman" size=2> </FONT></B><B><FONT face="Times New Roman" size=2>Fair Value Measurements
</FONT></B></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>The Company&#146;s assets that are
measured at fair value on a recurring basis</FONT><I><FONT face="Times New Roman" size=2>,</FONT></I><FONT face="Times New Roman" size=2> at June 30, 2012 and December 31,
2011, were as follows: </FONT></P>
<TABLE style="LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD noWrap align=left width="80%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="3%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid; text-align: center" noWrap width="14%" colSpan=7><B><FONT face="Times New Roman" size=2>Fair Value Measurements at
      Reporting Date Using</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="80%">
      <DIV style="WIDTH: 3%; BORDER-BOTTOM: #000000 1pt solid"><STRONG><FONT size=2 face="Times New Roman">At June 30, 2012</FONT></STRONG></DIV></TD>
    <TD noWrap style="text-align: center" width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid; text-align: center" noWrap width="4%" colSpan=2><B><FONT face="Times New Roman" size=2>Fair Value</FONT></B></TD>
    <TD noWrap style="text-align: center" width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid; text-align: center" noWrap width="4%" colSpan=2><B><FONT face="Times New Roman" size=2>Quoted Prices in</FONT></B><BR><B><FONT face="Times New Roman" size=2>Active
      Markets</FONT></B><BR><B><FONT face="Times New Roman" size=2>for Identical</FONT></B><BR><B><FONT face="Times New Roman" size=2>Assets</FONT></B><BR><B><FONT face="Times New Roman" size=2>(Level
      1)</FONT></B></TD>
    <TD noWrap style="text-align: center" width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid; text-align: center" noWrap width="4%" colSpan=2><B><FONT face="Times New Roman" size=2>Significant Other</FONT></B><BR><B><FONT face="Times New Roman" size=2>Observable
      Inputs</FONT></B><BR><B><FONT face="Times New Roman" size=2>(Level 2)</FONT></B></TD>
    <TD noWrap style="text-align: center" width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid; text-align: center" noWrap width="4%"><B><FONT face="Times New Roman" size=2>Significant</FONT></B><BR><B><FONT face="Times New Roman" size=2>Unobservable</FONT></B><BR><B><FONT face="Times New Roman" size=2>Inputs</FONT></B><BR><B><FONT face="Times New Roman" size=2>(Level 3)</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="80%" bgColor=#cceeff><I><FONT face="Times New Roman" size=2>Unrestricted</FONT></I></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="3%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="3%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="3%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="4%" bgColor=#cceeff></TD></TR>

  <TR vAlign=bottom>
    <TD noWrap align=left width="80%"><FONT face="Times New Roman" size=2>Available-for-sale marketable <FONT STYLE="BACKGROUND-COLOR: TRANSPARENT">securities:</FONT></FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="3%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="3%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="4%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="80%" bgColor=#cceeff><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;U.S. government
      obligations</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="3%" bgColor=#cceeff><FONT face="Times New Roman" size=2>351,788</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="3%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="3%" bgColor=#cceeff><FONT face="Times New Roman" size=2>351,788</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="4%" bgColor=#cceeff></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="80%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;U.S. government
      guaranteed</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="3%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="3%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="4%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="80%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;corporate
      bonds</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=2>50,654</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=2>50,654</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="4%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="80%" bgColor=#cceeff><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Municipal
      bonds</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="3%" bgColor=#cceeff><FONT face="Times New Roman" size=2>12,386</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="3%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="3%" bgColor=#cceeff><FONT face="Times New Roman" size=2>12,386</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="4%" bgColor=#cceeff></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="80%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Mortgage-backed
      securities</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=2>117</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=2>117</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="4%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="80%" bgColor=#cceeff><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Equity
      security</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%" bgColor=#cceeff><FONT face="Times New Roman" size=2>2,455</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%" bgColor=#cceeff><FONT face="Times New Roman" size=2>2,455</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="3%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="4%" bgColor=#cceeff></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="80%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="3%"><FONT face="Times New Roman" size=2>417,400</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="3%"><FONT face="Times New Roman" size=2>2,455</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="3%"><FONT face="Times New Roman" size=2>414,945</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="4%"></TD></TR>
  <TR>
    <TD width="100%" colSpan=12>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="80%" bgColor=#cceeff><I><FONT face="Times New Roman" size=2>Restricted</FONT></I></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="3%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="3%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="3%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="4%" bgColor=#cceeff></TD></TR>

  <TR vAlign=bottom>
    <TD noWrap align=left width="80%"><FONT face="Times New Roman" size=2>Available-for-sale marketable <FONT STYLE="BACKGROUND-COLOR: TRANSPARENT">securities:</FONT></FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="3%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="3%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="4%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="80%" bgColor=#cceeff><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;U.S. government
      obligations</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%" bgColor=#cceeff><FONT face="Times New Roman" size=2>8,044</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%" bgColor=#cceeff><FONT face="Times New Roman" size=2>8,044</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="4%" bgColor=#cceeff></TD></TR>
  <TR>
    <TD width="100%" colSpan=12>&nbsp; </TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="80%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD NOWRAP STYLE="border-bottom: Black 2pt double; text-align: left; width: 1%; background-color: #cceeff"><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD NOWRAP STYLE="border-bottom: Black 2pt double; text-align: right; width: 3%; background-color: #cceeff"><FONT face="Times New Roman" size=2>425,444</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD NOWRAP STYLE="border-bottom: Black 2pt double; text-align: left; width: 1%; background-color: #cceeff"><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD NOWRAP STYLE="border-bottom: Black 2pt double; text-align: right; width: 3%; background-color: #cceeff"><FONT face="Times New Roman" size=2>2,455</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD NOWRAP STYLE="border-bottom: Black 2pt double; text-align: left; width: 1%; background-color: #cceeff"><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD NOWRAP STYLE="border-bottom: Black 2pt double; text-align: right; width: 3%; background-color: #cceeff"><FONT face="Times New Roman" size=2>422,989</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="4%" bgColor=#cceeff></TD></TR>
  <TR>
    <TD width="100%" colSpan=12>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="80%" bgColor=#cceeff>
      <DIV style="WIDTH: 3%; BORDER-BOTTOM: #000000 1pt solid"><B><FONT face="Times New Roman" size=2>At December 31, 2011</FONT></B></DIV></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="3%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="3%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="3%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="4%" bgColor=#cceeff></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="80%"><I><FONT face="Times New Roman" size=2>Unrestricted</FONT></I></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="3%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="3%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="4%"></TD></TR>

  <TR vAlign=bottom>
    <TD noWrap align=left width="80%" bgColor=#cceeff><FONT face="Times New Roman" size=2>Available-for-sale
      marketable <FONT STYLE="BACKGROUND-COLOR: TRANSPARENT">securities:</FONT></FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="3%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="3%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="3%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="4%" bgColor=#cceeff></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="80%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;U.S. government
      obligations</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=2>284,819</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=2>284,819</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="4%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="80%" bgColor=#cceeff><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;U.S. government
      guaranteed</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="3%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="3%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="3%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="4%" bgColor=#cceeff></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="80%" bgColor=#cceeff><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;corporate
      bonds</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="3%" bgColor=#cceeff><FONT face="Times New Roman" size=2>15,316</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="3%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="3%" bgColor=#cceeff><FONT face="Times New Roman" size=2>15,316</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="4%" bgColor=#cceeff></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="80%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;U.S. government
      guaranteed</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="3%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="3%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="4%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="80%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;collateralized
      mortgage</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="3%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="3%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="4%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="80%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;obligations</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=2>622</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=2>622</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="4%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="80%" bgColor=#cceeff><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Municipal
      bonds</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="3%" bgColor=#cceeff><FONT face="Times New Roman" size=2>15,326</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="3%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="3%" bgColor=#cceeff><FONT face="Times New Roman" size=2>15,326</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="4%" bgColor=#cceeff></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="80%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Mortgage-backed
      securities</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=2>115</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=2>115</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="4%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="80%" bgColor=#cceeff><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Equity
      security</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%" bgColor=#cceeff><FONT face="Times New Roman" size=2>3,019</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%" bgColor=#cceeff><FONT face="Times New Roman" size=2>3,019</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="3%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="4%" bgColor=#cceeff></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="80%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%"><FONT face="Times New Roman" size=2>319,217</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%"><FONT face="Times New Roman" size=2>3,019</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%"><FONT face="Times New Roman" size=2>316,198</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="4%"></TD></TR>
  <TR>
    <TD width="100%" colSpan=12>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="80%" bgColor=#cceeff><I><FONT face="Times New Roman" size=2>Restricted</FONT></I></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="3%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="3%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="3%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="4%" bgColor=#cceeff></TD></TR>

  <TR vAlign=bottom>
    <TD noWrap align=left width="80%"><FONT face="Times New Roman" size=2>Available-for-sale marketable <FONT STYLE="BACKGROUND-COLOR: TRANSPARENT">securities:</FONT></FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="3%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="3%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="4%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="80%" bgColor=#cceeff><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;U.S. government
      obligations</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%" bgColor=#cceeff><FONT face="Times New Roman" size=2>5,940</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%" bgColor=#cceeff><FONT face="Times New Roman" size=2>5,940</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="4%" bgColor=#cceeff></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="80%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%"><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="3%"><FONT face="Times New Roman" size=2>325,157</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%"><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="3%"><FONT face="Times New Roman" size=2>3,019</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%"><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="3%"><FONT face="Times New Roman" size=2>322,138</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="4%"></TD></TR></TABLE><BR>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Marketable securities included in
Level 2 were valued using a market approach utilizing prices and other relevant
information, such as interest rates, yield curves, prepayment speeds, loss
severities, credit risks and default rates, generated by market transactions
involving identical or comparable assets. The Company considers market liquidity
in determining the fair value for these securities. The Company did not record
any charges for other-than-temporary impairment of its Level 2 marketable
securities during the three and six months ended June 30, 2012 and
2011.</FONT></P>
<P align=center><FONT face="Times New Roman" size=2></FONT><FONT face="Times New Roman" size=2>13</FONT></P>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<P align=justify><B><FONT face="Times New Roman" size=2>REGENERON PHARMACEUTICALS,
INC.<BR>Notes to Condensed Financial Statements
(Unaudited)</FONT></B><BR><B><I><FONT face="Times New Roman" size=2>(Unless otherwise noted,
dollars in thousands, except per share data) </FONT></I></B></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>The Company holds one Level 3
marketable security, which had a fair value of $0 at June 30, 2012 and December
31, 2011. This Level 3 security was valued using information provided by the
Company&#146;s investment advisors and other sources, including quoted bid prices
which took into consideration the security&#146;s lack of liquidity. There were no
purchases, sales, or maturities of Level 3 marketable securities and no
unrealized gains or losses related to Level 3 marketable securities for the
three months and six months ended June 30, 2012 and 2011. There were no
transfers of marketable securities between Levels 1, 2, or 3 classifications
during the three and six months ended June 30, 2012 and 2011.</FONT></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>As of June 30, 2012, the Company had
$400.0 million in aggregate principal amount of 1.875% convertible senior notes
that will mature on October 1, 2016 unless earlier converted or repurchased.
</FONT><FONT face="Times New Roman" size=2>The fair value of the outstanding convertible
senior notes was estimated to be $605.8 million as of June 30, 2012, and was
determined based on quoted market rates. </FONT></P>
<P align=justify><B><FONT face="Times New Roman" size=2>7.</FONT></B><B><FONT face="Times New Roman" size=2> </FONT></B><B><FONT face="Times New Roman" size=2>Inventory</FONT></B></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Inventories as of June 30, 2012 and
December 31, 2011 consist of the following: </FONT></P>
<DIV align=center>
<TABLE style="LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="80%" border=0>

  <TR vAlign=bottom>
    <TD noWrap style="text-align: center" width="94%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="2%" colSpan=2><B><FONT face="Times New Roman" size=2>June
      30,</FONT></B></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="2%" colSpan=2><B><FONT face="Times New Roman" size=2>December
      31,</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap style="text-align: center" width="94%"></TD>
    <TD noWrap style="text-align: center" width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid; text-align: center" noWrap width="2%" colSpan=2><B><FONT face="Times New Roman" size=2>2012</FONT></B></TD>
    <TD noWrap style="text-align: center" width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid; text-align: center" noWrap width="2%" colSpan=2><B><FONT face="Times New Roman" size=2>2011</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="94%" bgColor=#cceeff><FONT face="Times New Roman" size=2>Raw materials</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>6,975</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>4,666</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="94%"><FONT face="Times New Roman" size=2>Work in process</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=2>13,609</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=2>10,806</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="94%" bgColor=#cceeff><FONT face="Times New Roman" size=2>Finished goods</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>3,841</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>1,142</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="94%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%"><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="1%"><FONT face="Times New Roman" size=2>24,425</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%"><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="1%"><FONT face="Times New Roman" size=2>16,614</FONT></TD></TR></TABLE></DIV><BR>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>At June 30, 2012, $10.5 million of
inventories were included in prepaid expenses and other current assets and $13.9
million of inventories were included in other assets. At December 31, 2011, $3.7
million of inventories were included in prepaid expenses and other current
assets and $12.9 million of inventories were included in other
assets.</FONT></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>For the three and six months ended
June 30, 2012, cost of goods sold included inventory write-downs and reserves
totaling $6.5 million and $8.4 million, respectively. For the three and six
months ended June 30, 2011, there were no inventory write-downs or reserves
included in cost of goods sold.</FONT></P>
<P align=justify><B><FONT face="Times New Roman" size=2>8.</FONT></B><B><FONT face="Times New Roman" size=2> </FONT></B><B><FONT face="Times New Roman" size=2>Accounts Payable and Accrued
Expenses </FONT></B></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Accounts payable and accrued
expenses as of June 30, 2012 and December 31, 2011 consist of the following:
</FONT></P>
<DIV align=center>
<TABLE style="LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="80%" border=0>

  <TR vAlign=bottom>
    <TD noWrap align=left width="94%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap style="text-align: center" width="2%" colSpan=2><B><FONT face="Times New Roman" size=2>June
      30,</FONT></B></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="2%" colSpan=2><B><FONT face="Times New Roman" size=2>December
      31,</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="94%"></TD>
    <TD noWrap align=left width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid; text-align: center" noWrap width="2%" colSpan=2><B><FONT face="Times New Roman" size=2>2012</FONT></B></TD>
    <TD noWrap style="text-align: center" width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid; text-align: center" noWrap width="2%" colSpan=2><B><FONT face="Times New Roman" size=2>2011</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="94%" bgColor=#cceeff><FONT face="Times New Roman" size=2>Accounts payable</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>25,672</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>27,736</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="94%"><FONT face="Times New Roman" size=2>Accrued payroll and related costs</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=2>35,458</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=2>42,835</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="94%" bgColor=#cceeff><FONT face="Times New Roman" size=2>Accrued clinical trial
      expense</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>14,029</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>9,850</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="94%"><FONT face="Times New Roman" size=2>Accrued sales-related deductions and
      royalties</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=2>36,386</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=2>3,947</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="94%" bgColor=#cceeff><FONT face="Times New Roman" size=2>Other accrued expenses and
      liabilities</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>15,223</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>11,257</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="94%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%"><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="1%"><FONT face="Times New Roman" size=2>126,768</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%"><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="1%"><FONT face="Times New Roman" size=2>95,625</FONT></TD></TR></TABLE></DIV><BR>
<P align=justify><B><FONT face="Times New Roman" size=2>9.</FONT></B><B><FONT face="Times New Roman" size=2> </FONT></B><B><FONT face="Times New Roman" size=2>Income Taxes</FONT></B></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>For the three and six months ended
June 30, 2012, income tax expense relating to the Company&#146;s pre-tax income was
fully offset by a reversal of a portion of the Company&#146;s valuation allowance.
The Company continues to recognize a full valuation allowance against its net
operating loss carry-forward and other deferred tax assets since the Company has
an extended history of losses.</FONT></P>
<P align=center><FONT face="Times New Roman" size=2></FONT><FONT face="Times New Roman" size=2>14</FONT></P>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<P align=justify><B><FONT face="Times New Roman" size=2>REGENERON PHARMACEUTICALS,
INC.<BR>Notes to Condensed Financial Statements
(Unaudited)</FONT></B><BR><B><I><FONT face="Times New Roman" size=2>(Unless otherwise noted,
dollars in thousands, except per share data) </FONT></I></B></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>For the three and six months ended
June 30, 2011, the Company incurred a net loss for tax purposes and recognized a
full valuation allowance against deferred tax assets. For the three and six
months ended June 30, 2011, the Company recognized an income tax benefit of $0.9
million and $1.1 million, respectively, in connection with the net tax effect of
the change in the Company&#146;s unrealized gain/(loss) on &#147;available-for-sale&#148;
marketable securities, which is included in other comprehensive income
(loss).</FONT></P>
<P align=justify><B><FONT face="Times New Roman" size=2>10.</FONT></B><B><FONT face="Times New Roman" size=2> </FONT></B><B><FONT face="Times New Roman" size=2>Legal Matters </FONT></B><FONT face="Times New Roman" size=2></FONT></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>From time to time, the Company is a
party to legal proceedings in the course of the Company&#146;s business. The Company
does not expect any such current ordinary course legal proceedings to have a
material adverse effect on the Company&#146;s business or financial condition. Costs
associated with the Company&#146;s involvement in legal proceedings are expensed as
incurred.</FONT></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><EM>Genentech Patent Litigation
</EM></FONT></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>The Company is aware of issued
patents and pending patent applications owned by Genentech that claim certain
chimeric VEGF receptors. The Company does not believe that ZALTRAP<SUP>&#174;</SUP>
or EYLEA infringe any valid claim in these patents or patent applications. The
Company is involved in five patent litigations with Genentech, two in the United
States and three in Europe. In November 2010, the Company commenced a lawsuit
against Genentech in the U.S. District Court for the Southern District of New
York (the &#147;Court&#148;), seeking a declaratory judgment that no activities relating
to the Company&#146;s VEGF Trap infringe any valid claim of certain Genentech patents
referred to as the Davis-Smyth patents (the &#147;First Davis-Smyth Case&#148;). Genentech
answered the complaint and asserted counterclaims that the Company&#146;s prior or
planned activities relating to VEGF Trap have infringed or will infringe claims
of four of the five Davis-Smyth patents and requested a judgment against the
Company for damages, including for willful infringement, and other relief as the
Court deems appropriate.</FONT></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>On December 31, 2011, the Company
entered into a Non-Exclusive License and Partial Settlement Agreement with
Genentech (the &#147;Genentech Agreement&#148;) that covers making, using, and selling
EYLEA in the United States for the prevention and treatment of human eye
diseases and disorders in the United States, and ends the litigation relating to
those matters. Under the Genentech Agreement, the Company received a
non-exclusive license to the Davis-Smyth patents, and certain other technology
patents owned or co-owned by Genentech. The Genentech Agreement does not cover
any non-U.S. patent rights or non-U.S. patent disputes, and does not cover any
use of aflibercept other than for prevention and treatment of human eye diseases
and disorders in the United States. The First Davis-Smyth Case is continuing
with respect to matters not covered by the Genentech Agreement. The Genentech
Agreement provides for the Company to make payments to Genentech based on U.S.
sales of EYLEA through May 7, 2016, the date the Davis-Smyth patents expire. The
Company will make a lump-sum payment of $60 million once cumulative U.S. sales
of EYLEA reach $400 million. The Company will also pay royalties of 4.75% on
cumulative U.S. sales of EYLEA between $400 million and $3 billion and 5.5% on
any cumulative U.S. sales of EYLEA over $3 billion. As a result of the Genentech
Agreement, on January 17, 2012 Genentech filed a second amended answer and
counterclaim in the First Davis-Smyth Case, in which it amended its
counterclaims alleging infringement of four of the five Davis-Smyth patents. On
December 23, 2011, Genentech initiated a related case in the Court against
Regeneron and Sanofi alleging infringement of four of the five Davis-Smyth
Patents by activities relating to VEGF Trap (but excluding EYLEA) (the &#147;Second
Davis-Smyth Case&#148;). As in the First Davis-Smyth Case, in the new complaint
Genentech requests a judgment against the Company for damages, including for
willful infringement, and other relief as the Court deems
appropriate.</FONT></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>The Company believes Genentech's
remaining claims in the First Davis Smyth Case and the Second Davis Smyth Case
are without merit and intends to continue to defend against all of Genentech&#146;s
remaining claims vigorously. As this litigation is at an early stage, at this
time the Company is not able to predict the probability of the outcome or an
estimate of loss, if any, related to these matters. </FONT></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>The Company has initiated
patent-related actions against Genentech in Germany, the United Kingdom, and
Italy relating in each case to a patent that expires on October 28, 2012. The
Company may initiate other actions in other countries outside the United States,
which could have similar or other adverse outcomes that would materially harm
its business and which, irrespective of the outcomes, may also entail
significant costs and expenses. In the United Kingdom, an adverse decision dated
March 22, 2012 is under appeal. This decision found the designation of European
patent EP 1 238 986 in the United Kingdom to be valid and potential acts
relating to VEGF Trap Eye in the United Kingdom before expiration of the patent
on October 28, 2012 to infringe this patent.</FONT></P>
<P align=center><FONT face="Times New Roman" size=2></FONT><FONT face="Times New Roman" size=2>15</FONT></P>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<P align=justify><B><FONT face="Times New Roman" size=2>REGENERON PHARMACEUTICALS,
INC.<BR>Notes to Condensed Financial Statements
(Unaudited)<BR></FONT></B><B><I><FONT face="Times New Roman" size=2>(Unless otherwise noted,
dollars in thousands, except per share data) </FONT></I></B></P>
<P align=justify><B><FONT face="Times New Roman" size=2>11.</FONT></B><B><FONT face="Times New Roman" size=2> </FONT></B><B><FONT face="Times New Roman" size=2>Recently Issued Accounting
Standards </FONT></B></P>
<P align=justify><B><FONT face="Times New Roman" size=2>Presentation of comprehensive income
</FONT></B></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>In June and December 2011, the
Financial Accounting Standards Board (&#147;FASB&#148;) amended its authoritative guidance
on the presentation of comprehensive income. Under the amendments, an entity has
the option to present comprehensive income and net income either in a single
continuous statement or in two separate but consecutive statements. This
amendment, therefore, eliminated the option to present the components of other
comprehensive income as part of the statement of changes in stockholders'
equity. The amendment did not change the items that must be reported in other
comprehensive income or when an item of other comprehensive income must be
reclassified to net income. The Company adopted this amended guidance for the
fiscal year beginning January 1, 2012. As this guidance relates to presentation
only, the adoption of this guidance did not have any other effect on the
Company's financial statements.</FONT></P>
<P align=center><FONT face="Times New Roman" size=2>16</FONT></P>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<TABLE cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR>
    <TD vAlign=top noWrap width="1%"><STRONG><FONT size=2 face="Times New Roman"><A NAME="item2"></A>ITEM
      2.&nbsp;</FONT></STRONG></TD>
    <TD vAlign=top width="99%">
      <P align=justify><B><FONT face="Times New Roman" size=2>MANAGEMENT&#146;S DISCUSSION AND
      ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF
  OPERATIONS</FONT></B></P></TD></TR></TABLE>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><I>The discussion below contains
forward-looking statements that involve risks and uncertainties relating to
future events and the future financial performance of Regeneron Pharmaceuticals,
Inc., and actual events or results may differ materially from these
forward-looking statements. These statements concern, and these risks and
uncertainties include, among others, the nature, timing, and possible success
and therapeutic applications of EYLEA<SUP>&#174;</SUP> and ARCALYST<SUP>&#174;</SUP> and our
product candidates, potential new indications for marketed products, and
research and clinical programs now underway or planned; the likelihood and
timing of possible regulatory approval and commercial launch of our late-stage
product candidates and new indications for marketed products; determinations by
regulatory and administrative governmental authorities which may delay or
restrict our ability to continue to develop or commercialize EYLEA and other
product and drug candidates and possible new indications for marketed products;
the ability for us to manufacture and manage supply chains for multiple products
and product candidates; competing drugs that may be superior to EYLEA and our
product and drug candidates and possible new indications for marketed products;
uncertainty of market acceptance of EYLEA and our product and drug candidates
and possible new indications for marketed products; coverage and reimbursement
determinations by third-party payers, including Medicare and Medicaid;
unforeseen safety issues resulting from the administration of products and
product candidates in patients; unanticipated expenses; the costs of developing,
producing, and selling products; the ability for us to meet any of our financial
projections or guidance and changes to the assumptions underlying those
projections or guidance; the potential for any license or collaboration
agreement, including our agreements with Sanofi and Bayer HealthCare LLC, to be
canceled or terminated without any product success; and risks associated with
third-party intellectual property and pending or future litigation relating
thereto. These statements are made by us based on management's current beliefs
and judgment. In evaluating such statements, shareholders and potential
investors should specifically consider the various factors identified under the
caption &#147;Risk Factors&#148; which could cause actual events and results to differ
materially from those indicated by such forward-looking statements. We do not
undertake any obligation to update publicly any forward-looking statement,
whether as a result of new information, future events, or otherwise, except as
required by law.</I></FONT></P>
<P align=justify><B><FONT face="Times New Roman" size=2>Overview </FONT></B></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Regeneron Pharmaceuticals, Inc. is a
fully integrated biopharmaceutical company that discovers, invents, develops,
manufactures, and commercializes medicines for the treatment of serious medical
conditions. We currently have two marketed products:</FONT></P>
<UL style="FONT-SIZE: 10pt; TEXT-ALIGN: justify"><LI>EYLEA<SUP>&#174;</SUP> (aflibercept) Injection, known in the scientific
  literature as VEGF Trap-Eye, which is available in the United States for the
  treatment of neovascular age-related macular degeneration (wet AMD). Wet AMD
  is the leading cause of acquired blindness for people over the age of 65 in
  the United States and Europe.
  </LI><LI>ARCALYST<SUP>&#174;</SUP> (rilonacept) Injection for Subcutaneous Use, which is
  available by prescription in the United States for the treatment of
  Cryopyrin-Associated Periodic Syndromes (CAPS), including Familial Cold
  Auto-inflammatory Syndrome (FCAS) and Muckle-Wells Syndrome (MWS), in adults
  and children 12 and older. </LI></UL>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Net product sales of our two
marketed products totaled </FONT><FONT face="Times New Roman" size=2>$199.5 million
</FONT><FONT face="Times New Roman" size=2>in the second quarter and $327.5 million in the
first half of 2012. This</FONT><FONT face="Times New Roman" size=2> contributed to our
overall </FONT><FONT face="Times New Roman" size=2>net income of $76.7 million in the second
quarter and $88.4 million in the first half of 2012. </FONT><FONT face="Times New Roman" size=2>Our operating results over the next several years will be largely
dependent upon our ability to continue to successfully commercialize EYLEA and
the market penetration it achieves.</FONT></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>We have 13 product candidates in
clinical development, all of which were discovered in our research laboratories.
Our Trap-based, late-stage programs are: </FONT></P>
<UL style="FONT-SIZE: 10pt; TEXT-ALIGN: justify"><LI>EYLEA, which is being developed for the treatment of additional serious
  eye diseases;
  </LI><LI>ZALTRAP<SUP>&#174;</SUP> (aflibercept), known in the scientific literature as
  VEGF Trap, which is being developed in oncology in collaboration with Sanofi;
  and
  </LI><LI>ARCALYST, which is being developed for the prevention of gout flares in
  patients initiating uric acid-lowering treatment. </LI></UL>
<P align=center><FONT face="Times New Roman" size=2>17</FONT></P>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Our antibody-based clinical programs
include ten fully human monoclonal antibodies. The following seven are being
developed in collaboration with Sanofi: </FONT></P>
<UL style="FONT-SIZE: 10pt; TEXT-ALIGN: justify"><LI>Sarilumab (REGN88), an antibody to the interleukin-6 receptor (IL-6R),
  which is being developed in rheumatoid arthritis;
  </LI><LI>REGN727, an antibody to Proprotein Convertase Subtilisin/Kexin type 9
  (PCSK9), which is being developed for low-density lipoprotein (LDL)
  cholesterol reduction;
  </LI><LI>REGN668, an antibody to the interleukin-4 receptor (IL-4R), which is being
  developed in atopic dermatitis and eosinophilic asthma;
  </LI><LI>REGN421, an antibody to Delta-like ligand-4 (Dll4), a novel angiogenesis
  target, which is being developed in oncology;
  </LI><LI>REGN910, an antibody to Angiopoietin-2 (ANG2), another novel angiogenesis
  target, which is being developed in oncology;
  </LI><LI>REGN728, an antibody in clinical development against an undisclosed
  target; and
  </LI><LI>REGN1033, an antibody in clinical development against an undisclosed
  target. </LI></UL>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>In addition, we are developing the
following three antibodies independently:</FONT></P>
<UL style="FONT-SIZE: 10pt; TEXT-ALIGN: justify"><LI>REGN475, an antibody to Nerve Growth Factor (NGF), which is being
  developed for the treatment of pain (currently on clinical hold);
  </LI><LI>REGN846, an antibody in clinical development against an undisclosed
  target, which is being developed in atopic dermatitis; and
  </LI><LI>REGN1154, an antibody in clinical development against an undisclosed
  target. </LI></UL>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Our core business strategy is to
maintain a strong foundation in basic scientific research and discovery-enabling
technologies, and to combine that foundation with our clinical development,
manufacturing, and commercial capabilities. Our long-term objective is to build
a successful, integrated, multi-product biopharmaceutical company that provides
patients and medical professionals with innovative options for preventing and
treating human diseases.</FONT></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>We believe that our ability to
develop product candidates is enhanced by the application of our </FONT><I><FONT face="Times New Roman" size=2>VelociSuite&#153;</FONT></I><FONT face="Times New Roman" size=2> technology
platforms. Our discovery platforms are designed to identify specific proteins of
therapeutic interest for a particular disease or cell type and validate these
targets through high-throughput production of genetically modified mice using
our <I>VelociGene</I><SUP>&#174;</SUP> technology to understand the role of these proteins in
normal physiology, as well as in models of disease. Our human monoclonal
antibody technology (<I>VelocImmune</I><SUP>&#174;</SUP>) and cell line
expression technologies (<I>VelociMab</I><SUP>&#174;</SUP>) may then be
utilized to discover and produce new product candidates directed against the
disease target. Our antibody product candidates currently in clinical trials
were developed using <I>VelocImmune</I>. Under the terms of our
antibody collaboration with Sanofi, which was expanded during 2009, we plan to
advance a total of 20 to 30 candidates into clinical development over the life
of the agreement. We continue to invest in the development of enabling
technologies to assist in our efforts to identify, develop, manufacture, and
commercialize new product candidates. </FONT></P>

<P align=center><FONT face="Times New Roman" size=2>18</FONT></P>
<HR align=center width="100%" noShade SIZE=2>


<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>

<P align=justify><B><U><FONT face="Times New Roman" size=2>Commercial
Products:</FONT></U></B><FONT face="Times New Roman" size=2> </FONT></P>

<P align=justify><B><I><FONT face="Times New Roman" size=2>EYLEA</FONT></I></B><B><I><FONT face="Times New Roman" size=2><SUP> </SUP></FONT></I></B><B><I><FONT face="Times New Roman" size=2>(aflibercept) Injection &#150; wet AMD </FONT></I></B></P>
<P align=justify><B><I><FONT face="Times New Roman" size=2></FONT></I></B><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp; </FONT>In November 2011, we
received U.S. marketing approval from the U.S. Food and Drug Administration
(FDA) for EYLEA<SUP> </SUP>Injection for the treatment of patients with wet AMD.
Net product sales of EYLEA were $194.0 in the second quarter and $317.5 million
in the first half of 2012.</FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp; <FONT face="Times New Roman" size=2>EYLEA, known
in the scientific literature as VEGF Trap-Eye, is a fusion protein locally
administered in the eye that is designed to bind Vascular Endothelial Growth
Factor-A (VEGF-A) and Placental Growth Factor (PlGF) proteins that are involved
in the abnormal growth of new blood vessels. The abnormal growth of new blood
vessels could leak blood and fluid, which causes disruption and dysfunction of
the retina creating distortion and/or blind spots in central vision.</FONT></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>We are collaborating with Bayer HealthCare on the global development of
EYLEA. In February 2012, Bayer HealthCare received marketing approval in
Australia for EYLEA for the treatment of patients with wet AMD, and is expected
to launch in the second half of 2012. In June 2012, Bayer HealthCare received
marketing approval in Colombia for EYLEA for the treatment of patients with wet
AMD, and is expected to launch in the second half of 2012. Bayer HealthCare has
also submitted applications for marketing authorization in the European Union,
Japan, and other countries for wet AMD, and expects regulatory decisions
beginning in the second half of 2012. Bayer HealthCare will market EYLEA outside
the United States, where, for countries other than Japan, the companies will
share equally the profits from any future sales of EYLEA. We are entitled to a
royalty on annual sales of EYLEA in Japan, as described below. We maintain
exclusive rights to EYLEA in the United States and are entitled to all profits
from any such sales. </FONT></P>
<P align=justify><B><I><FONT face="Times New Roman" size=2>ARCALYST</FONT></I></B><B><I><FONT face="Times New Roman" size=2><SUP>
</SUP></FONT></I></B><B><I><FONT face="Times New Roman" size=2>&#150; CAPS </FONT></I></B></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Net product sales of ARCALYST (rilonacept) for the treatment of CAPS were
$5.5 million in the second quarter of 2012, compared to $5.0 million in the same
quarter of 2011. ARCALYST net product sales in the first half of 2012 were $9.9
million, compared to $9.5 million in the first half of 2011. We do not expect
future net product sales of ARCALYST for the treatment of CAPS to be
significant. </FONT></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>ARCALYST is a protein-based product designed to bind the interleukin-1
(called IL-1) cytokine and prevent its interaction with cell surface receptors.
ARCALYST is available by prescription in the United States for the treatment of
CAPS, including FCAS and MWS in adults and children 12 and older. CAPS are a
group of rare, inherited, auto-inflammatory conditions characterized by
life-long, recurrent symptoms of rash, fever/chills, joint pain, eye
redness/pain, and fatigue. Intermittent, disruptive exacerbations or flares can
be triggered at any time by exposure to cooling temperatures, stress, exercise,
or other unknown stimuli.</FONT></P>
<P align=justify><B><U><FONT face="Times New Roman" size=2>Clinical
Programs:</FONT></U></B><B><FONT face="Times New Roman" size=2> </FONT></B></P>
<P align=justify><B><I><FONT face="Times New Roman" size=2>1. EYLEA &#150; Ophthalmologic
Diseases </FONT></I></B></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>We, together with our ex-U.S. collaborator Bayer HealthCare, are
evaluating EYLEA in Phase 3 programs in patients with central retinal vein
occlusion (CRVO), branch retinal vein occlusion (BRVO), diabetic macular edema
(DME), and choroidal neovascularisation (CNV) of the retina as a result of
pathologic myopia. Wet AMD, diabetic retinopathy (which includes DME), and
retinal vein occlusion are three of the leading causes of adult blindness in the
developed world. In these conditions, severe visual loss is caused by a
combination of retinal edema and neovascular proliferation.</FONT></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>A study to fulfill a post-marketing requirement by the FDA, </FONT><FONT face="Times New Roman" size=2>RE-VIEW (</FONT><U><FONT face="Times New Roman" size=2>R</FONT></U><FONT face="Times New Roman" size=2>igorous </FONT><U><FONT face="Times New Roman" size=2>E</FONT></U><FONT face="Times New Roman" size=2>valuation of </FONT><U><FONT face="Times New Roman" size=2>V</FONT></U><FONT face="Times New Roman" size=2>ision and safety with </FONT><U><FONT face="Times New Roman" size=2>I</FONT></U><FONT face="Times New Roman" size=2>ntravitreal aflibercept
injection dosed </FONT><U><FONT face="Times New Roman" size=2>E</FONT></U><FONT face="Times New Roman" size=2>very 8 </FONT><U><FONT face="Times New Roman" size=2>W</FONT></U><FONT face="Times New Roman" size=2>eeks over 2 years in wet AMD), will evaluate the effect of EYLEA on
corneal endothelium. This study is expected to be initiated in the</FONT><FONT face="Times New Roman" size=2> fourth quarter of 2012. </FONT></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>In November 2011, we submitted a supplemental Biologics License
Application (sBLA) for U.S. regulatory approval of EYLEA in CRVO based on the
positive results in the Phase 3 COPERNICUS and GALILEO studies. Under the
Prescription Drug User Fee Act (PDUFA), we were granted a target date for an FDA
decision on our EYLEA sBLA of September 23, 2012. Bayer HealthCare plans to
submit regulatory applications in this indication in Europe in late 2012 or
early 2013 and in Japan during the second half of 2012.&nbsp;</FONT></P>
<P align=center><FONT face="Times New Roman" size=2>19</FONT></P>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp; <FONT face="Times New Roman" size=2>In the second
quarter of 2011, we and Bayer HealthCare initiated Phase 3 studies to evaluate
the safety and efficacy of EYLEA in DME. We are conducting one of these studies,
VISTA-DME, in the United States. Bayer HealthCare is conducting the second
study, <FONT STYLE="background-color: TRANSPARENT">VIVID-DME,</FONT> in Europe, Japan, and Australia. Both the VISTA-DME and
VIVID-DME trials are fully enrolled. An additional Phase 3 safety study in Japan
was initiated in the first quarter of 2012 by Bayer HealthCare (VIVID-Japan).
This study anticipates the enrollment of approximately 65 patients and is
required for approval in Japan.</FONT></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>In the first quarter of 2011, we and Bayer HealthCare initiated a Phase 3
trial in Asia in collaboration with the Singapore Eye Research Institute (SERI)
investigating the efficacy and safety of EYLEA in patients with CNV of the
retina as a result of pathologic myopia. The study will enroll approximately 110
patients. </FONT></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>In the fourth quarter of 2011, we and Bayer HealthCare initiated a Phase
3 trial in China evaluating the efficacy and safety of EYLEA in neovascular wet
AMD (SIGHT). The trial is expected to include approximately 300 patients and
will be the largest retinal trial conducted in China. The SIGHT trial is being
led by Bayer HealthCare.</FONT></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>In the second quarter of 2012, we initiated a multinational study of
EYLEA in patients with BRVO (VIBRANT). Patients will be treated with either six
monthly intravitreal injections of EYLEA<SUP> </SUP>2.0 mg or laser. The primary
endpoint of the VIBRANT study is the proportion of patients who gain at least 15
letters in Best Corrected Visual Acuity (BCVA) after six months of treatment as
measured by the Early Treatment Diabetic Retinopathy Study (ETDRS) eye chart.
</FONT></P>
<P align=justify><B><FONT face="Times New Roman" size=2>Collaboration with Bayer HealthCare
</FONT></B></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>In October 2006, we entered into a license and collaboration agreement
with Bayer HealthCare for the global development and commercialization outside
the United States of EYLEA. Under the agreement, we and Bayer HealthCare
collaborate on, and share the costs of, the development of EYLEA through an
integrated global plan. Bayer HealthCare will market EYLEA outside the United
States, where, for countries other than Japan, the companies will share equally
in profits from any future sales of EYLEA. In May 2012, Bayer HealthCare&#146;s
Japanese subsidiary, Bayer Yakuhin, Ltd., and Santen Pharmaceutical Co., Ltd.
entered into an agreement to co-promote EYLEA in Japan should marketing approval
be achieved. In conjunction with this agreement, we and Bayer HealthCare amended
our existing global license and collaboration agreement for EYLEA to convert the
50/50 profit share for Japan into a royalty agreement under which we are
entitled to receive a tiered royalty of between 33.5% and 40.0% of EYLEA annual
net sales in Japan. In certain specified circumstances, the Japan royalty may
revert to a profit share arrangement.</FONT></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Commencing on the first commercial sale of EYLEA in a major market
country outside the United States, we will be obligated to reimburse Bayer
HealthCare for 50% of the development costs that it has incurred under the
agreement from our share of the collaboration profits. The reimbursement payment
in any quarter will equal 5% of the then outstanding repayment obligation, but
never more than our share of the collaboration profits in the quarter unless we
elect to reimburse Bayer HealthCare at a faster rate. Within the United States,
we retain exclusive commercialization rights to EYLEA and are entitled to all
profits from any such sales. We have received $60 million in development
milestone payments and can earn up to $50 million in future milestone payments
related to marketing approvals of EYLEA in major market countries outside the
United States. We can also earn up to $135 million in sales milestone payments
if total annual sales of EYLEA outside the United States achieve certain
specified levels starting at $200 million.</FONT></P>
<P align=justify><B><I><FONT face="Times New Roman" size=2>2. ZALTRAP (aflibercept) also
known as VEGF Trap &#150; Oncology </FONT></I></B></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>ZALTRAP is a fusion protein that is designed to bind all forms of VEGF-A,
VEGF-B, and PlGF, and prevent their interaction with cell surface receptors.
VEGF-A (and to a lesser degree, PlGF) is required for the growth of new blood
vessels (a process known as angiogenesis) that are needed for tumors to
grow.</FONT></P>
<P align=center><FONT face="Times New Roman" size=2>20</FONT></P>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp; <FONT face="Times New Roman" size=2>ZALTRAP is
being developed globally in cancer indications in collaboration with Sanofi. In
April 2011, we and Sanofi announced that the Phase 3 VELOUR trial evaluating
ZALTRAP<SUP> </SUP>in combination with the FOLFIRI chemotherapy regimen [folinic
acid (leucovorin), 5-fluorouracil, and irinotecan] versus a regimen of FOLFIRI
plus placebo met its primary endpoint of improving overall survival (OS) in
previously treated metastatic colorectal cancer (mCRC) patients. Based upon the
positive VELOUR data, Sanofi submitted regulatory applications for marketing
approval of ZALTRAP for the treatment of previously-treated mCRC patients to the
European Medicines Agency (EMA) in December 2011 and to the FDA in February
2012. Under PDUFA, we were granted Priority Review of the BLA for ZALTRAP with a
target date for an FDA decision of August 4, 2012. </FONT></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Another randomized, double-blind Phase 3 trial (VENICE), evaluated
ZALTRAP as a first-line treatment for metastatic androgen-independent prostate
cancer in combination with docetaxel/prednisone. In April 2012, we and Sanofi
announced that the results from the Phase 3 VENICE trial did not meet the
pre-specified criterion of improvement in overall survival. The safety profile
was generally consistent with previous studies of ZALTRAP in combination with
docetaxel</FONT><FONT face="Times New Roman" size=2>.</FONT></P>
<P align=justify><B><FONT face="Times New Roman" size=2>ZALTRAP</FONT></B><B><FONT face="Times New Roman" size=2><SUP> </SUP></FONT></B><B><FONT face="Times New Roman" size=2>Collaboration with Sanofi </FONT></B></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>We and Sanofi globally collaborate on the development and
commercialization of ZALTRAP. Under the terms of our September 2003
collaboration agreement, as amended, we and Sanofi will share co-promotion
rights and profits on sales, if any, of ZALTRAP outside of Japan for disease
indications included in our collaboration. In Japan, we are entitled to a
royalty of approximately 35% on annual sales of ZALTRAP, subject to certain
potential adjustments. We may also receive up to $400 million in milestone
payments upon receipt of specified marketing approvals, including up to $360
million related to the receipt of marketing approvals for up to eight ZALTRAP
oncology and other indications in the United States or the European Union and up
to $40 million related to the receipt of marketing approvals for up to five
oncology indications in Japan. </FONT></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Under the ZALTRAP collaboration agreement, as amended, agreed upon
worldwide development expenses incurred by both companies during the term of the
agreement will be funded by Sanofi. If the collaboration becomes profitable, we
will be obligated to reimburse Sanofi out of our share of ZALTRAP profits for
50% of the development expenses that they funded. The reimbursement payment in
any quarter will equal 5% of the then outstanding repayment obligation, but
never more than our share of the ZALTRAP profits in the quarter unless we elect
to reimburse Sanofi at a faster rate. As a result, if ZALTRAP receives
regulatory approval for patients previously treated for mCRC, we expect that,
initially, our share of any ZALTRAP profits will be diverted to reimburse Sanofi
for this repayment obligation. </FONT></P>
<P align=justify><B><I><FONT face="Times New Roman" size=2>3.
ARCALYST</FONT></I></B><B><I><FONT face="Times New Roman" size=2><SUP>
</SUP></FONT></I></B><B><I><FONT face="Times New Roman" size=2>(rilonacept) &#150; Inflammatory
Diseases</FONT></I></B></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>ARCALYST is being developed for the prevention of gout flares in patients
initiating uric acid-lowering therapy. Gout, a disease in which IL-1 may play an
important role in pain and inflammation, is a very painful and common form of
arthritis that results from high levels of uric acid, a bodily waste product
normally excreted by the kidneys. The elevated uric acid can lead to formation
of urate crystals in the joints of the toes, ankles, knees, wrists, fingers, and
elbows. Uric acid-lowering therapy, most commonly allopurinol, is prescribed to
eliminate the urate crystals and prevent them from reforming. Paradoxically, the
initiation of uric acid-lowering therapy often triggers an increase in the
frequency of gout attacks in the first several months of treatment, which may
lead to discontinuation of therapy. The break-up of urate crystals can result in
stimulation of inflammatory mediators, including IL-1, resulting in acute flares
of joint pain and inflammation. These painful flares generally persist for at
least five days. </FONT></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>We conducted a Phase 3 clinical development program with ARCALYST in gout
patients initiating uric acid-lowering therapy. The program consisted of three
studies: PRE-SURGE 1, PRE-SURGE 2, and RE-SURGE, as well as an ongoing long-term
safety study (UPSURGE). Based on the positive results of these studies, we
submitted a supplemental BLA for U.S. regulatory approval of ARCALYST for the
prevention of gout flares in patients initiating uric acid-lowering therapy. In
November 2011, the FDA accepted for review our supplemental BLA. Under PDUFA, we
were granted a target date for an FDA decision on the ARCALYST supplemental BLA
of July 30, 2012. On May 8, 2012, the Arthritis Advisory Committee of the FDA
voted against approval of ARCALYST for the prevention of gout flares in patients
initiating uric acid-lowering therapy.</font></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>We own
worldwide rights to ARCALYST.</FONT></P>
<P align=center><FONT face="Times New Roman" size=2>21</FONT></P>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<P align=justify><B><I><FONT face="Times New Roman" size=2>4. Sarilumab (REGN88; IL-6R
Antibody) for inflammatory diseases </FONT></I></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp; <FONT face="Times New Roman" size=2>IL-6 is a key
cytokine involved in the pathogenesis of rheumatoid arthritis, causing
inflammation and joint destruction. A therapeutic antibody to IL-6R,
ACTEMRA<SUP>&#174;</SUP> (tocilizumab), a registered trademark of Chugai Seiyaku
Kabushiki Kaisha, has been approved for the treatment of rheumatoid
arthritis.</FONT></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Sarilumab is a fully human monoclonal antibody to IL-6R generated using
our </FONT><I><FONT face="Times New Roman" size=2>VelocImmune</FONT></I><I><FONT face="Times New Roman" size=2><SUP> </SUP></FONT></I><FONT face="Times New Roman" size=2>technology. In July 2011,
we and Sanofi announced that in the Phase 2b stage of the MOBILITY trial in
rheumatoid arthritis, patients treated with sarilumab in combination with a
standard RA treatment, methotrexate (MTX), achieved a significant and clinically
meaningful improvement in signs and symptoms of moderate-to-severe RA compared
to patients treated with MTX alone. The primary endpoint of the study was the
proportion of patients achieving at least a 20% improvement in RA symptoms
(ACR20) after 12 weeks. During the third quarter of 2011, we and Sanofi
initiated the Phase 3 stage of the Phase 2/3 MOBILITY study in patients with
rheumatoid arthritis. In addition, we and Sanofi plan to initiate additional
Phase 3 studies of sarilumab in the second half of 2012. </FONT></P>
<P align=justify><B><I><FONT face="Times New Roman" size=2>5. REGN727 (PCSK9 Antibody) for
LDL cholesterol reduction </FONT></I></B></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Elevated LDL cholesterol (&#147;bad cholesterol&#148;) level is a validated risk
factor leading to cardiovascular disease. Statins are a class of drugs that
lower LDL cholesterol by up regulating the expression of the LDL receptor
(LDLR), which removes LDL from circulation. PCSK9 is a naturally occurring
secreted protein that also modulates LDL cholesterol levels through its
interaction with the LDL receptor. In a landmark study published in the
</FONT><I><FONT face="Times New Roman" size=2>New England Journal of
Medicine</FONT></I><FONT face="Times New Roman" size=2> in March 2006, patients with lower
than </FONT><FONT face="Times New Roman" size=2>n</FONT><FONT face="Times New Roman" size=2>ormal PCSK9
levels due to a genetic abnormality not only had significantly lower levels of
LDL cholesterol, but also a significant reduction in the risk of coronary heart
disease. We used our </FONT><I><FONT face="Times New Roman" size=2>VelocImmune</FONT></I><FONT face="Times New Roman" size=2> technology to generate a
fully human monoclonal antibody inhibitor of PCSK9, called REGN727, that is
intended to lower LDL cholesterol.</FONT></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>In March 2012, data from the Phase 1 program were published in the
</FONT><I><FONT face="Times New Roman" size=2>New England Journal of
Medicine</FONT></I><FONT face="Times New Roman" size=2>. In addition, data from two Phase 2
trials were presented at the American College of Cardiology (ACC) Annual
Meeting, one of which was also published in the Journal of the American College
of Cardiology. Study DFI11565, presented at a late-breaking clinical trials
session, was a Phase 2 dose-finding clinical trial, and enrolled 183 patients
with elevated LDL-C (greater than or equal to 100 mg/dL) despite being on a
stable dose of atorvastatin. The objective of the study was to evaluate the
effect of adding REGN727 to existing statin therapy. Across the five different
dose regimens tested, patients receiving REGN727 for 12 weeks achieved and
sustained a mean LDL-C reduction from baseline of 40% to 72%, compared to 5% in
patients receiving placebo (p&lt;0.0001). Patients in the study were followed
for a total of 20 weeks for safety. The most common adverse events (AEs) with
REGN727 were injection site reactions. Serious AEs occurred in one patient
receiving placebo and three patients in the active treatment arms, including a
patient on active treatment who experienced a skin rash diagnosed as
leukocytoclastic vasculitis. Six patients, all on active treatment, prematurely
discontinued therapy due to AEs. Muscle complaints were infrequent and similar
across all treatment groups. There were no significant elevations in liver
enzymes or other lab values in patients on active treatment. </FONT></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Data from a second trial, Study DFI11566, were also presented at an oral
session of the ACC meeting. The study enrolled patients with primary
hypercholesterolemia (heFH) with elevated LDL cholesterol (greater than or equal
to 100 mg/dL) who were on a stable low dose of atorvastatin (10 mg). The primary
objective of the study was to compare the effect on LDL cholesterol lowering of
switching to a high dose of atorvastatin alone (80 mg) versus a high dose of
atorvastatin combined with REGN727. Patients who received REGN727 plus
atorvastatin 80 mg achieved a mean reduction of 73% in LDL cholesterol, compared
to a mean reduction of 17% for patients who switched to atorvastatin 80 mg alone
(p&lt;0.001) after eight weeks. The study also included a third arm in which
REGN727 was added to the stable low dose of atorvastatin. Patients in this arm
achieved a 66% reduction in mean LDL cholesterol. Patients in the study were
followed for a total of 16 weeks for safety. In this trial, the most common AE
with REGN727 was infection. There was one serious adverse event in the REGN727
plus atorvastatin 80 mg group (dehydration) that was deemed not to be
treatment-related. </FONT></P>
<P align=center><FONT face="Times New Roman" size=2>22</FONT></P>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp; <FONT face="Times New Roman" size=2>Data from a
third Phase 2 trial were published online in </FONT><I><FONT face="Times New Roman" size=2>The Lancet</FONT></I><FONT face="Times New Roman" size=2> and also presented at the
European Atherosclerosis Society Congress (EAS) in May 2012. The trial
randomized 77 patients with heFH whose LDL-cholesterol levels remained
uncontrolled on statin therapy with or without ezetimibe. Across the four
different dosing regimens tested, patients receiving REGN727 for 12 weeks
achieved a mean LDL-cholesterol reduction from baseline of 28.9% to 67.9%,
compared to 10.7% in patients receiving placebo (p &lt; 0.05). In addition, in
the most intense dose regimen tested where the greatest LDL-cholesterol
reduction was observed (150 mg every two weeks), 93.8% of patients achieved
LDL-cholesterol levels lower than 100 mg/dL (2.59 mmol/L), compared to 13.3% of
patients on placebo, and 81.3% reached LDL-cholesterol levels lower than 70
mg/dL (1.81 mmol/L), compared to none on placebo. There were no serious adverse
events on active treatment, while a single serious adverse event was recorded
for a patient in the placebo group. There were no elevations in liver function
tests (LFT) &gt; 3 times the upper limit of normal (ULN) and no cases of
elevated creatinine kinase (CK) were reported. The most common adverse event
reported was injection-site reaction. </FONT></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>We, along with Sanofi, initiated a global Phase 3 program (ODYSSEY) for
REGN727 in June 2012. This was the first Phase 3 program of an investigational
drug targeting PCSK9. The ODYSSEY program will enroll more than 22,000 patients.
This includes over ten clinical trials evaluating the effect of REGN727 on
lowering LDL cholesterol and an 18,000 patient cardiovascular outcomes (e.g.,
heart attacks, stroke) study. LDL cholesterol is expected to be the primary
efficacy endpoint for regulatory filings. The studies will be conducted in
clinical centers around the world including the United States, Canada, Western
and Eastern Europe, South America, Australia and Asia. A Phase 3, long-term
safety and tolerability study of REGN727 is ongoing in patients with
hypercholesterolemia who are not adequately controlled with their current
lipid-modifying therapy.</FONT></P>
<P align=justify><B><I><FONT face="Times New Roman" size=2>6. REGN668 (IL-4R Antibody) for
allergic and immune conditions </FONT></I></B></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>IL-4R is required for signaling by the cytokines IL-4 and IL-13. Both of
these cytokines are critical mediators of immune response, which, in turn,
drives the formation of Immunoglobulin E (IgE) antibodies and the development of
allergic responses, as well as the atopic state that underlies asthma and atopic
dermatitis.</FONT></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>REGN668 is a fully human monoclonal</FONT><I><FONT face="Times New Roman" size=2><SUP> </SUP></FONT></I><FONT face="Times New Roman" size=2>antibody generated using
our </FONT><I><FONT face="Times New Roman" size=2>VelocImmune</FONT></I><FONT face="Times New Roman" size=2> technology that is designed to bind to IL-4R. REGN668 is in Phase 2
studies in patients with atopic dermatitis and eosinophilic asthma.</FONT></P>
<P align=justify><B><I><FONT face="Times New Roman" size=2>7. REGN421 (Dll4 Antibody) for
advanced malignancies </FONT></I></B></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>In many clinical settings, positively or negatively regulating blood
vessel growth could have important therapeutic benefits, as could the repair of
damaged and leaky vessels. VEGF was the first growth factor shown to be specific
for blood vessels, by virtue of having its receptor primarily expressed on blood
vessel cells. In the December 21, 2006 issue of the journal </FONT><I><FONT face="Times New Roman" size=2>Nature</FONT></I><FONT face="Times New Roman" size=2>, we reported data
from a preclinical study demonstrating that blocking an important cell signaling
molecule, known as Dll4, inhibited the growth of experimental tumors by
interfering with their ability to produce a functional blood supply. The
inhibition of tumor growth was seen in a variety of tumor types, including those
that were resistant to blockade of VEGF, suggesting a novel anti-angiogenesis
therapeutic approach. Moreover, inhibition of tumor growth is enhanced by the
combination of Dll4 and VEGF blockade in many preclinical tumor
models.</FONT></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>REGN421 is a fully human monoclonal antibody to Dll4 generated using our
</FONT><I><FONT face="Times New Roman" size=2>VelocImmune</FONT></I><FONT face="Times New Roman" size=2>
technology, and is in Phase 1 clinical development.</FONT></P>
<P align=justify><B><I><FONT face="Times New Roman" size=2>8. REGN910 (ANG2 Antibody) for
oncology </FONT></I></B></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The angiopoietins, which were discovered at Regeneron, are ligands for
the endothelial cell receptor Tie2 and are essential for vascular development
and angiogenesis. Unlike other family members, angiopoietin 2 (ANG2) is strongly
upregulated by endothelial cells at sites of angiogenesis and vascular
remodeling, including tumors.</FONT></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>REGN910 is a fully human monoclonal antibody generated using our
</FONT><I><FONT face="Times New Roman" size=2>VelocImmune</FONT></I><FONT face="Times New Roman" size=2>
technology that is designed to block ANG2. REGN910 is in Phase 1 clinical
development in oncology.</FONT></P>
<P align=center><FONT face="Times New Roman" size=2>23</FONT></P>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<P align=justify><B><I><FONT face="Times New Roman" size=2>9. REGN728</FONT></I></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp; <FONT face="Times New Roman" size=2>REGN728, a
fully human monoclonal antibody generated using our VelocImmune technology
against an undisclosed target, has completed a Phase 1 study</FONT><FONT face="Times New Roman" size=2>.</FONT></P>
<P align=justify><B><I><FONT face="Times New Roman" size=2>10. REGN1033</FONT></I></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp; <FONT face="Times New Roman" size=2>In January
2012, we initiated a Phase 1 clinical study for REGN1033, a fully human
monoclonal antibody generated using our </FONT><I><FONT face="Times New Roman" size=2>VelocImmune</FONT></I><FONT face="Times New Roman" size=2> technology, against an
undisclosed target.</FONT></P>
<P align=justify><B><I><FONT face="Times New Roman" size=2>11. REGN475 (NGF Antibody) for
pain</FONT></I></B><FONT face="Times New Roman" size=2> </FONT></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>REGN475 is a fully human monoclonal antibody to NGF, generated using our
</FONT><I><FONT face="Times New Roman" size=2>VelocImmune</FONT></I><FONT face="Times New Roman" size=2>
technology, which is designed to block pain sensitization in neurons.
Preclinical experiments indicate that REGN475 specifically binds to and blocks
NGF activity and does not bind to or block cell signaling for closely related
neurotrophins such as NT-3, NT-4, or BDNF.</FONT></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>In May 2010, we announced positive results from an interim analysis of a
randomized, double-blind, four-arm, placebo-controlled Phase 2 trial in 217
patients with osteoarthritis of the knee. In July 2010, we presented additional
results from this trial through 16 weeks.</FONT></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>In December 2010, the FDA placed REGN475 and other investigational agents
targeting NGF on clinical hold after a case of rapidly progressive
osteoarthritis leading to joint replacement was seen in another company&#146;s
anti-NGF program. At that time, the FDA expressed concern that this case, which
followed previously-reported cases of joint replacements in patients on an
anti-NGF drug candidate being developed by a different pharmaceutical company,
provided evidence to suggest a class effect.</FONT></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>An FDA Arthritis Advisory Committee met on March 12, 2012 to discuss
possible safety issues related to anti-NGF compounds and voted unanimously in
favor of continued development of anti-NGF agents in osteoarthritis. The
Arthritis Advisory Committee also voted twenty to one in favor for continued
development of anti-NGF agents to manage the pain associated with conditions for
which there are no agents with demonstrated analgesic efficacy. While the
committee's recommendation will be considered by the FDA, it is not binding on
the FDA. </FONT></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>There are currently no ongoing trials with REGN475 that are either
enrolling or treating patients, but we are finalizing plans to initiate new
trials, subject to FDA approval.</FONT></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>In February 2012, Sanofi elected not to continue co-development of
REGN475, and Regeneron now has sole global rights to REGN475. Under the terms of
our agreement, Sanofi remains obligated to fund agreed-upon REGN475 development
costs through the end of 2012 and is entitled to receive a mid-single digit
royalty on any future sales of REGN475. </FONT></P>
<P align=justify><B><I><FONT face="Times New Roman" size=2>12. REGN846 </FONT></I></B></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>REGN846 is a fully human monoclonal antibody generated using our
</FONT><I><FONT face="Times New Roman" size=2>VelocImmune</FONT></I><FONT face="Times New Roman" size=2>
technology, against an undisclosed target, and is being evaluated in a Phase 2a
study in patients with atopic dermatitis. In July 2011, Sanofi elected not to
continue co-development of REGN846, and Regeneron now has sole global rights to
REGN846. Under the terms of our agreement, Sanofi remains obligated to fund
agreed-upon REGN846 clinical costs through conclusion of a planned
proof-of-concept trial and is entitled to receive a mid-single digit royalty on
any future sales of REGN846.</FONT></P>
<P align=justify><B><I><FONT face="Times New Roman" size=2>13. REGN1154 </FONT></I></B></P>
<P align=justify><B><I><FONT face="Times New Roman" size=2></FONT></I></B><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp; </FONT>REGN1154 is a fully human
monoclonal antibody generated using our </FONT><I><FONT face="Times New Roman" size=2>VelocImmune</FONT></I><FONT face="Times New Roman" size=2> technology, against an
undisclosed target. In March 2012, we initiated a Phase 1 clinical study in
Australia. Sanofi decided not to opt-in to the REGN1154 program and we have sole
global rights. Under the terms of our agreement, Sanofi is entitled to receive a
mid-single digit royalty on any future sales of REGN1154.</FONT></P>
<P align=center><FONT face="Times New Roman" size=2>24</FONT></P>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<P align=justify><B><U><FONT face="Times New Roman" size=2>Research and Development
Technologies:</FONT></U></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp; <FONT face="Times New Roman" size=2>Many proteins
that are either on the surface of or secreted by cells play important roles in
biology and disease. One way that a cell communicates with other cells is by
releasing specific signaling proteins, either locally or into the bloodstream.
These proteins have distinct functions and are classified into different
&#147;families&#148; of molecules, such as peptide hormones, growth factors, and
cytokines. All of these secreted (or signaling) proteins travel to and are
recognized by another set of proteins, called &#147;receptors,&#148; which reside on the
surface of responding cells. These secreted proteins impact many critical
cellular and biological processes, causing diverse effects ranging from the
regulation of growth of particular cell types to inflammation mediated by white
blood cells. Secreted proteins can at times be overactive and thus result in a
variety of diseases. In these disease settings, blocking the action of specific
secreted proteins can have clinical benefit. In other cases, proteins on the
cell-surface can mediate the interaction between cells, such as the processes
that give rise to inflammation and autoimmunity.</FONT></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Our scientists have developed two different technologies to design
protein therapeutics to block the action of specific cell surface or secreted
proteins. The first technology, termed the &#147;Trap&#148; technology, was used to
generate our two approved products, ARCALYST and EYLEA, as well as ZALTRAP, for
which regulatory applications for marketing approval have been submitted. These
novel &#147;Traps&#148; are composed of fusions between two distinct receptor components
and the constant region of an antibody molecule called the &#147;Fc region&#148;,
resulting in high affinity product candidates. </FONT><I><FONT face="Times New Roman" size=2>VelociSuite</FONT></I><FONT face="Times New Roman" size=2> is our second technology
platform; it is used for discovering, developing, and producing fully human
monoclonal antibodies that can address both secreted and cell-surface
targets.</FONT></P>
<P align=justify><B><I><FONT face="Times New Roman" size=2>VelociSuite</FONT></I></B><B><FONT face="Times New Roman" size=2> </FONT></B></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><EM>VelociSuite</EM></FONT><FONT face="Times New Roman" size=2> consists of
</FONT><I><FONT face="Times New Roman" size=2>VelocImmune, VelociGene,
VelociMouse</FONT></I><I><FONT face="Times New Roman" size=2><SUP>&#174;</SUP></FONT></I><I><FONT face="Times New Roman" size=2>, and VelociMab</FONT></I><FONT face="Times New Roman" size=2>. The
</FONT><I><FONT face="Times New Roman" size=2>VelocImmune</FONT></I><FONT face="Times New Roman" size=2>
mouse platform is utilized to produce fully human monoclonal antibodies.
</FONT><I><FONT face="Times New Roman" size=2>VelocImmune</FONT></I><FONT face="Times New Roman" size=2>
was generated by exploiting our </FONT><I><FONT face="Times New Roman" size=2>VelociGene</FONT></I><FONT face="Times New Roman" size=2> technology (see below), in
a process in which six megabases of mouse immune gene loci were replaced, or
&#147;humanized,&#148; with corresponding human immune gene loci. </FONT><I><FONT face="Times New Roman" size=2>VelocImmune</FONT></I><FONT face="Times New Roman" size=2> mice can be
used to generate efficiently fully human monoclonal antibodies to targets of
therapeutic interest. </FONT><I><FONT face="Times New Roman" size=2>VelocImmune</FONT></I><FONT face="Times New Roman" size=2> and our entire
</FONT><I><FONT face="Times New Roman" size=2>VelociSuite</FONT></I><FONT face="Times New Roman" size=2>
offer the potential to increase the speed and efficiency through which human
monoclonal antibody therapeutics may be discovered and validated, thereby
improving the overall efficiency of our early stage drug development activities.
We are utilizing the </FONT><I><FONT face="Times New Roman" size=2>VelocImmune</FONT></I><FONT face="Times New Roman" size=2> technology to produce our
next generation of drug candidates for preclinical and clinical
development.</FONT></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Our </FONT><I><FONT face="Times New Roman" size=2>VelociGene</FONT></I><I><FONT face="Times New Roman" size=2><SUP> </SUP></FONT></I><FONT face="Times New Roman" size=2>platform allows
custom and precise manipulation of very large sequences of DNA to produce highly
customized alterations of a specified target gene, or genes, and accelerates the
production of knock-out and transgenic expression models without using either
positive/negative selection or isogenic DNA. In producing knock-out models, a
color or fluorescent marker may be substituted in place of the actual gene
sequence, allowing for high-resolution visualization of precisely where the gene
is active in the body during normal body functioning as well as in disease
processes. For the optimization of preclinical development and pharmacology
programs, </FONT><I><FONT face="Times New Roman" size=2>VelociGene</FONT></I><FONT face="Times New Roman" size=2> offers the opportunity to humanize targets by replacing the
mouse gene with the human homolog. Thus, </FONT><I><FONT face="Times New Roman" size=2>VelociGene</FONT></I><FONT face="Times New Roman" size=2> allows scientists to
rapidly identify the physical and biological effects of deleting or
over-expressing the target gene, as well as to characterize and test potential
therapeutic molecules.</FONT></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Our <EM>VelociMouse</EM> technology platform allows for the direct and
immediate generation of genetically altered mice from embryonic stem cells (ES
cells), thereby avoiding the lengthy process involved in generating and breeding
knockout mice from chimeras. Mice generated through this method are normal and
healthy and exhibit a 100% germ-line transmission. Furthermore, mice developed
using our <EM>VelociMouse</EM> technology are suitable for direct phenotyping or
other studies. We have also developed our <EM>VelociMab</EM> platform for the
rapid screening of antibodies and rapid generation of expression cell lines for
our Traps and our <EM>VelocImmune</EM> human monoclonal antibodies</FONT><FONT face="Times New Roman" size=2>.</FONT></P>
<P align=justify><B><FONT face="Times New Roman" size=2>Antibody Collaboration and License
Agreements </FONT></B></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><STRONG>Sanofi. </STRONG></FONT><FONT face="Times New Roman" size=2>In November 2007,
we and Sanofi entered into a global, strategic collaboration to discover,
develop, and commercialize fully human monoclonal antibodies. The collaboration
is governed by a Discovery and Preclinical Development Agreement and a License
and Collaboration Agreement. In connection with the execution of the discovery
agreement in 2007, we received a non-refundable, up-front payment of $85.0
million from Sanofi. Pursuant to the collaboration, Sanofi is funding our
research to identify and validate potential drug discovery targets and develop
fully human monoclonal antibodies against these targets. We lead the design and
conduct of research activities under the collaboration, including target
identification and validation, antibody development, research and preclinical
activities through filing of an Investigational New Drug Application (IND) or
its equivalent, toxicology studies, and manufacture of preclinical and clinical
supplies.&nbsp;</FONT></P>
<P align=center><FONT face="Times New Roman" size=2>25</FONT></P>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp; <FONT face="Times New Roman" size=2>For each drug
candidate identified through discovery research under the discovery agreement,
Sanofi has the option to license rights to the candidate under the license
agreement. If it elects to do so, Sanofi will co-develop the drug candidate with
us through product approval. Development costs for the drug candidate are shared
between the companies, with Sanofi generally funding these costs up front,
except that following receipt of the first positive Phase 3 trial results for a
co-developed drug candidate, subsequent Phase 3 trial-related costs for that
drug candidate are shared 80% by Sanofi and 20% by us. We are generally
responsible for reimbursing Sanofi for half of the total development costs for
all collaboration antibody products from our share of profits from
commercialization of collaboration products to the extent they are sufficient
for this purpose. However, we are not required to apply more than 10% of our
share of the profits from collaboration products in any calendar quarter towards
reimbursing Sanofi for these development costs.</FONT></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Sanofi will lead commercialization activities for products developed
under the license agreement, subject to our right to co-promote such products.
The parties will equally share profits and losses from sales within the United
States. The parties will share profits outside the United States on a sliding
scale based on sales starting at 65% (Sanofi)/35% (us) and ending at 55%
(Sanofi)/45% (us), and will share losses outside the United States at 55%
(Sanofi)/45% (us). In addition to profit sharing, we are entitled to receive up
to $250 million in sales milestone payments, with milestone payments commencing
after aggregate annual sales outside the United States exceed $1.0 billion on a
rolling 12-month basis. </FONT></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>In November 2009, we and Sanofi amended these agreements to expand and
extend our antibody collaboration. The goal of the expanded collaboration is to
advance a total of 20 to 30 new antibody product candidates into clinical
development from 2010 through 2017.</FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp; <FONT face="Times New Roman" size=2>Under the amended discovery agreement,
Sanofi agreed to fund up to $160 million per year of our antibody discovery
activities over the period from 2010-2017, subject to a one-time option for
Sanofi to adjust the maximum reimbursement amount down to $120 million per year
commencing in 2014 if over the prior two years certain specified criteria were
not satisfied. Sanofi has an option to extend the discovery program for up to an
additional three years after 2017 for further antibody development and
preclinical activities. Pursuant to the collaboration, Sanofi funded up to $30
million of agreed-upon costs we incur to expand our manufacturing capacity at
our Rensselaer, New York facilities. </FONT></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>From the collaboration's inception in November 2007 through June 30,
2012, Sanofi has funded a total of $565.7 million of our costs under the
discovery agreement and a total of $477.9 million of our development costs under
the license agreement, or a total of $1.0 billion in funding for our antibody
research and development activities during this period. </FONT></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>In August 2008, we entered into an agreement with Sanofi to use our
</FONT><I><FONT face="Times New Roman" size=2>VelociGene</FONT></I><I><FONT face="Times New Roman" size=2><SUP> </SUP></FONT></I><FONT face="Times New Roman" size=2>platform to supply Sanofi
with genetically modified mammalian models of gene function and disease. Under
this agreement, Sanofi is required to pay us a minimum of $21.5 million for the
term of the agreement, which extends through December 2012, for knock-out and
transgenic models of gene function for target genes identified by Sanofi. Sanofi
will use these models for its internal research programs that are outside of the
scope of our antibody collaboration. </FONT></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><STRONG>Astellas Pharma Inc. </STRONG></FONT><FONT face="Times New Roman" size=2>In
March 2007, we entered into a six-year, non-exclusive license agreement with
Astellas Pharma Inc. to allow Astellas to utilize our </FONT><I><FONT face="Times New Roman" size=2>VelocImmune</FONT></I><I><FONT face="Times New Roman" size=2><SUP>
</SUP></FONT></I><FONT face="Times New Roman" size=2>technology in its internal research
programs to discover human monoclonal antibodies. Under the terms of the
agreement, Astellas made a $20.0 million annual, non-refundable payment to us in
each of the second quarters of 2007, 2008, 2009, and 2010. In July 2010, the
license agreement with Astellas was amended and extended through June 2023.
Under the terms of the amended agreement, Astellas made a $165.0 million
up-front payment to us in August 2010. In addition, Astellas will make a $130.0
million second payment to us in June 2018 unless the license agreement has been
terminated prior to that date. Astellas has the right to terminate the agreement
at any time by providing 90 days&#146; advance written notice. Under certain limited
circumstances, such as our material breach of the agreement, Astellas may
terminate the agreement and receive a refund of a portion of its up-front
payment or, if such termination occurs after June 2018, a portion of its second
payment, to us under the July 2010 amendment to the agreement. We are entitled
to receive a  mid-single digit royalty on any future
sales of antibody products discovered by Astellas using our </FONT><I><FONT face="Times New Roman" size=2>VelocImmune</FONT></I><FONT face="Times New Roman" size=2>
technology.</FONT></P>
<P align=center><FONT face="Times New Roman" size=2>26</FONT></P>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<P align=justify><B><FONT face="Times New Roman" size=2>Royalty Agreement with Novartis
Pharma AG </FONT></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp; <FONT face="Times New Roman" size=2>Under a June
2009 agreement with Novartis (that replaced a previous collaboration and license
agreement), we receive royalties on worldwide sales of Novartis&#146; canakinumab, a
fully human anti-interleukin-IL1&#223; antibody. The royalty rates in the agreement
start at 4% and reach 15% when annual sales exceed $1.5 billion. Canakinumab is
marketed for the treatment of CAPS, has completed Phase 3 development for gout,
and is in earlier stage development for atherosclerosis and other inflammatory
diseases. We are unable to predict whether canakinumab will be approved for gout
or any other indication in addition to CAPS, or whether, even if approved,
canakinumab for such indication(s) will be successfully
commercialized.</FONT><FONT face="Arial" size=2> </FONT><FONT face="Times New Roman" size=2>Accordingly, we are unable to predict whether these royalties will ever
contribute materially to our results of operations or financial condition. To
date these royalties have been minimal.</FONT></P>
<P align=justify><B><FONT face="Times New Roman" size=2>Research Programs </FONT></B></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Our preclinical research programs are in the areas of oncology and
angiogenesis, ophthalmology, metabolic and related diseases, muscle diseases and
disorders, inflammation and immune diseases, bone and cartilage, pain,
cardiovascular diseases, and infectious diseases.</FONT></P>
<P align=justify><B><U><FONT face="Times New Roman" size=2>General:</FONT></U></B><B><FONT face="Times New Roman" size=2> </FONT></B></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Developing and commercializing new medicines entails significant risk and
expense. Before significant revenues from the commercialization of our antibody
candidates or new indications for our marketed products can be realized, we (or
our collaborators) must overcome a number of hurdles which include successfully
completing research and development and obtaining regulatory approval from the
FDA and regulatory authorities in other countries. In addition, the
biotechnology and pharmaceutical industries are rapidly evolving and highly
competitive, and new developments may render our products and technologies
uncompetitive or obsolete.</FONT></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>We expect to incur substantial costs to prepare for potential
commercialization of ZALTRAP for the treatment of previously-treated mCRC
patients and other late-stage product candidates and, if one or more of these
product candidates receive regulatory approval, to fund the launch of the
product(s). </FONT></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>From our inception in 1988 through 2011, we generally incurred net
losses. In addition, since our inception in 1988, we have generally incurred
negative cash flows from operations. Beginning in the first quarter of 2012, we
reported profitability. Our ability to continue to generate profits and to
generate positive cash flow from operations over the next several years depends
significantly on our success in commercializing EYLEA. We expect to continue to
incur substantial expenses related to our research and development activities, a
significant portion of which we expect to be reimbursed by our collaborators.
Also, our research and development activities outside our collaborations, the
costs of which are not reimbursed, will expand and require additional resources.
Our operating results may fluctuate from quarter to quarter and will depend on,
among other factors, the net sales of our marketed products, as well as the
scope and progress of our research and development efforts, the timing of
certain expenses, the continuation of our collaborations with Sanofi and Bayer
HealthCare, and the amount of reimbursement that we receive from collaborators.
We cannot predict whether or when ZALTRAP or new indications for our marketed
products will receive regulatory approval or, if any such approval is received,
whether we will be able to successfully commercialize such product(s) and
whether or when they may become profitable. </FONT></P>

<P align=center><FONT face="Times New Roman" size=2>27</FONT></P>
<HR align=center width="100%" noShade SIZE=2>


<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>

<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The planning, execution, and results of our clinical programs are
significant factors that can affect our operating and financial results. In our
clinical programs, key events in 2012 to date were, and plans for the next 12
months are, as follows: </FONT></P>

<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face="Times New Roman" size=3></FONT><FONT style="BORDER-BOTTOM: black 1pt solid" face="Times New Roman" size=2><STRONG><EM>Trap-based Clinical
Programs:</EM></STRONG></FONT><EM><FONT face="Times New Roman" size=2><STRONG>
</STRONG></FONT><FONT face="Times New Roman" size=2></FONT></EM></P>
<TABLE style="BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR style="LINE-HEIGHT: 14pt" vAlign=bottom>
    <TD style="TEXT-ALIGN: center" width="1%"></TD>
    <TD style="TEXT-ALIGN: center" width="49%"></TD>
    <TD style="TEXT-ALIGN: center" width="1%"></TD>
    <TD style="TEXT-ALIGN: center" width="49%"><B><FONT face="Times New Roman" size=2>2012-13
      Plans</FONT></B></TD></TR>
  <TR>
    <TD style="BORDER-BOTTOM: #000000 1pt solid; TEXT-ALIGN: center" width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid; TEXT-ALIGN: center" width="49%"><B><FONT face="Times New Roman" size=2>2012 Events to
      Date</FONT></B></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid; TEXT-ALIGN: center" width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid; TEXT-ALIGN: center" width="49%"><B><FONT face="Times New Roman" size=2>(next 12
  months)</FONT></B></TD></TR>
  <TR>
    <TD vAlign=top align=center width="1%"><STRONG><EM><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
      </FONT></EM></STRONG></TD>
    <TD vAlign=top align=center width="49%">
      <P align=justify><B><I><FONT face="Times New Roman" size=2>EYLEA</FONT></I></B></P></TD>
    <TD vAlign=top align=center width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </TD>
    <TD vAlign=top align=center width="49%"></TD></TR>
  <TR>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" vAlign=top align=center width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" vAlign=top align=left width="49%">
      <UL style="FONT-SIZE: 10pt; MARGIN-BOTTOM: -1pt; MARGIN-LEFT: 16px"><LI><FONT face="Times New Roman" size=2>Bayer HealthCare received
        approval for EYLEA from Australia and Colombia for the treatment of
        patients with wet AMD </FONT>
        </LI><LI><FONT face="Times New Roman" size=2>Bayer HealthCare continued to
        pursue regulatory applications for marketing approval for EYLEA for the
        treatment of wet AMD in various countries </FONT>
        </LI><LI><FONT face="Times New Roman" size=2>Initiated Phase 3 study in
        BRVO</FONT>
        </LI><LI><FONT face="Times New Roman" size=2>Completed enrollment of
        VISTA-DME and VIVID-DME studies&nbsp;<BR>&nbsp; </FONT></LI></UL></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" vAlign=top align=left width="1%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" vAlign=top align=left width="49%">
      <UL style="FONT-SIZE: 10pt; MARGIN-BOTTOM: -1pt; MARGIN-LEFT: 16px"><LI><FONT face="Times New Roman" size=2>EMA decision on regulatory
        applications for the treatment of wet AMD </FONT>
        </LI><LI><FONT face="Times New Roman" size=2>Japan authority decision on
        regulatory application for the treatment of wet AMD </FONT>
        </LI><LI><FONT face="Times New Roman" size=2>Target date for FDA decision on
        supplemental BLA for the treatment of CRVO is September 23, 2012</FONT>
        </LI></UL></TD></TR>
  <TR>
    <TD vAlign=top align=center width="1%"></TD>
    <TD vAlign=top align=left width="49%">
      <P align=justify><B><I><FONT face="Times New Roman" size=2>ZALTRAP
      </FONT></I></B></P></TD>
    <TD vAlign=top align=left width="1%"></TD>
    <TD vAlign=top align=left width="49%"></TD></TR>
  <TR>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" vAlign=top align=center width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" vAlign=top align=left width="49%">
      <UL style="FONT-SIZE: 10pt; MARGIN-BOTTOM: -1pt; MARGIN-LEFT: 16px"><LI><FONT face="Times New Roman" size=2>FDA granted Priority Review for
        the BLA for the treatment of mCRC </FONT>
        </LI><LI><FONT face="Times New Roman" size=2>Reported final results in the
        Phase 3 VENICE trial in prostate cancer<BR>&nbsp; </FONT></LI></UL></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" vAlign=top align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" vAlign=top align=left width="49%">
      <UL style="FONT-SIZE: 10pt; MARGIN-BOTTOM: -1pt; MARGIN-LEFT: 16px"><LI><FONT face="Times New Roman" size=2>Target date for FDA decision on
        BLA for the treatment of mCRC is August 4, 2012 </FONT>
        </LI><LI><FONT face="Times New Roman" size=2>EMA decision on regulatory
        applications in mCRC</FONT></LI></UL></TD></TR>
  <TR>
    <TD vAlign=top align=center width="1%"></TD>
    <TD vAlign=top align=left width="49%"><STRONG><EM><FONT face="Times New Roman" size=2>ARCALYST</FONT></EM></STRONG></TD>
    <TD vAlign=top align=left width="1%"></TD>
    <TD vAlign=top align=left width="49%">
      <P>&nbsp;</P></TD></TR>
  <TR>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" vAlign=top align=center width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" vAlign=top align=left width="49%">
      <UL style="FONT-SIZE: 10pt; MARGIN-BOTTOM: -1pt; MARGIN-LEFT: 16px"><LI><FONT face="Times New Roman" size=2>FDA Advisory Committee
        recommended against approval of ARCALYST for the prevention of gout
        flares in patients initiating uric acid-lowering treatment
        <BR>&nbsp;</FONT></LI></UL></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" vAlign=top align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" vAlign=top align=left width="49%">
      <UL style="FONT-SIZE: 10pt; MARGIN-BOTTOM: -1pt; MARGIN-LEFT: 16px">
<LI><FONT face="Times New Roman" size=2>Target date for FDA decision on
      ARCALYST supplemental BLA for gout is July 30, 2012</font></LI></ul>
</TD></TR></TABLE><BR>
<P align=center><FONT face="Times New Roman" size=2>28</FONT></P>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>

<P align=left>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B><I><FONT style="BORDER-BOTTOM: black 1pt solid" face="Times New Roman" size=2>Antibody-based Clinical
Programs:</FONT></I></B></P>


<TABLE style="BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR style="LINE-HEIGHT: 14pt" vAlign=bottom>
    <TD align=left width="1%"></TD>
    <TD align=left width="32%"></TD>
    <TD style="TEXT-ALIGN: center" width="1%"></TD>
    <TD style="TEXT-ALIGN: center" width="33%"></TD>
    <TD style="TEXT-ALIGN: center" width="1%"></TD>
    <TD style="TEXT-ALIGN: center" width="31%"><B><FONT face="Times New Roman" size=2>2012-13
      Plans</FONT></B></TD></TR>
  <TR style="LINE-HEIGHT: 14pt" vAlign=bottom>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=left width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=left width="32%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=left width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid; TEXT-ALIGN: center" align=left width="33%"><B><FONT face="Times New Roman" size=2>2012 Events to
    Date</FONT></B></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid; TEXT-ALIGN: center" width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid; TEXT-ALIGN: center" width="31%"><B><FONT face="Times New Roman" size=2>(next 12
  months)</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD vAlign=top align=left width="1%"></TD>
    <TD vAlign=top align=left width="32%"><B><I><FONT face="Times New Roman" size=2>Sarilumab<BR>(IL-6R Antibody)</FONT></I></B></TD>
    <TD vAlign=top align=left width="1%"></TD>
    <TD vAlign=top align=left width="33%">
      <UL style="FONT-SIZE: 10pt; MARGIN-BOTTOM: -1pt; MARGIN-LEFT: 16px"><LI>Continued patient enrollment in Phase 3 MOBILITY study </LI></UL></TD>
    <TD vAlign=top align=left width="1%"></TD>
    <TD vAlign=top align=left width="31%">
      <UL style="FONT-SIZE: 10pt; MARGIN-BOTTOM: -1pt; MARGIN-LEFT: 16px"><LI>Initiate additional Phase 3 studies</LI></UL></TD></TR>
  <TR>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" vAlign=top width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" vAlign=top width="98%" colSpan=5>&nbsp; </TD></TR>
  <TR vAlign=bottom>
    <TD vAlign=top align=left width="1%">&nbsp;</TD>
    <TD vAlign=top align=left width="32%"><B><I><FONT face="Times New Roman" size=2>REGN727<BR>(PCSK9 Antibody)</FONT></I></B></TD>
    <TD vAlign=top align=left width="1%">&nbsp;</TD>
    <TD vAlign=top align=left width="33%"><FONT face="Times New Roman" size=2>
      <UL style="FONT-SIZE: 10pt; MARGIN-BOTTOM: -1pt; MARGIN-LEFT: 16px"><LI>Initiated long-term safety study
        </LI><LI>Phase 1 data published in <EM>New England Journal of Medicine</EM>
        </LI><LI>Reported positive final data from three Phase 2 studies for LDL
        cholesterol reduction
        </LI><LI>Initiated Phase 3 ODYSSEY program for LDL cholesterol reduction.
        Phase 3 studies began enrolling patients with familial
        hypercholesterolemia or elevated cardiovascular risk, as well as
        patients unable to tolerate statin therapy</LI></UL></FONT></TD>
    <TD vAlign=top align=left width="1%"></TD>
    <TD vAlign=top align=left width="31%">
      <UL style="FONT-SIZE: 10pt; MARGIN-BOTTOM: -1pt; MARGIN-LEFT: 16px"><LI>Initiate Phase 3 ODYSSEY cardiovascular outcomes trial</LI></UL></TD></TR>
  <TR vAlign=bottom>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" vAlign=top align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" vAlign=top align=left width="32%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" vAlign=top align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" vAlign=top align=left width="33%"><FONT face="Times New Roman" size=2></FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" vAlign=top align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" vAlign=top align=left width="31%"></TD></TR>
  <TR vAlign=bottom>
    <TD vAlign=top align=left width="1%"></TD>
    <TD vAlign=top align=left width="32%"><STRONG><EM><FONT size=2 face="Times New Roman">REGN668<BR>(IL-4R Antibody)</FONT></EM></STRONG></TD>
    <TD vAlign=top align=left width="1%"></TD>
    <TD vAlign=top align=left width="33%">
      <UL style="FONT-SIZE: 10pt; MARGIN-BOTTOM: -1pt; MARGIN-LEFT: 16px"><LI>Initiated Phase 2 studies in atopic dermatitis</LI></UL></TD>
    <TD vAlign=top align=left width="1%"></TD>
    <TD vAlign=top align=left width="31%">
      <UL style="FONT-SIZE: 10pt; MARGIN-BOTTOM: -1pt; MARGIN-LEFT: 16px"><LI>Report initial results for Phase 1b study in atopic dermatitis
        </LI><LI>Report initial results for Phase 2 study in eosinophilic
      asthma</LI></UL></TD></TR>
  <TR>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" vAlign=top width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" vAlign=top width="98%" colSpan=5>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD vAlign=top align=left width="1%"></TD>
    <TD vAlign=top align=left width="32%"><STRONG><EM><FONT size=2 face="Times New Roman">REGN421<BR>(Dll4 Antibody)</FONT></EM></STRONG></TD>
    <TD vAlign=top align=left width="1%"></TD>
    <TD vAlign=top align=left width="33%">
      <UL style="FONT-SIZE: 10pt; MARGIN-BOTTOM: -1pt; MARGIN-LEFT: 16px"><LI>Continued patient enrollment in Phase 1 program</LI></UL></TD>
    <TD vAlign=top align=left width="1%"></TD>
    <TD vAlign=top align=left width="31%">
      <UL style="FONT-SIZE: 10pt; MARGIN-BOTTOM: -1pt; MARGIN-LEFT: 16px"><LI>Initiate expansion of the Phase 1 program</LI></UL></TD></TR>
  <TR>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" vAlign=top width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" vAlign=top width="98%" colSpan=5>&nbsp; </TD></TR>
  <TR vAlign=bottom>
    <TD vAlign=top align=left width="1%"></TD>
    <TD vAlign=top align=left width="32%"><STRONG><EM><FONT size=2 face="Times New Roman">REGN910<BR>(ANG2 Antibody)</FONT></EM></STRONG></TD>
    <TD vAlign=top align=left width="1%"></TD>
    <TD vAlign=top align=left width="33%">
      <UL style="FONT-SIZE: 10pt; MARGIN-BOTTOM: -1pt; MARGIN-LEFT: 16px"><LI>Continued patient enrollment in Phase 1 program</LI></UL></TD>
    <TD vAlign=top align=left width="1%">&nbsp;</TD>
    <TD vAlign=top align=left width="31%">
      <UL style="FONT-SIZE: 10pt; MARGIN-BOTTOM: -1pt; MARGIN-LEFT: 16px"><LI>Initiate a Phase 1b program in advanced malignancies </LI></UL></TD></TR>
  <TR>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" vAlign=top width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" vAlign=top width="98%" colSpan=5>&nbsp; </TD></TR>
<TR vAlign=bottom>
    <TD vAlign=top align=left width="1%"></TD>
    <TD vAlign=top align=left width="32%"><FONT STYLE="background-color: TRANSPARENT"><STRONG><EM><FONT size=2 face="Times New Roman">REGN1033<BR>(target not disclosed)</FONT></EM></STRONG></FONT></TD>
    <TD vAlign=top align=left width="1%"></TD>
    <TD vAlign=top align=left width="33%">
      <UL style="FONT-SIZE: 10pt; MARGIN-BOTTOM: -1pt; MARGIN-LEFT: 16px"><LI><FONT STYLE="background-color: TRANSPARENT">Initiated Phase 1 program</FONT></LI></UL></TD>
    <TD vAlign=top align=left width="1%"></TD>
    <TD vAlign=top align=left width="31%"></TD></TR>
  <TR>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" vAlign=top width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" vAlign=top width="98%" colSpan=5>&nbsp; </TD></TR>
  <TR vAlign=bottom>
    <TD vAlign=top align=left width="1%"></TD>
    <TD vAlign=top align=left width="32%"><STRONG><EM><FONT size=2 face="Times New Roman">REGN475<BR>(NGF Antibody)</FONT></EM></STRONG></TD>
    <TD vAlign=top align=left width="1%">&nbsp;</TD>
    <TD vAlign=top align=left width="33%">
      <UL style="FONT-SIZE: 10pt; MARGIN-BOTTOM: -1pt; MARGIN-LEFT: 16px"><LI>Anti-NGF class of antibodies is on clinical hold
        </LI><LI>FDA Advisory Committee voted unanimously in favor of a role for the
        ongoing development of anti-NGF agents in osteoarthritis
        </LI><LI>Sanofi elected not to co-develop REGN475</LI></UL></TD>
    <TD vAlign=top align=left width="1%"></TD>
    <TD vAlign=top align=left width="31%">
      <UL style="FONT-SIZE: 10pt; MARGIN-BOTTOM: -1pt; MARGIN-LEFT: 16px"><LI>Determine future development plan</LI></UL></TD></TR>
  <TR>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" vAlign=top width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" vAlign=top width="98%" colSpan=5>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD vAlign=top align=left width="1%"></TD>
    <TD vAlign=top align=left width="32%"><STRONG><EM><FONT size=2 face="Times New Roman">REGN846<BR>(target not disclosed)</FONT></EM></STRONG></TD>
    <TD vAlign=top align=left width="1%"></TD>
    <TD vAlign=top align=left width="33%">
      <UL style="FONT-SIZE: 10pt; MARGIN-BOTTOM: -1pt; MARGIN-LEFT: 16px"><LI>Continued patient enrollment in Phase 2a program in atopic
        dermatitis</LI></UL></TD>
    <TD vAlign=top align=left width="1%"></TD>
    <TD vAlign=top align=left width="31%"></TD></TR>
  <TR>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" vAlign=top width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" vAlign=top width="98%" colSpan=5>&nbsp; </TD></TR>

  <TR vAlign=bottom>
    <TD vAlign=top align=left width="1%"></TD>
    <TD vAlign=top align=left width="32%"><STRONG><EM><FONT size=2 face="Times New Roman">REGN1154<BR>(target not disclosed)</FONT></EM></STRONG></TD>
    <TD vAlign=top align=left width="1%"></TD>
    <TD vAlign=top align=left width="33%">
      <UL style="FONT-SIZE: 10pt; MARGIN-BOTTOM: -1pt; MARGIN-LEFT: 16px"><LI>Initiated Phase 1 program</LI></UL></TD>
    <TD vAlign=top align=left width="1%"></TD>
    <TD vAlign=top align=left width="31%"></TD></TR>
  <TR>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" vAlign=top width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" vAlign=top width="98%" colSpan=5>&nbsp; </TD></TR></TABLE><BR>
<P align=center><FONT face="Times New Roman" size=2>29</FONT></P>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<P align=justify><B><FONT face="Times New Roman" size=2>Results of Operations</FONT></B></P>
<P align=justify><B><I><FONT face="Times New Roman" size=2><U>Three Months Ended June 30,
2012 and 2011</U></FONT></I></B><B><I><FONT face="Times New Roman" size=2>
</FONT></I></B></P>
<P align=justify><B><I><FONT face="Times New Roman" size=2>Net Income (Loss)
</FONT></I></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face="Times New Roman" size=2>We
reported net income of $76.7 million, or $0.70 per diluted share, for the second
quarter of 2012, compared to a net loss of $62.5 million, or $0.69 per diluted
share, for the second quarter of 2011. Our net income in the second quarter of
2012 resulted from net product sales of EYLEA, which we launched in November
2011.</FONT></P>
<P align=justify><B><I><FONT face="Times New Roman" size=2>Revenues </FONT></I></B></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Revenues for the three months ended
June 30, 2012 and 2011 consist of the following: </FONT></P>
<DIV align=center>
<TABLE style="LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="80%" border=0>

  <TR vAlign=bottom>
    <TD noWrap align=left width="92%"><B><I><FONT face="Times New Roman" size=2>(In
      millions)</FONT></I></B></TD>
    <TD noWrap align=left width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid; text-align: center" noWrap width="3%" colSpan=2><B><FONT face="Times New Roman" size=2>2012</FONT></B></TD>
    <TD noWrap style="text-align: center" width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid; text-align: center" noWrap width="3%" colSpan=2><B><FONT face="Times New Roman" size=2>2011</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="92%" bgColor=#cceeff><FONT face="Times New Roman" size=2>Net product
sales</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD  noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD  noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=2>199.5</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD  noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD  noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=2>5.0</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="92%"><FONT face="Times New Roman" size=2>Collaboration revenue:</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="2%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="2%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="92%" bgColor=#cceeff><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Sanofi</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=2>89.0</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=2>84.5</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="92%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Bayer
      HealthCare</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="2%"><FONT face="Times New Roman" size=2>9.1</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="2%"><FONT face="Times New Roman" size=2>11.1</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="92%" bgColor=#cceeff><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total
      collaboration revenue</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=2>98.1</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=2>95.6</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="92%"><FONT face="Times New Roman" size=2>Technology licensing revenue</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="2%"><FONT face="Times New Roman" size=2>5.9</FONT></TD>
    <TD noWrap align=left width="1%">&nbsp;</TD>
    <TD noWrap align=left width="1%">&nbsp;</TD>
    <TD noWrap align=right width="2%"><FONT face="Times New Roman" size=2>5.2</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="92%" bgColor=#cceeff><FONT face="Times New Roman" size=2>Contract research and
      other revenue</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=2>0.9</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=2>2.0</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="92%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total
      revenue</FONT></TD>
    <TD noWrap align=right width="1%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%"><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="2%"><FONT face="Times New Roman" size=2>304.4</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%"><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="2%"><FONT face="Times New Roman" size=2>107.8</FONT></TD></TR></TABLE></DIV><BR>
<P align=justify><I><FONT face="Times New Roman" size=2>Net Product Sales </FONT></I></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Net product sales consist of U.S.
sales of our two marketed products, EYLEA and ARCALYST. In November 2011, we
received marketing approval from the FDA for EYLEA for the treatment of wet AMD,
at which time product sales commenced. For the three months ended June 30, 2012,
we recognized $194.0 million of EYLEA net product sales. For the three months
ended June 30, 2012 and 2011, we also recognized ARCALYST net product sales of
$5.5 million and $5.0 million, respectively.</FONT></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>We sell EYLEA in the United States
to three distributors and several specialty pharmacies. We sell ARCALYST in the
United States to two specialty pharmacies. Under these distribution models, the
distributors and specialty pharmacies (collectively, our customers) generally
take physical delivery of product. For EYLEA, the distributors and specialty
pharmacies generally sell the product directly to healthcare providers; whereas
for ARCALYST, the specialty pharmacies sell the product directly to patients. We
record revenue from product sales upon delivery to our customers. For the three
months ended June 30, 2012, we recorded 79% of our gross product revenue from
sales to our distributor, Besse Medical, a subsidiary of AmerisourceBergen
Corporation.</FONT></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>We record product sales net of
allowances and accruals for prompt pay discounts, rebates and chargebacks under
governmental programs (including Medicaid), product returns, and
distribution-related fees. The following table summarizes the provisions, and
credits/payments, for government rebates and chargebacks, distribution-related
fees, and other sales-related deductions; such amounts were not material for the
three months ended June 30, 2011.</FONT></P>
<TABLE style="LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD noWrap align=left width="73%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="4%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="6%" colSpan=3><B><FONT face="Times New Roman" size=2>Distribution-</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="6%" colSpan=3><B><FONT face="Times New Roman" size=2>Other Sales-</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="73%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="6%" colSpan=3><B><FONT face="Times New Roman" size=2>Rebates &amp;</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="6%" colSpan=3><B><FONT face="Times New Roman" size=2>Related</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="6%" colSpan=3><B><FONT face="Times New Roman" size=2>Related</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="73%"><B><I><FONT face="Times New Roman" size=2>(In millions)</FONT></I></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid; TEXT-ALIGN: center" noWrap width="6%" colSpan=3><B><FONT face="Times New Roman" size=2>Chargebacks</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid; TEXT-ALIGN: center" noWrap width="6%" colSpan=3><B><FONT face="Times New Roman" size=2>Fees</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid; TEXT-ALIGN: center" noWrap width="6%" colSpan=3><B><FONT face="Times New Roman" size=2>Deductions</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid; TEXT-ALIGN: center" noWrap width="4%" colSpan=3><B><FONT face="Times New Roman" size=2>Total</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="73%" bgColor=#cceeff><FONT face="Times New Roman" size=2>Balance as of March 31, 2012</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD noWrap align=right width="4%" bgColor=#cceeff><FONT face="Times New Roman" size=2>2.8</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD noWrap align=right width="4%" bgColor=#cceeff><FONT face="Times New Roman" size=2>5.5</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD noWrap align=right width="4%" bgColor=#cceeff><FONT face="Times New Roman" size=2>0.5</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=2>8.8</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="73%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Provision related to
      current period sales</FONT></TD>
    <TD noWrap align=left width="1%">&nbsp;</TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="4%"><FONT face="Times New Roman" size=2>3.8</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="4%"><FONT face="Times New Roman" size=2>11.0</FONT></TD>
    <TD noWrap align=left width="1%">&nbsp;</TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="4%"><FONT face="Times New Roman" size=2>1.6</FONT></TD>
    <TD noWrap align=left width="1%">&nbsp;</TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%">&nbsp;</TD>
    <TD noWrap align=right width="2%"><FONT face="Times New Roman" size=2>16.4</FONT></TD>
    <TD noWrap align=left width="1%">&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="73%" bgColor=#cceeff><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Credits/payments</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="4%" bgColor=#cceeff><FONT face="Times New Roman" size=2>(1.8</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>)</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="4%" bgColor=#cceeff><FONT face="Times New Roman" size=2>(5.4</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>)</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="4%" bgColor=#cceeff><FONT face="Times New Roman" size=2>(0.6</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>)</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=2>(7.8</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>)</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="73%"><FONT face="Times New Roman" size=2>Balance as of June 30, 2012</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%"><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="4%"><FONT face="Times New Roman" size=2>4.8</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%"><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="4%"><FONT face="Times New Roman" size=2>11.1</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%"><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="4%"><FONT face="Times New Roman" size=2>1.5</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%"><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="2%"><FONT face="Times New Roman" size=2>17.4</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%"></TD></TR></TABLE><BR>
<P align=justify><I><FONT face="Times New Roman" size=2>Sanofi Collaboration Revenue
</FONT></I></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>The collaboration revenue we earned
from Sanofi, as detailed below, consisted primarily of reimbursement for
research and development expenses that we incurred and recognition of revenue
related to non-refundable up-front payments of $105.0 million related to the
ZALTRAP collaboration and $85.0 million related to the antibody collaboration.
We subtract from Sanofi collaboration revenue amounts that we are obligated to
pay Sanofi to reimburse them for commercialization expenses that they incur.
</FONT></P>
<P align=center><FONT face="Times New Roman" size=2>30</FONT></P>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<TABLE style="LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD noWrap align=left width="87%" colSpan=2></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=center width="11%" colSpan=7><B><FONT face="Times New Roman" size=2>Three months ended</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="2%"><B><FONT face="Times New Roman" size=2>Sanofi Collaboration
      Revenue</FONT></B></TD>
    <TD noWrap align=left width="85%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="11%" colSpan=7><B><FONT face="Times New Roman" size=2>June 30,</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="87%" colSpan=2><B><I><FONT face="Times New Roman" size=2>(In millions)</FONT></I></B></TD>
    <TD noWrap align=left width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="5%" colSpan=3><B><FONT face="Times New Roman" size=2>2012</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap align=center width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="5%" colSpan=3><B><FONT face="Times New Roman" size=2>2011</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="87%" bgColor=#cceeff colSpan=2><FONT face="Times New Roman" size=2>ZALTRAP:</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="3%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="3%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="87%" colSpan=2><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Regeneron expense
      reimbursement</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=left width="1%"><FONT face="Times New Roman" size=2>$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=2>4.2</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=left width="1%"><FONT face="Times New Roman" size=2>$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=2>4.2</FONT></TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="87%" bgColor=#cceeff colSpan=2><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Recognition of deferred
      revenue related to up-front payments</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="3%" bgColor=#cceeff><FONT face="Times New Roman" size=2>2.9</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="3%" bgColor=#cceeff><FONT face="Times New Roman" size=2>2.5</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="87%" colSpan=2><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Regeneron share of
      ZALTRAP commercialization expenses</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%"><FONT face="Times New Roman" size=2>(8.4</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"><FONT face="Times New Roman" size=2>)</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%"><FONT face="Times New Roman" size=2>(1.3</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"><FONT face="Times New Roman" size=2>)</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="87%" bgColor=#cceeff colSpan=2><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total
      ZALTRAP</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%" bgColor=#cceeff><FONT face="Times New Roman" size=2>(1.3</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>)</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%" bgColor=#cceeff><FONT face="Times New Roman" size=2>5.4</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="87%" colSpan=2><FONT face="Times New Roman" size=2>Antibody:</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="3%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="3%"></TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="87%" bgColor=#cceeff colSpan=2><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Regeneron expense
      reimbursement</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="3%" bgColor=#cceeff><FONT face="Times New Roman" size=2>87.8</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="3%" bgColor=#cceeff><FONT face="Times New Roman" size=2>76.6</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="87%" colSpan=2><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Recognition of deferred
      revenue related to up-front and other</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="3%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="3%"></TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="87%" colSpan=2><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;payments</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=2>2.1</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=2>2.1</FONT></TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="87%" bgColor=#cceeff colSpan=2><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Recognition of revenue
      related to</FONT> <I><FONT face="Times New Roman" size=2>VelociGene</FONT></I> <FONT face="Times New Roman" size=2>agreement</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%" bgColor=#cceeff><FONT face="Times New Roman" size=2>0.4</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%" bgColor=#cceeff><FONT face="Times New Roman" size=2>0.4</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="87%" colSpan=2><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total
      antibody</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%"><FONT face="Times New Roman" size=2>90.3</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%"><FONT face="Times New Roman" size=2>79.1</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="87%" bgColor=#cceeff colSpan=2><FONT face="Times New Roman" size=2>Total Sanofi collaboration revenue</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="3%" bgColor=#cceeff><FONT face="Times New Roman" size=2>89.0</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="3%" bgColor=#cceeff><FONT face="Times New Roman" size=2>84.5</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%" bgColor=#cceeff></TD></TR></TABLE>
<BR>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face="Times New Roman" size=2>Sanofi&#146;s
reimbursement of our ZALTRAP expenses primarily consists of reimbursements for
manufacturing ZALTRAP supplies and research and development activities. We and
Sanofi equally share pre-launch commercialization expenses related to ZALTRAP in
accordance with the companies&#146; collaboration agreement. These expenses have
increased in the second quarter of 2012, compared to the same period in 2011,
due to an increase in commercialization activities in preparation for potential
regulatory approvals. In connection with recognition of deferred revenue related
to ZALTRAP, as of June 30, 2012, $17.3 million of the original $105.0 million of
up-front payments was deferred and will be recognized as revenue in future
periods.</FONT></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>In the second quarter of 2012,
Sanofi&#146;s reimbursement of our antibody expenses consisted of $46.5 million under
the discovery agreement and $41.3 million of development costs under the license
agreement, compared to $40.7 million and $35.9 million, respectively, in the
second quarter of 2011. The higher reimbursement amount under the discovery
agreement in the second quarter of 2012, compared to the same period in 2011,
was primarily due to an increase in our antibody discovery activities. The
higher reimbursement of development costs in the second quarter of 2012,
compared to the same period in 2011, was primarily due to an increase in
development activities related to REGN727.</FONT></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>In connection with recognition of
deferred revenue related to our antibody collaboration, as of June 30, 2012,
$73.4 million of the original $85.0 million up-front payment and other payments
was deferred and will be recognized as revenue in future periods. In connection
with the November 2009 amendment of the discovery agreement, Sanofi is funding
up to $30 mi<I>l</I>lion of agreed-upon costs incurred by us to expand our
manufacturing capacity at our Rensselaer, New York facilities, of which $29.6
million was received or receivable as of June 30, 2012. Revenue related to such
funding from Sanofi is deferred and recognized as collaboration revenue
prospectively over the related performance period in conjunction with the
recognition of the original $85.0 million up-front payment.</FONT></P>


<P align=center><FONT face="Times New Roman" size=2>31</FONT></P>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>

<P align=justify><I><FONT face="Times New Roman" size=2>Bayer HealthCare Collaboration
Revenue</FONT></I></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>The collaboration revenue we earned
from Bayer HealthCare, as detailed below, consisted of cost sharing of Regeneron
EYLEA development expenses and recognition of revenue related to a
non-refundable $75.0 million up-front payment received in October 2006 and a
$20.0 million milestone payment received in August 2007 (which, for the purpose
of revenue recognition, was not considered substantive).</FONT></P>

<TABLE style="LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD noWrap align=left width="91%" colSpan=2></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="7%" colSpan=5><B><FONT face="Times New Roman" size=2>Three months ended</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"><B><FONT face="Times New Roman" size=2>Bayer HealthCare
      Collaboration Revenue</FONT></B></TD>
    <TD noWrap align=left width="90%">&nbsp;</TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid; TEXT-ALIGN: center" noWrap width="7%" colSpan=5><B><FONT face="Times New Roman" size=2>June
      30,</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="91%" colSpan=2><B><I><FONT face="Times New Roman" size=2>(In millions)</FONT></I></B></TD>
    <TD noWrap align=left width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid; TEXT-ALIGN: center" noWrap width="3%" colSpan=2><B><FONT face="Times New Roman" size=2>2012</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid; TEXT-ALIGN: center" noWrap width="3%" colSpan=2><B><FONT face="Times New Roman" size=2>2011</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="91%" bgColor=#cceeff colSpan=2><FONT face="Times New Roman" size=2>Cost-sharing of Regeneron EYLEA development
      expenses</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=2>7.1</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=2>8.6</FONT></TD></TR>

  <TR vAlign=bottom>
    <TD noWrap align=left width="91%" colSpan=2><FONT face="Times New Roman" size=2>Recognition of deferred revenue related to up-front and other
      milestone <FONT STYLE="BACKGROUND-COLOR: TRANSPARENT">payments</FONT></FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="2%"><FONT face="Times New Roman" size=2>2.0</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="2%"><FONT face="Times New Roman" size=2>2.5</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="91%" bgColor=#cceeff colSpan=2><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total Bayer HealthCare
      collaboration revenue</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=2>9.1</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=2>11.1</FONT></TD></TR></TABLE><BR>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face="Times New Roman" size=2>Cost-sharing of our global EYLEA development expenses with Bayer
HealthCare decreased in the second quarter of 2012 compared to the same period
in 2011 due primarily to lower costs in connection with our Phase 3 VIEW 1 study
in wet AMD, which has concluded. Recognition of deferred revenue related to the
up-front and August 2007 milestone payments from Bayer HealthCare decreased in
the second quarter of 2012 from the same quarter in 2011 due to an extension in
the estimated performance period over which this deferred revenue is being
recognized, effective in the fourth quarter of 2011. As of June 30, 2012, $40.6
million of these up-front and milestone payments was deferred and will be
recognized as revenue in future periods.</FONT></P>
<P align=justify><I><FONT face="Times New Roman" size=2>Technology Licensing Revenue
</FONT></I></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>In connection with our
</FONT><I><FONT face="Times New Roman" size=2>VelocImmune </FONT></I><FONT face="Times New Roman" size=2>license agreement with Astellas, the $20.0 million non-refundable payment
received in the second quarter of 2010 was deferred upon receipt and recognized
as revenue ratably over the ensuing year. In addition, in connection with the
amendment and extension of our license agreement with Astellas, in August 2010,
we received a $165.0 million up-front payment, which was deferred upon receipt
and is being recognized as revenue ratably over a seven-year period beginning in
June 2011. In the second quarter of 2012 and 2011, we recognized $5.9 million
and $5.2 million, respectively, of technology licensing revenue related to this
agreement. As of June 30, 2012, $139.9 million of the August 2010 technology
licensing <FONT STYLE="background-color: TRANSPARENT">payment</FONT> received from Astellas was deferred and will be recognized as
revenue in future periods. </FONT></P>
<P align=justify><I><FONT face="Times New Roman" size=2>Contract Research and Other Revenue
</FONT></I></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Contract research and other revenue
for the three months ended June 30, 2011 included $1.2 million recognized in
connection with our five-year grant from the National Institutes of Health
(NIH), which we were awarded in September 2006 as part of the NIH&#146;s Knockout
Mouse Project. As of the end of 2011, no further revenue has been recognized by
us in connection with this NIH Grant. In addition, under a June 2009 agreement
with Novartis, we receive royalties on worldwide sales of Novartis&#146; canakinumab.
For the three months ended June 30, 2012 and 2011, contract research and other
revenue included $0.8 million and $0.5 million, respectively, of royalties from
Novartis.</FONT></P>
<P align=justify><B><I><FONT face="Times New Roman" size=2>Expenses </FONT></I></B></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Total operating expenses increased
to $216.9 million in the second quarter of 2012 from $168.1 million in the
second quarter of 2011. Our average headcount in the second quarter of 2012
increased to 1,783 from 1,497 in the same period of 2011 principally in
connection with commercializing EYLEA in wet AMD, and as a result of our
expanding research and development activities, which were primarily attributable
to our antibody collaboration with Sanofi.</FONT></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Operating expenses in the second
quarter of 2012 and 2011 included a total of $19.6 million and $12.4 million,
respectively, of non-cash compensation expense related to employee stock option
and restricted stock awards (Non-cash Compensation Expense). The increase in
total Non-cash Compensation Expense in the second quarter of 2012 was primarily
attributable to the higher fair market value of our Common Stock on the date of
our annual employee option grants made in December 2011 compared to recent prior
years.</FONT></P>

<P align=center><FONT face="Times New Roman" size=2>32</FONT></P>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>

<P align=justify><I><FONT face="Times New Roman" size=2>Research and Development Expenses
</FONT></I></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Research and development expenses
increased to $147.4 million in the second quarter of 2012 from $143.1 million in
the same period of 2011. The following table summarizes the major categories of
our research and development expenses for the three months ended June 30, 2012
and 2011: </FONT></P>



<TABLE style="LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD noWrap align=left width="86%" colSpan=2></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="7%" colSpan=5><B><FONT face="Times New Roman" size=2>For the three months ended</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="5%"><B><FONT face="Times New Roman" size=2>Research and Development
      Expenses*</FONT></B></TD>
    <TD noWrap align=left width="81%">&nbsp;</TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid; TEXT-ALIGN: center" noWrap width="7%" colSpan=5><B><FONT face="Times New Roman" size=2>June
      30,</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="4%" colSpan=3><B><FONT face="Times New Roman" size=2>Increase</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="86%" colSpan=2><B><I><FONT face="Times New Roman" size=2>(In millions)</FONT></I></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid; TEXT-ALIGN: center" noWrap width="3%" colSpan=2><B><FONT face="Times New Roman" size=2>2012</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid; TEXT-ALIGN: center" noWrap width="3%" colSpan=2><B><FONT face="Times New Roman" size=2>2011</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid; TEXT-ALIGN: center" noWrap width="4%" colSpan=3><B><FONT face="Times New Roman" size=2>(Decrease)</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="86%" bgColor=#cceeff colSpan=2><FONT face="Times New Roman" size=2>Payroll and benefits (1)</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=2>50.8</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=2>41.5</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=2>9.3</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="86%" colSpan=2><FONT face="Times New Roman" size=2>Clinical trial expenses</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="2%"><FONT face="Times New Roman" size=2>19.3</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="2%"><FONT face="Times New Roman" size=2>19.5</FONT></TD>
    <TD noWrap align=left width="1%">&nbsp;</TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="2%"><FONT face="Times New Roman" size=2>(0.2</FONT></TD>
    <TD noWrap align=left width="1%"><FONT face="Times New Roman" size=2>)</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="86%" bgColor=#cceeff colSpan=2><FONT face="Times New Roman" size=2>Clinical manufacturing costs (2)</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=2>39.3</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=2>34.0</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=2>5.3</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="86%" colSpan=2><FONT face="Times New Roman" size=2>Research and other development costs</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="2%"><FONT face="Times New Roman" size=2>13.0</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%">&nbsp;</TD>
    <TD noWrap align=right width="2%"><FONT face="Times New Roman" size=2>15.8</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="2%"><FONT face="Times New Roman" size=2>(2.8</FONT></TD>
    <TD noWrap align=left width="1%"><FONT face="Times New Roman" size=2>)</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="86%" bgColor=#cceeff colSpan=2><FONT face="Times New Roman" size=2>Occupancy and other operating
costs</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=2>20.4</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=2>15.0</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=2>5.4</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="86%" colSpan=2><FONT face="Times New Roman" size=2>Cost-sharing of Bayer HealthCare EYLEA</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="2%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="2%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="2%"></TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="86%" colSpan=2><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;development expenses
      (3)</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="2%"><FONT face="Times New Roman" size=2>4.6</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="2%"><FONT face="Times New Roman" size=2>17.3</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="2%"><FONT face="Times New Roman" size=2>(12.7</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"><FONT face="Times New Roman" size=2>)</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="86%" bgColor=#cceeff colSpan=2><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total research and
      development <FONT STYLE="background-color: TRANSPARENT">expenses</FONT></FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=2>147.4</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=2>143.1</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=2>4.3</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%" bgColor=#cceeff></TD></TR>
  </TABLE>____________________<BR>&nbsp;<BR>
<TABLE cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR>
    <TD width="100%">
      <P align=justify><FONT face="Times New Roman" size=2>* Certain prior year
      amounts have been reclassified to conform to the current year&#146;s
      presentation. </FONT></P></TD></TR></TABLE><BR>
<TABLE style="TEXT-ALIGN: justify" cellSpacing=0 cellPadding=0 border=0>

  <TR>
    <TD vAlign=top noWrap><FONT size=2 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD vAlign=top noWrap><FONT face="Times New Roman" size=2>(1)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD width="100%"><FONT face="Times New Roman" size=2>Includes Non-cash Compensation
      Expense of $10.3 million for the three months ended June 30, 2012 and $6.7
      million for the three months ended June 30, 2011.</FONT></TD></TR>
  <TR>
    <TD vAlign=top noWrap></TD>
    <TD vAlign=top noWrap><FONT face="Times New Roman" size=2>(2)</FONT></TD>
    <TD width="100%"><FONT face="Times New Roman" size=2>Represents the full cost of
      manufacturing drug for use in research, preclinical development, and
      clinical trials, including related payroll and benefits, Non-cash
      Compensation Expense, manufacturing materials and supplies, drug filling,
      packaging, and labeling costs, depreciation, and occupancy costs of our
      Rensselaer manufacturing facility. Includes Non-cash Compensation Expense
      of $1.2 million for the three months ended June 30, 2012 and $1.0 million
      for the three months ended June 30, 2011.</FONT></TD></TR>
  <TR>
    <TD vAlign=top noWrap></TD>
    <TD vAlign=top noWrap><FONT face="Times New Roman" size=2>(3)</FONT></TD>
    <TD width="100%"><FONT face="Times New Roman" size=2>Under our collaboration with
      Bayer HealthCare, in periods when Bayer HealthCare incurs EYLEA
      development expenses, we also recognize, as additional research and
      development expense, the portion of Bayer HealthCare&#146;s EYLEA development
      expenses that we are obligated to reimburse. Bayer HealthCare provides us
      with estimated EYLEA development expenses for the most recent fiscal
      quarter. Bayer HealthCare&#146;s estimate is reconciled to its actual expenses
      for such quarter in the subsequent fiscal quarter and our portion of its
      EYLEA development expenses that we are obligated to reimburse is adjusted
      accordingly.</FONT></TD></TR></TABLE>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face="Times New Roman" size=2>Payroll
and benefits increased principally due to the increase in employee headcount and
Non-cash Compensation Expense, as described above. Clinical trial expenses
decreased due primarily to lower costs related to our Phase 3 VIEW 1 trial of
EYLEA in wet AMD, which has concluded, partly offset by higher costs related to
our Phase 3 studies of EYLEA in DME and BRVO, and higher costs for clinical
studies of our antibody candidates. Clinical manufacturing costs increased
primarily due to higher costs related to manufacturing REGN727 and ARCALYST
supplies. Research and other development costs decreased primarily due to lower
preclinical development costs associated with our antibody programs. Occupancy
and other operating costs increased principally in connection with our higher
headcount and expanded research and development activities. Cost-sharing of
Bayer HealthCare&#146;s EYLEA development expenses decreased primarily due to lower
costs in connection with Bayer HealthCare&#146;s wet AMD development activities,
including the VIEW 2 trial, which has concluded.</FONT></P>

<P align=center><FONT face="Times New Roman" size=2>33</FONT></P>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>

<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>We prepare estimates of research and
development costs for projects in clinical development, which include direct
costs and allocations of certain costs such as indirect labor, Non-cash
Compensation Expense, and manufacturing and other costs related to activities
that benefit multiple projects, and, under our collaboration with Bayer
HealthCare, the portion of Bayer HealthCare&#146;s EYLEA development expenses that we
are obligated to reimburse. Our estimates of research and development costs for
clinical development programs are shown below: </FONT></P>

<TABLE style="LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD noWrap align=left width="86%" colSpan=2></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap align=left width="7%" colSpan=5><B><FONT face="Times New Roman" size=2>For the three
      months</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="3%"><B><FONT face="Times New Roman" size=2>Project
    Costs</FONT></B></TD>
    <TD noWrap align=left width="83%">&nbsp;</TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid; TEXT-ALIGN: center" noWrap align=left width="7%" colSpan=5><B><FONT face="Times New Roman" size=2>ended June 30,</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="4%" colSpan=3><B><FONT face="Times New Roman" size=2>Increase</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="86%" colSpan=2><B><I><FONT face="Times New Roman" size=2>(In millions)</FONT></I></B></TD>
    <TD noWrap align=left width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid; TEXT-ALIGN: center" noWrap align=left width="3%" colSpan=2><B><FONT face="Times New Roman" size=2>2012</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid; TEXT-ALIGN: center" noWrap align=left width="3%" colSpan=2><B><FONT face="Times New Roman" size=2>2011</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid; TEXT-ALIGN: center" noWrap width="4%" colSpan=3><B><FONT face="Times New Roman" size=2>(Decrease)</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="86%" bgColor=#cceeff colSpan=2><FONT face="Times New Roman" size=2>ARCALYST</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=2>15.0</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=2><FONT STYLE="background-color: TRANSPARENT">8.0</FONT></FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=2><FONT STYLE="background-color: TRANSPARENT">7.0</FONT></FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="86%" colSpan=2><FONT face="Times New Roman" size=2>EYLEA</FONT></TD>
    <TD noWrap align=left width="1%">&nbsp;</TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="2%"><FONT face="Times New Roman" size=2>27.3</FONT></TD>
    <TD noWrap align=left width="1%">&nbsp;</TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="2%"><FONT face="Times New Roman" size=2>44.1</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="2%"><FONT face="Times New Roman" size=2>(16.8</FONT></TD>
    <TD noWrap align=left width="1%"><FONT face="Times New Roman" size=2>)</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="86%" bgColor=#cceeff colSpan=2><FONT face="Times New Roman" size=2>ZALTRAP</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=2>5.7</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=2>4.0</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=2>1.7</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="86%" colSpan=2><FONT face="Times New Roman" size=2>Sarilumab</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%">&nbsp;</TD>
    <TD noWrap align=right width="2%"><FONT face="Times New Roman" size=2>5.9</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="2%"><FONT face="Times New Roman" size=2>7.3</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%">&nbsp;</TD>
    <TD noWrap align=right width="2%"><FONT face="Times New Roman" size=2>(1.4</FONT></TD>
    <TD noWrap align=left width="1%"><FONT face="Times New Roman" size=2>)</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="86%" bgColor=#cceeff colSpan=2><FONT face="Times New Roman" size=2>REGN727</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=2>18.0</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=2>9.7</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=2>8.3</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="86%" colSpan=2><FONT face="Times New Roman" size=2>Other antibody candidates in clinical development</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="2%"><FONT face="Times New Roman" size=2>15.2</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="2%"><FONT face="Times New Roman" size=2>15.4</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="2%"><FONT face="Times New Roman" size=2>(0.2</FONT></TD>
    <TD noWrap align=left width="1%"><FONT face="Times New Roman" size=2>)</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="86%" bgColor=#cceeff colSpan=2><FONT face="Times New Roman" size=2>Other research programs &amp; unallocated
      costs</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=2>60.3</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=2><FONT STYLE="background-color: TRANSPARENT">54.6</FONT></FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=2><FONT STYLE="background-color: TRANSPARENT">5.7</FONT></FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="86%" colSpan=2><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total research and
      development expenses</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%"><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="2%"><FONT face="Times New Roman" size=2>147.4</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%"><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="2%"><FONT face="Times New Roman" size=2>143.1</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%"><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="2%"><FONT face="Times New Roman" size=2>4.3</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%"></TD></TR></TABLE><BR>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face="Times New Roman" size=2>Drug
development and approval in the United States is a multi-step process regulated
by the FDA. The process begins with discovery and preclinical evaluation,
leading up to the submission of an IND to the FDA which, if successful, allows
the opportunity for study in humans, or clinical study, of the potential new
drug. Clinical development typically involves three phases of study: Phases 1,
2, and 3. The most significant costs in clinical development are in Phase 3
clinical trials, as they tend to be the longest and largest studies in the drug
development process. Following successful completion of Phase 3 clinical trials
for a biological product, a BLA must be submitted to, and accepted by, the FDA,
and the FDA must approve the BLA prior to commercialization of the drug. It is
not uncommon for the FDA to request additional data following its review of a
BLA, which can significantly increase the drug development timeline and
expenses. We may elect either on our own, or at the request of the FDA, to
conduct further studies that are referred to as Phase 3b and 4 studies. Phase 3b
studies are initiated and either completed or substantially completed while the
BLA is under FDA review. These studies are conducted under an IND. Phase 4
studies, also referred to as post-marketing studies, are studies that are
initiated and conducted after the FDA has approved a product for marketing. In
addition, as discovery research, preclinical development, and clinical programs
progress, opportunities to expand development of drug candidates into new
disease indications can emerge. We may elect to add such new disease indications
to our development efforts (with the approval of our collaborator for joint
development programs), thereby extending the period in which we will be
developing a product.</FONT></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>There are numerous uncertainties
associated with drug development, including uncertainties related to safety and
efficacy data from each phase of drug development, uncertainties related to the
enrollment and performance of clinical trials, changes in regulatory
requirements, changes in the competitive landscape affecting a product
candidate, and other risks and uncertainties described in Part II, Item 1A,
&#147;Risk Factors&#148;. The lengthy process of seeking FDA approvals, and subsequent
compliance with applicable statutes and regulations, require the expenditure of
substantial resources. Any failure by us to obtain, or delay in obtaining,
regulatory approvals could materially adversely affect our business.</FONT></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>For these reasons and due to the
variability in the costs necessary to develop a pharmaceutical product and the
uncertainties related to future indications to be studied, the estimated cost
and scope of the projects, and our ultimate ability to obtain governmental
approval for commercialization, accurate and meaningful estimates of the total
cost to bring our product candidates to market are not available. Similarly, we
are currently unable to reasonably estimate if our product candidates in
clinical development will generate material product revenues and net cash
inflows.</FONT><I><FONT face="Times New Roman" size=2> </FONT></I></P>
<P align=justify><I><FONT face="Times New Roman" size=2>Selling, General, and Administrative
Expenses </FONT></I></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Selling, general, and administrative
expenses increased to $47.7 million in the second quarter of 2012 from $24.6
million in the same period of 2011 due to higher selling expenses in connection
with commercialization of EYLEA in wet AMD, higher headcount, and higher
Non-cash Compensation Expense principally for the reason described above.
Selling, general, and administrative expenses included $7.8 million and $4.7
million of Non-cash Compensation Expense for the three months ended June 30,
2012 and 2011, respectively.</FONT></P>
<P align=center><FONT face="Times New Roman" size=2>34</FONT></P>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<P align=justify><I><FONT face="Times New Roman" size=2>Cost of Goods Sold
</FONT></I></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face="Times New Roman" size=2>Cost of
goods sold increased to $21.8 million in the second quarter of 2012 from $0.4
million in the same period of 2011 due primarily to our launch of EYLEA for the
treatment of wet AMD in November 2011. Cost of goods sold primarily consisted of
royalties, as well as costs in connection with producing EYLEA and ARCALYST
commercial supplies. In addition, in the second quarter of 2012, cost of goods
sold included inventory write-downs and reserves totaling $6.5 million. We
record a charge to cost of goods sold to write down our inventory to its
estimated realizable value if certain batches or units of product do not meet
quality specifications or may be expected to expire prior to sale.</FONT></P>
<P align=justify><B><I><FONT face="Times New Roman" size=2>Other Income and Expense
</FONT></I></B></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Investment income decreased to $0.5
million in the second quarter of 2012 from $1.0 million in the same period of
2011 due primarily to lower yields on cash and marketable securities.</FONT></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Interest expense increased to $11.2
million in the second quarter of 2012 from $4.0 million in the same period of
2011. In October 2011, we issued $400.0 million aggregate principal amount of
1.875% convertible senior notes. Total interest expense in the second quarter of
2012 associated with these notes, including amortization of the note discount
and debt issuance costs, was $7.2 million.</FONT></P>
<P align=justify><B><I><FONT face="Times New Roman" size=2>Income Taxes</FONT></I></B></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Despite achieving profitability in
the first quarter of 2012, we continue to recognize a full valuation allowance
against our net operating loss carry-forward and other deferred tax assets since
we have an extended history of losses. For the three months ended June 30, 2011,
we recognized an income tax benefit of $0.9 million in connection with the net
tax effect of the change in our unrealized gain/(loss) on &#147;available-for-sale&#148;
marketable securities, which is included in other comprehensive income
(loss).</FONT></P>
<P align=justify><B><I><FONT face="Times New Roman" size=2><U>Six Months Ended June 30, 2012
and 2011</U></FONT></I></B><B><I><FONT face="Times New Roman" size=2> </FONT></I></B></P>
<P align=justify><B><I><FONT face="Times New Roman" size=2>Net Income (Loss)
</FONT></I></B></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>We reported net income of $88.4
million, or $0.81 per diluted share, for the first half of 2012, compared to a
net loss of $106.0 million, or $1.18 per diluted share, for the first half of
2011. Our net income in the first half of 2012 resulted from net product sales
of EYLEA, which we launched in November 2011.</FONT></P>
<P align=justify><B><I><FONT face="Times New Roman" size=2>Revenues </FONT></I></B></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Revenues for the six months ended
June 30, 2012 and 2011 consist of the following: </FONT></P>
<DIV align=center>
<TABLE style="LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="80%" border=0>

  <TR vAlign=bottom>
    <TD noWrap align=left width="90%"><B><I><FONT face="Times New Roman" size=2>(In
      millions)</FONT></I></B></TD>
    <TD noWrap align=left width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid; text-align: center" noWrap width="4%" colSpan=2><B><FONT face="Times New Roman" size=2>2012</FONT></B></TD>
    <TD noWrap style="text-align: center" width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid; text-align: center" noWrap width="4%" colSpan=2><B><FONT face="Times New Roman" size=2>2011</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="90%" bgColor=#cceeff><FONT face="Times New Roman" size=2>Net product
sales</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="3%" bgColor=#cceeff><FONT face="Times New Roman" size=2>327.4</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="3%" bgColor=#cceeff><FONT face="Times New Roman" size=2>9.5</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="90%"><FONT face="Times New Roman" size=2>Collaboration revenue:</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="3%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="3%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="90%" bgColor=#cceeff><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Sanofi</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="3%" bgColor=#cceeff><FONT face="Times New Roman" size=2>174.0</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD noWrap align=right width="3%" bgColor=#cceeff><FONT face="Times New Roman" size=2>169.8</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="90%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Bayer
      HealthCare</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%"><FONT face="Times New Roman" size=2>21.6</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%"><FONT face="Times New Roman" size=2>23.6</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="90%" bgColor=#cceeff><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total
      collaboration revenue</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="3%" bgColor=#cceeff><FONT face="Times New Roman" size=2>195.6</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="3%" bgColor=#cceeff><FONT face="Times New Roman" size=2>193.4</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="90%"><FONT face="Times New Roman" size=2>Technology licensing revenue</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%">&nbsp;</TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=2>11.8</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=2>13.0</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="90%" bgColor=#cceeff><FONT face="Times New Roman" size=2>Contract research and
      other revenue</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%" bgColor=#cceeff><FONT face="Times New Roman" size=2>1.4</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%" bgColor=#cceeff><FONT face="Times New Roman" size=2>4.1</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="90%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total
    revenue</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="1%"><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="3%"><FONT face="Times New Roman" size=2>536.2</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="1%"><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="3%"><FONT face="Times New Roman" size=2>220.0</FONT></TD></TR></TABLE></DIV><BR>
<P align=justify><I><FONT face="Times New Roman" size=2>Net Product Sales </FONT></I></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Net product sales consist of U.S.
sales of our two marketed products, EYLEA and ARCALYST. In November 2011, we
received marketing approval from the FDA for EYLEA for the treatment of wet AMD,
at which time product sales commenced. For the six months ended June 30, 2012,
we recognized $317.5 million of EYLEA net product sales. For the six months
ended June 30, 2012 and 2011, we also recognized ARCALYST net product sales of
$9.9 million and $9.5 million, respectively.</FONT></P>
<P align=center><FONT face="Times New Roman" size=2>35</FONT></P>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face="Times New Roman" size=2>We sell
EYLEA in the United States to three distributors and several specialty
pharmacies. We sell ARCALYST in the United States to two specialty pharmacies.
Under these distribution models, the distributors and specialty pharmacies
(collectively, our customers) generally take physical delivery of product. For
EYLEA, the distributors and specialty pharmacies generally sell the product
directly to healthcare providers; whereas for ARCALYST, the specialty pharmacies
sell the product directly to patients. We record revenue from product sales upon
delivery to our customers. For the six months ended June 30, 2012, we recorded
79% of our gross product revenue from sales to Besse Medical, a subsidiary of
AmerisourceBergen Corporation.</FONT></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>We record product sales net of
allowances and accruals for prompt pay discounts, rebates and chargebacks under
governmental programs (including Medicaid), product returns, and
distribution-related fees. The following table summarizes the provisions, and
credits/payments, for government rebates and chargebacks, distribution-related
fees, and other sales-related deductions; such amounts were not material as of
and for the six months ended June 30, 2011.</FONT></P>
<TABLE style="LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD noWrap align=left width="79%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="4%" colSpan=3><B><FONT face="Times New Roman" size=2>Distribution-</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="4%" colSpan=3><B><FONT face="Times New Roman" size=2>Other Sales-</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="79%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="4%" colSpan=3><B><FONT face="Times New Roman" size=2>Rebates &amp;</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="4%" colSpan=3><B><FONT face="Times New Roman" size=2>Related</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="4%" colSpan=3><B><FONT face="Times New Roman" size=2>Related</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="79%"><B><I><FONT face="Times New Roman" size=2>(In millions)</FONT></I></B></TD>
    <TD noWrap align=left width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid; TEXT-ALIGN: center" noWrap width="4%" colSpan=3><B><FONT face="Times New Roman" size=2>Chargebacks</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid; TEXT-ALIGN: center" noWrap width="4%" colSpan=3><B><FONT face="Times New Roman" size=2>Fees</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid; TEXT-ALIGN: center" noWrap width="4%" colSpan=3><B><FONT face="Times New Roman" size=2>Deductions</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid; TEXT-ALIGN: center" noWrap width="4%" colSpan=3><B><FONT face="Times New Roman" size=2>Total</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="79%" bgColor=#cceeff><FONT face="Times New Roman" size=2>Balance as of December 31, 2011</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=2>0.6</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=2>1.5</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=2>0.2</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=2>2.3</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="79%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Provision related to
      current period sales</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%">&nbsp;</TD>
    <TD noWrap align=right width="2%"><FONT face="Times New Roman" size=2>6.2</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%">&nbsp;</TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="2%"><FONT face="Times New Roman" size=2>17.9</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%">&nbsp;</TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="2%"><FONT face="Times New Roman" size=2>2.4</FONT></TD>
    <TD noWrap align=left width="1%">&nbsp;</TD>
    <TD noWrap align=left width="1%">&nbsp;</TD>
    <TD noWrap align=left width="1%">&nbsp;</TD>
    <TD noWrap align=right width="2%"><FONT face="Times New Roman" size=2>26.5</FONT></TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="79%" bgColor=#cceeff><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Credits/payments</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=2>(2.0</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>)</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=2>(8.3</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>)</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=2>(1.1</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>)</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=2>(11.4</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>)</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="79%"><FONT face="Times New Roman" size=2>Balance as of June 30, 2012</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%"><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="2%"><FONT face="Times New Roman" size=2>4.8</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%"><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="2%"><FONT face="Times New Roman" size=2>11.1</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%"><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="2%"><FONT face="Times New Roman" size=2>1.5</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%"><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="2%"><FONT face="Times New Roman" size=2>17.4</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%"></TD></TR></TABLE><BR>
<P align=justify><I><FONT face="Times New Roman" size=2>Sanofi Collaboration Revenue
</FONT></I></P>
<P align=justify><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The collaboration revenue we earned
from Sanofi, as detailed below, consisted primarily of reimbursement for
research and development expenses and recognition of revenue related to
non-refundable up-front payments of $105.0 million related to the ZALTRAP
collaboration and $85.0 million related to the antibody
collaboration. <FONT STYLE="background-color: TRANSPARENT">We subtract from Sanofi collaboration revenue amounts that we are obligated to pay Sanofi to reimburse them for commercialization expenses that they incur.</FONT></FONT></P>
<TABLE style="LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD noWrap align=left width="89%" colSpan=2></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap align=center width="9%" colSpan=7><B><FONT face="Times New Roman" size=2>Six months
      ended</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="3%"><B><FONT face="Times New Roman" size=2>Sanofi Collaboration
      Revenue</FONT></B></TD>
    <TD noWrap align=left width="86%">&nbsp;</TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid; TEXT-ALIGN: center" noWrap align=center width="9%" colSpan=7><B><FONT face="Times New Roman" size=2>June 30,</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="89%" colSpan=2><B><I><FONT face="Times New Roman" size=2>(In millions)</FONT></I></B></TD>
    <TD noWrap align=left width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid; TEXT-ALIGN: center" noWrap align=center width="4%" colSpan=3><B><FONT face="Times New Roman" size=2>2012</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap align=center width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid; TEXT-ALIGN: center" noWrap align=center width="4%" colSpan=3><B><FONT face="Times New Roman" size=2>2011</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="89%" bgColor=#cceeff colSpan=2><FONT face="Times New Roman" size=2>ZALTRAP:</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="2%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="2%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="89%" colSpan=2><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Regeneron expense
      reimbursement</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=left width="1%"><FONT face="Times New Roman" size=2>$&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD noWrap align=right width="2%"><FONT face="Times New Roman" size=2>7.0</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=left width="1%"><FONT face="Times New Roman" size=2>$&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD noWrap align=right width="2%"><FONT face="Times New Roman" size=2>11.4</FONT></TD>
    <TD noWrap align=left width="1%">&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="89%" bgColor=#cceeff colSpan=2><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Recognition of deferred
      revenue related to up-front payments</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=2>5.4</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=2>5.0</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="89%" colSpan=2><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Regeneron share of
      ZALTRAP commercialization expenses</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="2%"><FONT face="Times New Roman" size=2>(12.1</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"><FONT face="Times New Roman" size=2>)</FONT></TD>
    <TD noWrap align=left width="1%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="2%"><FONT face="Times New Roman" size=2>(1.3</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"><FONT face="Times New Roman" size=2>)</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="89%" bgColor=#cceeff colSpan=2><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total
      ZALTRAP</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=2>0.3</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=2>15.1</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="89%" colSpan=2><FONT face="Times New Roman" size=2>Antibody:</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%">&nbsp;</TD>
    <TD noWrap align=left width="2%">&nbsp;</TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="2%"></TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="89%" bgColor=#cceeff colSpan=2><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Regeneron expense
      reimbursement</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=2>168.6</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=2>149.8</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="89%" colSpan=2><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Recognition of deferred
      revenue related to up-front and other</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="2%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="2%"></TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="89%" colSpan=2><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;payments</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="2%"><FONT face="Times New Roman" size=2>4.3</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="2%"><FONT face="Times New Roman" size=2>4.1</FONT></TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="89%" bgColor=#cceeff colSpan=2><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Recognition of revenue
      related to </FONT><I><FONT face="Times New Roman" size=2>VelociGene
      </FONT></I><FONT face="Times New Roman" size=2>agreement</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=2>0.8</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=2>0.8</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="89%" colSpan=2><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total
      antibody</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="2%"><FONT face="Times New Roman" size=2>173.7</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="2%"><FONT face="Times New Roman" size=2>154.7</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="89%" bgColor=#cceeff colSpan=2><FONT face="Times New Roman" size=2>Total Sanofi collaboration revenue</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=2>174.0</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=2>169.8</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%" bgColor=#cceeff></TD></TR></TABLE><BR>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face="Times New Roman" size=2>Sanofi&#146;s
reimbursement of our ZALTRAP expenses decreased in the first half of 2012
compared to same period in 2011, primarily due to lower costs related to
manufacturing ZALTRAP supplies and a decrease in other research and development
activities. Effective in the second quarter of 2011, we and Sanofi began equally
sharing pre-launch commercialization expenses related to ZALTRAP in accordance
with the companies&#146; collaboration agreement. These expenses have increased in
the first half of 2012, compared to the same period in 2011, due to an increase
in commercialization activities in preparation for potential regulatory
approvals. </FONT></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>In the first half of 2012, Sanofi&#146;s
reimbursement of our antibody expenses consisted of $91.1 million under the
discovery agreement and $77.5 million of development costs under the license
agreement, compared to $82.8 million and $67.0 million, respectively, in the
first half of 2011. The higher reimbursement amount under the discovery
agreement in the first half of 2012, compared to the same period in 2011, was
primarily due to an increase in our antibody discovery activities. The higher
reimbursement of development costs in the first half of 2012, compared to the same period in 2011, was primarily due to an increase in development activities related to REGN727 and REGN1033.</FONT></P>
<P align=center><FONT face="Times New Roman" size=2>36</FONT></P>
<HR align=center width="100%" noShade SIZE=2>


<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>


<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>As it relates to recognition of
deferred revenue, in connection with the November 2009 amendment of the
discovery agreement, Sanofi is funding up to $30 million of agreed-upon costs
incurred by us to expand our manufacturing capacity at our Rensselaer, New York
facilities<FONT STYLE="background-color: TRANSPARENT">, of which $29.6 million was received or receivable as of June 30, 2012</FONT>. Revenue related to such funding from Sanofi is deferred and
recognized as collaboration revenue prospectively over the related performance
period in conjunction with the recognition of the original $85.0 million
up-front payment.</FONT></P>
<P align=justify><I><FONT face="Times New Roman" size=2>Bayer HealthCare Collaboration
Revenue </FONT></I></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>The collaboration revenue we earned
from Bayer HealthCare, as detailed below, consisted of cost sharing of Regeneron
EYLEA development expenses and recognition of revenue related to a
non-refundable $75.0 million up-front payment received in October 2006 and a
$20.0 million milestone payment received in August 2007 (which, for the purpose
of revenue recognition, was not considered substantive).</FONT></P>
<DIV align=center>
<TABLE style="LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD noWrap align=left width="92%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="7%" colSpan=5><B><FONT face="Times New Roman" size=2>Six months
      ended</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="92%">
      <DIV style="WIDTH: 3%; BORDER-BOTTOM: #000000 1pt solid"><B><FONT face="Times New Roman" size=2>Bayer HealthCare Collaboration
    Revenue</FONT></B></DIV></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid; text-align: center" noWrap width="7%" colSpan=5><B><FONT face="Times New Roman" size=2>June 30,</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="92%"><B><I><FONT face="Times New Roman" size=2>(In
      millions)</FONT></I></B></TD>
    <TD noWrap style="text-align: center" width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid; text-align: center" noWrap width="3%" colSpan=2><B><FONT face="Times New Roman" size=2>2012</FONT></B></TD>
    <TD noWrap style="text-align: center" width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid; text-align: center" noWrap width="3%" colSpan=2><B><FONT face="Times New Roman" size=2>2011</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="92%" bgColor=#cceeff><FONT face="Times New Roman" size=2>Cost-sharing of Regeneron
      EYLEA development expenses</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=2>17.6</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=2>18.7</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="92%"><FONT face="Times New Roman" size=2>Recognition of deferred revenue related to
      up-front and other
      milestone payments</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="2%"><FONT face="Times New Roman" size=2>4.0</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="2%"><FONT face="Times New Roman" size=2>4.9</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="92%" bgColor=#cceeff><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total Bayer HealthCare
      collaboration revenue</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=2>21.6</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=2>23.6</FONT></TD></TR></TABLE></DIV><BR>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Cost-sharing of our global EYLEA
development expenses with Bayer HealthCare decreased slightly in the first half
of 2012 compared to the same period in 2011. In the first half of 2012, we
incurred lower costs in connection with our Phase 3 VIEW 1 study in wet AMD,
which has concluded, partly offset by higher costs in connection with regulatory
and other development activities. Recognition of deferred revenue related to the
up-front and August 2007 milestone payments from Bayer HealthCare decreased in
the first half of 2012 from the same quarter in 2011 due to an extension in the
estimated performance period over which this deferred revenue is being
recognized, effective in the fourth quarter of 2011.</FONT></P>
<P align=justify><I><FONT face="Times New Roman" size=2>Technology Licensing Revenue
</FONT></I></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>In connection with our
</FONT><I><FONT face="Times New Roman" size=2>VelocImmune </FONT></I><FONT face="Times New Roman" size=2>license agreement with Astellas, the $20.0 million non-refundable payment
received in the second quarter of 2010 was deferred upon receipt and recognized
as revenue ratably over the ensuing year. In addition, in connection with the
amendment and extension of our license agreement with Astellas, in August 2010,
we received a $165.0 million up-front payment, which was deferred upon receipt
and is being recognized as revenue ratably over a seven-year period beginning in
June 2011. In connection with our </FONT><I><FONT face="Times New Roman" size=2>VelocImmune</FONT></I><FONT face="Times New Roman" size=2> license agreement with
AstraZeneca, which terminated effective as of February 2011, the $20.0 million
non-refundable payment received in the first quarter of 2010 was deferred upon
receipt and recognized as revenue ratably through February 2011. In the first
half of 2012 and 2011, we recognized $11.8 million and $13.0 million,
respectively, of technology licensing revenue related to these
agreements.</FONT></P>
<P align=justify><I><FONT face="Times New Roman" size=2>Contract Research and Other Revenue
</FONT></I></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Contract research and other revenue
for the six months ended June 30, 2011 included $2.2 million recognized in
connection with our five-year grant from the NIH, which we were awarded in
September 2006 as part of the NIH&#146;s Knockout Mouse Project. As of the end of
2011, no further revenue has been recognized by us in connection with this NIH
Grant. In addition, under a June 2009 agreement with Novartis, we receive
royalties on worldwide sales of Novartis&#146; canakinumab. For the six months ended
June 30, 2012 and 2011, contract research and other revenue included $1.3
million and $1.2 million, respectively, of royalties from Novartis.</FONT></P>
<P align=justify><B><I><FONT face="Times New Roman" size=2>Expenses </FONT></I></B></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Total operating expenses increased
to $426.5 million in the first half of 2012 from $321.3 million for the same
period of 2011. Our average headcount in the first half of 2012 increased to
1,756 from 1,464 in the same period of 2011 principally in connection with
commercializing EYLEA in wet AMD, and as a result of our expanding research and
development activities, which were primarily attributable to our antibody
collaboration with Sanofi.</FONT></P>
<P align=center><FONT face="Times New Roman" size=2>37</FONT></P>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Operating expenses in the first half
of 2012 and 2011 included a total of $42.9 million and $27.2 million,
respectively, <FONT STYLE="background-color: TRANSPARENT">of Non-cash Compensation Expense</FONT>. The increase in
total Non-cash Compensation Expense in the first half of 2012 was primarily
attributable to the higher fair market value of our Common Stock on the date of
our annual employee option grants made in December 2011 compared to recent prior
years.</FONT></P>
<P align=justify><I><FONT face="Times New Roman" size=2>Research and Development Expenses
</FONT></I></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Research and development expenses
increased to $286.2 million in the first half of 2012 from $272.5 million in the
same period of 2011. The following table summarizes the major categories of our
research and development expenses for the six months ended June 30, 2012 and
2011: </FONT></P>
<DIV align=center>
<TABLE style="LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="80%" border=0>

  <TR vAlign=bottom>
    <TD noWrap align=left width="83%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="7%" colSpan=5><B><FONT face="Times New Roman" size=2>For the six
      months ended</FONT></B></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="6%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="83%">
      <DIV style="WIDTH: 3%; BORDER-BOTTOM: #000000 1pt solid"><B><FONT face="Times New Roman" size=2>Research and Development Expenses*</FONT></B></DIV></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid; text-align: center" noWrap width="7%" colSpan=5><B><FONT face="Times New Roman" size=2>June 30,</FONT></B></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="8%" colSpan=3><B><FONT face="Times New Roman" size=2>Increase</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="83%"><B><I><FONT face="Times New Roman" size=2>(In
      millions)</FONT></I></B></TD>
    <TD noWrap style="text-align: center" width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid; text-align: center" noWrap width="3%" colSpan=2><B><FONT face="Times New Roman" size=2>2012</FONT></B></TD>
    <TD noWrap style="text-align: center" width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid; text-align: center" noWrap width="3%" colSpan=2><B><FONT face="Times New Roman" size=2>2011</FONT></B></TD>
    <TD noWrap style="text-align: center" width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid; text-align: center" noWrap width="8%" colSpan=3><B><FONT face="Times New Roman" size=2>(Decrease)</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="83%" bgColor=#cceeff><FONT face="Times New Roman" size=2>Payroll and benefits
      (1)</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=2>102.2</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=2>84.1</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff><FONT size=2 face="Times New Roman">$</FONT> </TD>
    <TD noWrap align=right width="6%" bgColor=#cceeff><FONT face="Times New Roman" size=2>18.1</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="83%"><FONT face="Times New Roman" size=2>Clinical trial expenses</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="2%"><FONT face="Times New Roman" size=2>42.6</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="2%"><FONT face="Times New Roman" size=2>35.6</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="6%"><FONT face="Times New Roman" size=2>7.0</FONT></TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="83%" bgColor=#cceeff><FONT face="Times New Roman" size=2>Clinical manufacturing
      costs (2)</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=2>66.3</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=2>59.1</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="6%" bgColor=#cceeff><FONT face="Times New Roman" size=2>7.2</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="83%"><FONT face="Times New Roman" size=2>Research and other development
    costs</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="2%"><FONT face="Times New Roman" size=2>25.8</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="2%"><FONT face="Times New Roman" size=2>31.1</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="6%"><FONT face="Times New Roman" size=2>(5.3</FONT></TD>
    <TD noWrap align=left width="1%"><FONT face="Times New Roman" size=2>)</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="83%" bgColor=#cceeff><FONT face="Times New Roman" size=2>Occupancy and other
      operating costs</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=2>39.2</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=2>29.0</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="6%" bgColor=#cceeff><FONT face="Times New Roman" size=2>10.2</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="83%"><FONT face="Times New Roman" size=2>Cost-sharing of Bayer HealthCare
    EYLEA</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="2%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="2%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="6%"></TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="83%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;development
      expenses (3)</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="2%"><FONT face="Times New Roman" size=2>10.1</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="2%"><FONT face="Times New Roman" size=2>33.6</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="6%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(23.5</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"><FONT face="Times New Roman" size=2>)</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="83%" bgColor=#cceeff><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total
      research and
      development expenses</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=2>286.2</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=2>272.5</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%" bgColor=#cceeff><FONT size=2 face="Times New Roman">$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="6%" bgColor=#cceeff><FONT face="Times New Roman" size=2>13.7</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%" bgColor=#cceeff></TD></TR></TABLE></DIV>____________________<BR>&nbsp;<BR>
<TABLE cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR>
    <TD width="100%"><FONT size=2 face="Times New Roman">*&nbsp;Certain prior year amounts have been
      reclassified to conform to the current year&#146;s
  presentation.</FONT></TD></TR></TABLE><BR>
<TABLE style="TEXT-ALIGN: justify" cellSpacing=0 cellPadding=0 border=0>

  <TR>
    <TD vAlign=top noWrap>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD vAlign=top noWrap><FONT face="Times New Roman" size=2>(1)</FONT></TD>
    <TD vAlign=top noWrap>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD vAlign=top width="100%"><FONT face="Times New Roman" size=2>Includes Non-cash
      Compensation Expense of $19.8 million for the six months ended June 30,
      2012 and $13.6 million for the six months ended June 30,
2011.</FONT></TD></TR>
  <TR>
    <TD vAlign=top noWrap></TD>
    <TD vAlign=top noWrap><FONT face="Times New Roman" size=2>(2)</FONT></TD>
    <TD vAlign=top noWrap></TD>
    <TD vAlign=top width="100%"><FONT face="Times New Roman" size=2>Represents the full
      cost of manufacturing drug for use in research, preclinical development,
      and clinical trials, including related payroll and benefits, Non-cash
      Compensation Expense, manufacturing materials and supplies, drug filling,
      packaging, and labeling costs, depreciation, and occupancy costs of our
      Rensselaer manufacturing facility. Includes Non-cash Compensation Expense
      of $2.2 million for the six months ended June 30, 2012 and $1.9 million
      for the six months ended June 30, 2011.</FONT></TD></TR>
  <TR>
    <TD vAlign=top noWrap></TD>
    <TD vAlign=top noWrap><FONT face="Times New Roman" size=2>(3)</FONT></TD>
    <TD vAlign=top noWrap></TD>
    <TD vAlign=top width="100%"><FONT face="Times New Roman" size=2>Under our
      collaboration with Bayer HealthCare, in periods when Bayer HealthCare
      incurs EYLEA development expenses, we also recognize, as additional
      research and development expense, the portion of Bayer HealthCare&#146;s EYLEA
      development expenses that we are obligated to reimburse. Bayer HealthCare
      provides us with estimated EYLEA development expenses for the most recent
      fiscal quarter. Bayer HealthCare&#146;s estimate is reconciled to its actual
      expenses for such quarter in the subsequent fiscal quarter and our portion
      of its EYLEA development expenses that we are obligated to reimburse is
      adjusted accordingly.</FONT></TD></TR></TABLE>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Payroll and benefits increased
principally due to the increase in employee headcount and Non-cash Compensation
Expense, as described above. Clinical trial expenses increased due primarily to
higher costs related to our Phase 3 studies of EYLEA in DME and BRVO, as well as
and higher costs for clinical studies of our antibody candidates, partly offset
by lower costs related to our Phase 3 VIEW 1 trial of EYLEA in wet AMD, which
has concluded. Clinical manufacturing costs increased primarily due to higher
costs related to manufacturing REGN727 and ARCALYST supplies. Research and other
development costs decreased primarily due lower preclinical development costs
associated with our antibody programs. Occupancy and other operating costs
increased principally in connection with our higher headcount and expanded
research and development activities. Cost-sharing of Bayer HealthCare&#146;s EYLEA
development expenses decreased primarily due to lower costs in connection with
Bayer HealthCare&#146;s wet AMD development activities, including the VIEW 2 trial,
which has concluded.</FONT></P>
<P align=center><FONT face="Times New Roman" size=2>38</FONT></P>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>We prepare estimates of research and
development costs for projects in clinical development, which include direct
costs and allocations of certain costs such as indirect labor, Non-cash
Compensation Expense, and manufacturing and other costs related to activities
that benefit multiple projects, and, under our collaboration with Bayer
HealthCare, the portion of Bayer HealthCare&#146;s EYLEA development expenses that we
are obligated to reimburse. Our estimates of research and development costs for
clinical development programs are shown below: </FONT></P>
<DIV align=center>
<TABLE style="LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="80%" border=0>

  <TR vAlign=bottom>
    <TD noWrap align=left width="88%" colSpan=2></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="7%" colSpan=5><B><FONT face="Times New Roman" size=2>For the six
      months</FONT></B></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="2%"><B><FONT face="Times New Roman" size=2>Project Costs</FONT></B></TD>
    <TD noWrap align=left width="86%">&nbsp;</TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid; text-align: center" noWrap width="7%" colSpan=5><B><FONT face="Times New Roman" size=2>ended June 30,</FONT></B></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="3%" colSpan=3><B><FONT face="Times New Roman" size=2>Increase</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="88%" colSpan=2><B><I><FONT face="Times New Roman" size=2>(In millions)</FONT></I></B></TD>
    <TD noWrap style="text-align: center" width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid; text-align: center" noWrap width="3%" colSpan=2><B><FONT face="Times New Roman" size=2>2012</FONT></B></TD>
    <TD noWrap style="text-align: center" width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid; text-align: center" noWrap width="3%" colSpan=2><B><FONT face="Times New Roman" size=2>2011</FONT></B></TD>
    <TD noWrap style="text-align: center" width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid; text-align: center" noWrap width="3%" colSpan=3><B><FONT face="Times New Roman" size=2>(Decrease)</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="88%" bgColor=#cceeff colSpan=2><FONT face="Times New Roman" size=2>ARCALYST</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=2>25.8</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=2><FONT STYLE="background-color: TRANSPARENT">16.6</FONT></FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2><FONT STYLE="background-color: TRANSPARENT">9.2</FONT></FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="88%" colSpan=2><FONT face="Times New Roman" size=2>EYLEA</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="2%"><FONT face="Times New Roman" size=2>62.2</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="2%"><FONT face="Times New Roman" size=2>83.7</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=2>(21.5</FONT></TD>
    <TD noWrap align=left width="1%"><FONT face="Times New Roman" size=2>)</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="88%" bgColor=#cceeff colSpan=2><FONT face="Times New Roman" size=2>ZALTRAP</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=2>8.5</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=2>10.4</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>(1.9</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>)</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="88%" colSpan=2><FONT face="Times New Roman" size=2>Sarilumab</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="2%"><FONT face="Times New Roman" size=2>17.2</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="2%"><FONT face="Times New Roman" size=2>14.0</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=2>3.2</FONT></TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="88%" bgColor=#cceeff colSpan=2><FONT face="Times New Roman" size=2>REGN727</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=2>25.1</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=2>16.8</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>8.3</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="88%" colSpan=2><FONT face="Times New Roman" size=2>Other antibody candidates
      in clinical development</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="2%"><FONT face="Times New Roman" size=2>29.9</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="2%"><FONT face="Times New Roman" size=2>28.0</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=2>1.9</FONT></TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="88%" bgColor=#cceeff colSpan=2><FONT face="Times New Roman" size=2>Other research programs &amp; unallocated costs</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=2>117.5</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=2><FONT STYLE="background-color: TRANSPARENT">103.0</FONT></FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2><FONT STYLE="background-color: TRANSPARENT">14.5</FONT></FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="88%" colSpan=2><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total research and
      development expenses</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%"><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="2%"><FONT face="Times New Roman" size=2>286.2</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%"><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="2%"><FONT face="Times New Roman" size=2>272.5</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%"><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="1%"><FONT face="Times New Roman" size=2>13.7</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%"></TD></TR></TABLE></DIV><BR>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>For the reasons described above
under &#147;Research and Development Expenses&#148; for the three months ended June 30,
2012 and 2011, and due to the variability in the costs necessary to develop a
pharmaceutical product and the uncertainties related to future indications to be
studied, the estimated cost and scope of the projects, and our ultimate ability
to obtain governmental approval for commercialization, accurate and meaningful
estimates of the total cost to bring our product candidates to market are not
available. Similarly, we are currently unable to reasonably estimate if our
product candidates will generate material product revenues and net cash
inflows.</FONT><I><FONT face="Times New Roman" size=2> </FONT></I></P>
<P align=justify><I><FONT face="Times New Roman" size=2>Selling, General, and Administrative
Expenses </FONT></I></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Selling, general, and administrative
expenses increased to $106.1 million in the first half of 2012 from $48.0
million in the same period of 2011 due to higher selling expenses in connection
with commercialization of EYLEA in wet AMD, higher headcount, and higher
Non-cash Compensation Expense principally for the reason described above.
Selling, general, and administrative expenses includes $20.4 million and $11.7
million of Non-cash Compensation Expense for the six months ended June 30, 2012
and 2011, respectively.</FONT></P>
<P align=justify><I><FONT face="Times New Roman" size=2>Cost of Goods Sold </FONT></I></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Cost of goods sold increased to
$34.1 million in the first half of 2012 from $0.8 million in the same period of
2011 due primarily to our launch of EYLEA for the treatment of wet AMD in
November 2011. Cost of goods sold primarily consisted of royalties, as well as
costs in connection with producing EYLEA and ARCALYST commercial supplies. In
addition, in the first half of 2012, cost of goods sold included inventory
write-downs and reserves totaling $8.4 million. We record a charge to cost of
goods sold to write down our inventory to its estimated realizable value if
certain batches or units of product do not meet quality specifications or may be
expected to expire prior to sale.</FONT></P>
<P align=justify><B><I><FONT face="Times New Roman" size=2>Other Income and Expense
</FONT></I></B></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Investment income decreased to $1.1
million in the first half of 2012 from $2.0 million in the same period of 2011
due primarily to lower yields on cash and marketable securities.</FONT></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Interest expense increased to $22.4
million in the first half of 2012 from $7.8 million in the same period of 2011.
In October 2011, we issued $400.0 million aggregate principal amount of 1.875%
convertible senior notes. Total interest expense in the first half of 2012
associated with these notes, including amortization of the note discount and
debt issuance costs, was $14.3 million.</FONT></P>
<P align=center><FONT face="Times New Roman" size=2>39</FONT></P>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<P align=justify><B><I><FONT face="Times New Roman" size=2>Income Taxes</FONT></I></B></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Despite achieving profitability in
the first half of 2012, we continue to recognize a full valuation allowance
against our net operating loss carry-forward and other deferred tax assets since
we have an extended history of losses. For the six months ended June 30, 2011,
we recognized an income tax benefit of $1.1 million in connection with the net
tax effect of the change in our unrealized gain/(loss) on &#147;available-for-sale&#148;
marketable securities, which is included in other comprehensive income
(loss).</FONT></P>
<P align=justify><B><FONT face="Times New Roman" size=2>Liquidity and Capital
Resources</FONT></B></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Since our inception in 1988, we have
financed our operations primarily through offerings of our equity securities,
private placements of convertible debt, purchases of our equity securities by
our collaborators, including Sanofi, revenue earned under our past and present
research and development agreements, including our agreements with Sanofi and
Bayer HealthCare, EYLEA and ARCALYST product revenue, our technology licensing
agreements, our past contract manufacturing agreements, and investment
income.</FONT></P>
<P align=justify><B><I><FONT face="Times New Roman" size=2>Six months ended June 30, 2012
and 2011 </FONT></I></B></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>At June 30, 2012, we had $597.5
million in cash, cash equivalents, and marketable securities (including $8.1
million of restricted cash and marketable securities) compared with $810.6
million at December 31, 2011 (including $7.7 million of restricted cash and
marketable securities). In connection with our product launch of EYLEA in
November 2011, we have offered extended payment terms to our EYLEA customers. As
a result, only a small portion of the proceeds from our EYLEA product sales to
date have been collected and our net trade accounts receivable increased to
$349.6 million at June 30, 2012 from $28.3 million at December 31, 2011. We
expect collections of EYLEA trade receivables to increase effective in the third
quarter. </FONT></P>
<P align=justify><I><FONT face="Times New Roman" size=2>Cash Used in Operating Activities
</FONT></I></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Net cash used in operating
activities was $165.4 million in the first six months of 2012 and $44.6 million
in the first six months of 2011. Our net income of $88.4 million in the first
half of 2012, and our net loss of $106.0 million in the first half of 2011,
included $42.9 million and $27.2 million, respectively, of Non-cash Compensation
Expense, and $17.8 million and $14.9 million, respectively, of depreciation and
amortization. Our net income in the first half of 2012 also included non-cash
interest expense of $10.5 million resulting from the amortization of the
discount and debt issuance costs in connection with our convertible senior
notes, which were issued in October 2011.</FONT></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>At June 30, 2012, Sanofi and trade
accounts receivable increased by $332.3 million, compared to end-of-year 2011.
Trade accounts receivable increased primarily due to higher EYLEA product <FONT STYLE="background-color: TRANSPARENT">sales</FONT>
and the extended payment terms granted to our EYLEA <FONT STYLE="background-color: TRANSPARENT">customers,</FONT> as described
above. Our deferred revenue at June 30, 2012 decreased by $17.7 million,
compared to end-of-year 2011, primarily due to amortization of a previously
received and deferred $165.0 million payment under our license agreement with
Astellas and amortization of previously deferred payments under our Sanofi and
Bayer HealthCare collaborations. Accounts payable, accrued expenses, and other
liabilities increased by $32.8 million at June 30, 2012, compared to end-of-year
2011, primarily due to higher sales-related deductions and royalties in
connection with EYLEA.</FONT></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>At June 30, 2011, deferred revenue
decreased by $20.6 million, compared to end-of-year 2010, primarily due to the
amortization of previously received and deferred $20.0 million payments under
our license agreements with AstraZeneca and Astellas, as well as amortization of
<FONT STYLE="background-color: TRANSPARENT">previously deferred</FONT> payments under our Sanofi and Bayer HealthCare
collaborations. Accounts payable, accrued expenses, and other liabilities
increased by $38.6 million at June 30, 2011, compared to end-of-year 2010,
primarily in connection with our expanded levels of activities and expenditures,
including higher liabilities for pre-launch commercialization activities, higher
payroll-related liabilities, and an $8.8 million increase in cost-sharing
payments due to Bayer HealthCare in connection with our EYLEA collaboration.
</FONT></P>
<P align=justify><I><FONT face="Times New Roman" size=2>Cash (Used in) Provided by Investing
Activities </FONT></I></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Net cash used in investing
activities was $123.4 million in the first six months of 2012, compared with
cash provided by investing activities of $163.3 million in the first six months
of 2011. In the first half of 2012, purchases of marketable securities exceeded
sales or maturities by $99.0 million. In the first half of 2011, sales or
maturities of marketable securities exceeded purchases by $201.0 million.
Capital expenditures in the first half of 2012 and 2011 included costs in
connection with expanding our manufacturing capacity at our Rensselaer, New York
facilities and tenant improvement and associated costs related to our leased
facilities in Tarrytown, New York.</FONT></P>
<P align=center><FONT face="Times New Roman" size=2>40</FONT></P>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<P align=justify><I><FONT face="Times New Roman" size=2>Cash (Used in) Provided by Financing
Activities </FONT></I></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Net cash used in financing
activities was $22.8 million in the first six months of 2012, compared with net
cash provided by financing activities of $23.1 million in the first six months
of 2011. There was an increase in exercises of employee stock options in the
first six months of 2012 compared to the same period of 2011. As a result, net
proceeds from issuances of Common Stock were $39.6 million in the first six
months of 2012 as compared to $28.5 million in the first six months of 2011, and
payments for employee tax obligations in connection with Common Stock tendered
for stock option exercises were $61.4 million in the first six months of 2012
and $4.7 million in the first six months of 2011.</FONT></P>
<P align=justify><B><I><FONT face="Times New Roman" size=2>Fair Value of Marketable
Securities </FONT></I></B></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>At June 30, 2012 and December 31
2011, we held marketable securities whose aggregate fair value totaled $425.4
million and $325.2 million, respectively. The composition of our portfolio of
marketable securities on these dates was as follows: </FONT></P>
<TABLE style="LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD noWrap align=left width="82%" colSpan=2></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid; text-align: center" noWrap width="8%" colSpan=5><B><FONT face="Times New Roman" size=2>June 30, 2012</FONT></B></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid; text-align: center" noWrap width="8%" colSpan=5><B><FONT face="Times New Roman" size=2>December 31, 2011</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="7%"><B><FONT face="Times New Roman" size=2>Investment type</FONT></B></TD>
    <TD noWrap align=left width="75%">&nbsp;</TD>
    <TD noWrap style="text-align: center" width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid; text-align: center" noWrap width="3%" colSpan=2><B><FONT face="Times New Roman" size=2>Fair Value</FONT></B></TD>
    <TD noWrap style="text-align: center" width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid; text-align: center" noWrap width="4%" colSpan=2><B><FONT face="Times New Roman" size=2>Percent</FONT></B></TD>
    <TD noWrap style="text-align: center" width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid; text-align: center" noWrap width="3%" colSpan=2><B><FONT face="Times New Roman" size=2>Fair Value</FONT></B></TD>
    <TD noWrap style="text-align: center" width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid; text-align: center" noWrap width="4%" colSpan=2><B><FONT face="Times New Roman" size=2>Percent</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="82%" bgColor=#cceeff colSpan=2><I><FONT face="Times New Roman" size=2>Unrestricted</FONT></I></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="2%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="3%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="2%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="3%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="82%" colSpan=2><FONT face="Times New Roman" size=2>U.S. government
      obligations</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="2%"><FONT face="Times New Roman" size=2>351.8</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=2>83</FONT></TD>
    <TD noWrap align=left width="1%"><FONT face="Times New Roman" size=2>%</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="2%"><FONT face="Times New Roman" size=2>284.9</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=2>87</FONT></TD>
    <TD noWrap align=left width="1%"><FONT face="Times New Roman" size=2>%</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="82%" bgColor=#cceeff colSpan=2><FONT face="Times New Roman" size=2>U.S. government guaranteed corporate bonds</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=2>50.6</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="3%" bgColor=#cceeff><FONT face="Times New Roman" size=2>12</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>%</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=2>15.3</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="3%" bgColor=#cceeff><FONT face="Times New Roman" size=2>5</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>%</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="82%" colSpan=2><FONT face="Times New Roman" size=2>Municipal bonds</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="2%"><FONT face="Times New Roman" size=2>12.4</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=2>3</FONT></TD>
    <TD noWrap align=left width="1%"><FONT face="Times New Roman" size=2>%</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="2%"><FONT face="Times New Roman" size=2>15.3</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=2>5</FONT></TD>
    <TD noWrap align=left width="1%"><FONT face="Times New Roman" size=2>%</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="82%" bgColor=#cceeff colSpan=2><FONT face="Times New Roman" size=2>Equity securities</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=2>2.5</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="3%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=2>3.0</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="3%" bgColor=#cceeff><FONT face="Times New Roman" size=2>1</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>%</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="82%" colSpan=2><FONT face="Times New Roman" size=2>U.S. government guaranteed
      collateralized
      mortgage obligations</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="2%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="3%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="2%"><FONT face="Times New Roman" size=2>0.6</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="3%"></TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="82%" bgColor=#cceeff colSpan=2><FONT face="Times New Roman" size=2>Mortgage-backed securities</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=2>0.1</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="3%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=2>0.1</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="3%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="82%" colSpan=2><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total
      unrestricted marketable securities</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD NOWRAP STYLE="text-align: left; width: 1%"></TD>
    <TD NOWRAP STYLE="text-align: right; width: 2%"><FONT face="Times New Roman" size=2>417.4</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD NOWRAP STYLE="text-align: right; width: 3%"><FONT face="Times New Roman" size=2>98</FONT></TD>
    <TD NOWRAP STYLE="text-align: left; width: 1%"><FONT face="Times New Roman" size=2>%</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD NOWRAP STYLE="text-align: left; width: 1%"></TD>
    <TD NOWRAP STYLE="text-align: right; width: 2%"><FONT face="Times New Roman" size=2>319.2</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD NOWRAP STYLE="text-align: right; width: 3%"><FONT face="Times New Roman" size=2>98</FONT></TD>
    <TD NOWRAP STYLE="text-align: left; width: 1%"><FONT face="Times New Roman" size=2>%</FONT></TD></TR>
  <TR>
    <TD align=left width="100%" colSpan=14>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="82%" bgColor=#cceeff colSpan=2><I><FONT face="Times New Roman" size=2>Restricted</FONT></I></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="2%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="3%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="2%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="3%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="82%" colSpan=2><FONT face="Times New Roman" size=2>U.S. government
      obligations</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="2%"><FONT face="Times New Roman" size=2>8.0</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%"><FONT face="Times New Roman" size=2>2</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"><FONT face="Times New Roman" size=2>%</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="2%"><FONT face="Times New Roman" size=2>6.0</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%"><FONT face="Times New Roman" size=2>2</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"><FONT face="Times New Roman" size=2>%</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="82%" bgColor=#cceeff colSpan=2><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total
      marketable securities</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=2>425.4</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="3%" bgColor=#cceeff><FONT face="Times New Roman" size=2>100</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>%</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=2>325.2</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="3%" bgColor=#cceeff><FONT face="Times New Roman" size=2>100</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>%</FONT></TD></TR></TABLE><BR>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>In addition, at June 30, 2012 and
December 31, 2011, we had $172.0 million and $485.4 million, respectively, of
cash, cash equivalents, and restricted cash, primarily held in money market
funds that invest in U.S. government securities. </FONT></P>
<P align=justify><B><I><FONT face="Times New Roman" size=2>Capital
Expenditures</FONT></I></B></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Our cash expenditures for property,
plant, and equipment totaled $23.9 million for the first six months of 2012 and
$37.0 million for the first six months of 2011. In addition, in connection with
our antibody collaboration with Sanofi, Sanofi funded $1.4 million and $2.1
million, respectively, of agreed-upon capital expenditures incurred by us during
the first half of 2012 and 2011 to expand our manufacturing capacity at our
Rensselaer facilities, of which $0.2 million was receivable at June 30,
2012.</FONT></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>We expect to incur capital
expenditures of approximately $80 to $100 million during the remainder of 2012
and 2013 primarily in connection with expanding our manufacturing facilities for
the production of antibodies, tenant improvements at our leased Tarrytown
facilities, and purchases of equipment.</FONT></P>
<P align=center><FONT face="Times New Roman" size=2>41</FONT></P>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<P align=justify><B><I><FONT face="Times New Roman" size=2>Funding Requirements
</FONT></I></B></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>We expect to continue to incur
substantial funding requirements for our research and development activities
(including preclinical and clinical testing). As described above, research and
development expenses that we incur in connection with our ZALTRAP and antibodies
collaborations are generally funded by Sanofi. In addition, as described above,
we and Bayer HealthCare share agreed-upon development expenses that both
companies incur in connection with our EYLEA collaboration. After taking into
account anticipated reimbursements from our collaborators, we currently estimate
that approximately 50-60% of our funding requirements for 2012 will be directed
toward technology development, basic research and early preclinical activities,
and the preclinical and clinical development of our product candidates. For
2012, we also currently estimate that approximately 10-15% of our funding
requirements will be directed toward the planned commercialization of new
indications for our marketed products and ZALTRAP; approximately 15-20% of our
funding requirements will be applied to capital expenditures (as described
above); and the remainder of our funding requirements will be used for general
corporate purposes. </FONT></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Under our collaboration with Bayer
HealthCare, over the next several years we and Bayer HealthCare will share
agreed-upon EYLEA development expenses incurred by both companies, under a
global development plan, as described above. In addition, under our
collaboration agreements with Sanofi and Bayer HealthCare, if the applicable
collaboration becomes profitable, we have contingent contractual obligations to
reimburse Sanofi and Bayer HealthCare for a defined percentage (generally 50%)
of agreed-upon development expenses incurred by Sanofi and Bayer HealthCare,
respectively. Profitability under each collaboration will be measured by
calculating net sales less agreed-upon expenses. These reimbursements would be
deducted from our share of the collaboration profits (and, for our ZALTRAP
collaboration with Sanofi and our Bayer HealthCare collaboration, royalties on
product sales in Japan) otherwise payable to us, unless, in some cases, we elect
to reimburse these expenses at a faster rate. Given the uncertainties related to
drug development (including the development of ZALTRAP and co-developed antibody
candidates in collaboration with Sanofi and EYLEA in collaboration with Bayer
HealthCare), such as the variability in the length of time necessary to develop
a product candidate and the ultimate ability to obtain governmental approval for
commercialization, we are currently unable to reliably estimate if our
collaborations with Sanofi and Bayer HealthCare will become profitable. In
particular, for ZALTRAP, as of December 31, 2011, our reimbursement obligation
to Sanofi was $394.2 million. Therefore, <FONT STYLE="background-color: TRANSPARENT">we expect that,</FONT> initially<FONT STYLE="background-color: TRANSPARENT">, our</FONT> share of any
profits from sales of ZALTRAP will be diverted <FONT STYLE="background-color: TRANSPARENT">to reimburse Sanofi for this</FONT> obligation.</FONT></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>The amount we need to fund
operations will depend on various factors, including revenues from net product
sales, the potential regulatory approval and commercialization of our product
candidates and new indications for our marketed products, and the timing
thereof, the status of competitive products, the success of our research and
development programs, the potential future need to expand our professional and
support staff and facilities, the status of patents and other intellectual
property rights (and pending or future litigation related thereto), the delay or
failure of a clinical trial of any of our potential drug candidates, and the
continuation, extent, and success of our collaborations with Sanofi and Bayer
HealthCare. Clinical trial costs are dependent, among other things, on the size
and duration of trials, fees charged for services provided by clinical trial
investigators and other third parties, the costs for manufacturing the product
candidate for use in the trials, and for supplies, laboratory tests, and other
expenses. The amount of funding that will be required for our clinical programs
depends upon the results of our research and preclinical programs and
early-stage clinical trials, regulatory requirements, the duration and results
of clinical trials underway and of additional clinical trials that we decide to
initiate, and the various factors that affect the cost of each trial as
described above. Our commercialization costs over approximately the next few
years will depend on, among other things, whether or not new indications for our
marketed products or our late-stage product candidates receive regulatory
approval, the market potential for such new indications or product candidates,
and the commercialization terms of our collaboration agreements, if applicable
(whereby some or all commercialization costs may be shared with our
collaborators). Currently, we are required to pay royalties on product sales of
EYLEA for the treatment of wet AMD and ARCALYST for the treatment of CAPS.
Pursuant to our Non-Exclusive License and Partial Settlement Agreement with
Genentech, we expect to make a lump-sum payment of $60 million to Genentech in
the third quarter of 2012 once cumulative U.S. sales of EYLEA reach $400
million. In the future, if we are able to successfully develop, market, and sell
EYLEA or ARCALYST for other indications, or certain of our product candidates,
we may be required to pay royalties or share the profits from such sales
pursuant to our license or collaboration agreements. </FONT></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>We expect that expenses related to
the filing, prosecution, defense, and enforcement of patents and other
intellectual property will continue to be substantial.</FONT></P>
<P align=center><FONT face="Times New Roman" size=2>42</FONT></P>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Due to the amounts of our net
operating loss and tax credit carry-forwards available for tax purposes, which
totaled $800.2 million and $67.7 million, respectively, at December 31, 2011, we
do not anticipate incurring substantive obligations for federal and state
corporate income taxes over the next several years.</FONT></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Under the terms of our collaboration
agreement with Sanofi, we are entitled to receive milestone payments upon
receipt of specified ZALTRAP marketing approvals. In connection with our
collaboration with Bayer HealthCare, we are entitled to receive milestone
payments related to marketing approvals of EYLEA in major market countries
outside the United States, as well as sales milestones based on total annual
sales of EYLEA outside the United States achieving certain specified
levels.</FONT></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>We believe that our existing capital
resources, funds generated by anticipated EYLEA net product sales, and funding
for reimbursement of development costs that we are entitled to receive under our
collaboration agreements, will enable us to meet our projected operating needs
for the foreseeable future. Other than letters of credits totaling $4.6 million
as of June 30, 2012, including a $3.4 million letter of credit issued in
connection with our lease for facilities in Tarrytown, New York, we have no
off-balance sheet arrangements. In addition, we do not guarantee the obligations
of any other entity. As of June 30, 2012, we had no other established banking
arrangements through which we could obtain short-term financing or a line of
credit. In October 2011, we completed a private placement of convertible senior
notes. In addition, in October 2010, we filed a shelf registration statement on
Form S-3 registering the sale, in one or more offerings, of an indeterminate
amount of equity or debt securities, together or separately, and our October
2010 public offering of approximately 6.3 million shares of Common Stock was
completed under this shelf registration statement. There is no assurance,
however, that we will be able to complete any additional offerings of
securities. Factors influencing the availability of additional financing include
our progress in product development and commercialization, investor perception
of our prospects, and the general condition of the financial markets. We may not
be able to secure additional funding through new collaborative arrangements or
additional public or private offerings. If we require additional funding, and
cannot raise adequate funds to satisfy our capital requirements, we may have to
delay, scale-back, or eliminate certain of our research and development
activities or future operations. This could materially harm our
business.</FONT></P>
<P align=justify><B><FONT face="Times New Roman" size=2>Impact of Recently Issued Accounting
Standards</FONT></B></P>
<P align=justify><B><I><FONT face="Times New Roman" size=2>Presentation of comprehensive
income </FONT></I></B></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>In June and December 2011, the
Financial Accounting Standards Board (FASB) amended its authoritative guidance
on the presentation of comprehensive income. Under the amendments, an entity has
the option to present comprehensive income and net income either in a single
continuous statement or in two separate but consecutive statements. This
amendment, therefore, eliminated the option to present the components of other
comprehensive income as part of the statement of changes in stockholders'
equity. The amendment did not change the items that must be reported in other
comprehensive income or when an item of other comprehensive income must be
reclassified to net income. We have adopted this amended guidance for the fiscal
year beginning January 1, 2012. As this guidance relates to presentation only,
the adoption of this guidance did not have any other effect on our financial
statements.</FONT></P>
<P align=justify><B><A NAME="item3"></A><FONT face="Times New Roman" size=2>ITEM 3. QUANTITATIVE AND QUALITATIVE
DISCLOSURES ABOUT MARKET RISK </FONT></B></P>
<P align=justify><I><FONT face="Times New Roman" size=2>Interest Rate Risk </FONT></I></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Our earnings and cash flows are
subject to fluctuations due to changes in interest rates, principally in
connection with our investments in marketable securities, which consist
primarily of direct obligations of the U.S. government and its agencies, other
debt securities guaranteed by the U.S. government, and money market funds that
invest in U.S. government securities. We do not believe we are materially
exposed to changes in interest rates. Under our current policies, we do not use
interest rate derivative instruments to manage exposure to interest rate
changes. We estimate that a one percent unfavorable change in interest rates
would have resulted in approximately a $3.4 million and $1.4 million decrease in
the fair value of our investment portfolio at June 30, 2012 and 2011,
respectively. The increase in interest rate risk year over year is due primarily
to higher balances of marketable debt securities with maturities in excess of
one year that we held at June 30, 2012 compared to the same period of 2011.
</FONT></P>
<P align=center><FONT face="Times New Roman" size=2>43</FONT></P>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<P align=justify><I><FONT face="Times New Roman" size=2>Credit Quality Risk </FONT></I></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>We have an investment policy that
includes guidelines on acceptable investment securities, minimum credit quality,
maturity parameters, and concentration and diversification. Nonetheless,
deterioration of the credit quality of an investment security subsequent to
purchase may subject us to the risk of not being able to recover the full
principal value of the security. During the first six months of 2012 and 2011,
we did not recognize any other-than-temporary impairment charges.</FONT></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>We are also subject to credit risk
in connection with accounts receivable from our product sales of EYLEA and
ARCALYST. Our marketed products are sold in the United States, and related
accounts receivable are due from three distributors and several specialty
pharmacies, who are our customers. We have contractual payment terms with each
of our customers. We monitor our customers&#146; financial performance and credit
worthiness so that we can properly assess and respond to any changes in their
credit profile. During the first six months of 2012 and 2011, we did not
recognize any charges for write-offs of accounts receivable related to our
marketed products. At June 30, 2012 and December 31, 2011, one individual
customer accounted for 82% and 71%, respectively, of our net trade accounts
receivable balances.</FONT></P>
<P align=justify><A NAME="item4"></A><B><FONT face="Times New Roman" size=2>ITEM 4. CONTROLS AND PROCEDURES
</FONT></B></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Our management, with the
participation of our chief executive officer and chief financial officer,
conducted an evaluation of the effectiveness of our disclosure controls and
procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the
Securities Exchange Act of 1934, as amended (the &#147;Exchange Act&#148;)), as of the end
of the period covered by this report. Based on this evaluation, our chief
executive officer and chief financial officer each concluded that, as of the end
of such period, our disclosure controls and procedures were effective in
ensuring that information required to be disclosed by us in the reports that we
file or submit under the Exchange Act is recorded, processed, summarized, and
reported on a timely basis, and is accumulated and communicated to our
management, including our chief executive officer and chief financial officer,
as appropriate to allow timely decisions regarding required disclosure.
</FONT></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>There has been no change in our
internal control over financial reporting (as such term is defined in Rules
13a-15(f) and 15d-15(f) under the Exchange Act) during the quarter ended June
30, 2012 that has materially affected, or is reasonably likely to materially
affect, our internal control over financial reporting.</FONT><B><I><FONT face="Times New Roman" size=2> </FONT></I></B></P>
<P align=justify><A NAME="PartII"></A><B><FONT face="Times New Roman" size=2>PART II. OTHER INFORMATION
</FONT></B></P>
<P align=justify><A NAME="LegalProceedings"></A><B><FONT face="Times New Roman" size=2>ITEM 1. LEGAL
PROCEEDINGS</FONT></B><B><I><FONT face="Times New Roman" size=2> </FONT></I></B></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>From time to time, we are a party to
legal proceedings in the course of our business. We do not expect any such
current ordinary course legal proceedings to have a material adverse effect on
our business or financial condition.</FONT></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><EM>Genentech Patent Litigation
</EM></FONT></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>We are aware of issued patents and
pending patent applications owned by Genentech that claim certain chimeric VEGF
receptors. We do not believe that ZALTRAP or EYLEA infringe any valid claim in
these patents or patent applications. We are involved in five patent litigations
with Genentech, two in the United States and three in Europe. In November 2010,
we commenced a lawsuit against Genentech in the U.S. District Court for the
Southern District of New York (the Court), seeking a declaratory judgment that
no activities relating to our VEGF Trap infringe any valid claim of certain
Genentech patents referred to as the Davis-Smyth patents (the First Davis-Smyth
Case). Genentech answered the complaint and asserted counterclaims that our
prior or planned activities relating to VEGF Trap have infringed or will
infringe claims of four of the five Davis-Smyth patents and requested a judgment
against us for damages, including for willful infringement, and other relief as
the Court deems appropriate.</FONT></P>
<P align=center><FONT face="Times New Roman" size=2>44</FONT></P>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>On December 31, 2011, we entered
into a Non-Exclusive License and Partial Settlement Agreement with Genentech
(the Genentech Agreement) that covers making, using, and selling EYLEA in the
United States for the prevention and treatment of human eye diseases and
disorders in the United States, and ends the litigation relating to those
matters. Under the Genentech Agreement, we received a non-exclusive license to
the Davis-Smyth patents, and certain other technology patents owned or co-owned
by Genentech. The Genentech Agreement does not cover any non-U.S. patent rights
or non-U.S. patent disputes, and does not cover any use of aflibercept other
than for prevention and treatment of human eye diseases and disorders in the
United States. The First Davis-Smyth Case is continuing with respect to matters
not covered by the Genentech Agreement. The Genentech Agreement provides for us
to make payments to Genentech based on U.S. sales of EYLEA through May 7, 2016,
the date the Davis-Smyth patents expire. We will make a lump-sum payment of $60
million once cumulative U.S. sales of EYLEA reach $400 million. We will also pay
royalties of 4.75% on cumulative U.S. sales of EYLEA between $400 million and $3
billion and 5.5% on any cumulative U.S. sales of EYLEA over $3 billion. As a
result of the Genentech Agreement, on January 17, 2012 Genentech filed a second
amended answer and counterclaim in the First Davis-Smyth Case, in which it
amended its counterclaims alleging infringement of four of the five Davis-Smyth
patents. On December 23, 2011, Genentech initiated a related case in the Court
against Regeneron and Sanofi alleging infringement of four of the five
Davis-Smyth Patents by activities relating to VEGF Trap (but excluding EYLEA)
(the Second Davis-Smyth Case). As in the First Davis-Smyth Case, in the new
complaint Genentech requests a judgment against us for damages, including for
willful infringement, and other relief as the Court deems
appropriate.</FONT></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>We believe Genentech's remaining
claims in the First Davis Smyth Case and the Second Davis Smyth Case are without
merit and intend to continue to defend against all of Genentech&#146;s remaining
claims vigorously.</FONT></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>We have initiated patent-related
actions against Genentech in Germany, the United Kingdom, and Italy relating in
each case to a patent that expires on October 28, 2012. We may initiate other
actions in other countries outside the United States, which could have similar
or other adverse outcomes that would materially harm our business and which,
irrespective of the outcomes, may also entail significant costs and expenses. In
the United Kingdom, an adverse decision dated March 22, 2012 is under appeal.
This decision found the designation of European patent EP 1 238 986 in the
United Kingdom to be valid and potential acts relating to VEGF Trap Eye in the
United Kingdom before expiration of the patent on October 28, 2012 to infringe
this patent.</FONT></P>
<P align=justify><B><A NAME="RiskFactors"></A><FONT face="Times New Roman" size=2>ITEM 1A. RISK FACTORS
</FONT></B></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>We operate in an environment that
involves a number of significant risks and uncertainties. We caution you to read
the following risk factors, which have affected, and/or in the future could
affect, our business, prospects, operating results, and financial condition. The
risks described below include forward-looking statements, and actual events and
our actual results may differ materially from these forward-looking statements.
Additional risks and uncertainties not currently known to us or that we
currently deem immaterial may also impair our business, prospects, operating
results, and financial condition. Furthermore, additional risks and
uncertainties are described under other captions in this report and should also
be considered by our investors. </FONT></P>
<P align=justify><B><FONT face="Times New Roman" size=2>Risks Related to Our Financial
Results and Need for Additional Financing </FONT></B></P>
<P style="PADDING-LEFT: 8pt" align=justify><B><I><FONT face="Times New Roman" size=2>We have
a history of operating losses. If we cannot sustain profitability and continue
to incur operating losses, we may be unable to continue our operations.
</FONT></I></B></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>From inception on January 8, 1988
through June 30, 2012, we had a cumulative loss of $1.2 billion. If we cannot
sustain profitability and continue to incur operating losses, we may be unable
to continue our operations. In the absence of substantial revenue from the sale
of products on an ongoing basis, including our current sales of EYLEA, and
ARCALYST or from other sources, the amount, timing, nature or source of which
cannot be predicted, our substantial losses will continue as we conduct our
research and development activities, commercialize our approved products, and
prepare for possible commercialization of our other product candidates and new
indications of our marketed products.</FONT></P>
<P style="PADDING-LEFT: 8pt" align=justify><B><I><FONT face="Times New Roman" size=2>We may
need additional funding in the future, which may not be available to us, and
which may force us to delay, reduce or eliminate our product development
programs or commercialization efforts. </FONT></I></B></P>
<P align=center><FONT face="Times New Roman" size=2>45</FONT></P>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>We will need to expend substantial
resources for research and development, including costs associated with clinical
testing of our product candidates and new indications of our marketed products,
continued commercialization of EYLEA in the United States, to prepare for
potential commercialization of our late-stage product candidates and new
indications for our marketed products and, if one or more of those product
candidates or additional indications receive(s) regulatory approval, to fund the
launch of those product(s) or new indications. We believe our existing capital
resources, together with funds generated by current and anticipated EYLEA net
product sales and funding we are entitled to receive under our collaboration
agreements, will enable us to meet our anticipated operating needs for the
foreseeable future; however, one or more of our collaboration agreements may
terminate, our revenues may fall short of our projections or be delayed, or our
expenses may increase, which could result in our capital being consumed
significantly faster than anticipated. Our expenses may increase for many
reasons, including expenses in connection with the ongoing launch and marketing
of EYLEA and the potential commercial launches of our late-stage product
candidates and new indications for our marketed products, manufacturing
scale-up, expenses related to clinical trials testing ARCALYST, EYLEA, REGN475,
REGN846, or REGN1154, and expenses related to the potential requirement for us
to fund 20% of Phase 3 clinical trial costs for any of our antibody product
candidates being developed in collaboration with Sanofi.</FONT></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>We may require additional financing
in the future and we may not be able to raise additional funds. If necessary and
we are able to obtain additional financing through the sale of equity or
convertible debt securities, such sales will likely be dilutive to our
shareholders. Debt financing arrangements, if available given the current
uncertainties in the global credit and financial markets, may require us to
pledge certain assets or enter into covenants that would restrict our business
activities or our ability to incur further indebtedness and may be at interest
rates and contain other terms that are not favorable to our shareholders. Should
we require and be unable to (i) raise sufficient funds to complete the
development of our product candidates, (ii) successfully commercialize our
late-stage product candidates or new indications for our marketed products if
they obtain regulatory approval, and (iii) continue our manufacturing and
marketing of EYLEA for the treatment of wet AMD, we may face delay, reduction,
or elimination of our research and development or preclinical or clinical
programs and our commercialization activities, which would significantly limit
our potential to generate revenue. We cannot be certain how profitable our
current marketing of EYLEA for the treatment of wet AMD will be and, even if we
obtain regulatory approval for our product candidates or new indications for our
marketed products, they may never be successfully launched or become profitable,
in which case our business, prospects, operating results, and financial
condition may be materially harmed. </FONT></P>
<P style="PADDING-LEFT: 8pt" align=justify><B><I><FONT face="Times New Roman" size=2>The
value of our investment portfolio is influenced by varying economic and market
conditions and may experience losses.</FONT></I></B></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>As of June 30, 2012, our cash, cash
equivalents, and marketable securities totaled $597.5 million (including $8.1
million of restricted cash and marketable securities). We have invested our
excess cash primarily in direct obligations of the U.S. government and its
agencies, other debt securities guaranteed by the U.S. government, and money
market funds that invest in U.S. government securities. We consider assets
classified as marketable securities to be &#147;available-for-sale,&#148; as defined by
FASB authoritative guidance. Unrestricted and restricted marketable securities
totaled $425.4 million at June 30, 2012, are carried at fair value, and the
unrealized gains and losses are included in other accumulated comprehensive
income (loss) as a separate component of stockholders&#146; equity. If the decline in
the value of a security in our investment portfolio is deemed to be
other-than-temporary, we write down the security to its current fair value and
recognize a loss which may be fully charged against income. The current economic
environment and the volatility of securities markets increase the risk that we
may not recover the principal we invested and/or there may be further declines
in the market value of securities in our investment portfolio. As a result, we
may incur additional charges against income in future periods for
other-than-temporary impairments or realized losses upon a security&#146;s sale or
maturity, and such amounts may be material. </FONT></P>
<P align=justify><B><FONT face="Times New Roman" size=2>Risks Related to the Development and
Approval of Our Product Candidates and New Indications for Our Marketed Products
</FONT></B></P>
<P style="PADDING-LEFT: 8pt" align=justify><B><I><FONT face="Times New Roman" size=2>We
believe that a significant portion of the value attributed to our company by
investors is based on the commercial potential of EYLEA. If marketing approval
for EYLEA is not obtained in countries outside the United States, or approval is
not obtained for other indications, or if we fail to maintain regulatory
compliance and lose the marketing approval we have in the United States, or if
the product is withdrawn for any reason, our business, prospects, operating
results, and financial condition will be materially harmed.</FONT></I></B></P>
<P align=center><FONT face="Times New Roman" size=2>46</FONT></P>
<HR align=center width="100%" noShade SIZE=2>


<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>

<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp; <FONT face="Times New Roman" size=2>Whether EYLEA
is approved by regulatory authorities outside the United States or approved by
the FDA for new indications, and the timing thereof, will depend on many
factors, including the following:</FONT></P>
<UL style="TEXT-ALIGN: justify"><LI><FONT face="Times New Roman" size=2>whether or not the FDA determines that the evidence gathered in well-controlled clinical trials, other clinical trials and nonclinical studies of EYLEA demonstrates that it is safe and effective as a treatment for the indication under review; and</FONT>
  </LI><LI><FONT face="Times New Roman" size=2>whether or not the FDA is satisfied that the
  manufacturing facilities, processes, and controls for EYLEA are adequate, that
  the labeling is satisfactory, and that plans for post-marketing studies,
  safety monitoring, and risk evaluation and management are
  sufficient.</FONT></LI></UL>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Bayer HealthCare has submitted regulatory applications for marketing
approval of EYLEA in wet AMD in the European Union, Japan, and other countries.
Analogous regulatory authorities in these countries outside the United States
have similar discretion to the FDA as to approval of EYLEA in those
countries.</FONT></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>If Bayer HealthCare does not obtain approval to market EYLEA in the
European Union, Japan, or other countries, or if there are material delays in
obtaining such approvals, our business, prospects, operating results, and
financial condition will be materially harmed. </FONT></P>
<P style="PADDING-LEFT: 8pt" align=justify><FONT face="Times New Roman" size=2><STRONG><EM>If we do not obtain and maintain regulatory approval for our
products and product candidates or new indications for our marketed products, or
maintain regulatory approval for EYLEA in the United States, we will not be able
to market or sell them, which would materially and negatively impact our
business, results of operations, and prospects. </EM></STRONG></FONT></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>We cannot sell or market products without regulatory approval. If we do
not obtain and maintain regulatory approval for our products and product
candidates, including ARCALYST for the treatment of diseases other than CAPS,
EYLEA for the treatment of ophthalmologic diseases other than wet AMD and/or
ZALTRAP for one or more oncology indications, the value of our company, our
results of operations, and our prospects will be materially harmed. Our product
candidates, including ZALTRAP for the treatment of previously treated mCRC
patients and EYLEA for CRVO and DME, and ARCALYST for the prevention
of gout flares in patients initiating uric acid-lowering therapy, may not
receive regulatory approval. If we are unable to obtain such approval(s), or if
we are materially delayed in doing so, our business, prospects, results of
operations, and financial condition will be materially harmed. In addition, if
we fail to maintain regulatory approval for EYLEA for the treatment
of wet AMD, we may lose marketing approval and the ability to generate EYLEA
product sales revenue, which would materially and negatively impact our
business, prospects, results of operations, and financial condition. </FONT></P>
<P style="PADDING-LEFT: 8pt" align=justify><B><I><FONT face="Times New Roman" size=2>Obtaining and maintaining regulatory approval for drug products is
costly, time-consuming, and highly uncertain.</FONT></I></B></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>In the United States, we must obtain and maintain approval from the FDA
for each drug we intend to sell. Obtaining FDA approval is typically a lengthy
and expensive process, and approval is highly uncertain. Foreign governments
also regulate drugs distributed in their country and approval in any country is
likely to be a lengthy and expensive process, and approval is highly
uncertain.</FONT></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The FDA enforces Good Clinical Practices (GCPs) and other regulations
through periodic inspections of trial sponsors, clinical research organizations
(CROs), principal investigators, and trial sites. If we or any of the third
parties conducting our clinical studies are determined to have failed to fully
comply with GCPs, the study protocol or applicable regulations, the clinical
data generated in those studies may be deemed unreliable. This could result in
non-approval of our product candidates by the FDA, or we or the FDA may decide
to conduct additional audits or require additional clinical studies, which would
delay our development programs, require us to incur additional costs, and could
substantially harm our business. </FONT></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Before approving a new drug or biologic product, the FDA requires that
the facilities at which the product will be manufactured or advanced through the
supply chain be in compliance with current Good Manufacturing Practices, or
cGMP, requirements and regulations governing the shipment and storage of the
product. Manufacturing product candidates in compliance with these regulatory
requirements is complex, time-consuming, and expensive. To be successful, our
products must be manufactured for development, and following approval in
commercial quantities, in compliance with regulatory requirements, and at
competitive costs. If we or any of our product collaborators, or third-party
manufacturers, product packagers, labelers, or other parties performing steps in
the supply chain are unable to maintain regulatory compliance, the FDA can
impose regulatory sanctions, including, among other things, refusal to approve a
pending application for a new drug or biologic product, or revocation of a
pre-existing approval. As a result, our business, prospects, operating results,
and financial condition may be materially harmed.</FONT></P>
<P align=center><FONT face="Times New Roman" size=2>47</FONT></P>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp; <FONT face="Times New Roman" size=2>In addition to
the FDA and other regulatory agency regulations in the United States, we are
subject to a variety of foreign regulatory requirements governing human clinical
trials, manufacturing, marketing and approval of drugs, and commercial sale and
distribution of drugs in foreign countries. The foreign regulatory approval
process and requirements include all of the risks associated with FDA approval
as well as country specific regulations, and actions by a regulatory agency in a
country or region with respect to a product candidate may have an impact on the
approval process for that product candidate in another country or region.
Whether or not we obtain FDA approval for a product in the United States, we
must obtain approval of the product by the comparable regulatory authorities in
foreign countries before we can conduct clinical trials of or market that
product or any other product in those countries. </FONT></P>
<P style="PADDING-LEFT: 8pt" align=justify><B><I><FONT face="Times New Roman" size=2>Clinical trials required for our product candidates and new indications
of our marketed products are expensive and time-consuming, and their outcome is
highly uncertain. If any of our drug trials are delayed or yield unfavorable
results, regulatory approval for our product candidates or new indications of
our marketed products may be delayed or become unobtainable.</FONT></I></B></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>As described above, we must conduct extensive testing of our product
candidates and new indications of our marketed products before we can obtain
regulatory approval to market and sell them. We need to conduct both preclinical
animal testing and human clinical trials. Conducting these trials is a lengthy,
time-consuming, and expensive process. These tests and trials may not achieve
favorable results for many reasons, including, among others, failure of the
product candidate to demonstrate safety or efficacy, the development of serious
or life-threatening adverse events (or side effects) caused by or connected with
exposure to the product candidate, difficulty in enrolling and maintaining
subjects in the clinical trial, lack of sufficient supplies of the product
candidate or comparator drug, and the failure of clinical investigators, trial
monitors, contractors, consultants, or trial subjects to comply with the trial
plan, protocol, or applicable regulations related to GCPs. A clinical trial may
fail because it did not include and retain a sufficient number of patients to
detect the endpoint being measured or reach statistical significance. A clinical
trial may also fail because the dose(s) of the investigational drug included in
the trial were either too low or too high to determine the optimal effect of the
investigational drug in the disease setting. </FONT></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>We will need to reevaluate any drug candidate that does not test
favorably and either conduct new trials, which are expensive and time consuming,
or abandon that drug development program. The failure of clinical trials to
demonstrate the safety and effectiveness of our clinical candidates for the
desired indication(s) would preclude the successful development of those
candidates for such indication(s), in which event our business, prospects,
operating results, and financial condition may be materially harmed. </FONT></P>
<P style="PADDING-LEFT: 8pt" align=justify><B><I><FONT face="Times New Roman" size=2>Successful development of our current and future product candidates is
uncertain. </FONT></I></B></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Only a small minority of all research and development programs ultimately
result in commercially successful drugs. We are testing EYLEA in a number of
late-stage clinical trials in various indications and ARCALYST for the
prevention of gout flares in patients initiating uric acid-lowering drug
therapy. Clinical trials may not demonstrate statistically sufficient
effectiveness and safety to obtain the requisite regulatory approvals for these
product candidates in these indications. In a number of instances, we have
terminated the development of product candidates due to a lack of or only modest
effectiveness. Moreover, even if we obtain positive results from preclinical
testing or clinical trials, we may not achieve the same success in future
trials. Many companies in the biopharmaceutical industry, including our company,
have suffered significant setbacks in clinical trials, even after promising
results have been obtained in earlier trials.</FONT></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>In April 2011, we announced that our Phase 3 VELOUR trial of ZALTRAP met
its primary endpoint of improving overall survival in the treatment of patients
with previously treated mCRC. Based upon these positive results, we and Sanofi
submitted regulatory applications for marketing approval to the FDA and EMA.
Under PDUFA, we and Sanofi were granted a target date for an FDA decision on the
ZALTRAP in mCRC BLA of August 4, 2012. However, this expected timing for an FDA
decision may not be met, and the FDA may not grant such approval or such
approval may be substantially delayed. The FDA could also require us to provide
additional clinical data in connection with this application. There can be no
assurance that we will receive regulatory approval for ZALTRAP in mCRC. Also in
April 2011, we and Sanofi announced that the results from another randomized,
double-blind Phase 3 trial (VENICE), evaluated ZALTRAP as a first-line treatment
for metastatic androgen-independent prostate cancer in combination with
docetaxel/prednisone. The VENICE trial did not meet the pre-specified criterion
of improvement in overall survival. The safety profile was generally consistent
with previous studies of ZALTRAP in combination with docetaxel.</FONT></P>
<P align=center><FONT face="Times New Roman" size=2>48</FONT></P>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>In January 2012, Roche announced that a Phase 3 trial of
Avastin<SUP>&#174;</SUP> (bevacizumab) had met the primary endpoint of overall
survival in mCRC in patients who had previously received Avastin<SUP>&#174;</SUP>
with standard chemotherapy. The positive results of this trial in a similar
patient population could impact the potential commercial opportunity for ZALTRAP
in mCRC.</FONT></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>We also reported positive Phase 3 trial results with EYLEA in CRVO after
six months of treatment and, based on these results, have submitted a
supplemental BLA filing to the FDA for marketing approval in the United States
of EYLEA in CRVO. Under PDUFA, we were granted a target date for an FDA decision
on our EYLEA in CRVO supplemental BLA of September 23, 2012. However, this
expected timing for an FDA decision may not be met, and the FDA may not grant
such approval or such approval may be substantially delayed. The FDA could also
require us to provide additional clinical data in connection with this
application. There can be no assurance that we will receive regulatory approval
for EYLEA in CRVO.</FONT></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>We also reported positive results of a Phase 2 trial of EYLEA<SUP>
</SUP>for the treatment of DME and that we have initiated a Phase 3 program in
that indication. A number of other potential new drugs and biologics which
showed promising results in Phase 1 and 2 clinical trials subsequently failed to
establish sufficient safety and efficacy data to obtain necessary regulatory
approvals, and this could occur with respect to subsequent clinical trials of
EYLEA for the treatment of DME.</FONT></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Based on the results of three Phase 3 studies, we have submitted a
supplemental BLA filing to the FDA seeking approval of ARCALYST for the
prevention of gout flares in patients initiating uric acid-lowering drug therapy
and, under PDUFA, we were granted a target date
for an FDA decision on our </FONT><FONT face="Times New Roman" size=2>ARCALYST</FONT><FONT face="Times New Roman" size=2> supplemental BLA of July 30, 2012. </FONT><FONT face="Times New Roman" size=2>In May 2012, the Arthritis Advisory Committee of the FDA voted to
recommend against approval of ARCALYST for the prevention of gout flares in
patients initiating uric acid-lowering drug therapy. The Committee&#146;s
recommendation is not binding on the FDA, but it will be considered by the FDA
in its review of our ARCALYST supplemental BLA. For example, in June 2011,
following two positive Phase 3 trials, the Arthritis Advisory Committee, voted
to recommend against approval in a gout indication for Ilaris<SUP>&#174;
</SUP>(canikinumab), Novartis&#146; IL-1 inhibitor which works through a similar
mechanism as ARCALYST and, in August 2011, Novartis received a Complete Response
letter from the FDA requesting additional information, including clinical data
to evaluate the benefit-risk profile of Ilaris<SUP>&#174;</SUP> in refractory
patients. The expected timing for an FDA decision on our ARCALYST supplemental
BLA may not be met, and the FDA may not grant approval of ARCALYST for the
prevention of gout flares in patients initiating uric acid-lowering drug
therapy, or such approval may be substantially delayed. The FDA could also
require us to provide additional clinical data in connection with this
application. </FONT></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Many of our clinical trials are conducted under the oversight of <FONT STYLE="background-color: TRANSPARENT">Independent Data Monitoring Committees</FONT> <FONT STYLE="BACKGROUND-COLOR: TRANSPARENT">(IDMCs)</FONT>.
These independent oversight bodies are made up of external experts who review
the progress of ongoing clinical trials, including available safety and efficacy
data, and make recommendations concerning a trial&#146;s continuation, modification,
or termination based on interim, unblinded data. Any of our ongoing clinical
trials may be discontinued or amended in response to recommendations made by
responsible IDMCs based on their review of such interim trial results. For
example, in September 2009, a Phase 3 trial that was evaluating ZALTRAP as a
first-line treatment for <FONT STYLE="BACKGROUND-COLOR: TRANSPARENT">metastatic</FONT> pancreatic cancer in combination with
gemcitabine was discontinued at the recommendation of an IDMC after a planned
analysis of interim efficacy data determined that the trial would not meet its
efficacy endpoint. The recommended termination of any of our ongoing late-stage
clinical trials by an IDMC could negatively impact the future development of our
product candidate(s), and our business may be materially harmed.</FONT></P>
<P align=center><FONT face="Times New Roman" size=2>49</FONT></P>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp; <FONT face="Times New Roman" size=2>We are
studying our antibody candidates in a wide variety of indications in clinical
trials. Many of these trials are exploratory studies designed to evaluate the
safety profile of these compounds and to identify what diseases and uses, if
any, are best suited for these product candidates. These product candidates may
not demonstrate the requisite efficacy and/or safety profile to support
continued development for some or all of the indications that are being, or are
planned to be, studied, which would diminish our clinical &#147;pipeline&#148; and could
negatively affect our future prospects and the value of our company. </FONT></P>
<P style="PADDING-LEFT: 8pt" align=justify><B><I><FONT face="Times New Roman" size=2>Serious
complications or side effects in connection with the use of our products and in
clinical trials for our product candidates and new indications for our marketed
products could cause our regulatory approvals to be revoked or limited or lead
to delay or discontinuation of development of our product candidates or new
indications for our marketed products, which could severely harm our
business.</FONT></I></B></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>During the conduct of clinical trials, patients report changes in their
health, including illnesses, injuries, and discomforts, to their study doctor.
Often, it is not possible to determine whether or not the drug candidate being
studied caused these conditions. Various illnesses, injuries, and discomforts
have been reported from time-to-time during clinical trials of our product
candidates and new indications for our marketed products. It is possible that as
we test our drug candidates or new indications in larger, longer, and more
extensive clinical programs, or as use of these drugs becomes more widespread if
they receive regulatory approval, illnesses, injuries, and discomforts that were
observed in earlier trials, as well as conditions that did not occur or went
undetected in previous trials, will be reported by patients. Many times, side
effects are only detectable after investigational drugs are tested in large
scale, Phase 3 clinical trials or, in some cases, after they are made available
to patients after approval. If additional clinical experience indicates that any
of our product candidates or new indications for our marketed products has many
side effects or causes serious or life-threatening side effects, the development
of the product candidate may fail or be delayed, or if the product candidate has
received regulatory approval such approval may be revoked, which would severely
harm our business. </FONT></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>ZALTRAP is being studied for the potential treatment of mCRC and EYLEA is
being studied in diseases of the eye in addition to wet AMD. There are many
potential safety concerns associated with significant blockade of VEGF that may
limit our ability to successfully develop ZALTRAP and EYLEA<SUP> </SUP>in each
of the indications for which we are studying these product candidates. These
serious and potentially life-threatening risks, based on clinical and
preclinical experience of VEGF inhibitors, include bleeding, intestinal
perforation, hypertension, proteinuria, congestive heart failure, heart attack,
and stroke. In addition, patients given infusions of any protein, including
ZALTRAP delivered through intravenous administration, may develop severe
hypersensitivity reactions or infusion reactions. Other VEGF blockers have
reported side effects that became evident only after large scale trials or after
marketing approval when large numbers of patients were treated. There are risks
inherent in the intravitreal administration of drugs like EYLEA, which can cause
injury to the eye and other complications. For example, in our Phase 3 trials of
EYLEA</FONT><FONT face="Times New Roman" size=2> in wet AMD, the most frequent ocular
adverse events were conjunctival hemorrhage, macular degeneration, eye pain,
retinal hemorrhage, and vitreous floaters. </FONT><FONT face="Times New Roman" size=2>These
and other complications or side effects could harm the development and/or
commercialization of ZALTRAP for the treatment of mCRC or EYLEA for the
treatment of diseases of the eye.</FONT></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>As ARCALYST is studied for the prevention of gout flares in patients
initiating uric acid-lowering therapy and, potentially in new disease settings,
new risks and side effects associated with ARCALYST may be discovered, and risks
previously viewed as inconsequential could be determined to be significant. Like
cytokine antagonists such as Ilaris<SUP>&#174;</SUP> (canakinumab), a registered
trademark of Novartis, Kineret<SUP>&#174;</SUP> (anakinra) and Enbrel<SUP>&#174;</SUP>
(etanercept), registered trademarks of Amgen, and Remicade<SUP>&#174;</SUP>
(infliximab) a registered trademark of Centocor Ortho Biotech, ARCALYST<SUP>
</SUP>affects the immune defense system of the body by blocking some of its
functions. Therefore, ARCALYST may interfere with the body&#146;s ability to fight
infections. As noted above, in June 2011, following two positive Phase 3 trials,
the Arthritis Advisory Committee of the FDA voted to recommend against approval
in a gout indication for Ilaris<SUP>&#174;</SUP>, Novartis&#146; IL-1 inhibitor which
works through a similar mechanism as ARCALYST and, in August 2011, Novartis
received a Complete Response letter from the FDA requesting additional
information, including clinical data to evaluate the benefit-risk profile of
Ilaris<SUP>&#174;</SUP> in refractory patients. </FONT></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Treatment with Kineret<SUP>&#174;</SUP>, a medication that works through the
inhibition of IL-1, has been associated with an increased risk of serious
infections, and serious, life threatening infections have been reported in
patients taking ARCALYST. These or other complications or side effects could
cause regulatory authorities to revoke approvals of ARCALYST for the treatment
of CAPS or deny the approval of ARCALYST for the prevention of gout flares in
patients initiating uric acid-lowering treatment or other disease settings.
Alternatively, we may be required to conduct additional clinical trials, make
changes in the labeling of our product, or limit or abandon our efforts to
develop ARCALYST in new disease settings. Any such side effects may also result
in a reduction, or even the elimination, of sales of ARCALYST in the current or
future approved indications.</FONT></P>
<P align=center><FONT face="Times New Roman" size=2>50</FONT></P>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp; <FONT face="Times New Roman" size=2>We are
studying REGN475, a fully human monoclonal antibody to NGF, in a variety of pain
indications, including osteoarthritis of the knee. In December 2010, the FDA
placed REGN475 and other investigational agents targeting NGF on clinical hold
after a case of rapidly progressive osteoarthritis leading to joint replacement
was seen in another company&#146;s anti-NGF program. At that time, the FDA expressed
concern that this case, which followed previously-reported cases of joint
replacements in patients on an anti-NGF drug candidate being developed by a
different pharmaceutical company, provided evidence to suggest a class effect.
An FDA Arthritis Advisory Committee met on March 12, 2012 to discuss possible
safety issues related to anti-NGF compounds and voted unanimously in favor of a
role for the ongoing development of anti-NGF agents in osteoarthritis. The
Arthritis Advisory Committee also voted twenty to one in favor of a role for
development of anti-NGF agents to manage the pain associated with conditions for
which there are no agents with demonstrated analgesic efficacy. The committee's
recommendation will be considered by the FDA, but is not binding on the FDA.
There are currently no ongoing trials with REGN475 that are either enrolling or
treating patients. Discussions with the FDA about REGN475 are ongoing.
</FONT></P>
<P style="PADDING-LEFT: 8pt" align=justify><B><I><FONT face="Times New Roman" size=2>Our
product candidates in development are recombinant proteins that could cause an
immune response, resulting in the creation of harmful or neutralizing antibodies
against the therapeutic protein. </FONT></I></B></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>In addition to the safety, efficacy, manufacturing, and regulatory
hurdles faced by our product candidates, the administration of recombinant
proteins frequently causes an immune response, resulting in the creation of
antibodies against the therapeutic protein. The antibodies can have no effect or
can totally neutralize the effectiveness of the protein, or require that higher
doses be used to obtain a therapeutic effect. In some cases, the antibody can
cross react with the patient&#146;s own proteins, resulting in an &#147;auto-immune&#148; type
disease. Whether antibodies will be created can often not be predicted from
preclinical or clinical experiments, and their detection or appearance is often
delayed, so neutralizing antibodies may be detected at a later date, in some
cases even after pivotal clinical trials have been completed.</FONT></P>
<P style="PADDING-LEFT: 8pt" align=justify><B><I><FONT face="Times New Roman" size=2>We may
be unable to formulate or manufacture our product candidates in a way that is
suitable for clinical or commercial use, which would delay or prevent continued
development of such candidates and/or receipt of regulatory approval or
commercial sale, which could materially harm our business. </FONT></I></B></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>If we are unable to continue to develop suitable product formulations or
manufacturing processes to support large scale clinical testing of our product
candidates, including our antibody candidates, we may be unable to supply
necessary materials for our clinical trials, which would delay or prevent the
development of our product candidates. Similarly, if we are unable, directly or
through our collaborators or third parties, to supply sufficient quantities of
our products or develop formulations of our product candidates suitable for
commercial use, we will be unable to obtain regulatory approval for those
product candidates. </FONT></P>
<P align=justify><FONT face="Times New Roman" size=2></FONT><B><FONT face="Times New Roman" size=2>Risks
Related to Commercialization of EYLEA for the Treatment of Wet AMD
</FONT></B></P>
<P style="PADDING-LEFT: 8pt" align=justify><B><I><FONT face="Times New Roman" size=2>We are
subject to significant ongoing regulatory obligations and oversight with respect
to EYLEA for the treatment of wet AMD. If we fail to maintain regulatory
compliance for EYLEA, we may lose marketing approval, which would materially
harm our business, prospects, operating results, and financial condition.
</FONT></I></B></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>EYLEA is currently approved for treatment of wet AMD in the United States
and Bayer HealthCare is seeking approval in other countries. We are subject to
significant ongoing regulatory obligations with respect to EYLEA for the
treatment of wet AMD in the United States, and, if approved outside the United
States, commercialization of EYLEA will be subject to significant ongoing
regulatory obligations and oversight in those countries where approval is
obtained as well. If we fail to maintain regulatory compliance for EYLEA for the
treatment of wet AMD, we may lose marketing approval, which would materially
harm our business, prospects, operating results, and financial condition.
Failure to comply may also subject us to sanctions, product recalls, or
withdrawals of previously approved marketing applications. See also
&#147;</FONT><I><FONT face="Times New Roman" size=2>If we fail to meet the stringent requirements
of governmental regulation in the manufacture of drug products or product
candidates, we could incur substantial remedial costs, delays in the development
or approval of our product candidates or new indications for our marketed
products and/or in their commercial launch if they obtain regulatory approval,
and a reduction in sales.&#148;</FONT></I></P>
<P align=center><FONT face="Times New Roman" size=2>51</FONT></P>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<P style="padding-left: 8pt" align=justify><B><I><FONT face="Times New Roman" size=2>Serious complications or side
effects in connection with the use of EYLEA could materially harm our business,
prospects, operating results, and financial condition. </FONT></I></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp; <FONT face="Times New Roman" size=2>There are
risks inherent in intravitreal injections, including with EYLEA, such as
intraocular inflammation, sterile and culture positive endophthalmitis, corneal
decomposition, retinal detachment, retinal tear, and other side effects, all of
which are reported from time to time to the FDA. Serious complications or
serious, unexpected side effects in connection with the use of EYLEA could
materially harm our business, prospects, operating results, and financial
condition. </FONT></P>
<P style="padding-left: 8pt" align=justify><B><I><FONT face="Times New Roman" size=2>Our regulatory approval for sales
of EYLEA is limited to the treatment of wet AMD and is limited to sales in the
United States. If we don't receive approval for EYLEA for other indications, or
if approvals are not obtained for sales in other countries, sales and profits
will be limited. </FONT></I></B></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>We have received regulatory approval for sale of EYLEA for the treatment
of wet AMD only in the United States. If we do not receive approval for EYLEA
for other uses, or if approvals for sales in other countries are not obtained,
sales will be limited and our potential for profits will be limited. As a
result, our business, prospects, results of operations, and financial condition
would be materially impacted. </FONT></P>
<P style="padding-left: 8pt" align=justify><B><I><FONT face="Times New Roman" size=2>Our sales of EYLEA for the
treatment of wet AMD are dependent on the availability and extent of
reimbursement from third party payers, and changes to such reimbursement may
materially harm our sales and potential revenue and harm our business,
prospects, operating results, and financial condition.</FONT></I></B></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Our current sales in the United States of EYLEA for the treatment of wet
AMD are dependent, in part, on the availability and extent of reimbursement from
third-party payers, including government programs such as Medicare and Medicaid
and private payer healthcare and insurance programs. If approved for sale in
other countries, such sales will be dependent, in part, on similar programs in
these countries. In the United States, there is an increased focus from the
federal government and others on analyzing the impact of various regulatory
programs on the federal deficit, which could result in increased pressure on
federal programs to reduce costs, including limiting federal healthcare
expenditures. Economic pressure on state budgets may also have a similar impact.
A reduction in the availability or extent of reimbursement from U.S. government
programs could have a material adverse effect on the sales of EYLEA. Since EYLEA
for the treatment of wet AMD is too expensive for most patients to afford
without health insurance coverage, if adequate coverage and reimbursement by
third-party payers, including Medicare and Medicaid in the United States, is not
available, our ability to successfully commercialize EYLEA will be materially
adversely impacted. Our sales and potential profits and our business, prospects,
operating results, and financial condition would be materially harmed. See also
"</FONT><I><FONT face="Times New Roman" size=2>The successful commercialization of EYLEA for
the treatment of wet AMD as well as our late-stage product candidates or new
indications for our marketed products, if approved, will depend on obtaining
coverage and reimbursement for use of these products from third-party payers,
including Medicare and Medicaid in the United States, and these payers may not
agree to cover or adequately reimburse for use of our products or may do so at
levels that make our products uncompetitive and/or unprofitable, which would
materially harm our business, prospects, operating results, and financial
condition</FONT></I><FONT face="Times New Roman" size=2>."</FONT></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The status of a J-Code for EYLEA could also affect reimbursement. J-Codes
are permanent reimbursement codes maintained by Centers for Medicare and
Medicaid Services (CMS) that are a component of the Healthcare Common Procedure
Coding System (HCPCS), and are typically used to report injectable drugs that
ordinarily cannot be self-administered. We do not currently have a J-Code for
EYLEA, although we anticipate assignment of a J-Code for EYLEA in January 2013.
Since our product launch of EYLEA in November 2011, EYLEA has been billed using
a non-specific miscellaneous J-code. Since such codes may be used for a wide
variety of products, health plans may have more difficulty determining the
actual product used and billed for the patient. As a result, these claims must
often be submitted with additional information and manually processed, which can
create delays in claims processing times as well as increasing the likelihood
for claim errors. Effective July 1, 2012, CMS issued a Q-Code, which is a
temporary code to facilitate reimbursement for physician-administered EYLEA in
wet AMD pending the issuance of the J-Code expected in January 2013.</FONT></P>
<P align=center><FONT face="Times New Roman" size=2>52</FONT></P>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<P style="padding-left: 8pt" align=justify><B><I><FONT face="Times New Roman" size=2>The commercial success of EYLEA
currently being marketed for the treatment of wet AMD is subject to strong
competition. </FONT></I></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp; <FONT face="Times New Roman" size=2>The market for
eye disease products is very competitive. Novartis and Genentech are
collaborating on the commercialization and further development of a VEGF
antibody fragment, Lucentis<SUP>&#174; </SUP>for the treatment of wet AMD, CRVO, DME,
and other eye indications. Lucentis<SUP>&#174;</SUP> was approved by the FDA in June
2006 for the treatment of wet AMD and in June 2010 for the treatment of macular
edema following retinal vein occlusion (RVO), CRVO, and BRVO.
Lucentis<SUP>&#174;</SUP> was also approved by the EMA for wet AMD in January 2007
and for DME in January 2011. Many other companies are working on the development
of product candidates for the potential treatment of wet AMD and DME including
those that act by blocking VEGF and VEGF receptors, as well as small interfering
ribonucleic acids (siRNAs) that modulate gene expression. Ophthotech Corporation
is developing Fovista<SUP>TM</SUP>, an aptamer directed against platelet-derived
growth factor subunit B (PDGF-B), as a product candidate intended to be used in
combination with an anti-VEGF therapy in wet AMD. In June 2012, Ophthotech
announced results of a Phase 2b study in wet AMD that it claimed demonstrated
that Fovista<SUP>TM</SUP> administered in combination with Lucentis<SUP>&#174;</SUP>
resulted in increased visual outcomes compared to Lucentis<SUP>&#174;</SUP>
monotherapy. In addition, ophthalmologists are using off-label, third-party
repackaged versions of Genentech&#146;s approved VEGF antagonist, Avastin<SUP>&#174;
</SUP>with success for the treatment of wet AMD, DME, and RVO. The relatively
low cost of therapy with Avastin<SUP>&#174;</SUP> in patients with wet AMD presents a
significant competitive challenge in this indication. </FONT></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The National Eye Institute (NEI) and others are conducting long-term,
controlled clinical trials comparing Lucentis<SUP>&#174;</SUP> to Avastin<SUP>&#174;</SUP>
in the treatment of wet AMD. One-year data from the Comparison of Age-Related
Macular Degeneration Treatments Trial (CATT) were reported in April 2011 and
indicated that Avastin<SUP>&#174;</SUP> dosed monthly was non-inferior to
Lucentis<SUP>&#174;</SUP> dosed monthly in the primary efficacy endpoint of mean
visual acuity gain at 52 weeks. Two-year data from CATT were reported in April
2012 and indicated that monthly Avastin<SUP>&#174;</SUP> was non-inferior to monthly
Lucentis<SUP>&#174;</SUP> in mean visual acuity gain; as-needed dosing was
</FONT><I><FONT face="Times New Roman" size=2>not</FONT></I><FONT face="Times New Roman" size=2>
non-inferior to monthly dosing. Avastin<SUP>&#174;</SUP> is also being evaluated in
eye diseases in trials that have been initiated in the United Kingdom, Canada,
Brazil, Mexico, Germany, Israel, and other countries. It may be difficult for
EYLEA in this or other eye indications for which it may be approved to compete
against Lucentis<SUP>&#174;</SUP> and off-label use of Avastin<SUP>&#174;</SUP> because
doctors and patients have had significant experience using these medicines.
Moreover, the reported results of the CATT study, combined with the relatively
low cost of Avastin<SUP>&#174;</SUP> in treating patients with wet AMD, may well
exacerbate the competitive challenge which EYLEA will face in this or other eye
indications for which it may be approved. In addition, ZALTRAP has not been
manufactured and formulated for use in intravitreal injections, and while we
believe that ZALTRAP would not be well tolerated if administered directly to the
eye, if ZALTRAP is approved for the treatment of certain cancers, there is a
risk that third parties will attempt to repackage ZALTRAP for off-label use and
sale for the treatment of wet AMD and other diseases of the eye, which would
present a potential low-cost competitive threat to EYLEA for wet AMD or other
eye indications. See also &#147;</FONT><I><FONT face="Times New Roman" size=2>The commercial
success of EYLEA currently being marketed for the treatment of wet AMD, and for
our other product candidates or new indications for our marketed products, if
any are approved for marketing, is highly uncertain given their method of
administration, and because our competitors have received approval for and may
be marketing products with a similar mechanism of action or may enter the
marketplace with better or lower cost drugs.</FONT></I><FONT face="Times New Roman" size=2>&#148;
</FONT></P>
<P align=justify><B><FONT face="Times New Roman" size=2>Risks Related to Intellectual
Property and Market Exclusivity </FONT></B></P>
<P style="padding-left: 8pt" align=justify><B><I><FONT face="Times New Roman" size=2>If we cannot protect the
confidentiality of our trade secrets or our patents are insufficient to protect
our proprietary rights, our business and competitive position will be harmed.
</FONT></I></B></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Our business requires using sensitive and proprietary technology and
other information that we protect as trade secrets. We seek to prevent improper
disclosure of these trade secrets through confidentiality agreements. If our
trade secrets are improperly disclosed, by our own employees, our collaborators
or otherwise, it would help our competitors and adversely affect our business.
We will be able to protect our proprietary rights from unauthorized use by third
parties only to the extent that our rights are covered by valid and enforceable
patents or are effectively maintained as trade secrets. The patent position of
biotechnology companies, including our company, involves complex legal and
factual questions and, therefore, enforceability cannot be predicted with
certainty. Our patents may be challenged, invalidated, or circumvented. Patent
applications filed outside the United States may be challenged by third parties
who file an opposition. Such opposition proceedings are increasingly common in
the European Union and are costly to defend. We have pending patent applications
in the European Patent Office and it is likely that we will need to defend
patent applications from third-party challengers from time to time in the
future. Patent applications filed in the United
States may also be challenged by third parties who file a request for post-grant
review under the America Invents Act of 2011, beginning on September 16, 2012.
We expect that post-grant review proceedings will become common in the United
States and will be costly to defend. We have pending patent applications in the
United States Patent and Trademark Office and it is likely that we will need to
defend patent applications from third-party challengers from time to time in the
future. Our patent rights may not provide us with a proprietary position or
competitive advantages against competitors. Furthermore, even if the outcome is
favorable to us, the enforcement of our intellectual property rights can be
extremely expensive and time consuming. </FONT></P>

<P align=center><FONT face="Times New Roman" size=2>53</FONT></P>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>

<P style="PADDING-LEFT: 8pt" align=justify><B><I><FONT face="Times New Roman" size=2>We may
be restricted in our development, manufacturing, and/or commercialization
activities by, and could be subject to damage awards if we are found to have
infringed, third-party patents or other proprietary rights, and the costs and
expenses of ongoing patent litigation have been and will likely continue to be
significant. </FONT></I></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp; <FONT face="Times New Roman" size=2>Our commercial
success depends significantly on our ability to operate without infringing the
patents and other proprietary rights of third parties. Other parties may allege
that they have blocking patents to our products in clinical development or even
to products that have received regulatory approval and are being or have been
commercialized, either because they claim to hold proprietary rights to the
composition of a product or the way it is manufactured or used. Moreover, other
parties may allege that they have blocking patents to antibody products made
using our </FONT><I><FONT face="Times New Roman" size=2>VelocImmune</FONT></I><FONT face="Times New Roman" size=2> technology, either because of the way the antibodies are
discovered or produced or because of a proprietary composition covering an
antibody or the antibody&#146;s target. </FONT></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>We are aware of issued patents and pending patent applications owned by
Genentech that claim certain chimeric VEGF receptors. We do not believe that
ZALTRAP or EYLEA infringe any valid claim in these patents or patent
applications. We are involved in five patent litigations with Genentech, two in
the United States and three in Europe. In November 2010, we commenced a lawsuit
against Genentech in the U.S. District Court for the Southern District of New
York (the Court), seeking a declaratory judgment that no activities relating to
our VEGF Trap infringe any valid claim of certain Genentech patents referred to
as the Davis-Smyth patents (the First Davis-Smyth Case). Genentech answered the
complaint and asserted counterclaims that our prior or planned activities
relating to VEGF Trap have infringed or will infringe claims of four of the five
Davis-Smyth patents and requested a judgment against us for damages, including
for willful infringement, and other relief as the Court deems
appropriate.</FONT></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>On December 31, 2011, we entered into the Genentech Agreement that covers
making, using, and selling EYLEA in the United States for the prevention and
treatment of human eye diseases and disorders in the United States, and ends the
litigation relating to those matters. Under the Genentech Agreement, we received
a non-exclusive license to the Davis-Smyth patents, and certain other technology
patents owned or co-owned by Genentech. The Genentech Agreement does not cover
any non-U.S. patent rights or non-U.S. patent disputes, and does not cover any
use of aflibercept other than for prevention and treatment of human eye diseases
and disorders in the United States. The First Davis-Smyth Case is continuing
with respect to matters not covered by the Genentech Agreement. The Genentech
Agreement provides for us to make payments to Genentech based on U.S. sales of
EYLEA through May 7, 2016, the date the Davis-Smyth patents expire. We will make
a lump-sum payment of $60 million once cumulative U.S. sales of EYLEA reach $400
million. We will also pay royalties of 4.75% on cumulative U.S. sales of EYLEA
between $400 million and $3 billion and 5.5% on any cumulative U.S. sales of
EYLEA over $3 billion. As a result of the Genentech Agreement, on January 17,
2012 Genentech filed a second amended answer and counterclaim in the First
Davis-Smyth Case, in which it amended its counterclaims alleging infringement of
four of the five Davis-Smyth patents. On December 23, 2011, Genentech initiated
a related case in the Court against Regeneron and Sanofi alleging infringement
of four of the five Davis-Smyth Patents by activities relating to VEGF Trap (but
excluding EYLEA) (the Second Davis-Smyth Case). As in the First Davis-Smyth
Case, in the new complaint Genentech requests a judgment against us for damages,
including for willful infringement, and other relief as the Court deems
appropriate.</FONT></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>We believe Genentech's remaining claims in the First Davis Smyth Case and
the Second Davis Smyth Case are without merit and intend to continue to defend
against all of Genentech&#146;s remaining claims vigorously. However, it is possible
that there could be an adverse determination or judgment in either or both cases
that would materially harm our business by requiring us to seek a license for
matters not covered by the Agreement, which may not be available at all or on
reasonable terms, or precluding the manufacture, further development, or sale of
EYLEA outside the United States or ZALTRAP, or resulting in a damage award. In
addition, irrespective of the outcome of the Davis-Smyth cases, we have incurred
and will likely continue to incur significant costs and expenses associated with
them, which have negatively affected, and will likely continue to negatively
affect, our results of operations. An adverse determination in any of the
proceedings described herein may have a material adverse effect on our business,
prospects, results of operations, and financial condition.</FONT></P>
<P align=center><FONT face="Times New Roman" size=2>54</FONT></P>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp; <FONT face="Times New Roman" size=2>We have
initiated patent-related actions against Genentech in Germany, the United
Kingdom, and Italy relating in each case to a patent that expires on October 28,
2012. We may initiate other actions in other countries outside the United
States, which could have similar or other adverse outcomes that would materially
harm our business and which, irrespective of the outcomes, may also entail
significant costs and expenses. In the United Kingdom, an adverse decision dated
March 22, 2012 is under appeal. This decision found the designation of European
patent EP 1 238 986 in the United Kingdom to be valid and potential acts
relating to VEGF Trap Eye in the United Kingdom before expiration of the patent
on October 28, 2012 to infringe this patent.</FONT><FONT face="Times New Roman" size=2></FONT></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>We are aware of patents and pending applications owned by Roche that
claim antibodies to IL-6R and methods of treating rheumatoid arthritis with such
antibodies. We are developing sarilumab, an antibody to IL-6R, for the treatment
of rheumatoid arthritis. Although we do not believe that sarilumab infringes any
valid claim in these patents or patent applications, Roche could initiate a
lawsuit for patent infringement and assert its patents are valid and cover
sarilumab.</FONT></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>We are aware of a U.S. patent jointly owned by Genentech and City of Hope
relating to the production of recombinant antibodies in host cells. We currently
produce our antibody product candidates using recombinant antibodies from host
cells and may choose to produce additional antibody product candidates in this
manner. Neither ARCALYST, ZALTRAP, nor EYLEA are recombinant antibodies. If any
of our antibody product candidates are produced in a manner subject to valid
claims in the Genentech patent, then we may need to obtain a license from
Genentech, should one be available. Genentech has licensed this patent to
several different companies under confidential license agreements. If we desire
a license for any of our antibody product candidates and are unable to obtain a
license on commercially reasonable terms or at all, we may be restricted in our
ability to use Genentech&#146;s techniques to make recombinant antibodies in or to
import them into the United States. </FONT></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Further, we are aware of a number of other third-party patent
applications that, if granted with claims as currently drafted, may cover our
current or planned activities. It could be determined that our products and/or
actions in manufacturing or selling our product candidates infringe such
patents.</FONT></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Patent holders in addition to Genentech could assert claims against us
for damages and seek to prevent us from manufacturing, selling, or developing
our drug candidates, and a court may find that we are infringing validly issued
patents of third parties. In the event that the manufacture, use, or sale of any
of our drug candidates, including EYLEA or our other late-stage product
candidates, infringes on the patents or violates other proprietary rights of
third parties, we may be prevented from pursuing product development,
manufacturing, and commercialization of those drugs and may be required to pay
costly damages. Such a result may materially harm our business, prospects,
operating results, and financial condition. In any event, legal disputes are
likely to be costly and time consuming to defend. </FONT></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>We seek to obtain licenses to patents when, in our judgment, such
licenses are needed or advisable. If any licenses are required, we may not be
able to obtain such licenses on commercially reasonable terms, if at all. The
failure to obtain any such license could prevent us from developing or
commercializing any one or more of our product candidates, which could severely
harm our business.</FONT></P>
<P style="PADDING-LEFT: 8pt" align=justify><B><I><FONT face="Times New Roman" size=2>Loss or
limitation of patent rights, and new regulatory pathways for biosimilar
competition, could reduce the duration of market exclusivity for our
products.</FONT></I></B></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>In the pharmaceutical and biotechnology industries, the majority of an
innovative product&#146;s commercial value is usually realized during the period in
which it has market exclusivity. In the United States and some other countries,
when market exclusivity expires and generic versions of a product are approved
and marketed, there usually are very substantial and rapid declines in the
product&#146;s sales.</FONT></P>
<P align=center><FONT face="Times New Roman" size=2>55</FONT></P>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp; <FONT face="Times New Roman" size=2>If our
late-stage product candidates or other clinical candidates are approved for
marketing in the United States or elsewhere, market exclusivity for those
products will generally be based upon patent rights and/or certain regulatory
forms of exclusivity. As described above under "</FONT><I><FONT face="Times New Roman" size=2>If we cannot protect the confidentiality of our trade secrets or our
patents are insufficient to protect our proprietary rights, our business and
competitive position will be harmed</FONT></I><FONT face="Times New Roman" size=2>", the
scope and enforceability of our patent rights may vary from country to country.
The failure to obtain patent and other intellectual property rights, or
limitations on the use, or the loss, of such rights could be material to us.
Absent patent protection or regulatory exclusivity for our products, it is
possible, both in the United States and elsewhere, that generic and/or
biosimilar versions of those products may be approved and marketed which would
likely result in substantial and rapid reductions in revenues from sales of
those products. </FONT></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Under the federal Patient Protection and Affordable Care Act, or PPACA,
enacted in 2010, there is now a new, abbreviated path in the United States for
regulatory approval of biosimilar versions of biological products. The PPACA
provides a regulatory mechanism that allows for FDA approval of biologic drugs
that are similar to (but not generic copies of) innovative drugs on the basis of
less extensive data than is required by a full BLA. Under this new regulation,
an application for approval of a biosimilar may be filed four years after
approval of the innovator product. However, qualified innovative biological
products will receive 12 years of regulatory exclusivity, meaning that the FDA
may not approve a biosimilar version until 12 years after the innovative
biological product was first approved by the FDA. However, the term of
regulatory exclusivity may not remain at 12 years in the United States and could
be shortened. </FONT></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The increased likelihood of biosimilar competition has increased the risk
of loss of innovators&#146; market exclusivity. Due to this risk, and uncertainties
regarding patent protection, if our late-stage product candidates or other
clinical candidates are approved for marketing, it is not possible to predict
the length of market exclusivity for a particular product with certainty based
solely on the expiration of the relevant patent(s) or the current forms of
regulatory exclusivity. It is also not possible to predict changes in United
States regulatory law that might reduce biological product regulatory
exclusivity. The loss of market exclusivity for a product would likely
materially and negatively affect revenues from product sales of that product and
thus our financial results and condition. </FONT></P>
<P align=justify><B><FONT face="Times New Roman" size=2>Risks Related to Manufacturing and
Supply </FONT></B></P>
<P style="PADDING-LEFT: 8pt" align=justify><B><I><FONT face="Times New Roman" size=2>We rely
on limited internal and contracted manufacturing and supply chain capacity,
which could result in our being unable to continue to successfully commercialize
</FONT></I></B><B><I><FONT face="Times New Roman" size=2>EYLEA </FONT></I></B><B><I><FONT face="Times New Roman" size=2>and to commercialize our other product candidates or other
indications for our marketed products if they receive regulatory approval and
are unable to continue to develop our clinical candidates. </FONT></I></B></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Our manufacturing facility would be inadequate to produce the active
pharmaceutical ingredients of (a) EYLEA,<SUP> </SUP>ZALTRAP, and<SUP>
</SUP>ARCALYST for the treatment of gout flares in patients initiating uric-acid
lowering therapies in sufficient commercial quantities if these late-stage
product candidates were all to receive regulatory approval, and (b) our earlier
stage product candidates in sufficient clinical quantities if our clinical
pipeline advances as planned. In addition to expanding our internal capacity, we
intend to rely on our corporate collaborators, as well as contract
manufacturers, to produce commercial quantities of drug material needed for
commercialization of our products to the extent such quantities are not
manufactured at our own facility. We rely entirely on third-parties and our
collaborators for filling and finishing services. Generally, in order for other
parties to perform any step in the manufacturing and supply chain, we must
transfer technology to the other party which can be time consuming and may not
be successfully accomplished without considerable cost and expense, or at all.
We will have to depend on these other parties to perform effectively on a timely
basis and to comply with regulatory requirements. If for any reason they are
unable to do so, and as a result we are unable to directly or through such third
parties manufacture and supply sufficient commercial quantities of our products
on acceptable terms, or if we should encounter delays or other difficulties in
our relationships with our corporate collaborators, third-party manufacturers,
or other parties involved in our supply chain which adversely affect the timely
manufacture and supply of our products, our business, prospects, operating
results, and financial condition may be materially harmed. </FONT></P>
<P style="PADDING-LEFT: 8pt" align=justify><B><I><FONT face="Times New Roman" size=2>Expanding our manufacturing capacity will be costly and we may be
unsuccessful in doing so in a timely manner, which could delay or prevent the
launch and successful commercialization of our marketed products and late-stage
product candidates or other indications for our marketed products if they are
approved for marketing and could jeopardize our current and future clinical
development programs. </FONT></I></B></P>
<P align=center><FONT face="Times New Roman" size=2>56</FONT></P>
<HR align=center width="100%" noShade SIZE=2>


<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>


<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Expanding our manufacturing capacity
to supply commercial quantities of the active pharmaceutical ingredients for our
marketed products and our late-stage product candidates if they are approved for
marketing, and to supply clinical drug material to support the continued growth
of our clinical programs, will require substantial additional expenditures, and
we will need to hire and train significant numbers of employees and managerial
personnel to staff our manufacturing and supply chain operations. Start-up costs
can be large and scale-up entails significant risks related to process
development and manufacturing yields. In addition, we may face difficulties or
delays in developing or acquiring the necessary production equipment and
technology to manufacture sufficient quantities of our product candidates at
reasonable costs and in compliance with applicable regulatory requirements. The
FDA and analogous foreign regulatory authorities must determine that our
existing and any expanded manufacturing facilities comply, or continue to
comply, with cGMP requirements for both clinical and commercial production and
license them, or continue to license them, accordingly, and such facilities must
also comply with applicable environmental, safety, and other governmental
permitting requirements. We may not successfully expand or establish sufficient
manufacturing capabilities or manufacture our products economically or in
compliance with cGMPs and other regulatory requirements, and we and our
collaborators may not be able to build or procure additional capacity in the
required timeframe to meet commercial demand for our late-stage product
candidates if they receive regulatory approval, and to continue to meet the
requirements of our clinical programs. This would interfere with our efforts to
successfully commercialize EYLEA and, if they receive regulatory approval,
ZALTRAP and ARCALYST for the prevention of gout flares in patients initiating
uric acid-lowering treatment, and could also delay or require us to discontinue
one or more of our clinical development programs. As a result, our business,
prospects, operating results, and financial condition could be materially
harmed. </FONT></P>
<P style="PADDING-LEFT: 8pt" align=justify><B><I><FONT face="Times New Roman" size=2>Our
ability to manufacture our products may be impaired if any of our manufacturing
activities, or the activities of third parties involved in our manufacture and
supply chain, are found to infringe third-party patents. </FONT></I></B></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Our ability to continue to
manufacture ARCALYST, EYLEA, and ZALTRAP in our Rensselaer, New York facilities,
or to utilize third parties to produce our products or perform fill/finish
services or other steps in our manufacture and supply chain, depends on our and
their ability to operate without infringing the patents or other intellectual
property rights of third parties. Other parties may allege that our
manufacturing activities, or the activities of third parties involved in our
manufacture and supply chain, infringe patents or other intellectual property
rights. A judicial decision in favor of one or more parties making such
allegations could preclude the manufacture of our products where those
intellectual property rights apply which could materially harm our business,
results of operations, and prospects.</FONT></P>
<P style="PADDING-LEFT: 8pt" align=justify><B><I><FONT face="Times New Roman" size=2>If
sales of EYLEA for the treatment of wet AMD do not meet the levels currently
expected, or if the launch of our late-stage product candidates or new
indications of our marketed products, or any of our clinical programs, are
delayed or discontinued, we may face costs related to unused capacity at our
manufacturing facilities and at the facilities of third parties.
</FONT></I></B></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>We have large-scale manufacturing
operations in Rensselaer, New York. We use our facilities to produce bulk
product of ARCALYST for the treatment of CAPS, bulk product of EYLEA for the
treatment of wet AMD and clinical and preclinical candidates for ourselves and
our collaborations, and plan to use such facilities to produce bulk product for
commercial supply of our late-stage product candidates or new indications of our
marketed products if they are approved for marketing. If our clinical candidates
are discontinued or their clinical development is delayed, if the launch of any
of our late-stage product candidates or new indications for our marketed
products is delayed or does not occur, or if such products are launched and
subsequently recalled or marketing approval is rescinded, we may have to absorb
one hundred percent of related overhead costs and inefficiencies, as well as
similar costs of third-party contract manufacturers performing services for us.
</FONT></P>
<P style="PADDING-LEFT: 8pt" align=justify><B><I><FONT face="Times New Roman" size=2>Third-party service or supply failures, or other failures, business
interruptions, or natural disasters affecting our manufacturing facilities in
Rensselaer, New York or the facilities of any other party participating in the
supply chain, would adversely affect our ability to supply our products.
</FONT></I></B></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>We currently manufacture all of our
bulk drug materials at our manufacturing facilities in Rensselaer, New York. We
would be unable to manufacture these materials if our Rensselaer facilities were
to cease production due to regulatory requirements or action, business
interruptions, labor shortages or disputes, contaminations, fire, natural
disasters, or other problems at the facilities. </FONT></P>
<P align=center><FONT face="Times New Roman" size=2>57</FONT></P>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Also, certain raw materials
necessary for the manufacture and formulation of ARCALYST and EYLEA and of our
product candidates, including ZALTRAP, are provided by single-source
unaffiliated third-party suppliers. In addition, we rely on certain third
parties to perform filling, finishing, distribution, laboratory testing, and
other services related to the manufacture of ARCALYST, EYLEA, and our product
candidates. We would be unable to obtain these raw materials or services for an
indeterminate period of time if any of these third parties were to cease or
interrupt production or otherwise fail to supply these materials, products, or
services to us for any reason, including due to regulatory requirements or
action, adverse financial developments at or affecting the supplier, failure by
the supplier to comply with cGMPs, business interruptions, or labor shortages or
disputes. This, in turn, could materially and adversely affect our ability to
manufacture or supply ARCALYST for the treatment of CAPS and EYLEA for the
treatment of wet AMD and to manufacture and supply commercial quantities of
EYLEA for other ophthalmologic diseases, ZALTRAP for
previously-treated mCRC, and ARCALYST for the prevention of gout flares in
patients initiating uric-acid lowering therapy if they receive regulatory
approval, which could materially and adversely affect our business and future
prospects. </FONT></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Certain of the raw materials
required in the manufacture and the formulation of our product candidates may be
derived from biological sources, including mammalian tissues, bovine serum, and
human serum albumin. There are certain European regulatory restrictions on using
these biological source materials. If we are required to substitute for these
sources to comply with European regulatory requirements, our clinical
development activities may be delayed or interrupted. </FONT></P>
<P style="PADDING-LEFT: 8pt" align=justify><B><I><FONT face="Times New Roman" size=2>If we
fail to meet the stringent requirements of governmental regulation in the
manufacture of drug products or product candidates, we could incur substantial
remedial costs, delays in the development or approval of our product candidates
or new indications for our marketed products and/or in their commercial launch
if they obtain regulatory approval, and a reduction in sales.</FONT></I></B></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>We and our third-party providers are
required to maintain compliance with cGMP, and are subject to inspections by the
FDA or comparable agencies in other jurisdictions to confirm such compliance.
Changes of suppliers or modifications of methods of manufacturing may require
amending our application(s) to the FDA or such comparable foreign agencies and
acceptance of the change by the FDA or such comparable foreign agencies prior to
release of product(s). Because we produce multiple product candidates at our
facility in Rensselaer, New York, including ARCALYST, EYLEA, and ZALTRAP, there
are increased risks associated with cGMP compliance. Our inability, or the
inability of our third-party fill/finish or other service providers, to
demonstrate ongoing cGMP compliance could require us to engage in lengthy and
expensive remediation efforts, withdraw or recall product, halt or interrupt
clinical trials, and/or interrupt commercial supply of any marketed products,
and could also delay or prevent our obtaining regulatory approval for our
late-stage product candidates or new indications for our marketed products. Any
delay, interruption, or other issue that arises in the manufacture, fill/finish,
packaging, or storage of any drug product or product candidate as a result of a
failure of our facilities or the facilities or operations of third parties to
pass any regulatory agency inspection or maintain cGMP compliance could
significantly impair our ability to develop, obtain approval for, and
successfully commercialize our products, which would substantially harm our
business and prospects. Any finding of non-compliance could also increase our
costs, cause us to delay the development of our product candidates, result in
delay in our obtaining, or our not obtaining, regulatory approval of product
candidates or new indications for our marketed products, and cause us to lose
revenue from any marketed products, which could be seriously detrimental to our
business, prospects, operating results, and financial condition.</FONT></P>
<P align=justify><B><FONT face="Times New Roman" size=2>Risks Related to Commercialization
of Products </FONT></B></P>
<P style="PADDING-LEFT: 8pt" align=justify><B><I><FONT face="Times New Roman" size=2>We may
be unsuccessful in continuing our commercialization of EYLEA for the treatment
of wet AMD or commercializing our late stage product candidates or new
indications for our marketed products, if approved, which would materially delay
or prevent our achieving long-term profitability. </FONT></I></B></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Even if clinical trials demonstrate
the safety and effectiveness of any of our product candidates for a specific
disease and the necessary regulatory approvals are obtained, the commercial
success of any of our product candidates or new indications for our marketed
products will depend upon, among other things, their acceptance by patients, the
medical community, and third-party payers and on our and our collaborators'
ability to successfully manufacture and commercialize those products or new
indications. Even if we obtain regulatory approval for our product candidates or
new indications, if they are not successfully commercialized, we will not be
able to recover the significant investment we have made in developing such
products and our business, prospects, operating results, and financial condition
would be severely harmed.</FONT></P>
<P align=center><FONT face="Times New Roman" size=2>58</FONT></P>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>In particular, we are in the launch
phase of commercialization of EYLEA for wet AMD and cannot be sure that EYLEA
will be successful longer term. In addition to the challenges we face related to
a company launching its first major commercial drug, as described in detail in
the risk factor immediately below, we and Bayer HealthCare will face intense
competition from Lucentis<SUP>&#174;</SUP> and from off-label use of
Avastin<SUP>&#174;</SUP>, both of which have been on the market for a number of
years. We expect that the continued commercial success of EYLEA for the
treatment of wet AMD will depend on many factors, including the following:
</FONT></P>
<UL style="FONT-SIZE: 10pt; TEXT-ALIGN: justify"><LI>the effectiveness of our and Bayer HealthCare's commercial strategies for
  the launch and marketing of EYLEA in and outside the United States,
  respectively, including pricing strategy and the effectiveness of efforts to
  obtain, and the timing of obtaining, adequate third-party reimbursements;
  </LI><LI>maintaining and successfully monitoring commercial manufacturing
  arrangements for EYLEA with third parties who perform fill/finish or other
  steps in the manufacture of EYLEA to ensure that they meet our standards and
  those of regulatory authorities, including the FDA, which extensively regulate
  and monitor pharmaceutical manufacturing facilities;
  </LI><LI>our ability to meet the demand for commercial supplies of EYLEA;
  </LI><LI>our ability to effectively communicate to the marketplace the benefits of
  the dosing regimen of EYLEA as compared to the dosing regimen of Lucentis<sup>&#174;</sup>,
  and the willingness of retinal specialists and patients to switch from
  Lucentis<sup>&#174;</sup> or off-label use of Avastin<sup>&#174;</sup> to EYLEA for the treatment of wet AMD;
  </LI><LI>the ability of patients, retinal specialists, and other providers to
  obtain and maintain sufficient coverage and reimbursement from third-party
  <FONT STYLE="BACKGROUND-COLOR: TRANSPARENT">payers</FONT>, including Medicare and Medicaid in the United States and other
  government and private <FONT STYLE="BACKGROUND-COLOR: TRANSPARENT">payers</FONT> in the United States and foreign jurisdictions; and
  </LI><LI>the effect of new health care legislation currently being implemented
  in the United States. </LI></UL>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>While we believe that EYLEA for the
treatment of wet AMD has a commercially competitive profile, we cannot predict
whether ophthalmologists, particularly retinal specialists, and patients, will
continue to accept and utilize EYLEA. Our and Bayer HealthCare's efforts to
educate the relevant medical community and third-party <FONT STYLE="BACKGROUND-COLOR: TRANSPARENT">payers</FONT> regarding the
benefits of EYLEA for the treatment of wet AMD will require significant
resources and may not be successful in achieving our objectives. If EYLEA is
approved for marketing but does not achieve significant market acceptance for
the treatment of wet AMD, our ability to sustain profitability would be
materially impaired.</FONT></P>
<P style="PADDING-LEFT: 8pt" align=justify><B><I><FONT face="Times New Roman" size=2>If we
are unable to establish, and effectively deploy and manage, sales, marketing,
and distribution capabilities in the applicable markets or to enter into
agreements with third parties to do so, we will not generate our expected sales
of EYLEA for treatment of wet AMD or successfully launch and commercialize our
late-stage product candidates or new indications for our marketed products if
they receive regulatory approval, which would materially harm our business,
prospects, operating results, and financial condition.</FONT></I></B></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>We currently sell EYLEA in the United States to three distributors and several specialty
pharmacies. We currently sell ARCALYST for the treatment of CAPS in the United
States to two specialty pharmacies. Under these distribution models, we enter
into written contracts with our distributors and specialty pharmacies
(collectively, our &#147;customers&#148;), and our customers generally take physical
delivery of product. For EYLEA, the distributors and specialty pharmacies
generally sell the product directly to healthcare providers, whereas for
ARCALYST, the specialty pharmacies sell the product directly to
patients.</FONT></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>We have established our own sales
and marketing organization for EYLEA in the United States for the
treatment of wet AMD, and in anticipation of filing for and receiving regulatory
approval to market and sell EYLEA in the United States for the
treatment of CRVO. However, we may be unsuccessful in achieving a successful
commercialization of EYLEA in the United States, which would materially harm our
business, prospects, operating results, and financial condition.</FONT></P>
<P align=center><FONT face="Times New Roman" size=2>59</FONT></P>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>If ARCALYST receives regulatory
approval, we will have to rely on a third party or devote significant resources
to develop our own sales and marketing capabilities, and our distribution
network, for patients with gout flares initiating uric acid-lowering drug
therapy. If we are unable to obtain these capabilities, either by developing our
own organizations or entering into agreements with others to provide these
functions, even if ARCALYST for the prevention of gout flares for patients
initiating uric-acid lowering therapy receives marketing approval, we will not
be able to successfully launch and commercialize this product, which would also
materially harm our business, prospects, operating results, and financial
condition.</FONT></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>We have limited experience in sales,
marketing, or distribution of products in substantial commercial quantities or
in establishing and managing the required infrastructure to do so, including
large-scale information technology systems and a large-scale distribution
network, and we may be unable to establish such infrastructure on a timely
basis. To the extent we determine to utilize third parties to provide sales,
marketing, or distribution capabilities for ARCALYST if it is approved for the
prevention of gout flares in patients initiating uric-acid lowering therapy or
any of our other product candidates or new indications for marketed products if
they receive regulatory approval, we may encounter difficulties in retaining
such parties on acceptable terms. Even if we hire qualified sales and marketing
personnel, and establish the required infrastructure we need to support our
objectives, or enter into marketing and distribution agreements with third
parties on acceptable terms, we may not do so in an efficient manner or on a
timely basis. We may not be able to correctly judge the size and experience of
the sales and marketing force and the scale of distribution capabilities
necessary to successfully market and sell in the United States EYLEA, ARCALYST
if approved for the prevention of gout flares in patients initiating uric-acid
lowering therapy, or any of our other product candidates or new indications if
they receive regulatory approval in the United States and as to which we retain
sales and marketing responsibility in that market. Establishing and maintaining
sales, marketing, and distribution capabilities are expensive and
time-consuming. Our expenses associated with building up and maintaining a sales
force and distribution capabilities may be disproportional, particularly in the
near term, compared to the revenues we may be able to generate on sales in the
United States of EYLEA or ARCALYST if approved for the prevention of gout flares
in patients initiating uric-acid lowering therapy. Ultimately neither we nor our
collaborators may be successful in commercializing EYLEA or, if they received
regulatory approval, ZALTRAP, ARCALYST for the prevention of gout flares in
patients initiating uric-acid lowering therapy, or any of our other product
candidates.</FONT></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Under the terms of our collaboration
agreement, Sanofi has primary responsibility for sales, marketing, and
distribution of ZALTRAP in cancer indications, should it be approved in the
future by regulatory authorities for marketing.</FONT></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>We currently have no sales,
marketing, commercial, or distribution capabilities outside the United States.
Under the terms of our license and collaboration agreement with Bayer
HealthCare, we will rely on Bayer HealthCare for sales, marketing, and
distribution of EYLEA in countries outside the United States should it be
approved for marketing in such countries.</FONT></P>
<P style="PADDING-LEFT: 8pt" align=justify><B><I><FONT face="Times New Roman" size=2>The
commercial success of EYLEA currently being marketed for the treatment of wet
AMD, and for our other product candidates or new indications for our marketed
products, if any are approved for marketing, is highly uncertain given their
method of administration, and because our competitors have received approval for
and may be marketing products with a similar mechanism of action or may enter
the marketplace with better or lower cost drugs. </FONT></I></B></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Our product candidates are delivered
either by intravenous infusion or by intravitreal or subcutaneous injections,
which are generally less well received by patients than tablet or capsule
delivery and this could adversely affect the commercial success of those
products if they receive marketing approval.</FONT></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>There is substantial competition in
the biotechnology and pharmaceutical industries from biotechnology,
pharmaceutical, and chemical companies. Many of our competitors have
substantially greater research, preclinical and clinical product development and
manufacturing capabilities, and financial, marketing, and human resources than
we do. Our smaller competitors may also enhance their competitive position if
they acquire or discover patentable inventions, form collaborative arrangements,
or merge with large pharmaceutical companies. Even if we achieve
commercialization of our product candidates, our competitors have achieved, and
may continue to achieve, product commercialization before our products are
approved for marketing and sale.</FONT></P>
<P align=center><FONT face="Times New Roman" size=2>60</FONT></P>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>As previously noted, Genentech has
an approved VEGF antagonist, Avastin<SUP>&#174;</SUP>, on the market for treating
certain cancers and many different pharmaceutical and biotechnology companies
are working to develop competing VEGF antagonists, including Novartis, Amgen,
Imclone LLC/Eli Lilly, Pfizer, AstraZeneca, and GlaxoSmithKline. Some of these
molecules are further along in development than ZALTRAP and may offer
competitive advantages over our molecule. Each of Pfizer, Onyx (together with
its partner Bayer HealthCare), and GlaxoSmithKline are marketing and selling
oral medications that target tumor cell growth and new vasculature formation
that fuels the growth of tumors. The marketing approvals for Genentech&#146;s VEGF
antagonist, Avastin<SUP>&#174;</SUP>, and their extensive, ongoing clinical
development plan for Avastin<SUP>&#174;</SUP> in other cancer indications, make it
more difficult for us to enroll patients in clinical trials to support ZALTRAP
for those indications and to obtain regulatory approval of ZALTRAP in those
indications. This may delay or impair our ability to successfully develop and
commercialize ZALTRAP for various cancer indications. In addition,
even if ZALTRAP is approved for sale for the treatment of mCRC, it will be
difficult for our drug to compete against Avastin<SUP>&#174;</SUP> and the FDA
approved kinase inhibitors, because doctors and patients will have significant
experience using these medicines. In addition, an oral medication may be
considerably less expensive for patients than a biologic medication, providing a
competitive advantage to companies that market such products. </FONT></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>The market for eye disease products
is also very competitive. Novartis and Genentech are collaborating on the
commercialization and further development of a VEGF antibody fragment,
Lucentis<SUP>&#174;</SUP> for the treatment of wet AMD, CRVO, DME, and other eye
indications. Lucentis<SUP>&#174;</SUP> was approved by the FDA in June 2006 for the
treatment of wet AMD and in June 2010 for the treatment of macular edema
following retinal vein occlusion (RVO), CRVO, and BRVO. Lucentis<SUP>&#174;</SUP> was
also approved by the EMA for wet AMD in January 2007 and for DME in January
2011. Many other companies are working on the development of product candidates
for the potential treatment of wet AMD and DME including those that act by
blocking VEGF and VEGF receptors, as well as small interfering ribonucleic acids
(siRNAs) that modulate gene expression. Ophthotech Corporation is developing
Fovista<SUP>TM</SUP>, an aptamer directed against platelet-derived growth factor
subunit B (PDGF-B), as a product candidate intended to be used in combination
with an anti-VEGF therapy. In June 2012, Ophthotech announced results of a Phase
2b study that it claimed demonstrated that Fovista<SUP>TM</SUP> administered in
combination with Lucentis<SUP>&#174;</SUP> resulted in increased visual outcomes
compared to Lucentis<SUP>&#174;</SUP> monotherapy. In addition, ophthalmologists are
using off-label, with success for the treatment of wet AMD, DME, and RVO,
third-party repackaged versions of Genentech&#146;s approved VEGF antagonist,
Avastin<SUP>&#174;</SUP>.</FONT></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>The National Eye Institute (NEI) and
others are conducting long-term, controlled clinical trials comparing
Lucentis<SUP>&#174;</SUP> to Avastin<SUP>&#174;</SUP> in the treatment of wet AMD.
One-year data from the CATT study were reported in April 2011 and indicated that
Avastin<SUP>&#174;</SUP> dosed monthly was non-inferior to Lucentis<SUP>&#174;</SUP> dosed
monthly in the primary efficacy endpoint of mean visual acuity gain at 52 weeks.
Two-year data from CATT were reported in April 2012 and indicated that
Avastin<SUP>&#174;</SUP> was non-inferior to Lucentis<SUP>&#174;</SUP> in mean visual
acuity gain; as-needed dosing was not non-inferior to monthly dosing. It may be
difficult for EYLEA in this or other eye indications for which it may be
approved to compete against Lucentis<SUP>&#174;</SUP> and off-label use of
Avastin<SUP>&#174;</SUP> because doctors and patients have had significant experience
using these medicines. Moreover, the reported results of the CATT study,
combined with the relatively low cost of Avastin<SUP>&#174;</SUP> in treating
patients with wet AMD, may well exacerbate the competitive challenge which EYLEA
will face in this or other eye indications for which it may be approved. In
addition, while we believe that ZALTRAP would not be well tolerated if
administered directly to the eye, if ZALTRAP is approved for the treatment of
certain cancers, there is a risk that third parties will attempt to repackage
ZALTRAP for off-label use and sale for the treatment of wet AMD and other
diseases of the eye, which would present a potential low-cost competitive threat
to EYLEA for wet AMD or other eye indications. </FONT></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>The availability of highly effective
FDA approved Tumor Necrosis Factors-antagonists (TNF-antagonists) such as
Enbrel<SUP>&#174;</SUP>, Remicade<SUP>&#174;</SUP>, Humira<SUP>&#174;</SUP> (adalimumab), a
registered trademark of Abbott Laboratories, Simponi<SUP>&#174;</SUP> (golimumab), a
registered trademark of Johnson &amp; Johnson, the IL-1 receptor antagonist
Kineret<SUP>&#174;</SUP>, Ilaris<SUP>&#174;</SUP> (canakinumab), and other marketed
therapies makes it more difficult to successfully develop and commercialize
ARCALYST in indications other than CAPS, and this is one of the reasons we
discontinued the development of ARCALYST in adult rheumatoid arthritis. In
addition, even if ARCALYST is ever approved for sale in indications where
TNF-antagonists are approved, it will be difficult for our drug to compete
against these FDA approved TNF-antagonists because doctors and patients have had
significant experience using these effective medicines. Moreover, in such
indications these approved therapeutics may offer competitive advantages over
ARCALYST, such as requiring fewer injections.</FONT></P>
<P align=center><FONT face="Times New Roman" size=2>61</FONT></P>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>There are both small molecules and
antibodies in development by other companies that are designed to block the
synthesis of IL-1 or inhibit the signaling of IL-1. For example, Eli Lilly, Xoma
(in collaboration with Servier), and Novartis are each developing antibodies to
IL-1 and both Amgen and MedImmune are developing antibodies to the IL-1
receptor. In 2009, Novartis received regulatory approval in the United States
and Europe for Ilaris<SUP>&#174;</SUP>, a fully human anti-interleukin-IL1&beta; antibody,
for the treatment of CAPS. Ilaris<SUP>&#174;</SUP> is also in development for
atherosclerosis and a number of other inflammatory diseases. Novartis&#146; IL-1
antibody and these other drug candidates could offer competitive advantages over
ARCALYST. For example, Ilaris<SUP>&#174;</SUP> is dosed once every eight weeks
compared to the once-weekly dosing regimen for ARCALYST. The successful
development and/or commercialization of these competing molecules could
adversely affect sales of ARCALYST for the treatment of CAPS and
delay or impair our ability to commercialize ARCALYST for indications
other than CAPS.</FONT></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>We are developing ARCALYST for the
prevention of gout flares in patients initiating uric acid-lowering therapy and
have submitted a supplemental BLA filing for U.S. regulatory approval in this
indication. In May 2012, the Arthritis Advisory Committee of the FDA, voted to
recommend against approval of ARCALYST for the prevention of gout flares in
patients initiating uric acid-lowering drug therapy. In January 2011, Novartis
announced that the results of two Phase 3 studies with Ilaris<SUP>&#174;</SUP>
focused on reducing pain and preventing recurrent attacks or &#147;flares&#148; in
patients with hard-to-treat gout were positive. In June 2011, the Arthritis
Advisory Committee voted to recommend against approval in a gout indication for
Ilaris<SUP>&#174;</SUP> (canikinumab), Novartis&#146; IL-1 inhibitor which works through a
similar mechanism as ARCALYST and, in August 2011, Novartis received a Complete
Response letter from the FDA requesting additional information, including
clinical data to evaluate the benefit-risk profile of Ilaris<SUP>&#174;</SUP> in
refractory patients. Novartis has also reported that regulatory filings for the
use of Ilaris<SUP>&#174;</SUP> in gouty arthritis have been completed in the European
Union in 2010 and in the United States in the first quarter of 2011, based on
the results of these two Phase 3 studies. Ilaris<SUP>&#174;</SUP> is dosed less
frequently for the treatment of CAPS, and if it is approved for the treatment of
gout flares in patients initiating uric-acid lowering therapy, it may be
perceived by some physicians as offering competitive advantages over ARCALYST,
which would make it difficult for us to successfully commercialize ARCALYST in
that disease if ARCALYST receives regulatory approval.</FONT></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Currently, inexpensive, oral
therapies such as analgesics and other Non-Steroidal Anti-Inflammatory Drugs
(NSAIDS), are used as the standard of care to treat the symptoms of gout
diseases. These established, inexpensive, orally delivered drugs may make it
difficult for us to successfully commercialize ARCALYST in these diseases.
</FONT></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Our earlier-stage clinical
candidates in development are all fully human monoclonal antibodies, which were
generated using our </FONT><I><FONT face="Times New Roman" size=2>VelocImmune</FONT></I><FONT face="Times New Roman" size=2> technology. Our antibody
generation technologies and earlier-stage clinical candidates face competition
from many pharmaceutical and biotechnology companies using various
technologies.</FONT></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Numerous other companies are
developing therapeutic antibody products. Companies such as Pfizer, Johnson
</FONT><FONT face="Times New Roman" size=2>&amp; Johnson, AstraZeneca, Amgen, Biogen Idec,
Novartis, Genentech/Roche, Bristol-Myers Squib, Abbott, and GlaxoSmithKline have
generated therapeutic products that are currently in development or on the
market that are derived from recombinant DNA that comprise human antibody
sequences.</FONT></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>We are aware of several
pharmaceutical and biotechnology companies actively engaged in the research and
development of antibody products against targets that are also the targets of
our early-stage product candidates. For example, Pfizer, Johnson &amp; Johnson,
and Abbott are developing antibody product candidates against NGF.
Genentech/Roche is marketing an antibody against IL-6R (tocilizumab) for the
treatment of rheumatoid arthritis, and several other companies, including
Centocor/Johnson &amp; Johnson, and Bristol-Myers Squibb, have antibodies
against IL-6 in clinical development for this disease. GlaxoSmithKline, in
partnership with OncoMed Pharmaceuticals, has a Dll4 antibody in clinical
development for the treatment of solid tumors. Aerovance has two formulations of
a biologic directed against IL-4 in clinical development. Amgen previously had
an antibody against IL-4R in clinical development for the treatment of asthma.
Several companies, including <FONT STYLE="background-color: TRANSPARENT">Amgen, Pfizer, and Roche,</FONT> have development programs for
antibodies against PCSK9. Amgen, Pfizer, and AstraZeneca have development
programs underway for antibodies against ANG2. If any of these or other
competitors announces a successful clinical study involving a product that may
be competitive with one of our product candidates or the grant of marketing
approval by a regulatory agency for a competitive product, such developments may
have an adverse effect on our business or future prospects. </FONT></P>
<P style="PADDING-LEFT: 8pt" align=justify><B><I><FONT face="Times New Roman" size=2>The
successful commercialization of EYLEA for the treatment of wet AMD as well as
our late-stage product candidates or new indications for our marketed products,
if approved, will depend on obtaining coverage and reimbursement for use of
these products from third-party payers, including Medicare and Medicaid in the
United States, and these payers may not agree to cover or adequately reimburse
for use of our products or may do so at levels that make our products
uncompetitive and/or unprofitable, which would materially harm our business,
prospects, operating results, and financial condition.</FONT></I></B></P>
<P align=center><FONT face="Times New Roman" size=2>62</FONT></P>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Our product candidates, if
commercialized, may be significantly more expensive than traditional drug
treatments. For example, we are developing ARCALYST for the prevention of gout
flares in patients initiating uric acid-lowering drug therapy. Patients
suffering from this gout indication are currently treated with inexpensive
therapies, including NSAIDS. These existing treatment options are likely to be
considerably less expensive and may be preferable to a biologic medication for
some patients. Our future revenues and profitability will be adversely affected
in a material manner if United States and foreign governmental, private
third-party insurers and payers, and other third-party payers, including
Medicare and Medicaid, do not agree to defray or reimburse the cost of our
products to the patients. If these entities do not provide coverage and
reimbursement with respect to our products or provide an insufficient level of
coverage and reimbursement, our products may be too costly for many patients to
afford them, and physicians may not prescribe them. Many third-party payers
cover only selected drugs, making drugs that are not preferred by such payers
more expensive for patients, and require prior authorization or failure on
another type of treatment before covering a particular drug. In particular,
payers may impose these obstacles to coverage on higher-priced drugs, as our
product candidates are likely to be.</FONT></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Government and other third-party
payers are challenging the prices charged for healthcare products and
increasingly limiting, and attempting to limit, both coverage and level of
reimbursement for prescription drugs. In March 2010, the PPACA and a related
reconciliation bill were enacted in the United States. This legislation imposes
cost containment measures that are likely to adversely affect the amount of
reimbursement for our future products. The full effects of this legislation are
unknown at this time and will not be known until regulations and guidance are
issued by CMS and other federal and state agencies. Further, in September 2011
the Office of Inspector General (OIG) of the Department of Health and Human
Services issued a report entitled &#147;Review of Medicare Part B Avastin and
Lucentis Treatments for Age-Related Macular Degeneration&#148; in which the OIG
details possible savings to the Medicare program by using off-label
Avastin<SUP>&#174;</SUP> rather than Lucentis<SUP>&#174;</SUP> for the treatment of wet
AMD. Some states are also considering legislation that would control the prices
of drugs, and state Medicaid programs are increasingly requesting manufacturers
to pay supplemental rebates and requiring prior authorization by the state
program for use of any drug for which supplemental rebates are not being paid.
It is likely that federal and state legislatures and health agencies will
continue to focus on additional health care reform in the future that will
impose additional constraints on prices and reimbursements for our products.
</FONT></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Since EYLEA for the treatment of wet
AMD and other eye diseases, and if approval, ZALTRAP for oncology indications,
and ARCALYST for the prevention of gout flares in patients initiating uric-acid
lowering therapy, will likely be too expensive for most patients to afford
without health insurance coverage, if these products are unable to obtain
adequate coverage and reimbursement by third-party payers, including Medicare
and Medicaid in the United States, our ability to successfully commercialize
these products would be materially adversely impacted. The status of a J-Code
for our marketed products could also affect reimbursement. J-Codes are permanent
reimbursement codes maintained by CMS that are a component of HCPCS, and are
typically used to report injectable drugs that ordinarily cannot be
self-administered. Although we have a J-Code for ARCALYST, we do not currently
have a J-Code for EYLEA, although we anticipate assignment of a J-Code for EYLEA
in January 2013. Effective July 1, 2012, CMS issued a Q-Code which is a
temporary code to facilitate reimbursement for physician-administered EYLEA in
wet AMD pending the issuance of the J-Code expected in January 2013. Without a
unique J-Code identifier and prior to the effective date of the Q-code,
EYLEA has been billed using a non-specific miscellaneous
J-Code. Since such codes may be used for a wide variety of products, health
plans may have more difficulty determining the actual product used and billed
for the patient. As a result, these claims must often be submitted with
additional information and manually processed, which can create delays in claims
processing times as well as increasing the likelihood for claim errors.
Third-party payers, including Medicare and Medicaid in the United States, may
not cover and/or reimburse for these products at levels required for us to
successfully commercialize these products. Any limitation imposed by third-party
payers on the use of our products if they are approved for marketing, or any
action or decision by CMS or analogous foreign agencies or authorities which for
any reason denies coverage or reimbursement for our products or provides
coverage or reimbursement at levels that harm our products&#146; competitiveness or
leads to lower prices for those products, will have a material negative effect
on our ability to sustain profitability. In certain foreign countries, pricing,
coverage, and level of reimbursement of prescription drugs are subject to
governmental control, and we and our collaborators may be unable to obtain
coverage, pricing, and/or reimbursement on terms that are favorable to us or
necessary for us or our collaborators to successfully commercialize our products
in those countries. In some foreign countries, the proposed pricing for a drug
must be approved before it may be lawfully marketed. The requirements governing
drug pricing vary widely from country to country. For example, the European
Union provides options for its member states to restrict the range of medicinal
products for which their national health insurance systems provide reimbursement
and to control the prices of medicinal products for human use. A member state
may approve a specific price for the medicinal product or it may instead adopt a
system of direct or indirect controls on the profitability of the company
placing the medicinal product on the market. Our results of operations may
suffer if we or our collaborators are unable to market our products in foreign
countries or if coverage and reimbursement for our products in foreign countries
is limited or delayed.</FONT></P>
<P align=center><FONT face="Times New Roman" size=2>63</FONT></P>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<P align=justify><B><FONT face="Times New Roman" size=2>Regulatory and Litigation Risks
</FONT></B></P>
<P style="PADDING-LEFT: 8pt" align=justify><B><I><FONT face="Times New Roman" size=2>If the
testing or use of our products harms people, we could be subject to costly and
damaging product liability claims.</FONT></I></B></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>The testing, manufacturing,
marketing, and sale of drugs for use in people expose us to product liability
risk. Any informed consent or waivers obtained from people who enroll in our
clinical trials may not protect us from liability or the cost of litigation. We
may also be subject to claims by patients who use our approved products,
ARCALYST for the treatment of CAPS, or EYLEA for the treatment of wet AMD, or
EYLEA for other indications, ZALTRAP for previously-treated mCRC, or ARCALYST
for the prevention of gout flares in patients initiating uric-acid lowering
therapy if those product candidates receive regulatory approval and become
commercially available, that they have been injured by a side effect associated
with the drug. We may face product liability claims and be found responsible
even if injury arises from the acts or omissions of our third-party fill/finish
or other providers. Our product liability insurance may not cover all potential
liabilities or may not completely cover any liability arising from any such
litigation. Moreover, in the future we may not have access to liability
insurance or be able to maintain our insurance on acceptable terms. </FONT></P>
<P style="PADDING-LEFT: 8pt" align=justify><B><I><FONT face="Times New Roman" size=2>If we
market and sell approved products, in a way that violates federal or state
healthcare laws, we may be subject to civil or criminal penalties.
</FONT></I></B></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>In addition to FDA and related
regulatory requirements, we are subject to health care &#147;fraud and abuse&#148; laws,
such as the federal False Claims Act, the anti-kickback provisions of the
federal Social Security Act, and other state and federal laws and regulations.
Federal and state anti-kickback laws prohibit, among other things, payments or
other remuneration to induce or reward someone to purchase, prescribe, endorse,
or recommend a product that is reimbursed under federal or state healthcare
programs. If we provide payments or other remuneration to a healthcare
professional to induce the prescribing of our products, we could face liability
under state and federal anti-kickback laws. </FONT></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Federal false claims laws prohibit
any person from knowingly presenting, or causing to be presented, a false claim
for payment to the federal government, or knowingly making, or causing to be
made, a false statement to get a false claim paid. Pharmaceutical companies have
been prosecuted under these laws for a variety of alleged promotional and
marketing activities, such as allegedly providing free product to customers with
the expectation that the customers would bill federal programs for the product;
reporting to pricing services inflated average wholesale prices that were then
used by federal programs to set reimbursement rates; engaging in promotion for
uses that the FDA has not approved, known as off-label uses, that caused claims
to be submitted to Medicaid for non-covered off-label uses, and submitting
inflated best price information to the Medicaid Rebate program. </FONT></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>The majority of states also have
statutes or regulations similar to the federal anti-kickback law and false
claims laws, which apply to items and services reimbursed under Medicaid and
other state programs, or, in several states, apply regardless of the payer.
Sanctions under these federal and state laws may include civil monetary
penalties, exclusion of a manufacturer&#146;s products from reimbursement under
government programs, criminal fines, and imprisonment. </FONT></P>
<P align=center><FONT face="Times New Roman" size=2>64</FONT></P>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Even if it is determined that we
have not violated these laws, government investigations into these issues
typically require the expenditure of significant resources and generate negative
publicity, which would harm our business and financial results and condition.
Because of the breadth of these laws and the narrowness of the safe harbors, it
is possible that some of our business activities could be challenged under one
or more of such laws. </FONT></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>In recent years, several states and
localities, including California, the District of Columbia, Massachusetts,
Minnesota, Nevada, New Mexico, Vermont, and West Virginia, have enacted
legislation requiring pharmaceutical companies to establish marketing compliance
programs, and file periodic reports with the state or make periodic public
disclosures on sales, marketing, pricing, clinical trials, and other activities.
Similar requirements are being considered in other states. In addition, as part
of the PPACA, pharmaceutical companies will be required to file reports with the
federal government regarding payments made to healthcare professionals. Many of
these requirements are new and uncertain, and the penalties for failure to
comply with these requirements are unclear. Nonetheless, if we are found not to
be in full compliance with these laws, we could face enforcement actions, fines,
and other penalties, and could receive adverse publicity, which would harm our
business and financial results and condition. </FONT></P>
<P style="PADDING-LEFT: 8pt" align=justify><B><I><FONT face="Times New Roman" size=2>Risks
from the improper conduct of employees, agents or contractors, or collaborators
could adversely affect our business or reputation.</FONT></I></B><FONT face="Times New Roman" size=2> </FONT></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>We cannot ensure that our compliance
controls, policies, and procedures will in every instance protect us from acts
committed by our employees, agents, contractors, or collaborators that would
violate the laws or regulations of the jurisdictions in which we operate,
including without limitation, healthcare, employment, foreign corrupt practices,
environmental, competition, and privacy laws. Such improper actions could
subject us to civil or criminal investigations, and monetary and injunctive
penalties, and could adversely impact our ability to conduct business, results
of operations, and reputation. </FONT></P>
<P style="PADDING-LEFT: 8pt" align=justify><B><I><FONT face="Times New Roman" size=2>Our
operations may involve hazardous materials and are subject to environmental,
health, and safety laws and regulations. Compliance with these laws and
regulations is costly, and we may incur substantial liability arising from our
activities involving the use of hazardous materials. </FONT></I></B></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>As a biopharmaceutical company with
significant manufacturing operations, we are subject to extensive environmental,
health, and safety laws and regulations, including those governing the use of
hazardous materials. Our research and development and manufacturing activities
involve the controlled use of chemicals, viruses, radioactive compounds, and
other hazardous materials. The cost of compliance with environmental, health,
and safety regulations is substantial. If an accident involving these materials
or an environmental discharge were to occur, we could be held liable for any
resulting damages, or face regulatory actions, which could exceed our resources
or insurance coverage. </FONT></P>
<P style="PADDING-LEFT: 8pt" align=justify><B><I><FONT face="Times New Roman" size=2>Our
business is subject to increasingly complex corporate governance, public
disclosure, and accounting requirements and regulations that could adversely
affect our business and financial results and condition.</FONT></I></B></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>We are subject to changing rules and
regulations of various federal and state governmental authorities as well as the
stock exchange on which our Common Stock is listed. These entities, including
the Public Company Accounting Oversight Board (PCAOB), the Securities and
Exchange Commission (SEC), and The NASDAQ Stock Market LLC, have issued a
significant number of new and increasingly complex requirements and regulations
over the course of the last several years and continue to develop additional
requirements and regulations in response to laws enacted by Congress, including
the Sarbanes-Oxley Act of 2002 and, most recently, the Dodd-Frank Wall Street
Reform and Protection Act, or the Dodd-Frank Act. There are significant
corporate governance and executive compensation-related provisions in the
Dodd-Frank Act that expressly authorized or required the SEC to adopt additional
rules in these areas. Our efforts to comply with these requirements and
regulations have resulted in, and are likely to continue to result in, an
increase in expenses and a diversion of management&#146;s time from other business
activities.</FONT></P>
<P align=center><FONT face="Times New Roman" size=2>65</FONT></P>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<P style="PADDING-LEFT: 8pt" align=justify><B><I><FONT face="Times New Roman" size=2>Changes
in laws and regulations affecting the healthcare industry could adversely affect
our business. </FONT></I></B></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>All aspects of our business,
including research and development, manufacturing, marketing, pricing, sales,
litigation, and intellectual property rights, are subject to extensive
legislation and regulation. Changes in applicable federal and state laws and
agency regulations could have a materially negative impact on our business.
These include:</FONT></P>
<UL style="FONT-SIZE: 10pt; TEXT-ALIGN: justify"><LI>changes in the FDA and foreign regulatory processes for new therapeutics
  that may delay or prevent the approval of any of our current or future product
  candidates;
  </LI><LI>new laws, regulations, or judicial decisions related to healthcare
  availability or the payment for healthcare products and services, including
  prescription drugs, that would make it more difficult for us to market and
  sell products once they are approved by the FDA or foreign regulatory
agencies;
  </LI><LI>changes in FDA and foreign regulations that may require additional safety
  monitoring prior to or after the introduction of new products to market, which
  could materially increase our costs of doing business; and
  </LI><LI>changes in FDA and foreign cGMPs that may make it more difficult and
  costly for us to maintain regulatory compliance and/or manufacture our
  marketed product and product candidates in accordance with cGMPs. </LI></UL>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>As described above, the PPACA and
potential regulations thereunder easing the entry of competing follow-on
biologics into the marketplace, other new legislation or implementation of
existing statutory provisions on importation of lower-cost competing drugs from
other jurisdictions, and legislation on comparative effectiveness research are
examples of previously enacted and possible future changes in laws that could
adversely affect our business. </FONT></P>
<P align=justify><B><FONT face="Times New Roman" size=2>Risks Related to Our Reliance on
Third Parties </FONT></B></P>
<P style="PADDING-LEFT: 8pt" align=justify><B><I><FONT face="Times New Roman" size=2>If our
antibody collaboration with Sanofi is terminated, our business operations and
financial condition, and our ability to discover, develop, manufacture, and
commercialize our pipeline of product candidates in the time expected, or at
all, would be materially harmed. </FONT></I></B></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>We rely heavily on funding from
Sanofi to support our target discovery and antibody research and development
programs. Sanofi has committed to pay up to $160 million per year, or a total of
$1.28 billion, between 2010 and 2017 to fund our efforts to identify and
validate drug discovery targets and pre-clinically develop fully human
monoclonal antibodies against such targets. Sanofi has a one-time option to
adjust the maximum reimbursement amount down to $120 million per year commencing
in 2014 if over the prior two years certain specified criteria are not
satisfied. If this downward adjustment occurs, it will reduce our resources
available for antibody discovery activities and negatively affect our clinical
pipeline. Sanofi also initially funds almost all of the development expenses
incurred by both companies in connection with the clinical development of
antibodies that Sanofi elects to co-develop with us. We rely on Sanofi to fund
these activities. In addition, with respect to those antibodies that Sanofi
elects to co-develop with us, such as sarilumab, REGN727, REGN668, REGN421,
REGN910, and REGN1033, we rely on Sanofi to lead much of the clinical
development efforts and assist with obtaining regulatory approval, particularly
outside the United States. We also rely on Sanofi to lead the commercialization
efforts to support all of the antibody products that are co-developed by Sanofi
and us if they receive regulatory approval. If Sanofi does not elect to
co-develop the antibodies that we discover or opts-out of their development, we
would be required to fund and oversee on our own the clinical trials, any
regulatory responsibilities, and the ensuing commercialization efforts to
support those antibody products. For example, during 2011 and 2012 to date,
Sanofi elected not to continue co-development of REGN846 and REGN475, and
decided not to opt-in to the REGN1154 program. If Sanofi terminates the antibody
collaboration or fails to comply with its payment obligations thereunder, our
business, prospects, operating results, and financial condition would be
materially harmed. We would be required to either expend substantially more
resources than we have anticipated to support our research and development
efforts, which could require us to seek additional funding that might not be
available on favorable terms or at all, or materially cut back on such
activities. Even though none of the antibodies from this collaboration may ever
be successfully developed and commercialized, if Sanofi does not perform its
obligations with respect to antibodies that it elects to co-develop, our ability
to develop, manufacture, and commercialize these antibody product candidates
will be significantly adversely affected.</FONT></P>
<P style="PADDING-LEFT: 8pt" align=justify><B><I><FONT face="Times New Roman" size=2>If our
collaboration with Sanofi for ZALTRAP is terminated, or Sanofi materially
breaches its obligations thereunder, our business operations, prospects, and
financial condition, and our ability to develop, manufacture, and commercialize
ZALTRAP in the time expected, or at all, would be materially
harmed.</FONT></I></B></P>
<P align=center><FONT face="Times New Roman" size=2>66</FONT></P>
<HR align=center width="100%" noShade SIZE=2>


<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>


<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face="Times New Roman" size=2>We rely
heavily on Sanofi to lead much of the development of ZALTRAP. Sanofi initially
funds all of the development expenses incurred by both companies in connection
with the ZALTRAP program. If the ZALTRAP program continues, we will rely on
Sanofi to assist with funding the ZALTRAP program, provide commercial
manufacturing capacity, enroll and monitor clinical trials, obtain regulatory
approval, particularly outside the United States, and lead the commercialization
of ZALTRAP. While ZALTRAP may not ever be successfully developed and
commercialized, if Sanofi fails to perform its obligations in a timely manner,
or at all, our ability to develop, manufacture, and commercialize ZALTRAP in
previously-treated mCRC will be significantly adversely affected. Sanofi has the
right to terminate its collaboration agreement with us at any time upon twelve
months advance notice. If Sanofi were to terminate its collaboration agreement
with us, we would not have the resources or skills to replace those of our
partner, which could require us to seek additional funding that might not be
available on favorable terms or at all, and could cause significant delays in
the development and/or manufacture of ZALTRAP and result in substantial
additional costs to us. We have limited commercial capabilities and would have
to develop or outsource these capabilities. Termination of the Sanofi
collaboration agreement for ZALTRAP would create substantial new and additional
risks to the successful development and commercialization of ZALTRAP.
</FONT></P>
<P align=justify style="padding-left: 8pt"><B><I><FONT face="Times New Roman" size=2>If our collaboration with Bayer
HealthCare for EYLEA is terminated, or Bayer HealthCare materially breaches its
obligations thereunder, our business operations, prospects, and financial
condition, and our ability to continue to develop EYLEA and commercialize EYLEA
outside the United States in the time expected, or at all, would be materially
harmed. </FONT></I></B></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>We rely heavily on Bayer HealthCare
to assist with the development, and the commercialization outside the United
States, of EYLEA. Under our agreement with them, Bayer HealthCare is required to
fund approximately half of the development expenses incurred by both companies
in connection with the global EYLEA development program. As the EYLEA program
continues, we will continue to rely on Bayer HealthCare to assist with funding
the EYLEA development program, continue to lead the development of EYLEA outside
the United States, obtain regulatory approval outside the United States, and
provide all sales, marketing, and commercial support for the product outside the
United States. In particular, Bayer HealthCare has responsibility for selling
EYLEA outside the United States using its sales force in countries other than
Japan. In Japan, Santen Pharmaceuticals Co. Ltd. will sell EYLEA pursuant to a
Co-Promotion and Distribution Agreement with Bayer HealthCare&#146;s Japanese
affiliate. While we cannot assure you that EYLEA will receive regulatory
approval in or outside the United States or be successfully commercialized, if
Bayer HealthCare and, in Japan, Santen do not perform their obligations in a
timely manner, or at all, our ability to develop, manufacture, and commercialize
EYLEA outside the United States will be significantly adversely affected. Bayer
HealthCare has the right to terminate its collaboration agreement with us at any
time upon six or twelve months advance notice, depending on the circumstances
giving rise to termination. If Bayer HealthCare were to terminate its
collaboration agreement with us, we would not have the resources or skills to
replace those of our partner, which could require us to seek additional funding
or another collaboration that might not be available on favorable terms or at
all, and could cause significant delays in the development and/or
commercialization of EYLEA outside the United States and result in substantial
additional costs to us. We currently have limited commercial capabilities and
would have to develop or outsource these capabilities outside the United States.
Termination of the Bayer HealthCare collaboration agreement would create
substantial new and additional risks to the successful development and
commercialization of EYLEA, particularly outside the United States. </FONT></P>
<P align=justify style="padding-left: 8pt"><B><I><FONT face="Times New Roman" size=2>Our collaborators and service
providers may fail to perform adequately in their efforts to support the
development, manufacture, and commercialization of our drug candidates and
current and future products. </FONT></I></B></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>We depend upon third-party
collaborators, including Sanofi, Bayer HealthCare, and service providers such as
CROs, outside testing laboratories, clinical investigator sites, and third-party
manufacturers, fill/finish, and product packagers and labelers, to assist us in
the manufacture and preclinical and clinical development of our product
candidates. We also depend, or will depend, on some of these third parties in
connection with the commercialization of EYLEA for the treatment of wet AMD,
ARCALYST for the treatment of CAPS, and our late-stage product candidates and
new indications for our marketed products if they are approved for marketing. If
any of our existing collaborators or service providers breaches or terminates
its agreement with us or does not perform its development or manufacturing
services under an agreement in a timely manner or in compliance with applicable
GMPs, Good Laboratory Practices (GLPs), or GCP Standards, we could experience
additional costs, delays, and difficulties in the manufacture or development of,
or in obtaining approval by regulatory authorities for and successfully
commercializing, our product candidates. </FONT></P>
<P align=center><FONT face="Times New Roman"></FONT><FONT face="Times New Roman" size=2>67</FONT></P>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face="Times New Roman" size=2>We rely
on third-party service providers to support the distribution of EYLEA and
ARCALYST and for many other related activities in connection with the
commercialization of these marketed products. Despite our arrangements with
them, these third parties may not perform adequately. If these service providers
do not perform their services adequately, our sales of EYLEA for the treatment
of wet AMD and ARCALYST for the treatment of CAPS will suffer. </FONT></P>
<P align=justify><B><FONT face="Times New Roman" size=2>Risk Related to Employees
</FONT></B></P>
<P style="PADDING-LEFT: 8pt" align=justify><B><I><FONT face="Times New Roman" size=2>We are
dependent on our key personnel and if we cannot recruit and retain leaders in
our research, development, manufacturing, and commercial organizations, our
business will be harmed. </FONT></I></B></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>We are highly dependent on certain
of our executive officers, other key members of our senior management team, and
our Chairman. If we are not able to retain any of these persons, our business
may suffer. In particular, we depend on the services of P. Roy Vagelos, M.D.,
the Chairman of our board of directors, Leonard S. Schleifer, M.D., Ph.D., our
President and Chief Executive Officer, George D. Yancopoulos, M.D., Ph.D., our
Executive Vice President, Chief Scientific Officer and President, Regeneron
Research Laboratories, and Neil Stahl, Ph.D., our Senior Vice President,
Research and Development Sciences. As we commercialize EYLEA in the United
States for the treatment of wet AMD and prepare for commercialization in the
United States of EYLEA for the treatment of CRVO and ARCALYST for the treatment
of gout flares in patients initiating uric acid-lowering therapy, should they
receive regulatory approval, we will also be highly dependent on the expertise
and services of members of our senior management leading these commercialization
efforts. There is intense competition in the biotechnology industry for
qualified scientists and managerial personnel in the development, manufacture,
and commercialization of drugs. We may not be able to continue to attract and
retain the qualified personnel necessary to continue to advance our business and
achieve our strategic objectives. </FONT></P>
<P align=justify><B><FONT face="Times New Roman" size=2>Information Technology Risks
</FONT></B></P>
<P style="PADDING-LEFT: 8pt" align=justify><B><I><FONT face="Times New Roman" size=2>Significant disruptions of information technology systems or breaches of
data security could adversely affect our business.</FONT></I></B></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Our business is increasingly
dependent on critical, complex, and interdependent information technology
systems, including Internet-based systems, to support business processes as well
as internal and external communications. The size and complexity of our computer
systems make them potentially vulnerable to breakdown, malicious intrusion, and
computer viruses which may result in the impairment of production and key
business processes.</FONT></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>In addition, our systems are
potentially vulnerable to data security breaches&#151;whether by employees or
others&#151;which may expose sensitive data to unauthorized persons. Such data
security breaches could lead to the loss of trade secrets or other intellectual
property, or could lead to the public exposure of personal information
(including sensitive personal information) of our employees, clinical trial
patients, customers, and others.</FONT></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Such disruptions and breaches of
security could have a material adverse effect on our business, prospects,
operating results, and financial condition.</FONT></P>
<P align=justify><B><FONT face="Times New Roman" size=2>Risks Related to Our Common Stock
</FONT></B></P>
<P style="PADDING-LEFT: 8pt" align=justify><B><I><FONT face="Times New Roman" size=2>Our
stock price is extremely volatile. </FONT></I></B></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>There has been significant
volatility in our stock price and generally in the market prices of
biotechnology companies&#146; securities. Various factors and events may have a
significant impact on the market price of our Common Stock. These factors
include, by way of example: </FONT></P>
<UL style="FONT-SIZE: 10pt; TEXT-ALIGN: justify"><LI><FONT face="Times New Roman" size=2>announcement of actions by the FDA or foreign
  regulatory authorities or their respective advisory committees regarding our,
  or our collaborators&#146; currently pending or future application(s) for
  regulatory approval of our product candidate(s) or new indications for our
  marketed products; </FONT></LI></UL>
<P align=center><FONT face="Times New Roman" size=2>68</FONT></P>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<UL style="FONT-SIZE: 10pt; TEXT-ALIGN: justify"><LI><FONT face="Times New Roman" size=2>announcement of submission of an application for
  regulatory approval of one or more of our product candidates or new
  indications for our marketed products;</FONT>
  </LI><LI><FONT face="Times New Roman" size=2>progress, delays, or results in clinical trials of
  our or our competitors&#146; product candidates or new indications for marketed
  products;</FONT>
  </LI><LI><FONT face="Times New Roman" size=2>announcement of technological innovations or
  product candidates by us or competitors;</FONT>
  </LI><LI><FONT face="Times New Roman" size=2>fluctuations in our operating results; in
  particular, net product sales of, and profits from, EYLEA and, if any of our
  product candidates or our new indications for our marketed products receive
  regulatory approval, net product sales of, and profits from, these product
  candidates and new indications;</FONT>
  </LI><LI><FONT face="Times New Roman" size=2>market acceptance of, and fluctuations in market
  share for, our marketed products, especially EYLEA, and whether these factors,
  including our net products sales, underperform, meet, or exceed the
  expectations of investors or analysts;</FONT>
  </LI><LI><FONT face="Times New Roman" size=2>third-party claims that our products or
  technologies infringe their patents;</FONT>
  </LI><LI><FONT face="Times New Roman" size=2>third-party challenges to our patents in the
  European Patent Office and in the U.S. Patent and Trademark Office;</FONT>
  </LI><LI><FONT face="Times New Roman" size=2>public concern as to the safety or effectiveness
  of any of our marketed products or product candidates or new indications for
  our marketed products, including EYLEA or, if approved, ZALTRAP, or ARCALYST
  for the prevention of gout flares in patients initiating uric acid-lowering
  therapy;</FONT>
  </LI><LI><FONT face="Times New Roman" size=2>pricing or reimbursement actions or decisions by
  government authorities or insurers affecting the coverage or reimbursement of
  any of our marketed products or competitors&#146; products;</FONT>
  </LI><LI><FONT face="Times New Roman" size=2>our ability to raise additional capital as needed
  on favorable terms;</FONT>
  </LI><LI><FONT face="Times New Roman" size=2>developments in our relationship with
  collaborative partners;</FONT>
  </LI><LI><FONT face="Times New Roman" size=2>developments in the biotechnology industry or in
  government regulation of healthcare;</FONT>
  </LI><LI><FONT face="Times New Roman" size=2>large sales of our Common Stock by our executive
  officers, directors, or significant shareholders;</FONT>
  </LI><LI><FONT face="Times New Roman" size=2>arrivals and departures of key personnel;
  and</FONT>
  </LI><LI><FONT face="Times New Roman" size=2>general market conditions.</FONT></LI></UL>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face="Times New Roman" size=2>The
trading price of our Common Stock has been, and could continue to be, subject to
wide fluctuations in response to these and other factors, including the sale or
attempted sale of a large amount of our Common Stock in the market. Broad market
fluctuations may also adversely affect the market price of our Common Stock.
</FONT></P>
<P style="PADDING-LEFT: 8pt" align=justify><B><I><FONT face="Times New Roman" size=2>Future
sales of our Common Stock by our significant shareholders or us may depress our
stock price and impair our ability to raise funds in new share offerings.
</FONT></I></B></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>A small number of our shareholders
beneficially own a substantial amount of our Common Stock. As of April 11, 2012,
our seven largest shareholders plus Leonard S. Schleifer, M.D, Ph.D., our Chief
Executive Officer, beneficially owned 67.4% of our outstanding shares of Common
Stock, assuming, in the case of our Chief Executive Officer, the conversion of
his Class A Stock into Common Stock and the exercise of all options held by him
which are exercisable within 60 days of April 11, 2012. In September 2003,
Sanofi (then Aventis Pharmaceuticals Inc.) purchased 2,799,552 newly issued,
unregistered shares of our Common Stock, and in December 2007 Sanofi purchased
an additional 12,000,000 newly issued, unregistered shares of our Common Stock.
Under our investor agreement, as amended, with Sanofi, these shares may not be
sold until December 20, 2017 except under limited circumstances and subject to
earlier termination of these restrictions upon the occurrence of certain events.
In addition, in October 2010, Sanofi purchased an additional 1,017,401 shares of
Common Stock in our underwritten public offering. As of April 11, 2012, Sanofi
beneficially owned 15,816,953 shares of our Common Stock, representing
approximately 17.0% of the shares of Common Stock then outstanding. If Sanofi,
or our other significant shareholders or we, sell substantial amounts of our
Common Stock in the public market, or the perception that such sales may occur
exists, the market price of our Common Stock could fall. Sales of Common Stock
by our significant shareholders, including Sanofi, also might make it more
difficult for us to raise funds by selling equity or equity-related securities
in the future at a time and price that we deem appropriate. </FONT></P>
<P align=center><FONT face="Times New Roman"></FONT><FONT face="Times New Roman" size=2>69</FONT></P>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<P style="PADDING-LEFT: 8pt" align=justify><B><I><FONT face="Times New Roman" size=2>Our
existing shareholders may be able to exert significant influence over matters
requiring shareholder approval. </FONT></I></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face="Times New Roman" size=2>Holders
of Class A Stock, who are generally the shareholders who purchased their stock
from us before our initial public offering, are entitled to ten votes per share,
while holders of Common Stock are entitled to one vote per share. As of April
11, 2012, holders of Class A Stock held 18.3% of the combined voting power of
all shares of Common Stock and Class A Stock then outstanding. These
shareholders, if acting together, would be in a position to significantly
influence the election of our directors and the vote on certain corporate
transactions that require majority or supermajority approval of the combined
classes, including mergers and other business combinations. This may result in
our taking corporate actions that other shareholders may not consider to be in
their best interest and may affect the price of our Common Stock. As of April
11, 2012: </FONT></P>
<UL style="FONT-SIZE: 10pt; TEXT-ALIGN: justify"><LI><FONT face="Times New Roman" size=2>our current executive officers and directors
  beneficially owned 11.1% of our outstanding shares of Common Stock, assuming
  conversion of their Class A Stock into Common Stock and the exercise of all
  options held by such persons which are exercisable within 60 days of April 11,
  2012, and 24.0% of the combined voting power of our outstanding shares of
  Common Stock and Class A Stock, assuming the exercise of all options held by
  such persons which are exercisable within 60 days of April 11, 2012;
and</FONT>
  </LI><LI><FONT face="Times New Roman" size=2>our seven largest shareholders plus Leonard S.
  Schleifer, M.D., Ph.D. our Chief Executive Officer, beneficially owned 67.4%
  of our outstanding shares of Common Stock, assuming, in the case of our Chief
  Executive Officer, the conversion of his Class A Stock into Common Stock and
  the exercise of all options held by him which are exercisable within 60 days
  of April 11, 2012. In addition, these seven shareholders held 69.8% of the
  combined voting power of our outstanding shares of Common Stock and Class A
  Stock, assuming the exercise of all options held by our Chief Executive
  Officer which are exercisable within 60 days of April 11, 2012.
</FONT></LI></UL>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Pursuant to an investor agreement,
as amended, Sanofi has agreed to vote its shares, at Sanofi&#146;s election, either
as recommended by our board of directors or proportionally with the votes cast
by our other shareholders, except with respect to certain change of control
transactions, liquidation or dissolution, stock issuances equal to or exceeding
10% of the then outstanding shares or voting rights of Common Stock and Class A
Stock, and new equity compensation plans or amendments if not materially
consistent with our historical equity compensation practices.</FONT></P>
<P style="PADDING-LEFT: 8pt" align=justify><B><I><FONT face="Times New Roman" size=2>The
anti-takeover effects of provisions of our charter, by-laws, and of New York
corporate law and the contractual &#147;standstill&#148; provisions in our investor
agreement with Sanofi, could deter, delay, or prevent an acquisition or other
&#147;change in control&#148; of us and could adversely affect the price of our Common
Stock. </FONT></I></B></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Our restated certificate of
incorporation, our by-laws, and the New York Business Corporation Law contain
various provisions that could have the effect of delaying or preventing a change
in control of our company or our management that shareholders may consider
favorable or beneficial. Some of these provisions could discourage proxy
contests and make it more difficult for shareholders to elect directors and take
other corporate actions. These provisions could also limit the price that
investors might be willing to pay in the future for shares of our Common Stock.
These provisions include: </FONT></P>
<UL style="FONT-SIZE: 10pt; TEXT-ALIGN: justify"><LI><FONT face="Times New Roman" size=2>authorization to issue &#147;blank check&#148; preferred
  stock, which is preferred stock that can be created and issued by the board of
  directors without prior shareholder approval, with rights senior to those of
  our Common Stock and Class A Stock;</FONT>
  </LI><LI><FONT face="Times New Roman" size=2>a staggered board of directors, so that it would
  take three successive annual meetings to replace all of our directors;</FONT>
  </LI><LI><FONT face="Times New Roman" size=2>a requirement that removal of directors may only
  be effected for cause and only upon the affirmative vote of at least eighty
  percent (80%) of the outstanding shares entitled to vote for directors, as
  well as a requirement that any vacancy on the board of directors may be filled
  only by the remaining directors;</FONT>
  </LI><LI><FONT face="Times New Roman" size=2>a provision whereby any action required or
  permitted to be taken at any meeting of shareholders may be taken without a
  meeting, only if, prior to such action, all of our shareholders consent, the
  effect of which is to require that shareholder action may only be taken at a
  duly convened meeting;</FONT>
  </LI><LI><FONT face="Times New Roman" size=2>a requirement that any shareholder seeking to
  bring business before an annual meeting of shareholders must provide timely
  notice of this intention in writing and meet various other requirements; and
  </FONT></LI></UL>
<P align=center><FONT face="Times New Roman" size=2>70</FONT></P>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<UL style="FONT-SIZE: 10pt; TEXT-ALIGN: justify"><LI><FONT face="Times New Roman" size=2>under the New York Business Corporation Law, in
  addition to certain restrictions which may apply to &#147;business combinations&#148;
  involving our company and an &#147;interested shareholder&#148;, a plan of merger or
  consolidation of our company must be approved by two-thirds of the votes of
  all outstanding shares entitled to vote thereon. See the risk factor
  immediately above captioned </FONT><I><FONT face="Times New Roman" size=2>&#147;Our existing
  shareholders may be able to exert significant influence over matters requiring
  shareholder approval.&#148;</FONT></I><FONT face="Times New Roman" size=2> </FONT></LI></UL>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face="Times New Roman" size=2>Until the
later of the fifth anniversaries of the expiration or earlier termination of our
antibody collaboration agreements with Sanofi or our ZALTRAP collaboration with
Sanofi, Sanofi will be bound by certain &#147;standstill&#148; provisions, as amended,
which contractually prohibit Sanofi from acquiring more than certain specified
percentages of our Class A Stock and Common Stock (taken together) or otherwise
seeking to obtain control of our company.</FONT></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>In addition, we have a Change in
Control Severance Plan and our Chief Executive Officer has an employment
agreement that provides severance benefits in the event our officers are
terminated as a result of a change in control of our company. Many of our stock
options issued under our Second Amended and Restated 2000 Long-Term Incentive
Plan, as amended and restated, may become fully vested in connection with a
&#147;change in control&#148; of our company, as defined in the plan. These contractual
provisions may also have the effect of deterring, delaying, or preventing an
acquisition or other change in control. </FONT></P>
<P align=justify><B><FONT face="Times New Roman" size=2>Risks Relating to Our Convertible
Senior Notes and Related Hedge Transactions </FONT></B></P>
<P style="PADDING-LEFT: 8pt" align=justify><B><I><FONT face="Times New Roman" size=2>The
convertible note hedges and warrant transactions we entered into in connection
with our 1.875% Convertible Senior Notes issuance may affect the trading price
of our Common Stock. </FONT></I></B></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>In connection with our offering of
our 1.875% Convertible Senior Notes due October 1, 2016, we entered into
convertible note hedge transactions with four financial institutions (the &#147;hedge
counterparties&#148;). The convertible note hedge transactions are expected to reduce
the potential dilution to our Common Stock and/or offset potential cash payments
in excess of the principal amount of the notes, as the case may be upon
conversion of the notes. In the event that the hedge counterparties fail to
deliver shares to us or potential cash payments as the case may be as required
under the convertible note hedge documents, we would not receive the benefit of
such transactions. Separately, we also entered into warrant transactions with
the hedge counterparties. The warrant transactions could separately have a
dilutive effect from the issuance of Common Stock pursuant to the
warrants.</FONT></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>In connection with hedging these
transactions, the hedge counterparties and/or their affiliates may enter into
various derivative transactions with respect to our Common Stock, and may enter
into, or may unwind, various derivative transactions and/or purchase or sell our
Common Stock or other securities of ours in secondary market transactions prior
to maturity of the notes (and are likely to do so during any conversion period
related to any conversion of the notes). These activities could have the effect
of increasing or preventing a decline in, or could have a negative effect on,
the value of our Common Stock and could have the effect of increasing or
preventing a decline in the value of our Common Stock during any cash settlement
averaging period related to a conversion of the notes. </FONT></P>
<P align=justify><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>In addition, we intend to exercise
options under the convertible note hedge transactions whenever notes are
converted. In order to unwind its hedge position with respect to the options we
exercise, the hedge counterparties and/or their affiliates may sell shares of
our Common Stock or other securities in secondary market transactions or unwind
various derivative transactions with respect to our Common Stock during the cash
settlement averaging period for the converted notes. The effect, if any, of any
of these transactions and activities on the trading price of our Common Stock or
the notes will depend in part on market conditions and cannot be ascertained at
this time, but any of these activities could adversely affect the value of our
Common Stock and the value of the notes. The derivative transactions that the
hedge counterparties and/or their affiliates expect to enter into to hedge these
transactions may include cash-settled equity swaps referenced to our Common
Stock. In certain circumstances, the hedge counterparties and/or their
affiliates may have derivative positions that, when combined with the hedge
counterparties&#146; and their affiliates&#146; ownership of our Common Stock, if any,
would give them economic exposure to the return on a significant number of
shares of our Common Stock. </FONT></P>
<P align=center><FONT face="Times New Roman"></FONT><FONT face="Times New Roman" size=2>71</FONT></P>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<P style="PADDING-LEFT: 8pt" align=justify><B><I><FONT face="Times New Roman" size=2>The
fundamental change provisions of our 1.875% Convertible Senior Notes and certain
of the terms of the convertible note hedge and warrant transactions may delay or
prevent an otherwise beneficial takeover attempt of us. </FONT></I></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face="Times New Roman" size=2>The
fundamental change purchase rights, which will allow noteholders to require us
to purchase all or a portion of their notes upon the occurrence of a fundamental
change, as defined in the indenture governing the notes, and the provisions
requiring an increase to the conversion rate for conversions in connection with
make-whole fundamental changes, as set forth in the indenture, may in certain
circumstances delay or prevent a takeover of us and the removal of incumbent
management that might otherwise be beneficial to investors. In addition, upon
the occurrence of certain extraordinary events, the convertible note hedge
transactions would be exercised upon the conversion of notes, and the warrant
transactions may be terminated. It is possible that the proceeds we receive upon
the exercise of the convertible note hedge transactions would be significantly
lower than the amounts we would be required to pay upon termination of the
warrant transactions. Such differences may result in the acquisition of us being
on terms less favorable to our shareholders than it would otherwise
be.</FONT></P>
<P align=justify><B><FONT face="Times New Roman" size=2><A NAME="item6"></A>ITEM 6. EXHIBITS </FONT></B></P>
<TABLE style="LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD noWrap align=left width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD noWrap align=left width="96%" colSpan=6><FONT face="Times New Roman" size=2>(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT size=2 face="Times New Roman">Exhibits</FONT></TD>
    <TD noWrap align=left width="2%"></TD></TR>
  <TR>
    <TD width="1%"></TD>
    <TD width="98%" colSpan=7>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="2%"><B><FONT face="Times New Roman" size=2>Exhibit</FONT></B></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="91%" colSpan=2></TD>
    <TD noWrap align=left width="2%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="2%"><B><FONT face="Times New Roman" size=2>Number</FONT></B></TD>
    <TD noWrap align=left width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="3%" colSpan=3><B><FONT face="Times New Roman" size=2>Description</FONT></B></TD>
    <TD noWrap align=left width="90%">&nbsp;</TD>
    <TD noWrap align=left width="2%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=2>10.1*</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD noWrap style="text-align: center" width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>-</FONT></TD>
    <TD noWrap align=left width="91%" bgColor=#cceeff colSpan=2><FONT face="Times New Roman" size=2>Amendment Agreement, dated May 7, 2012, by and between Bayer
      HealthCare LLC</FONT></TD>
    <TD noWrap align=left width="2%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="2%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap style="text-align: center" width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="91%" bgColor=#cceeff colSpan=2><FONT face="Times New Roman" size=2>and the Registrant.</FONT></TD>
    <TD noWrap align=left width="2%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="2%"><FONT face="Times New Roman" size=2>31.1</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"><FONT face="Times New Roman" size=2>-</FONT></TD>
    <TD noWrap align=left width="91%" colSpan=2><FONT face="Times New Roman" size=2>Certification of CEO
      pursuant to Rule 13a-14(a) under the Securities Exchange Act</FONT></TD>
    <TD noWrap align=left width="2%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="1%">&nbsp;</TD>
    <TD noWrap align=left width="2%"></TD>
    <TD noWrap align=left width="1%">&nbsp;</TD>
    <TD noWrap align=left width="1%">&nbsp;</TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap align=left width="91%" colSpan=2><FONT face="Times New Roman" size=2>of 1934.</FONT></TD>
    <TD noWrap align=left width="2%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=2>31.2</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap style="text-align: center" width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>-</FONT></TD>
    <TD noWrap align=left width="91%" bgColor=#cceeff colSpan=2><FONT face="Times New Roman" size=2>Certification of CFO pursuant to Rule 13a-14(a) under the
      Securities Exchange Act</FONT></TD>
    <TD noWrap align=left width="2%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="2%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap style="text-align: center" width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="91%" bgColor=#cceeff colSpan=2><FONT face="Times New Roman" size=2>of
      1934.</FONT></TD>
    <TD noWrap align=left width="2%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="2%"><FONT face="Times New Roman" size=2>32</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"><FONT face="Times New Roman" size=2>-</FONT></TD>
    <TD noWrap align=left width="91%" colSpan=2><FONT face="Times New Roman" size=2>Certification of CEO and
      CFO pursuant to 18 U.S.C. Section 1350.</FONT></TD>
    <TD noWrap align=left width="2%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=2>101</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap style="text-align: center" width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>-</FONT></TD>
    <TD noWrap align=left width="91%" bgColor=#cceeff colSpan=2><FONT face="Times New Roman" size=2>Interactive Data File</FONT></TD>
    <TD noWrap align=left width="2%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="2%"><FONT face="Times New Roman" size=2>101.INS</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"><FONT face="Times New Roman" size=2>-</FONT></TD>
    <TD noWrap align=left width="91%" colSpan=2><FONT face="Times New Roman" size=2>XBRL Instance
      Document</FONT></TD>
    <TD noWrap align=left width="2%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=2>101.SCH</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap style="text-align: center" width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>-</FONT></TD>
    <TD noWrap align=left width="91%" bgColor=#cceeff colSpan=2><FONT face="Times New Roman" size=2>XBRL Taxonomy Extension Schema</FONT></TD>
    <TD noWrap align=left width="2%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="2%"><FONT face="Times New Roman" size=2>101.CAL</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"><FONT face="Times New Roman" size=2>-</FONT></TD>
    <TD noWrap align=left width="91%" colSpan=2><FONT face="Times New Roman" size=2>XBRL Taxonomy Extension
      Calculation Linkbase</FONT></TD>
    <TD noWrap align=left width="2%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=2>101.LAB</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap style="text-align: center" width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>-</FONT></TD>
    <TD noWrap align=left width="91%" bgColor=#cceeff colSpan=2><FONT face="Times New Roman" size=2>XBRL Taxonomy Extension Label Linkbase</FONT></TD>
    <TD noWrap align=left width="2%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="2%"><FONT face="Times New Roman" size=2>101.PRE</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"><FONT face="Times New Roman" size=2>-</FONT></TD>
    <TD noWrap align=left width="91%" colSpan=2><FONT face="Times New Roman" size=2>XBRL Taxonomy Extension
      Presentation Linkbase</FONT></TD>
    <TD noWrap align=left width="2%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="2%" bgColor=#cceeff><FONT face="Times New Roman" size=2>101.DEF</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap style="text-align: center" width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>-</FONT></TD>
    <TD noWrap align=left width="91%" bgColor=#cceeff colSpan=2><FONT face="Times New Roman" size=2>XBRL Taxonomy Extension Definition Document</FONT></TD>
    <TD noWrap align=left width="2%"></TD></TR></TABLE>____________________<BR><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;<BR></FONT>* The Company has requested
confidential treatment of certain information contained in this exhibit. Such
information has been filed separately with the Commission pursuant to the
Company&#146;s application for confidential treatment.</FONT>
<P align=center><FONT face="Times New Roman" size=2>72</FONT></P>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<P align=justify><B><U><FONT face="Times New Roman" size=2><A NAME="Signatures"></A>SIGNATURE</FONT></U></B><FONT face="Times New Roman" size=2> </FONT></P>
<P align=justify><FONT face="Times New Roman" size=2>Pursuant to the requirements of the
Securities Exchange Act of 1934, the Registrant has duly caused this report to
be signed on its behalf by the undersigned thereunto duly authorized.
</FONT></P>
<TABLE style="LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD noWrap align=left width="50%"></TD>
    <TD noWrap align=left width="50%" colSpan=3><FONT face="Times New Roman" size=2>REGENERON PHARMACEUTICALS, INC.</FONT></TD></TR>
  <TR>
    <TD width="100%" colSpan=4>&nbsp;</TD></TR>
  <TR>
    <TD width="100%" colSpan=4>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="50%"><FONT face="Times New Roman" size=2>Date: July 25, 2012</FONT></TD>
    <TD noWrap align=left width="1%"><FONT size=2 face="Times New Roman">By:&nbsp;&nbsp;</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="10%"><FONT face="Times New Roman" size=2>/s/ M</FONT><FONT face="Times New Roman" size=1>URRAY </FONT><FONT face="Times New Roman" size=2>A. G</FONT><FONT face="Times New Roman" size=1>OLDBERG</FONT></TD>
    <TD noWrap align=left width="39%">&nbsp;</TD></TR>
  <TR>
    <TD width="100%" colSpan=4>&nbsp; </TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="50%"></TD>
    <TD noWrap align=left width="50%" colSpan=3><FONT face="Times New Roman" size=2>Murray A. Goldberg</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="50%"></TD>
    <TD noWrap align=left width="50%" colSpan=3><FONT face="Times New Roman" size=2>Senior Vice President, Finance &amp;
  Administration,</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="50%"></TD>
    <TD noWrap align=left width="50%" colSpan=3><FONT face="Times New Roman" size=2>Chief Financial Officer, Treasurer, and</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="50%"></TD>
    <TD noWrap align=left width="50%" colSpan=3><FONT face="Times New Roman" size=2>Assistant Secretary</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="50%"></TD>
    <TD noWrap align=left width="50%" colSpan=3><FONT face="Times New Roman" size=2>(Principal Financial Officer and</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="50%"></TD>
    <TD noWrap align=left width="50%" colSpan=3><FONT face="Times New Roman" size=2>Duly Authorized Officer)</FONT></TD></TR></TABLE><BR>
<P align=center><FONT face="Times New Roman" size=2>73</FONT></P>
<HR align=center width="100%" noShade SIZE=2>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
